var title_f36_23_37232="Patch granuloma annulare";
var content_f36_23_37232=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F75365&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F75365&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Patch granuloma annulare",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 324px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAFEAbADASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwDULbsFSOMU4tlRwM+tYdtqStsy34VtRSLIqspFeqeMWYGww+UflT9UXzdNdcDI56VFFIA1SGQSI6NxkYpgY2nsTx3+lbCsB1wTWHb4WU/7JNXxOD2pEo00lGGDAYIpY5EC47j0rPWYtwOlSq4CgHg0FXNKOYEEhQKtRSD+EDP0rIV+wPNTJK0YwDQUmbUbcHfjB9qQuvT3qukhZRT+CcDr1pFlreABxwfajfn5QP0qNnBHoRSE45NAWJlOGGAOPapWlCgbce/FV0cHuM0oZSdvFIZOZeD0/Kh2Uhe4+lV8gZBNJI3zLjpTEWVK7jkDFBCHqBUG8jkdKVn4ytIfQkLk4G3gU8kDgc1DHLnjFSKQGBPIoFYRsA5OPyqNyOy5H0qZgOaq3LBV+XHPWgLEU7Kp+XFJuLrx6dMVAzBh8tPL7VA9aYEmFVRwPekByQeKiVgM+mKZvwRtoEW1+U/L1p0zBVzxmq7NgA55qJ5fMGCee1ANmrp0m2QNxk9q0JZQW5A574rmkuzBLESeM4Nb9w0ZjXa2aTHF3QyAKsxzjGavnYBuXFZyFN+VPJFPYuwAHSgosSyA4IA47YpHnUJnHP0qvgr96nRBSct0pWAaHV2B60xpSMheB9KmdQv3QB3ppClScUybEfmtjpz9KjUu5OcVbAV49w7cdKq3R8s0BYQKSTvxijYoc4GaiMo2DJ5pBNg9fxphYsq4QZKj8qjd9zdAPwqIyhhzgYqKWdSOo4oAmYnILYx0pSwC4OPyqqZhsyTwO9QtcbvTHsaBbFsToR0HFNkmGDjBrMaYgsvrTDIx4H607EuRcluFUY4z7CqxuCW7fSoWVuc5INMlUoAQeaaRDbJZJ97k4GR0qN2JIGAKYvXJpxPINNi1Y4AAnd0xUe1ST/hSs3PHIpu8c+uKQ7Hn0CHjmt7RZGyFY1jREEjGMGtKzyuMGhalNHSpkKT+dTkhxyMfSsyCY7doOT3zVhJyuOM56UhFJE2XMo9D+dShQWzSzjE+7+8OgpP4enSi4WJx8q5FSbsYOKij5+lSr0Oe1A7FmPBUetKp5ycVErgYx1pystAGlG5KjB4qQy/KD0NZ8TYIx0qRmOQc0FcxeWY5wB1qRZsnBxkVnmbpjIp68tkE0DTLiP8AMckUu4B+O9VQdp3d6ZI+XyOKB3sX92cA89+KarfNgnioFk2uA3BpVcbzjnPNILlkOBwfWnsRj61UMoHXGadHLuc5PFAywh2HAHFSRyhiR/nNVXOCCG4NPQAgnPTvQCLZIYdeaguYv3ZA5PXFNSQ7t2DUhYk5yaQ7FFY8cniiReQvPsatsob8KagB5/WgVim0bqTjnFNZWwDitAqoHPQ+tKCOmBimLlKaRNKvcAUiWkgPOBVneFyF4pRMAoJJ96B2XUw9VRoZFDHI4NdLZulxaxEY+7XNa1L5mCh6dqvaNfZhVSMkDtQyIvWx0BVSowACKcMLx1NU0uDkjHH8qe8pDAZzmpsa3JiSee1I2ACM1XebDDFQvPnI700Jl3eASA3BqKRiCB2qr5u0dRUbXGHGadhNmmsqgAAY5qtftkBmPFQCcBjk8GlYh4irHJ9aLBcpTOFHBNRvdfJgelSTQls7T0qkcZ2/nTM5NjxdNkjNMaY7yRxUbDac4pwAH40EB5zbSOdvpQuduRk0jZQ8DNIrgZDUBYkJy2eppe2TUSnjJ6UxpDuOOlA7dSaRm2ZU8UwvlcmmbztAHIqNzt564oAFc5IP605nJGc4FQnkg0pOCB2NAbD/ADDtwPzpgzk80jHaMnpUXmemcUDscRaygsoJ6VswYBGTwK5eKQKy811NgqzQocjPekmU0aMDYyRUysepPTpmqyDbxT93y5zTZNmOd2aUEmpRLwQTUJBIyOtTJbHGXNIEn0GLKc9eKcJT2NTi3XgjvTWhEYyOTQFmh0bb+vGKlHCkVDbk5z0qR3wc9jQNalqFsd8VOW4IqlHKB0qYPubrTAlTkcHNSB8Yx19arxtxtA5FPXJXNAIsJKc85xQDkkk9ajBIHNShQU9/WgaG7wZBk8dKdHlTgH6UxQOG4ODTnkABORnNArFhlzjI5pQMEEd/1qBp1WMYbmomvMHtSKui+T68CnjABO6sqS9JTHeoftj45zQHMbnmqvJIzSNcr/e4rDe6LADP0pvmlgOvHaiwOZrm7AyPyqP7WQMZzWerFup5oz35/wAaBczL0l0xXrSi5O0EHPrVLAZeCc0iYQEZoFzM0I7gbgH796juJixZUzVZuGBz0pXZc8DFMLtoz7qUxv8ANk5q7okoaRwnFQ3kYljPTOKqaRM0V2BnrxSJWjOnkfb8wyCaYZGGCOTTZMuvXFV0chmBycUF31LpyfmBOTzTS3PXnFRLIRznAFRqxdsk4+lA2yaQ84zkio3fJ44qORijihpdx54pktgZCTgHHvQJ2V+pIHrQwUqWUYqEHd1oJd0XFnyT6mqs6bJNw6UgbnB/OiZzs45I4pFbrUQkMCMcioVc5K96dGTxnvUTja/pTuKxIx4wTURYB8npSMc96hY5OAaAsTeYc47U0tkkA9aROnNMkGTkcUh2JN+BgUOxIyOajHIJqNcquOxoAkOQAc80hJc46EVC7kHDetKpJww7daBMlySuG60xQozjvQWwpbq1M3ZQkc8UBoedSW8xHEbZHoavaZcTQkK24Y9RVzy84yKUR5zn6dK89YuXY9h5fHoy9Hdu5+8PzqxHI7AcjrzzWOYcGhYuTV/W+6I/s/8AvHQRynvir8UrbBuGc1yGzilCMMcnHsaPri7C/s59GdpHk4xx3pzqSME1xZDju2PqaBux99vX71P62uwf2dLudcsbBskfhT/LYkcYFcioPG1n6+pp+WOfmbP1NH1tdg/s2Xc7JIju6VMox0XiuGDkHG9yf940pkkB/wBY4H1o+trsP+zZdzt1GGPHWnhsJnoa4czSpGjNK6oxwDvIzTxPMRxJIfxNP63HsL+zZ9zsmlUcdaabr5cZ6VyS3Ew6SOMe9Kt1MD/rX/Gn9aj2IeX1F1Oke7IBAJqJrg8c1iG6n7sT70v2uUHBKn6rVLFQM3gKptifcT81NdmIytZK3cgbPy/TFPF7IpHyg/nT+swJeDq9jVXkAsOadj5azF1FwMGIZ9jUiamo+9CT9DTVeD6kvC1V0NDIBGVqRWU1n/2rC3BikBpyahb4GQ4P+7VKrDuS8NU7Gj0TIpASRgmq8WpWeCGdsf7ppxurNl4nA79DVe0i+pLozXQsr93734UjgfxEioI54SPlmQ++anMkbIMMrfjT5kQ4PsBcMoHemM5AGOoqJmKnI5FRNIWPQ+1O9xepY3cVmK5iut3TmrSMWyvQ1TuOJMAUyX5HUpJvt9w4qDzNp+veorGbfaL0okYMcenSkNk4lx15oLDORkCqynaDnmk3MegOKY0WXcO4zS8An09KrhgMFgaTzc9KALZcE4PSosAH2qJZDnJ6UjSMre9AEsmBytIMHgg8immTj3Pakyeo7UrgkIp2mmTHIyOgprnBznk0hPBHUd6RVhiMOelR7uTgdKRflkwO9LIMHGcCmSxyycdRzQzcdarqD5mD0NSjnjv7UhJtgOScflUb9ABxUmBkE5U0mRigbI5QflJ6CkLEKcdD6UpI3ADoeOaRgVIXFMhiqAy8nBNKqbG5Jxg1EpIbIFWchl59KBqxzflgjn0pWXt7VNtyMd8Z57U5eCABwR2rwbn1/KVzFkZoMeBgjqKsleeO3HFLsHbrTuFikIxnGSPrTwgq0YsDkUvlkDJxz6U7hylYRenNIYiAD29KtiMAgk0/aM46mlcfKVRH/sk+uKY8JbGCevQVcaM5GCAPakCHvnNK40ikISxI5/LNKIEUYU4HTFWmwMHByeOlNCgvjjOMkUylczbzTorg4fzMjupxVpITGoAyR2Oas7N3sTUgQY5oQMrAc/WmuMjp+tWguQaiKDd0zTuTykCqSvoe9OCkHAJPpVhVCjofrmmleaLk8hGuQcEA8dDUnYdqNpB6UoGBk5/+vRcHBCgBh1ORSlM5weMUdOnNKACcY5p8wvZiBDjpzSeWevpUqHnBGfpUo68cg0+Yl0yqAT1p+zHPGKsCNCcdDS+UuOG60+YnkRW2gkc8/SlC5GcAY5zVjbwcUmwdutCmxezXYhAb+9175qQO6kYdh+NO2/gaAvHU5qlUa6kOhF7oaJZRg7s+vFNaRifmA/Cn4x/Dk+opCg5q1XkuplLCQfQtWWoCCIo0RZfY1YXUITyyuD+dZwQj8ehApCh44wO+KtYmSMpYCDNRryBgCr4buGGKekyMMB1/Oscx7s4J+mKayEL8vWtFimYvL10ZuOdw68djTMkDOKxlLqc5I+hqRZ51/jP41osUuplLAT6M1N7MwAGMUrOfxrNW7nHIKN+FOS/YfejUj2NUq8GZvB1V0L6OeTmpFclSM+9Z41KNB88DfgaVNVtC/wB2RSeOVqlVi+pm8PUXQvPzx6UwNt6d6r/b7c/dc59MU5bqAAZkUfWqU49yXTkugs2Q6v8AhihlLLwPelkuIGU/vovbLVFbzo3AdePenzIlxfUCCvLjrTgFLHHBHSpHwy4yCO1RKvJ6g07k2sOYjGWHPtSEDAxxjrRnA5HNNOOR3NAmRuxz6AelSh90YJHI70gUMhB60Rx8EDpRcVmNYDPp7U4g7eKQD5sH6ZoIIXAB5oEZwTPp700p1I698VY2AjAxSBRgD8TivAPsiKNRjINSKvanFAD8uDSqOMZ5oAQDI+Xk47UCM5xil5VuOtKSOw5pgNKg/hQFDZ46elPIPHXn0oJwOvHXHegBioqrgNk+9Mcc/L9DTywJz+XtTMlj/jRcpJjBjoRnPrTsbs9BSgcY9O1K6g9D27UFEeOeO9PXp6CkwByO3pTiCOgyT1oJasBAByMmmkj7xHPcdqkQjoeOMUgUZPJxnrTERnnIAwKTBPABNTFRk4P4U5FXJBOcigZXyehAFKBjuOvSpiAMDFNKc4x78UDsRbVPfml2lucDFSlM8gYNG3C7WFMLDF4zg9OKfg8Adueacq5P9DT/ACuTgH8aBWCJMnGeamwoHI9ulLHGTjoGqz5YPX1ouQ0UwpGMcDFIwyQc5OOMGrDxDGc5+lM2Zzg4x60XEQhOhzihUI7HAPepWQgqARg0Ko7sOe47UwIipBx60KmenbrVnhh1HpQFOA2Bjrx3FFxWKDW8mSYmYHOSCalRG2YkAJ9hV0DdyQPoKQx9duM9xSuKxWKcfL/hTdg7girWzP41GVIJxgn0p3DlITHjB649KaU45GasFABlgSPamkYPX9KdxcpXMYB54pPLPPfHtmrKorAjOMHIpRFuH6c0cwchSZO2PpUEkOeg5rTeNcHnmo1XzCRjFHMxchkpySCDkcfSrCLkcD86tyWvOR+g5pUhYYx2HeqUmDpplUxLjJX9KY1sM5wK0BF6enJoMXfNHMyPZozhCV6Fh9DTx5i8rI351bVeSG/M0BAegyfaq9oyHRi90VzLcD+PP1FAubgEk7SfcVZaIdulRmMDuapVpLqZPDQfQjN7KSAVB7HtUiajtBBiyPrUTL1H86jIB7Zq1Xl3IeCg+hZe+Rjnayn2pyajB0YsPwqmQuMdKQxg5xjpVLEyM3gIF3twefamlTzj16VKFwcHHPr3NMYEjjg+lcB7I1QBjkZ70rDBwfzoUYbr145p+3JxjrSAaADxt/GkkGHO3kfWpkUAfMx5ocnHPA9aYWIDk9OOKZ827np3IqUxjBI4GaaQoXrwOx759KB2sRKMdTntQ3Qg7uac3yqB2PrTSpUAZ6evpQFwGfXinBsgYP4UIgXnJz2OKcYxzjAJOaCk7jPlI6fNnvTlyE5OOKTaWI2gGlUbjwRlhikDA7scHA6UKdgxz/jShPm5bb6UvJwHB/u8DrVEDeOe4PrTxHlcqC3bApyxlQD0ycYx2pyjy+44PWgtDRGW3AZIIpChBH94cYFTj5s9iKdgqxDqSR3oGVlYEcjqc9KkAxkEen1FEqEscEHnIzSxJ/e4I9qAsSxoCRjp6iplg+XJx+dIjlXAOCQOT7VZjzgcckcYpXExgi27cDgc0/bjPX2FShRn/PWl/jIVj78daVyWiuYwzZU9P0pjxcjBAOastGq4JP1weKQgE4AOR7UElF8hSOgz0FQhsMEAzntir08fy5XI4zVVIuTkE+uapFJDZMDbtbnGaeshOAcbfX1poQ5ztOOhJNPC5wuCOORnihjsiZdpG3pSlOAcEjHWlVBvPQk9MU/gfd7HmkS0Q4IPX5fp0pdoEgx1xzxipggJz6980FAG4J+hoEVyg3HkdKPLL4wMsfU9KshWUcHP4U4oC2R0oArpGFXkYx6ikUEr8xzUoGM4zg9B2oKZIJAxQGhEYhyOlGwEZPAHTipwWAIAyOuaFUMMk8evSi4WK6p1B5PWkEWeo561a2gdF49cUYyc5IpisVSg2njA96Y8eRnB9QMVdKA4BOMmo3TB4I5oCxQeIrk5P5VC7YbBGPwrSkQNk96pzR5UjqR2qrkkSOrDHT6jpTtxOPTOKhAIG08Y7Uqjafm6dqZLQ54y2Rg+tQtD1IxirQ2kDI7dqkMQbHsOaBmcVUjDZppQKQBk8VelTy+MZ/Co3UckqD2zSDlJmjPIU8A/nUKjDYORjtVhowzrtPyjAJzSBGLNzu7ZzWZqRbec47ZzUwQBNxGM9KdFGgQkgZWpQjAHvngE0DIRHlsMCMnk9zUMhK4B7c8fyq6YmODzioJo8FucJuxxxQWiDbtXdtOc0jKpJYDk9sdKmOSCCc5AwKQkb1baDu4wP1pjsMwXjHPOcbcYpnVlHPAzU7RbACWDAHt1BpVBAU4GV68daYWIVT5R0ww49/SkIbG0DLDj/Oan2qGB5I6gdhmnMhO5WOQG25xyOP8AP5UhcpVCZI3H5SOueBSGLpj5T0xV1YixwBx129/8mo/KYKwLH2460MTiQCMnGTjBPzYp4RioyRkHBb/Pep0DHcMjauM7ehpSgZxkYye3cf40AokSJ8mQSSO47e9PkUZycsG6jHf/AAqbZuIUDO4ZBAwce49Kc0bK/r83Q8H8KCrEWCEGO3AIpGUqMk8nn2FT+SzuVBKtxz6/4U3Y+3cTu3Hnuc0ILEHlqeFwW6nHP4g1IqllYluR0HTP4U/yg2QThlHXtU3klyCQMjlcHqMUMZAqg4B2lvcVcjiI6kD0p0ULNksCSepAqx5PGcjGOKQpEMafOVyM0pUAZxgc9eeal2Bclu5p20sCeQPftSJKzJu6Hgc0yRMsSrEEcVbyNo7MOopDGSMYBBP5fSmPcoMhGCRggcZGai2ll6ge+K0mi6hRjGepqGWDJDjj8aY0iiV3L04PfNPjO0dCTnkk1KVKNgfMcZKmmgFsfKArcZ9aBNDWTdxty+fpSBChOCQAcbc9asBPl28Y7ZP6UjRln2uMAdBjkUBYZvYZU7s9eRUqMSDnnHUe9NCdiDx8vX9RQFZVwSCPegmwpBIz078U8rkDbjmkyjY7N6GlJwD646jigVhCBxjOTQABgnHHHTpQj5IU9BznOOakzlR15/GgdhqrjgjAzn60YAGBn6Yp4Uj7qjJ9KEyOO3uaLisRKmeN3zdenWnYIyvAweRmn7cNx35zQcZy2T6g0XCxGFOORjP40NGdoOOO1SKDuAzx6Uu0AHqD+VArFV1AJx1I5GKryxNuHHPoK0MAAgnj0pjRnd9ymmJoyzCWJOc/pml8llyMD6+laQhU/X3NNEO488Z681VyOUz1gK8hePepkj45BAHFWhCNxIGT+n4Upiw/HBHPPagfKQNZysIvkGJPuEkDP+FQXcG2Z1MPlsMBkJzjFb6wJeRRPLHcAqoQ+Wm5WA9Ko6iDJdvlCnAUK3DAAcZoErmZIm2MgrtfjO3pipsKqbEUd9x7UrREKvJXjhTyaROGKqu5eo5znHasjW1xY4h5mc7SD3Gak25UFux+7UsVuwQnA257+/8A+unLH8xwMKcAnNBSREFIQlAMAEjnnFVrhSSVJB3HnsW960kiJ+ZSQP8APP1qlJCzyLhSob5iw6HGc4plRKjKQqIuVcNgY6A+/wCNOZN0mdpHOCDwB/nmptu4c/MxADcdRwM/hTiJCpJX8D3IP9aZRAAGbONzbcYxip4UGxS2Nu3ggdKWP51MiLwc8txg+1SBUVjuwwkJOwDv/hQIgMOFU4GRwCf8/wCTSQpG4DNuA5OR19qsSDeGWNXZQec9M8gGkUBciPhRgsT7kg4oQ7EaqdqHAK7yBk9/p6elNMWwKQpQg5OO1SpESNoCts+Uv29j9KkCBGJDAg8Enr7UCsRRwYk342qRhuOAM1OkQQDOMAkcjANShiqBejAjCjt+Hemtl5GUDICnHHX60mFiHGwtt9eB/SkMTOwdGGSOTU0aeaoVtwY8gkcHj2qVV37tp5A688Hscd+KAKxUktnBPR/9r/69B2FRhSGHUe1SHqgKhRyGAPQ/40gjMe4bgVP3c9qB2RLHF0ClfcVOsO9SE4xyR70QDIBzvXjtg49qs7SoJC5Q8HnrQJjNuAeSVxxkcj1oA2rtxnH504fe44OeM+lORQVwRyfQ0gIiBvzxzyDjr9RTXQOCefUc9astGVyCwwORznvQ0YAAf5lHIwOMmgTKYVifmAyBzx1FPVCp5X7vb0qwqnzACV64z1o2/vNuVEmMEf570AQBed314IpzRYXGSBg9P6U8Mcb1/EYFPVdx/iz1oAqNBuAACjnPIwM1GYAJCCuGPUHjmruxtuADtxkjOcUKBtAbOOOuP50wKBgBJ3c4/hqNx04xzjOORV0De2c4J7/0phjYN8wOCM8c5pjKAXr13dPal2O77TwDnt09asTKQ+Fxxz2poLODkNk8YH8qAsQ7Of4seuM49KV17sQAO5qaOIjocA8r3NOUApuwVYYAB6UCsViu7aBtLDrmhBg5Vth7g5xUsifdO5lBOA3cf40pQthSVJ6bugIosAsYGODz25qQIN2QccdDUYXa5yDg+lWYkJUZKlsHJPb3oFYYBn5uAOlMaPd/ATirCITwMZ9zTgvHqPpigCqqnLAAHHp2p5UnBzk9qtMqjA7D9Kb5YB3EDj36UCK/lBl7jBwBjik2kqOcH0JqcjkDHPXBpxhO7LDnrQKxVKEgAD3x7UghIbGPpVvYdxKt81IRhjxwOCehNMVioy46jBFIyM+BgAH0FXGjBxwPoaEfypQ0Z+Yd+v1pgkSOEljh/wBMEZVApTDcVn3EREzfP5oH8fr+daf2u4XkSDk8HaKgmVpXaSQgueuPp6UyUmjJERVCwyzLkNnuMfzzmpAnl7SAd4HVf1H8qkQHcCQFJ4PYEmpAuxU2MWw+SR19KyNBoU4LbwBnIJ6k9ckU9l3tiMjnHB69P8mnAFnDyY2469j2x+lCIN+Cu9SMbRj8Tn8DQNDXG452H5spg8e3FQTwsUyWK7uhPrVtWOByQOe2cdf/AK1LHl1O9VG1gBk9+31pj2Mpo1W3LORtyduPTjI/r+FKWbzyqfM/yuVI6nB/WrVyscsz4BLKcnccggf41C0UpkQp8xj4DZ5XAyo/mKZQxdsjKsbkZXcDjGKkVCTlohtycr0+tIg3lBglAJAONuB/k0/5gctIzq8ZLY7df1z/ADoCwjIqbkVg5POAff8AniiWIyggkb3XKhR97HX8etKYv3kQQnI2lSeCPf8AA/zqWVi8okUAEEsD2wRk496QyKEbYw3TgK43duqk1NJFEEL5LMPvc8EcZz+v5VKsAbcSvysCRkfe9R/WpxEsUQMh5AIwDnqP5HrTAqvEAvzY6fKG659KiiUljGAUyCwbOcsO/wBKvlPOdS2F3DIz06fyyKg2stuFPC7uAR7YOD7UAMBwDKAx28OCecHofwOfyocf6Qux8Ery3UD0JqypQkCRm8wHY5HVge/503Z+6wzDzYssFOeVyc4/CmSyrsZXchV3L1XqG/zzRHEqlUOWj3YDHHp0P0qd04DJkhTgf7Q9PyqW2jV2kQHdITwrHGc9D+FA0R28aAMhZTGTxnqOOPwq3tIVcAsx9D1pttA0cSkpksvy5OcnoR+NTom1W8s8qNykHqakTIGT5QxwwXAI9vWpsADsyj5sY6+h/KneWQWRiwbHH0ByRTog2HIOSRngYGDRYVxksaAsCBuYAqwyFz6UxBhU2gjd0781IhO3b0J5IB7+3+e9NlLoi79pVRwB/IfzoSGiBd2zbgnBySPSkKsrgugB6fU9RVklQMNyrYGfbH+RQVG4JJwpIHAPHf8ApTsMojerfNwegJ6D3qxCwMWSxOP5fX0qdtpZc/dcEA44NRNCu4nPB/LmiwaMV/lAbtjOR1IpihcAEqMjpjjH+NKkZ5UHJJ5U8YP+H+FN2LIowcNnKBjjgjp/P8qLCsMYYIKEYJ4NLHhZMKTg84am+UrPn7rKMEe9PCFmIZT6Ht04/Dmiw7BJbhQrMBu9QMEj/Go2iAkyRtjbgHGean3NCeh46gU8hQpPLDI6mgNSoluQcumMnafQUrQoQTlc5x0/X6e1WGQcFyWxzwMU2SPHzRgY4PPOPwpgVtpDAleRxjrQ8B+6GIHUY5z9KmO7d85JHUt2pCADgqNx6H1+lAEAixne3K1YixjAwBznIzineXgn5drY701d27lRnoR2AoE1fYkWMsckbRj8qfsXaMNz04pYx13nAJ6DtUpGByQSD1FIm5Aqn5TtxnjFKYU5xkDGee1SlQBweB3zTyinkHHGKdhlcx4Ungn+96ijYSpBJ/GrL7cAHHHIP4UwEZDjnPBA9KLAQbTkjAwDn0pDGGOGAHpVpQNp465xjvTNvPXIP60EldhkEY6cbvWmbdu3qaskYyv8J96j8s4+UjjigdhYLV3KEKDuBZSxxx60lySrsjIsbKMDAPpWgA5ttxjYblWNm3DBAPb61VuxvmYupTbwF7gYxzTJWrOfzj5W43Hkn19amQkja2RnAA/l/WqyjcfmIwFAHfqP881OQC6jOOxxn24/z61BRLGcZQuSQcgDkg+v05qcDDfLxg7h3wPf8z+dV1bJYBiufXuKmi4AOcuQBgmgYrKqogO0gA5I7D/PrUR4GWygRgOvXjrUrBVc7W4bG0evJzVa7dlHG0tgBgf1pAMkZRcCSY5cIA2Og45I/D+VMJdjFEFK/fBCtggE/wA/8ahj/wBURIzM+SpGMcYyP5GrHErHDJy3mZ3c5KD8umPwplMas6755h800eJEQ/xDkNj880NvjEexmZPNB+bjJOMjP1GKhtNzQS7vvKgCYGCTjjn8/wAqtoyeZhiPKeLKMTgK2eSfxBqkCZGEdpSHRiEbYMenXI/CrTq0UsaD5nQ7sleXBB6ilEsZEK+WNm3BKHO5iM/1IpkBLmNxwg6knJ4PGfpkUWC5JHJlCIm6k5yM9s/zFPRwFYEE5By2efUVGd0ayRScurgLjtk+v0BqZFKsA6YG5ge4OM//AFhilYZbkQGJAh2knCgHp8vf8f51EseQVCkHhnUfTk/XjNOgK4ieQ/NtV1I5Hp/L+VTvyjHkBnK49ARnOPbOaPQVymocSOknJVt+QOwPJH5ZowyOQ7K+1vlPTg9f51ahdIpJCy5VQFJxu4yTnHrmoSRHv2YSMEDa3UDr/SiwXIbYKJWCYYqFJU9COoH15xT/AC0UmUOwfjGeSOcYP4ZohJZmKg73U7s84IPB9jnNWPmMUezAKKA3P3hnP507EtjykZKqMjGSpP8ADnv+f86ci7sMG4c9SDj1P4U1CVRl2qV5YZGeOKmg5DxMu5S2E/HH/wBb86BXGICy/IxLKC3zdwRwB+v5UoVlVtykAjOMj5uP8mnxrmUDABZgDu9M4I/SlVB5JDLucDOM4wQeaQrlecAK+P4WHJ68gc1GyNuIdiDs5yAQeT/Wproq+9V3BDkMQOnJxkfT9Kglwrfe4OUIA4HdSKEWh6tghySAy42nsPX+WKiXIZ488Zwmcnd7H3zSt8yFGJUg8MeoGCQR/Ko9jPGWGFdTvKnjge3aqKHbt9uyAtnIPzHjjPf8KnLKZhuHJO089ajRVypc5VgeD0bHr+dNjBjJAywXpn0HQ/rikwDdtK7gTtI69MZxjnrQ+0tIrIA+47gR78AflT5SSSQeSp2/5+lV+PnUsSw+6T1x1/x5oGWQgD84JIwMnvjNIQ6FQ7AqV5OMcelI5YjP3jge2cc/nSM5xggHjqOh+tMkkAIBKjoB7/56frSNsG7Leg6g1AoCtncd3Q+9LJyOPvDqcc4pNAOkLBmJz5h4xUOSOo4PQHtTmVjggYPQ54JxTTmRQAQCDgZ/WlYY/Adl2tgj19KcQN+WGQeTj/PamRjJ2lixAwGp54YDHB9+hpibHyKQjZzkHpnP0qPYTjbg44/On4OSOQKeEAYg59KBCRo+eWOcdBUuG6E4U88inAEjuCOOalHygMR1HOaLENkWMAjb161Io4GfSlK46ngnH+FObJ5brVWFcgkjUkdznHNKVCsOD9akKjjjrxxTSMg9QB+dKwXEXG4jOO1JwD0/+tQqnHA/WgA7OTj0xzk0BchkHOOMevQUqrtPA5Bp+CSAeA3b0pXBBAX6HJ5FFirllHilibexjbYFK7c9DUF2VklJAbGMDPB4HFWt8uyIwTgBVwQWA5980tzKssUhLhhu+T16c/hTsZp2ZxKNsIDdTwfyqysjDYOCxz1PSqhLBcNyPY9fepduFC5JHUc1mWTA5Aw5JUY9sVKjEDIYHHIGP1qFWGWA5bpx0H+eakVgAG4A4A9hzSKFXICg4IB3CkLAsSq54zz7+lOU4BOc+pFNPVewA9P0/OgCKcZLNyC2M56ggDOP1qq/JEyKPlJI7554/nVtn285Vi3Bz2/ziqTuNrxuPkdBtJPvTHcsGTypYgpZXRif7w6/0OahmWQRZfhWDFQT0IIb+v8AOmo4eDdt+bkcnrnn+Yqx5qkFiAVSXcp9ARjH05qgJoCI4iQWVFYOoH908cfrVhXVmKqi7fMfg9cEYz+fNVrdCLh4ixYbSAf1H8qZG22MbupHGBnIP/6qGBeVdzKjLhyFDFxyTjH5dKlLtPkKAFOxvlPHpUAkZsvI5MijLZ744/lj8qVXKgBGY/Jg8dep49uaRSJ0OWD+WM5aMgj8QB+tOkkZgi/IylV9yoBK/nVTzQI+WwCwIAHH1H4VHFM7Ise4nK7eB+INAWL5kCyFzgbxndnBPbH41AGLxNHKdzD5WLdhnCt/OoxI8sCYchnC7Seuf8inM6NJFMzYb7jAjoTx/OmDZOoc3L8bXU9e20inJIefMUhCWXIOCpB/+vVdGxLG0WP3iYYnoDjr+lPLEhJAeOuDwGOOn1pkbl2JnYu6KDsYg4HQ9cD19qltyGkcbu4wxGeQOP8APtVZpTIXdCxKfxED5sYwfrUTzFVXeT13AA8ehP14FIVjReaJmUMAYyQcHrjv9KjVnxIgwxU7ue/I5HvxVJHyDgAjrjpkH/62amhlZEGcls5GOThhzz/npQOxNI6iRl3MAflBHoM4/KoCoZA5O1xg4HA96RsPGPmwTyAOcAf5FOEmRv2k8gNj/PSgpCSoXPyE4PAAOcH/ADmmByrOWXeikFcdge3+fSiMv5Q2YTA/oaQsvmvGuTG+MA9zj+dMBzKcqcHcpLDIyFBpYyWfDdcZ/wA/lTMspQBmBGdmBncRSk/OrP1xuAoC5N/d2AYBzzzVZeNoHzY+YA+melT7dhIbn2qKXcFZQSxQcN7f5NIRJvIUlcjHTPb2qLzFCclSvc0o3ZGdpyCeOe1SlVAZdvy4HQdKY2MOXAAz/vY5pxGBgcn6dqdGCQOSOhBPAIqRUKoTggnt3HNBJHsLAg5B9emarxhc/KSB7VcwVPPHvnFVmGQGAAAxkEk5+lOwXGIzF8EgjBAyOtSZzwSD246c0kin5SASccnoKk8vs4U5xjjH4CgVxoO8DZk8YA9atIG+VWUc9VqBRtHyjaPQDoatgEglvbGO1Fgewm3C/MCSvGD1+lSAgDLHcPSgIQ2GJznGexH+f51KFAz3HoRke3400RcYQV9M9KQkgKSOTT26dPlHXJ4pJFO3Kgn09TTYhqjJ5HU5pGUsTzx0/GnEbO2e+Dzj2poBKncQP4ufQCgQ3G1TgjGe3v7UvyhQf1NB2ruHRvU9KaxA4/iA+b39qdhCBSCGBPsP6UrDIyeCRzg9aAw4OTtPXP8AOnxbSQGLcDkkjmiw7lqMLsURxI/7sMpIyWPeoLtcTuVUDoeB046VP5aiOPyrfzeM78nr36VBJhHIdfLI4K85xRYlPU4gYAzyV6dMnt0qcNtXHUYP4elVQwILZxnHQ1aiUFeGyR8vNc5sP+ZlGT16npkd/wAacpYF+mOMcdBTFO4Fc85X+VOHXHrkfTgmgZIM4YEDGMde9NJZQxz3Oc/Wky3lkg4Ve3pxSKwDtlyQucE80XApyuysN3JxjAHBB71GYwXEbH+IAnsMdKkmYCQEjKD5to79ajdx5qs5+9jcVGcjOP8ACmhokRmG8sDt65HbqaFI8iNTyCwLducnmklTypQOgK4wD3Ax/n609gG8wkKBhcKB1OTTGTzFlPyox5CZB7qc/wAqHWMLGo4G1V+U++c/oagd5JjI+7DEgjnGSeo/Q/lSSFThFBA8rcOenHH9aYF5Wyzo5wu/aTjJ5BGKdA5dsYO4AAe46f4VAAHmzy77gMHvx19sAUJIY/Mdc5XAPvlsgUrXAkOGtEy3PU+wyRU5J88MB1G044HHeqzMVWVCCqlCxA6nI4z+QNSsSYGXOJBtck+nSnYoccRpNECCUbco6+/5daSIiUNxxuLKD78j+Qp5UFlIYAyIAxPQn/DmnKAHjKnbuwuf9ocf1oJZF8pkjXy8sAfzHFWJGIibOACCh4784qGYcfISHR84J5wTz+VSqiAyEZ+Ydxnsf8596YloDXDK4XcA+/Yc8Y4A/lUMyyg/vFACknI6D/P9KfcqwzgZOEJXH8WP/rGhg6QiSXcUIXjPQEYI/lS6lIfFMC6PlcMpBwPoalRmjZFAwqkZ98mqVpFmNUfAIJX5eAcYGfyqcnyrj53JVgByuB7c/jR0Ey2q/dVDyG27sZA+n4URlCRnPAxxz/kU+L5JYVXDEd88MQSD/P8AWoY5UJBbBRiQ/UnGf0oSEhwUquDwRyAfrTAWJJXOcZAHXI//AFVPHKHYkqCVyh28ZHPNO8s4G0KSg8wnrlemPb6VVirkXIYOeAxCnHQA8inMuGUBTt6MRztx6etDwjyZRs+WPnA9xkf1qULuk+8doG8jrtyucZ/SgQzywy7Tnc3pyT9PypY+YkOCBjgevvUpjbEQJ2uzKFPXn/J6VMn+oA2t+B7DPT8jRYCunDRsD+7wVVu2RzgVKRsQll2jPGR+lOjhA4GQqgEEDOCRkj6U9fmU4ZBkAHvkk9B/jTsSVYdvl7lOdnBUn/P1p+wo4VSFRuTnkAipZYgrFQp2lAAMYOD3IpHkXnDK4OA3IOMnHI7c0WC5GQQrsRgLkE4xz2NRuFw5dht6n5uvt+XepbuN1Qpj5xlvk9O+PWlUCWF/L/iz8zHqcdDQiWRKI9oxjYR6ZPt+P+FOjAcky43cHdjlhUkRQpvVUxjGG+n6GpYoxgMGI29cL0H8sZpgNWJmRSBkMCCMc4/z/KpVBUk9xwRnOPT9KFcMAyoUweSvOD2pQXwpxhWBIJYZJ9v8KLCuSx7g21GyqjjB+Xp05/GmeZuO1WwoO5RyRn0oWXaxJG4tycqOeR2pXVQysw2leM56mgQjkbM9WJAPHf0pBEAo3N14BBHHrmnqdzneTyBtbHBPv9KTzCwJRQW3AbSuB+v0pgNeIgK0jBQMAgr7dajuPvEABcrn5TkfnT2UqjgqDjow7dsVEXzICybhySQMDOOtAhEwFYvHndxgnkH1pVO5wrNvI5x03e/r/wDqqB8LG/KhhgKM9Pp7U+N3ZmYZQngMvQj/AD/OmJiylslQF55OKcCVQJtMjkDGOKVS+5d4y3XdjnPrigTtA58tlJJ4+XgUgJsxvEmZZI2VQCoHA+lV22GVyrNJjnLDBH1BqRb2Qgsz4xwSUH51BO/mO7PtckdVGMn0pEpHDCRSVYkjHr25qykn74KG+624Ej2zWWH4OzO44GT0+n8qmV/mJJBzk88fhWJqjUEhCgK5AznpyRmleQE9DnHX0GMCs1X27eOG9KstLucclTkBWx/ntQVcneT906pkEjbk+tRlm3SByMqMfjUYmBbJfcTj9cU122ow7NyT69cUBcllVTKoLYjIGMdsio7Vis53fcIVd4Gemaj3ElgBn+E8/j+lNJ3DjIDEEn17f1NMEyUSK1yJpNzFFC46EkKBSx5CAZy2whOP9rg/rVcttMeG29cnHrinvKVVCBhhCq8duM/nxQUTyTKkrqg3IjtwRg8j/EUk0qLsABz5Plf8CamS3C3LqPKUESq24nkk9R+dM2LKYAzBXI3En64/pQM0INyvMwDfKMR5P8XAOPWnpGAxVXK+awK98jnn8xVa2l2w+a5f90+FUdQSR1/Cp0/1iTliBDBke+Bj+tUhMfat590wAx5rABWHQbf8/nSyZZiyt/ywDZA4we34E4oiVlEU5yJIRtdT1J5YfyxTg5MrqgDNJGoweOcjIpjTJY4cQtHIzfIhYsOSuOP5jge9TMmJAAcMFWTAGSTg8n24zVaKdZdQjLYTzYwoVe57AfzqaFwZIXUD5htVT32gAfqentSEwtYvPeJmyIGibgHGOcZ/l+dSKzyRQEPvaVTwevB28/l0qOzAihjZdxXbmQ9AMMen6U62lEcsJiXzFCMqY6ZwOfzNOwk9RdjRl3kfd5J+cKOcBhg5+hp+0JFEVCyCMdx97kDP5YpDGjrKEk+Z8xAD1BH6cn8hT1eWa7GxUKMoUqDwOMgf+O0WGOuIwj42lo9+S2NuDgDI/SqtxG8UEiYBZCCue4z3HuRVqUxmyzGMpsLICckHJ5x3HAFOkkjuJ5EaNVRx5gAzgcgnHucd/WnYLkcBS5WVlBjcqGAzyHJ6gU3TwPNKSYbD7SF4GP8AH/CgqEDeYoZk2seuVX7uPyIpGjEMcz8qyyDPPA56flSAuShY5VKcrsCyMf7wyT+PNTS25Fvlj8uzdwc84zj8u3SkYQzQE7cNIC+E6qAOP5jrTEn2zJMrtnY2AB90BTxiqJuG3zDNLlfmYknrkAjjP4ippIpLe3mQj7gO09QcjufpUMX+iwlPvIVwyZHXHGD+dTzSBIz57CRQuSE6sT0yfbFAJkihZZI1yVwQwweVHt6npVmGWO2jkiKZeFTnJzu75/EEfrVO1idnWMk4Kjg8dF56fXNMmCvHI27Mv3iP4QACCvrjAxRtqMsrA0UqBnZQVUHI7gf/AFqQx7oWLAL5ZAZsY4OCPxAwaieR3RjLIfLxuU7ccnnp2FSPNmRmY743Xa5PIz2P0piJZleFlQKzswB+9k8E9MdKiMaSyMIsxsy5Y7QC2CMZ+gpiTlVSESDBBJbaOQAMfpTDtkuS5woHzKc4OcY6/gaCWSMrIJFncq6Lj5P4wT/PrxTzEg2ujbkJJDcHr/Oq4kDDln3gbWUtn36Uu5lZgOE6jI5B/rzSBEjoYpR5BySd6kevHFOmmVhGSScAE7hgdTkH1qsJhtbHyh2Az2H4frTJJwJGYkE5GD0wO/tQJsuxyFE2jCBifMIYDr/D9ajQ+amwYQdAuOEPuT+dVEYGTO8qCRt3c7fw/CpN5C4UEZBPXgj/ADmlcZbEhZg20BewPHt9KUykFS5BJAGT+oqmkpWMNuAPGM9ucdaGujjEfRhyMdOKdxWLsku04VFByR936cf/AKqRiu1w2cdMFTnPrmqYmZirnkg+nQ0izFmG7IwPrQIszFsFzjaSRlTj8cVGwChghUj1FRSSgjhlQnIwOaiaZcAsxB4HPQ+9MTHlhuD7V3A49M8UjSM4BXPvzyKreYAfM44OTxgU5J13dfoRjrQybllpNvO4Ng8HpTfNRHVhHlfQ88+tVBJk5PR+571GZcKNwII6fWkNG7GWEas32RARuIK84PT9aqXUpSaRWVNw4JQYH0xVaO4cGFZYhtmj8sneBkA8N7YqC8l33MhdNjAbQvXGBjrQJaM4hn3JznHFSF9pAyeAcE1nwyknII7D9KmWQsvXkiudM1sXFmYcAcj+L0p6N0wzYz1NUxJlWx0749akR8kngE8D2p3Hc0Q205QBT1/DFNkmwDk8kY5qskhZQDjnjNGcgH35p3FcsiUrJnO1M9voM0RNkAAdMDHXnFVdy7CB608FVAOcZ4+lArkrlQqEg4xg59aHfbbtknIPB7471H5nc/dznBpjOWPyHoeP50DRPDOXut4wCYy5I6cKQP060itvcFyD5Y25x16nI9+apqdrEhQDtwB17GpSWJnxlWHLYHA5/pVGhq2b+Y7M6gRlyUB5wSM4P44FJG3mxESADCKCPTI6/p+tZ8Ejrb5PVSWUj+9xU24+c7bQEKr09cDH8qYGhJIfLMxIJJVuvb7tCktLCEwrlCep79P6VRDfu/LUAsuSS3Q5IPH5UhuJEkiZGBKAp6544P600BqRMubYIF2kOo4+7nHP1HrUjzqql5DzBtZFbtuILZ/L9ayln3yp5TCLZwM5IPGMn8AalmnWWKTavDKQGz6AcUENmlC7W0U4kZ9wIbGcgdP6H9KZLG0ReFnb9wGLFT1ORn6dKgRyFZZCflG0gnuPWoJbh2e5EindKPmf8M9PrQxxNOwdUZVLfKBv44LEnOPwOal0643uj4ymFQgngnd/9c/nWQJQ2d7AcHDZPzEt1q1bTtFAyKqsqvg4H3sEYJ/KkmUX1bFrIuAokbC5PTB4we3Xp7VNbygPIpfJDAFuhIOCT+dZil49gY8FCW9ARkY/OpUuWV3lPzLJ8pwehHP496dxWLVzIJY5+QSFCHOeWJGSB7Yp4ZRFMskgDnBwMfN7k/nVMXMLs4ky8hyQVIGOD1/Onu37xjKEG7BAxkY6jNK4FlZUit43XDS7MgnvkD+VKkh8xo2AAkA259sfzJqkLhXaJWXGCSD78fpTXm3MWJ5C7Rjryc5zVXBo1RcK9vv2bnDeWsarjuefxqbAkt3R1PmuCoPfjp/n61hRyAQrlVzt+9k/5z9KnjneOUMJQpUDg5I+tFxWL8krmWIfdfYPmU9T/nPFIZcwrJtzublh/D149azjJIAXbdx0YdhnOfxp7SEIfm3KDkEjt16UhmpFOE3KwPykbT2xjjNQictbhF5ycjPOPcdsVUZ1Y5Y4AIzzwOKiMip338evancRca4MbqGdSQAMsuCw/pjrn2qY3EgiK7sIOQxHJ/EVk7y2RyOc9e9OEmUKZUcdRTuKxpi5yAWzgAAMOvSkLnyyrN8xOV4yfp+dZYkJyFYDHfvUiSqAArMCcAj/ABqRM0DIAGVWwvUKeOajMhLY7Ecn6VWjlUjJ5XvgUrSbgNuQpoJRZDgJJGzYJ/2Tn25/pSiRVA4PToedp9BVPK4IHJPqfSmSThUOT0wBgUDLxl3DqDtIyKjeVlOM5xjg9ves17k+xPemrcHeG4yOeKBs1zOc5GPfv+NDSqM4+bj7x71mJLwecD19ac0hZSWIHtQSyy1xtXAyW+n9aa03JA5H8qr78rgEjb0wMVGXG44yF9enNUQ9S2ZUy3zZ6dOmKaZgoUjuenSqpkXJwOBTHkHGOpPAoGXTPnuM549qQFpW2qCWIJwKoLOAduQTx0pzyuBkHkelArmyIftMUTz29yWVAoMYBDDt16VSv5mFy+9DEcYCHkgY4pkk1rbrAs0U7yNGHZllIAz6UapHDGsjwCRTGyg72yCCMj8faglS1PPoiSvzHPoKmjky3Q46cVTUEHr2qWNgmMfrXMjW5cDs33R34qaN8gbuuOaqRSgDk5JxUiSfKcnr7daLDuXFk9+3FSeZx71R8zbzz6daUXOcc471SFcubwAfpxSb8rjOMjpVQS7MnOc08SB89jnt6U7jRaDjnPK96QkY4JGfeoFOFJz1GOaYHOB6+9CGTI+XQN+lL543lTyW4x71VeTD5xgdMCnwzjzF+Xjdu/CnctF5JGCMBjjB2+n+eKmEpKynGFOBn6VQjk3hhnPapvMAj2of9nAPWne4iyxACYbaemcdc9abAwWSJXyUL8e/YVAzl+ByB0qZR+6B6kDAOaaC45xuUDIzuzx6A4qRpN2FYYGMfp/9YVX3sSw65wv0py4LHJxk55ouDaLgcyFucjnqetSGMCPnIOMZ9ahgAXAxkA5yam3FlB65Pc9KT1J5hHTdluAOOB0FTJKECg4PzAn2qF2A+/0Pp1qRXAz6j1oHzDonOXLMSSce4/zmnmYFSAq7eD6YqsPnUZY4zkn0/GnqwQfrzzmgdyaBERCSfmx1J9amllZgSeg6AfrVVJdy4xjnPWh5ckcfKvXNBLYpk5yMgdCMdO9OLE7AQAc4AH061BI4YhSQO1NZ2RX2jp70yuYtsxVWVsYHTHQGmwMWdi7AjPAxVT7QRzuPtzSoeeSOeOe9MVy60pMfA29vrTg7Icjp6H096pZJIKuV5/GgShTsZtx96AuW3lYIWQgHHtQpL+mffpVNXDHGcGpo5NmeTkcZx2oE5E7Z4+bvnrTgoOQW59u9QiVDgjjA55pjzBT8mSR6UieYnPy5CgD3oD/L90dvxqBZl+ULjPekM5Y9OB054xTJbJ0c529R3NOkmx1PHQEdKp+cqfMc5xjrUU0y9weelNiiXWmCffJBPNQy3A4w5HfHrWezEx7s5PYd6haQtnGcHjJ4xSNEaDXCEhsEYOMY60NN5jKoPB7YqgJflIBDe/eiFtjEkn8DQK5siTauNxPb6UpmBxjB+tZ0co3YAwO/NNMoDHBOOlOxm2anmjG5unpmq8swzjOPaqJmO7G79aYXA5bv0AoEaKzDaST+FRtN83OAO1UTNjnt9aY1xn3PrQFy9LIB9zjFMebG0MfxrNNxznOTUUlyD1PFUK51Ud+tlBDHLcT7nUOFVVYRg9Ov9Kz9TmlieSB52kUHzAT/ABZGcn3rNTWSsSJPbwT+WMK0gOVHpwefxqLWJ5Fvn85xI7AOTjA5UHFFyOphu5zkHn2p27A681WBwo4JBHXtTs5wST9BXLZm9yyJNuPUCpVm559eaoLJknH6mneZjBPI71QFouSOuBUbS7ec9u9VjOB0J+hpFfIyw/8ArUikWluCR8p61aicgcHOe+elZkcm2Qg4/wA+1TxyAn5c8ZoLNVGXAz/+ulLqzYyeM1QSTIzjmpC7NkjqaLiJX2EngnFPjKnIYY/GoO4B/nTxwG6KeuKYKVh6k7wQRVqJgRgEZz096qKRnrknHapMjcMnHamhuZeTqOeKfnB4OcVTEgUjByfrTxMQR0/CqM2yyGIODjHXpUyMmQzAdOlUTLluueaeHJ5PT0oFcuiUg5/GlDEAAtkD0/xqpvwev1pTJ8o96ALvm8BgeR605ZflK4BOOfSqG/B65PvS+Zg4HU0DLxkPA/hGMmpVdf4BnAP4VmtIduB096ekrKMZ6/jmiwy8GBzjAXJz70x3+XAOT1/xqsZSw+Y4pfNJDY79/enYVyZpeSGHQ0jMSjbcgDoT1zVZmOAe5pd/Bye1Argx2EnqPekBYnOenPFMJA4XPvQZgvyg9eeKY7lgtnHz4OO1MZuQvLHNIki54AzTS+7jpzxQLmJo2IbJqZXLAZFUN4U46n3pTJjgNz7UCbNASBVwQM55wKHm+X07VnmYDpwaPN7miwi5uXAK8YHegyKSP6VSM5wPQetHnLgHIFArlt5QM4PbFU5jkHJzTJJ1P0qNpv8AJpjTsBmK455z2oZuCDyAetVzMD1HNKJwAQMUrDcy4rALzxSCQDOcD61Ra5yOtRtdLsJPB7UyHIvmXqRk+1NMwxgDn0rNa67FsCoWvPlGPzzQTzGr5+R0+b0BpjXHoTk1lG84PzYqu12OdpoFzGu1wAOCT9Kikuju9j6ViPd+5/PrTGuwTwSQB2p2YnI2XugBjdTIr2OKdXnjEyDrGWK5/EVhtcuw+XoKv6Np9zqV/HDsmEbZLFF5IAJwM9zjFUoSfQzlVjHdmrLrOnj72lRZP/TZ6ztV1UXd282wR5AUIDkDAwOfwrSt9JimbbJpXkp0y903mfljGamuvB9tbXrRvcyyJwQuNpAIzg+9bRw03ujmnjacepz+8kDBwMU8NkdcVUDgj6d6VZeMEgnNcNj00yaRiSMZOOoqubg5KjgdqmLg/U1VaP58g0DTLDliqkdPanKWO0A9sYqIAgEA4HY0oY7hgj0osFyyAM5Gd3XFWIThSOhx0FVFkbkYqQS88ZI70WHzGhG+E68jv1pTIABWek7AkdfpUiytz8uARwaVguXUk3jg55p4PHJ79KqR5AAyAakDc8fjTEWo8Z+7+NBbLdcYqBHyfrTy+DyBxTHcmVjnJPHapVYZGDzVHep4JP4VIsgXjoMUxNl3AKkk4P8ASjztuAATzVQ3C5B6mlDKBx09BQFy8shJPBA6H2oMoGefzqo0o2g9KQTLjPX3oC5cEuRk5NL5oGOKo+aASc5z2pROOmDnPpQDL6yFsdNpoMgUcVSMhGBnA70hlUngceuaYXLxc8HIAFK02RgYx61TDgKc8mopJM/dx6YHSgRdSbP165qQPl+cdO1Zsbc/NnPpUxlJGMgfSmg5i60mBgHPPrTDIGPA/GqHnnH3hjHWkE5HTgUBc0hLhcjHpTWl3Acn8KzjcDBBz+FI0oB65HtQTc0vMAHJqNpsD0z71mNNyep/GkeYlucGi4Gi02TncMYqP7RgjJDY9azWnznGOmODTFm7bqYnI1RcYxxntTGugeOlZUlzgdartc5HU4oJ5jZNzyDk003QJ5JNYzXRzjPJ9ahe8JPFOxPMbL3AbuMVGbkZPI/CsX7Ud2cD8aTz3bAAOT2ApqLZLnbc1pboAY/yagN3xwelQw2F7c48q3lYepGB+ZrQt/C99KcyvFEvoTk/pWioTlsjGWKhHdmfJd9eaha6Axzz9a6WHwrbqR9onkf2Uba0rfQtPgYhbZSQOC+WNbxwcnucs8wgttThQ01wf3aO5P8AdBNXYNF1OcZFuyKf75xXfwKioURFTA42jFRFyQe/vW0cJFbs5pZhJ/CjlIfCkm4Ge5RP7wQZrRt/DdggBkEkxHXLYH6VsrknB6GpEG1SCa2jRhHZHPLFVZbspw2NpCB5dvEAP9nP8604Ee4dEgYLJn5Pm289uar7Rt96daRPPKscXLnp/wDrq7JbGPM29TXb+1ASrXMIccEmRMisu5jkjnZZXDP1LBt2fxq1cWyTSEy39s0p4PBwfxx+tUpYnt3aGUYZfQ5H1pRCR5akmSDk1IHAb61nrKAMjFOE/uK8Gx9WmXfN2k+h/nT/ADBnmqDSZOSacJvoR60WHzGkrhlzTWJzwaoiYg/eqZZweAcU7BcuiUAccEenek34PA+X3qksgByvf3qRZB9frSKUi4JAR1xUqtkgbuKoiYA8Dr2p3mADGQD2osFzQ34xj8zUpYDHOCazhcccGlMpIHbNFhXLwn6gk/SniQFeTmqAlbtigTYA6D2osHMaAcelBlxnnpzxVDzSepA+lL5yjkkn6UFXLwlPT1p/nAjGTkVmtNxxx9KVZmPrmgLml5vtz60wSkdSBmqfmep4+tIZM5AJJ/SgXMX/ADcimrMe5wD3qj5pzyCKFlAHfBFMOY0vOGOaRZQw6YrO889aDKAvJGO9Acxo+dgctkZ7U15hkE1mtcYAwfzqL7QCMk5I9aLCbNQzZP17Ued74/rWYJwcZ4NOFx83amkxcxoeeR15pTPn0rKkuQM4FRPd4zgj86aRLka7XBB44qGS6wMbunpWO9yWJAY00OzHCk57gc01FkuaRqm6HdjSG7GMjNVYLG8mx5cEmD3Ix/OtCHw/eSDMzxRg9idx/StY4ectkYSxVOO7KZu+PcVE1w3c8VuxeG4ioM1w7eoUYq9Do1lEAfJV8f3uc1tHBy6nNPMILY5Eysx+XPTtzU6Wd5KFZLeUg9CVxXbRRxxbVijjRewVQKSVTk5PFbxwcVuznnmMnsjlrLQby7uViLwxFv77f4Vvw+CkiH+lXbOc9Ilx+pp9q2y+if3xXYSkmMHFaxw9NdDnljKsupzVp4c0yF+bcye8jZq+ttBE+LeGOP8A3VAq3J8rc1XY8k55rXlUdkYSqSluxNik/NnIp6sqKAB071HkNkjn1xTWyKZK0JH2sN3p0qEzjfj8KUtkYAqHZ82aCWOErB8YoBO/AHvUjDLIxHFPlARg2D7U7aDEZcqOx9Kan3uetEkm7DCjfhTnrSAVmA471LZSPFco0K73zjZ/ezxiqjv7VYsblbe6SRw2wZB29QCCMikwT1NK9itraNTPYzoT0HmjB9s4rP1CSRrpzOqxtgYQHhRjj9MU5LtIDJA7NPZvweMH/eHoah1S4inv3kgJaMqACRjOFA6URVmOTTWh4kJeOeacsh9jk1nCU460qygGvEsfUcxqeafY+1KZcgdRWd5pJPAP0NKJKVguaSzY65NOExHQCs7zMilEmeuSPaiw0zUEvH19KcJAe5NZqyADtThNyOlFh3NJJO/Bp3nY/Cs0T07zsf8A16LBzGkJe+cnr0p3ncAMSB7VnecfUGl809ytFg5jTWYY4bFJ5w65zWcJxgHpSG4AySaLBzGkJxjg0vnnPJ4rNWbIzkfnS+aCeTRYOY0xMO55pwuMH2rLMvHIHFKJePQ0rBzGp53fBoE/y1m+c3Y0hmIosLmNEzn1pDNkDFZwm9SaXzDnvTsLmLjTYOCTQZyMHqD2xVFnyQd2DVqG1uLgDyoJXB7qnFUqbexMqsVuxXmz09aUSHPvWhb+H72UbnWOFf8AabJ/IVoQeHolP7+4dj6INoreOFm+hzTxtOPUwQ5XJJwO9CF5f9SjyH/ZGa6+20uyhJKW6lh3c7v51ZiADEAAA8YAxW8cHbdnNPMP5UchDo+oTn5kESnu7YrStvDQ2g3FyMdxGuP1NdABwcY4p47etbxwtNdDmljastnYyoNEsYXG6Myc/wAZrThghiIEccaD/ZUCh1BbHanFT2PFbKEVsc8qkpfExTxJ8tSKCc0nygBu9MV+W5wKqxBKw9BTQcnFOBAzk9aiICtlf5UkgJAMHr0oY7hzQMAU3POPWmIrSLsfOc45rrrN/OskJPOK5WTBc5HB71ueH33wsmeF6UwJpuB+lVmfJwBz61busnIFUGIJx1NIBwO1SM9aVCCOvSoWcBhzTWuFXjilYCYY5IPFJgFic9aqGfPQ0eaT0FMC2XAQZ5NRtLuQk54qsQ7EjNPEZKketAD/ADgF7fWmGTIGc0qW7E4xxU62vPOKAsVwc1NDE80ixpjLevQe9Sm3VMGrVnsinBl+4ylCR2BGM0mgS11I/skTuYh9p3Bd+8oNuPXHXFVJrOWKVo2A3DjjofeuhEf7/wC0hTvx9/evl9MZz1x7Vn3ciy3DeWSUVQoJ7gDGaUXcuSSR81BjTldh370UV47PpR+8gDvT9xDY4oopCFMhDdBzT1Y5PtRRSYx6MWzk9KVnIxjvRRUiHhj60jyMKKKAHhzS+Yxz04oooAb5jck84oDtuz3HSiigB6sRin7zkUUUDY7zCPSgOcmiimhChzxwKCxooqiZF3ToFuZgrlgM4+Wuqg0CxRA7LJIf9t+P0xRRXZhop7o8/FTktmaVpZ20AHk28SZ9Fq+33TRRXda2x57be4gOFXgc1G5+boOtFFDIEVjk00HAooqhdRUY7xU2eSMUUUANHBBp+fnxgUUUAgmY7Kapx0oopAhxb5RwKex+boOlFFAxqtyeBxTN3zduKKKZKEkPzjgeta3h9sSSAdPSiikMm1Wd4z8mBmsT7Q5cnIoopMT3E3luSe9TKikciiiqGWIo12dO1TJGuPuiiikgJCq5xiliAGaKKCepYTAPQU2T73QUUUFA4Hl9BSxngDAoooF1IycE8Cmo3zHgUUUID//Z);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    An erythematous, nonscaly patch is present on the leg of this patient with patch-type granuloma annulare.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f36_23_37232=[""].join("\n");
var outline_f36_23_37232=null;
var title_f36_23_37233="Deep femoral lymph nodes";
var content_f36_23_37233=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F74932&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F74932&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 537px\">",
"   <div class=\"ttl\">",
"    Anatomic view of the deep inguinal lymph nodes with deep fascia removed",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 517px; height: 417px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Mann WJ, Stovall TG. Gynecologic Surgery. Churchill Livingstone, New York 1996. Copyright &copy; 1996 Elsevier.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f36_23_37233=[""].join("\n");
var outline_f36_23_37233=null;
var title_f36_23_37234="Left right atrial pressures MR";
var content_f36_23_37234=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F64953&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F64953&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Left atrial and right atrial pressure in MR",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 400px; height: 234px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCADqAZADASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwD6pooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiivkD4T65rl18OfEN1o+sfb/ABWujzvHEup3VxeKBOoZzA48tSExtKEtyvcmgD6/or5qvNQ0ZPhrqc/wx1vX7vUzb2zau6XNxNNHEZF82QB8hZsbs7cEDccDANdp8Eta0a/8T+JrHw3aTLptmkIjvF1ea9hugxba22QDy5MY3AE8nBzjNAHsNFcl491rxXo7ad/wiPhNfESytIbsHUI7QwgAbQC/UsSTkZwEIx8wI881m++OXibUoYtE0XSfBVnDH5jyXt7Demd92Nm5FcgEEHAQfdPzcgUAd3/wld9/wuj/AIRDyrb+zf8AhH/7V8za3neb9p8rbnONu3nGM579qxvgH40vfHeh+JNVu7lri2TXbmCw3RLGY7ULG0aEKBkgOeTk+pryLWda+Knh34rahqN94Xt9c11PD8elwz6IsjQossrPFcOpDE4kjlBBCA7ewwS/4ReIdL+Cl94q8L6+t3dat5mmmCzso/OuLq4ngUyRRqMAhGbGSRkEY5IBAPqiivJ4fjLIYUM3w2+IySlQXVNF3AHuAd4yPfA+lEnxx0exaKTxF4X8aeH9PdtjX+qaQ0cEZwSASrM2TjAwDyfTJoA9Yorx/Vfjpp9xbSN4E8NeJPF8gRHWSysJY7cEuVKvIy7lICseEIJGM9cUX8dfGOHUZoZfhhast0f9CEepRkQhRlxNIGKkkYwf3fP96gD26uA/4SHU/wDhfZ8N/aR/Y3/CM/2j5Hlr/r/tXl792N33eMZx7Vg2njP4sqP9L+FMEp2j/Va/bx/Nk5PO7jG0Y9QTnnA5KLWPiLL8aLjxCnw1ze2/h+Kwl0/+3rb5Y5LmR0l8zGDkxSLtAyNuSeRkA+iqyvFmr/8ACP8AhXWdZ8j7R/Z1lNeeTv2eZ5aF9u7BxnGM4OPSvMJ9a+Nuq3M02m+FfDegWtugdbfUr37VJdNhsqrxNgduoTnHzEZrjfHni74sa94UuvBl58OLy11nVIVhfUrC432wRn+YEgMihkBQ7peN2eOBQB7j8NfEM/ivwHoeuXkMUNzfWqyypCTsD9DtzyBkHgk46ZPWuP8ADfjvWPEH7O974zl+zWmtf2Zf3CG2jPlxyQmZUIVy2fuKcHIJ9uK8Z+Gfx707wb8GLXR4dK1a71uwSWKOdoVazE0kkrxK7eYGxjtgE7GA6ZrDsF+Mtt8Erey0vS4LPwXFp11NNOpt/NubWXdI7OJHLABWfbsVTg9zg0Ae9+BPGPiTVviRomm63Pbpb3vg6PWprSC18pUuJLgAfeLONqEKQWwSCcDOBW/aZ+IGt/D7QNBvPDkkUdxPqA83zYxIskaoSY2BGQGJGSpDDHBGa8T0r4l+N9S+JGi6r4O8Ft/aj+HotLjt7pJJ0lt/Pz9pDDy9qF8LuJ2jByfTK/aCX4rahZ2eqfEjT4NP0hLjybW3tZYTFHKyZOAjs5JEbHLk45AxnFAH3NXkHwx+LN94q+KfizwbqGmW0f8AZM120F5A7LuiinSJVZDnLHcSWDAdto61w1/+0B4v1fxRdReAfA15f6Rp3lrfQXNnK14rbiGU+WxWMnBUAhj8rMQeQPKPhN8TYPBPxe8TeJfGenXyXOoJcx3FrZwAPDcSXCSMpSRwVAKsMEkjgetAH1h498a3/hz4g+AtDtbe1ls9fmuYrlpA3mJ5aoVKEHA5c5yDnHbrUnwu8V6t4qvPGP8AacNhFaaTrlxpVp9nVw7LEeTJuJGcMvIx34HFfNnjz4k+KfiV458HXngvwzd2M1tNeLok84DG7YhQ75YCMFAikjLKpzkkVu/Br4j+J/B0/inQ9Z8E65rurtqcmo6hNpsYlaOeZU+V0jUqoOx2yD7BeKAPb/jT411LwPouhXekQ2c01/rEGnyC6RmURurkkbWHzfIOeR14r0Kvkz4tfEx/irp/hLTfCWg6tZ202vW4h1bU4vLtxc/MiRZTeD9/cecgKflPbubnxF+0HA6rH4N8LXAK5LxzAAH0+a5HP4YoA96ryz9nrxnqXjnw1r2qardi6VNbuILRhEsYS3CRsi4ABON55bLc8muJlg/aGut/iES6PaTwyoqeHUMRSWPK7/mJIwcA8yhsF9pXgHgfgj8Qtb+HOi6v4SsPA+q+IdattVnlvorRyRbYWKIDMaSbjujkBPA4GCc8AH0F8KPGWqeK9c8dWuprbLDo2tS2Fr5KFT5aEqN2Scn5c59Se2APRa+UvhD8S9R0NvHlynw88T3+p6lrVxeCOyhklSOQnLW0p2/IYywywUk7+VGBnrbLxF+0C2k29/H4X8N3P2xfPFtNmKa3VicIytMmCAAcElhuAPIIAB9AV5P8Y/HWseFvHHw30jR5LdLbW9U8m93xh3aLfEm0E/dB81jkc5VecZB5O51v9ojUovscfhjw/pLTMqfbo5YmMA3DLYaeQEY6/IxxnAzivLPiDqXjfTviT4S1v4sWQt7PQLmFEurKFSt6Ym80snzYZ32gcbVXIyE5FAH2vRXkl78b7extJrq+8AfEO2tYUMks02jBERRyWZjJgAeprn9b+MviHxR4hTTvghpNj4jgt7X7RfXV4kkKoxcqsY8xogCAM9Tu3cAbGoA9H+GXiu98VHxZ9vhtohpOv3elQeSrDdFFs2s2ScsdxyRge1Zv7P8A4r1bxp8NLPWNfw19JPOhkWMIsiiQ7doAAwB8vGfu8knNeIfDPxn4y+FzeIPCkngO+8S6ul6upX0mnTMwge4giYIwjicZ+U8g4zuxkDJvfCH4m6x4e+CFjpmg+BPE+rapAs4tLqLT3ksZS07tuLr8xCliCoHJXGRnIAPqeivApfE37QiSuq+CPDEiqSA6zrhh6jN0Dj6gU3/hKP2hv+hE8N/9/wBP/kqgD0Txf4l1HS/ij8P9CtHjGn6z/aH2tWTLHyYFdMHtyefWur8Q6pFomganqtwMw2NrLdOOeVRCx6AnoPQ18y69ffG7UviD4Uv7zwdoia1pUN7cWMEc6eXLG6xRTF/9IP3fMjwAynLdwDjoPEWpfHnxDoF5otz4G0G3t9QtJbO5lF1GSBIGUsv+kHbhWHBDcgnvgAHo37Pmt6j4i+EHh/VNbu5Ly/mE6yTyY3PtnkRc4/2VAz7V0/jzU7jRfA3iLVbEqLux065uoS4yA6RMy5HcZAr5+/Z8+LdlpHw003w/beFvF2s3mm+aLmTSdOW4jTzJpJF5Dgjg9wOQfSt3x58c/DN/8PvE2jahZ61pPia5sZbFdHvbF1n8yaIBWz90J+8z8xViFJC8qCAeyeA9TuNa8DeHdVvipu77Tra6mKDALvErNgdhkmt2vnTwR4v+LnhfwrpNtqHw4g1XSYLOC2smsLxUmKrGArSANITlVGflUZ+oFdA3xW+ISrGT8HNTxIu4Y1IHA3Ec/ueDkHg4OMHoQSAe115xqnjHVofjzo/g+3FoukTaO+oTlo2MrPvkUBW3YAGxT0PVvYjh/wDheXjj/oi/iT/vqf8A+Rqw9D8c694h+PHhvVdV+HWvaO0dm2nyf6PJK4SWTCyuWjTbGrE5JyBlj7UAfTdFFFABRRRQAUUUUAFFFFABRRRQByum/wDJU/EP/YF0z/0ff145omji8/bU8QXdwrJ9i05byAsp+fNvBASDkf8APRxnkcEdeR6zDJAPjPdxxySi6bQIWlTcdhQXEuw46EgmTnqM+9Nt/BckPxluvGiTRLbTaKumtCCxd5fO3lzngKFRAAOpz0xyAdtRRRQAUUUUAFcrpv8AyVPxD/2BdM/9H39dVXK6b/yVPxD/ANgXTP8A0ff0AdVRRRQB4R+xnaSW3wluZZCpW61WaVMHkARxJz75Q/pXRf8ANrH/AHJn/tjWv8D/AATe/D/wBb6Hql1bXN0k8srPb7tgDNwAWAJ4wTwOTjnGTD4c0mXXv2etL0e2kjjn1DwtFaRvJnarSWgUE45xk0Ac38Hf+Rn8P/8AYgaR/wChy0ftTf8AIseEP+xns/8A0CatXwTpH/CP/FCDRvP+0f2d4N0+z87Zs8zy55k3bcnGcZxk49al/aC8PXGv+EdLltZYoxpWr22oyCTPzou5Cq4HX94Dz6UAenV8ffCXTo5/2tNbvHmXdBqmrukat8wIZlywx90iU491Ppz9g182/AzwXfT/ABv8d+MvOtRptvrGp6d5RZ/OMplVsgDC7drdSTz/AA9GAB3vxE/5Lt8I/wDuL/8ApKtZnwY/5LN8Yv8Ar8sv/QZq0/iJ/wAl2+Ef/cX/APSVa3PA3gefw3428b69Nexzp4guYJYoUjKmJY0b7xJ5JZ2GB2UHPzYUAw/j7/zTj/sc9N/9qV6rXl/x0t5bmT4dJCu5h4wsJCMgfKqysx/AAmvUKACvAv2fLE23xe+MjXEKC4GqIyMQCwSSW4fAPYEbCR7D0r32uK8FeBj4a8ZeMdfOoi6PiGaGbyBB5f2fyw4xu3Hdnf1wOnvQBz/wC/5qP/2Oepf+069Vryr4Bf8ANR/+xz1L/wBp16rQAV8//tcaU+tWXgfToxua81lbQKsiq5Mg2jG4/r0HGeoz9AV5Z8YtAu/EHjD4axWPlBrPWhfytI2AIoQrtjgkk7cAepGcDJAB6nWfpuiaVpd1e3WmaZY2dzfP5l1LbwJG9w+Sd0hABY5Zjk5+8fWtCigDyr4d/wDJdvi5/wBwj/0latD9nePyvgt4UXEYzbM37tNg5kY9PXnk9zk966XRvCljpHizxH4htpblr3Xfs32lJGUxp5EZRNgABGQeck89MVz37P8A/wAkZ8J/9eY/9CagD0GiiigDldS/5Kn4e/7Aup/+j7CuqrlJIhJ8VbeZvvQaLKicDgSTxlsnqf8AVJ9MHHU11dAHiH7JtrDZ+D/FUFsgSKLxHdRIOpCrHCAM+1eleJ9D0lNP1vVU0uwXVJLSUveC3QTNiIoMvjccL8vXpxUfw88F2XgfSr+y0+aaf7bfz6hLJLjJeQjAwOOFVF464J4zirvju7j0/wAD+IbyYM0Vvp1xM4QZJCxMTj34oAs+Fv8AkWNI/wCvOH/0AVp1l+FSD4Y0cjp9jh/9AFalABXn51h/+F/LoohXy/8AhGDeGXPJP2oIFx+Z/EdMc+gV5V/zdP8A9yZ/7fUAeq0UUUAFFFFABRRRQAUVzcnjbQI/GZ8Ktfr/AG2tubp4QpxHGBnLN0U45wTnBB71R8I/Ejw74s1MWGkz3PnyQNdW5ntniW5hV9hkiLAbgG49aAOyooooA8+t/wDk4DUP+xYtv/SuevQa8+t/+TgNQ/7Fi2/9K569BoAKKKgv7u30+xuLy9mSC1t42mmlc4VEUZZifQAE0AT0V578Ivida/EddZ8nS7rTJdPljKw3Jy8lvKu6GU8AAuATtBYAYIYgg16FQAVyum/8lT8Q/wDYF0z/ANH39dVXK6b/AMlT8Q/9gXTP/R9/QB1VFFFABXK/Cf8A5JZ4N/7Atl/6ISuqrlfhP/ySzwb/ANgWy/8ARCUAZdt/yXrUv+xatf8A0quK0virN5HgTUX2O+XgTCDJ+aZFz9BnJ9gajsI5D8XtdkE7LEuhaerQ7Rhybi9wxOM5GGGAcfMc9Bin8cJHi+HF40TsjG8sFypwcG8hBH0IJH40Ad5XmvwS06607/hPvtkXl/afFl/cRfMDujby9rcHjp0PNelVzHgX/mYf+wxcf+y0Acj8RP8Aku3wj/7i/wD6SrXqteVfET/ku3wj/wC4v/6SrXqtAHn3xa/5CHw+/wCxng/9J7ivQa8e8ZeMtA8TeJvDmm6RevNe6J4tt7a8j8h1CSeTdDGWABGUcZGeV9CDXsNABRRRQB5V8Av+aj/9jnqX/tOvVa+b9AuvEOlaN421vwrDeXs+nfEC+kutOtULteW7eWjoFAySMhhjpg17d8O7XVrPwRo8XiO6mu9ZNuJLuSb7wkb5iv8AwHO0ey0AdFXM+IY1bxj4TcyL5iS3OIihOQYDlgc4BHA+jH3rpq5jxB/yO/hT/t7/APRQoA6eisnxegl8J61GxcBrKdSUcowzG3QjBB9xzWtQAV59+z//AMkZ8J/9eY/9CavQa4v4M2P9mfDHQLHzPN+zQtFv27d212GcdulAHaUUUUAcx/zU7/uD/wDtaunrlTLGPimsRdRK2jFgmeSBOATj0GR+YrqqACuV+LH/ACSzxl/2Bb3/ANEPXVVyvxY/5JZ4y/7At7/6IegDqqKKKACvKv8Am6f/ALkz/wBvq9Vryr/m6f8A7kz/ANvqAPVaKKKACiiigAooooA8Yj+Dl/b/ABGj1uDxDNLpk0V59sEyx/aGefqoIj5XGBktuAVQOBip/hp8M9d0DxBoV3r15pslroGmS6bZ/Yy5effJu8yQMoCYXjaC3POe1ewUUAcr468G/wDCW/Yf+Kj8SaJ9l3/8gW++zedu2/6z5Tuxt49Nx9a5T/hTf/VR/iT/AODz/wCwruvEuranpf2b+yvDt7rXmbvM+zXEEXlYxjPmyJnOT0z0OccVi/8ACWeJv+id63/4H2H/AMfoA8uh+F274wXmlf8ACc+Oxs0KC6+2DV/9JbNxKvll9nMY25C46knvXY/8Kb/6qP8AEn/wef8A2Fc3d+KPF0XxquLnTPh/d3N22gQRS2c+q2sLpGLmYiUMGdWBJI25B49MV0p8bfE7PHwj4/7GW1/+JoAT/hTf/VR/iT/4PP8A7CuK+L3w2n0XwZImn/EDxtdanqd1b6XZ2mpa0Xt7mSeRUMbqFGRsMhPOMA5z0r0LTfGXj+S5ddT+Ft1b24U7Xttcs5mLZGBtZkwMZ5z+HpwHxA8ReL9b8ceDNM1T4eXkEVvfz6rY2yatbO95JbRMYy7D5YQrOhbLEYYgBjigCvYfCldL+LQ8NWPi3xvaabN4fS7S6t9XEchaGbyhCcJyipIu0YG3Jx147r/hTf8A1Uf4k/8Ag8/+wrkJ/FvxAPxcsrpvhpjU10OeJbD+3rf5ojcQlpfM27Rhgq7ep3Z7V1//AAm3xP8A+iR/+XLa/wDxNAB/wpv/AKqP8Sf/AAef/YVz9l8KN/j7WbH/AIT74gL5OmWM32hdZxM++W7Gxm2cqvl5Udi7+tdB/wAJt8T/APokf/ly2v8A8TXP2Xi/4ir4/wBZnT4Xb719MsUltf8AhILYeVGst2UfftwdxaQYHI8vJ+8KAOg/4U3/ANVH+JP/AIPP/sKP+FN/9VH+JP8A4PP/ALCj/hNvif8A9Ej/APLltf8A4mj/AITb4n/9Ej/8uW1/+JoAjuvhCLe2lmb4ifE11jQuVj1ouxAGcBRHkn0A61ifD74T/wBoeAvDV4fH3j+1+06ZbTfZ7XWdkMW6JTsjXYcIM4AzwAK0dd8a/EhtE1Bbv4SItsbeQSl/EVu6hdpzlVAJGOwIPpVTwV4u+I9n4N0G2s/hS1xaw2EEcUr6/bQmRBGoVjGUBQkAHbgY6UAQWXwo3+PtZsf+E++IC+TpljN9oXWcTPvluxsZtnKr5eVHYu/rTfH3wjS28PwmXx349vI5dR0+3aK71fzI8SXkMZbbs+8u/cp7MoPanWXi/wCIq+P9ZnT4Xb719MsUltf+Egth5Uay3ZR9+3B3FpBgcjy8n7wo8ceL/iLcaLbJffC77HENT051k/4SC2k3SLeQtGmAv8bhUz0Xdk8CgDoP+FN/9VH+JP8A4PP/ALCud8GfCFZU1pU8eePbZYtUuExa6v5YkOQS7/Jy5JJLdzzXRf8ACbfE/wD6JH/5ctr/APE1z/g/xn8RFTWWsvha1yH1O4MobX7eIxSZAZMMuTjHDdCCCOCDQBgeM/hp9i+LHw60z/hNfG9x/aP9o/6XcarvuLXy4Fb9y+z5N2cNwcjiu/8A+FN/9VH+JP8A4PP/ALCuA8Z+KfHc/wAWPh1dXvw6+yalbf2j9isf7cgf7bugUSfvAMR7Fw3zfezgV03jTxz8SE8Ha8918LlsrdbCcyXTeILeUQL5bZcoBlto52jk4xQB89/D3wtPe+JvB8N3qviCyfxDGupyXNtcmJhMt1cQ7lJU5fYQwc8jzG6hq+nf+FN/9VH+JP8A4PP/ALCvBkvPEdrqvwXng8DNHPbWhGnD+2I3/tVfLjctzxB98thv7+P4a95/4Tb4n/8ARI//AC5bX/4mgA/4U3/1Uf4k/wDg8/8AsKP+FN/9VH+JP/g8/wDsKP8AhNvif/0SP/y5bX/4mj/hNvif/wBEj/8ALltf/iaAPlvWE8V6JqHiy28IeIPEirp2ranNfONVaPfDDJCnnuAV3SEyDc3JbI4G05+pP+FN/wDVR/iT/wCDz/7CvmnRl8QXHiH4yaqnhNrpntr+31OL+0okGmebK8hbJH74o0JxsxnafUV9E6J8RviRq2i2Go2nwqW4tru3juIpl8Q28YkV1DBgrLlQQc4PI70AXf8AhTf/AFUf4k/+Dz/7Cud1z4RKvi3wzA3jzx7KXa5ZZptX3SwlYusbbPkJDEE85BIrov8AhNvif/0SP/y5bX/4muf1rxn8RD4s8OPP8LWjuQbkQQjX7dxLmP5ssFwmAM89enWgC74n+Dijw1qxk+IHxBuEFpNuhuNZ8yKQbD8rrs+ZT0I7itP/AIU3/wBVH+JP/g8/+wrJ8XeO/iNB4U1qW9+FgtLWOynea4PiG3kESCNiz7FXLYGTgcnGKuaT8RviLq+lWepaf8KPOsryFLiCT/hI7Zd8bqGU4KgjII4IzQBcT4OBTk/EX4kNwRg66fTrwlYHw4+E0cvguxYeNvHNurIyJFa6uYYoQrso2IFwOnQ5rd/4Tb4n/wDRI/8Ay5bX/wCJrA8B+MviLF4UsUsPhabu2G8pMfEFvEWy7E/Ky5GDkc+lAHRS/B5XkLL8QviNGp/gXXTgfmhP60z/AIU3/wBVH+JP/g8/+wo/4Tb4n/8ARI//AC5bX/4mj/hNvif/ANEj/wDLltf/AImgDjpvhdt+MFnpX/Cc+Ozv0Ke6+2HV/wDSVxcRL5YfZxGd2SuOoB7V2P8Awpv/AKqP8Sf/AAef/YVx83izx+fjBZ3bfDTGqLoU8S2H9vW/zQm4iJl8zG0YYKu3qd2e1dh/wm3xP/6JH/5ctr/8TQAf8Kb/AOqj/En/AMHn/wBhWB8QvhR/Z3gDxLff8J98QLv7NplzN9nutZ3wy7YmOx12fMpxgjuCa6/SvGPjqXzf7W+F97a4x5f2bWrOfd1znc6Y7eucnpjnL+JXibxDcfDnxVDceBNXtYZNKu0eeS9smWJTCwLkLMWIA5wATxwDQBJ/wpv/AKqP8Sf/AAef/YUf8Kb/AOqj/En/AMHn/wBhXQf8JZ4m/wCid63/AOB9h/8AH6Q+LPE2OPh3rWf+v+w/+P0AYH/Cm/8Aqo/xJ/8AB5/9hXHaF4GbR/2lbS0TxX4qvDb+HRqHn3t8s0so+17DbuSmDCRztwDu5BBxXrSeKdZIO/wH4jByeBcaeeM8f8vXp/k1wNpqOqz/ALSUN9L4U1u2ik8MrZsJWtT5YN5kysyzFdo7qGL+iEc0Ae1UUUUAFFFFABRRRQAUUUUARTXEMBUTSxxls43sBn86Z9utP+fqD/v4Kpa74c0PxB5H9vaNpup+Ru8r7bapN5e7G7buBxnAzjrgVlf8K48D/wDQm+G//BXB/wDE0AYEF9aL+0Be7rqAb/DFuVzIOcXc2cfTI/MV3V5rOmWNs1xe6lZW9upAaSWdUUEkKASTjkkAe5FefWPgHwifilqKR+F9Cjis9ItJFjWwj2F5Z7j5wuMBgIcbgMnd14Fdhd+CfCt4MXnhnQ5xu3YlsIn59eV68mgDSttY0y7EptdRs5xFK0MhjnVtkinDIcHhgeCOorzQXlrfftLFxcWc9tpvhfYXDxsYLiS5zgnqGMYzj+6f9rntrXwJ4RtN32XwroMO7G7y9OhXOOmcLXn3gjwD4X1T4g/EXU7nRdFvrAX9tYW9tNp8bLbvDaxmUqGXA3NLzgDJTPORQBU+I/jyx8L/ABQttVsVh1i8Xw/LbW2n29yvmXM0l9bosaYDEtkOcAE/I3HBr2DQL6bU9C02/ubOaxnuraOeS0mBDwMyhjG2QDlScHgdOlecReCPCtn8atOaz0LRLXyNFkuIreKxjT96LmLbMoC4DJjAbqN/BrzPTvj94puvDeihtOs11ie9RrqbyW8j7E7qiMo3ffZ2Zepx5bHFAH1FXNWFtOvxJ126aGUW0mk6fGkpU7GdZr0soPQkB0JHbcPUVycPxgsp/G8mhxaTdvZRag+ly34YERzJncWTHEYIxvJ/DFZVj8dbSWHWXutDmjNhph1VDBcrMk8QkWMhXwFzlxyu5evNAHs1FcX4H8cS+I9d1fSL/RLnSL6wiguAks8cokilBKtlCQD8pyOfrUXw68V3uv6h40i1Q26Q6NrEtjAyLtxEiqQWJPXk88UAdR4kjebw7qkcSM8j2sqqijJYlDgAdzR4bjeHw7pccqMkiWsSsjDBUhBkEdjXlHwh+Ld14x8calpWoHT1sbqGS90fyG/eeSkzxlZuTiQgK+MD5ee9dH43+Jh8M6xq1jDoVzqA0rT49Tu5UnSMLAzMpwG5ZhtJx39RQB0FhbTr8SddumhlFtJpOnxpKVOxnWa9LKD0JAdCR23D1FHxBtp7rQbWO1hlmkGraZIVjQsQiX8DO2B2CqWJ7AEnpXJ33xgtLUeIbkaFqMukaIqNc36SRBfniV41CFg5LF1XpgdSRVE/GpYvD+o39z4Z1COezuoLdlV90G2ZWIkM23hF2MGO04O0c5zQB6/XJ/Dv7WYPEDX1pNau2t3mxZY2TfGHwjrkDKsoBBHBzxnrXEal8cLaytNEl/sdGGpQNOJm1GJbUYlaPy1nxsZ/l3bTtwCN2DkDoY/ifZSCErp85Evid/DIIdf9Yu797/u/L0680ATeLdEuL/4r+ANUjiZrfTY9RMj+U7BDJFGi/MPlXPP3uvYHkjjJPFV6P2bb1viNqEVh4o1LSdTjEGohLOedx5qoqxELk7THwF53L686o+M8Y8IweIJPDd/DZ3l2LCwaS4i23M/mSKRwSyKvlMSzL9Aaw/ilrmj+NfgNr3iDVdDjtbyxElrCb23WV7aVpETdE5XO1iU+ZQM/hQBT8VeI/B9t8UPhDHpPiXRG0rR4tQhkmjv4jHboLZFjDsrALu24GcAnjB6V6x/wsfwP/wBDl4b/APBpB/8AFV5/43+H3haH4pfDf7N4d0OGymnv4bm0j0+JY7j/AEVnQuAuG2lCRkHBORivQP8AhXHgf/oTfDf/AIK4P/iaAD/hY/gf/ocvDf8A4NIP/iqP+Fj+B/8AocvDf/g0g/8AiqP+FceB/wDoTfDf/grg/wDiaP8AhXHgf/oTfDf/AIK4P/iaAPm3wX4g0VJP2hI5dZ0qJtWa5XTzLeRRi7LfbNvllmAcHenI4+Yete3fDXx54PsPhz4Vs73xZ4egurfSrSKWKTU4AyOsKhlI3cEEEV5X8FPBmga944+Mmm3mjaVJHbai1vZedZRyLZgy3Sjy1I+UDC8Lj7o9BXpvwn8FeCdX+GPhW+k8K6BczS6Zb+dNNpkRd5RGA5YsmSdwbnv15zmgDq/+Fj+B/wDocvDf/g0g/wDiq5zXPH3g6Txh4Zmj8WeH3hh+0+ZIupQlUzGAMndxk10f/CuPA/8A0Jvhv/wVwf8AxNc3rvw/8Gp4y8MRR+E9ASKT7UZI106EK+IxjcAuGx2z0oAb8TfH3g68+G3iy1s/Fnh+e5n0m7jiii1GF3kdoXAVQGySSQABR8MvH3g6z+G3hO1vPFnh+C5g0m0jlil1GFHjdYUBVgWyCCCCDR8TfAPg6z+G3iy6s/Cfh+C5g0m7kili06FHjdYXIZSFyCCAQRR8MvAPg68+G3hO6vPCfh+e5n0m0klll06F3kdoUJZiVySSSSTQB03/AAsfwP8A9Dl4b/8ABpB/8VXEfBPx74VsvhV4bt9V8V6Hb30driaK51GJJFbcfvBmyD9a7f8A4Vx4H/6E3w3/AOCuD/4muG+B/gbwlqXwm8M3mo+F9Cu7ua1DSTz6fDI7nceSxXJP1oA7n/hY/gf/AKHLw3/4NIP/AIqj/hY/gf8A6HLw3/4NIP8A4qj/AIVx4H/6E3w3/wCCuD/4mj/hXHgf/oTfDf8A4K4P/iaAOGn8c+Ej8cLG/HijQjYr4duIGuP7Qh8sSG5hYIW3Y3EAnHXANdz/AMLH8D/9Dl4b/wDBpB/8VXDT+BvCQ+OFjYDwvoQsW8O3E7W/9nw+WZBcwqHK7cbgCRnrgmu5/wCFceB/+hN8N/8Agrg/+JoA1dK8R6HrFu1xpOs6bfQK5jaS1uklUMADglSRnBBx7is7x7cWFz4F8RwTXtvHFJptyjuXUhVMTZODwcD14qP/AIVx4H/6E3w3/wCCuD/4msvxT8OfBI8MauU8I+H42FnNh4tOhR1Ow8qwUEH0IORQB2xvrQHBuoM/9dBSNqFmoy13bge8i/41z3/CuPA//Qm+G/8AwVwf/E0n/CuPA+c/8Ib4b/8ABXB/8TQB1dcmJ4T8VzbiRPPGiCQx5+YKZyAcemQfyp3/AArjwP8A9Cb4b/8ABXB/8TXN2ngDwlZ/FuG6tPDmk28kGlLJEsVqiJHItxkSKgG0SDAw4G7HGaAPTqKKKACiiigAooqK6uIbS1mubqRIreFDJJI5wqKBkkn0AoAlorKtvEejXM2mxW+p2kkupRNPZKsoJuI1GSyf3gAQcitWgDG8R2mvXX2f/hHtXsNN27vO+1ae115mcbcYlj2459c5HTHOL/ZPjz/obdC/8EEn/wAlVua/4hsdCNuL+PUXM+7Z9j064u8bcZ3eSjbeoxnGecZwayf+Fg6J/wA+/iL/AMJ3UP8A4xQByllpfjVviVrQTxToyXKaRYeY/wDYblJFM15sG37TkFSH53YIYcDbk9L/AGT48/6G3Qv/AAQSf/JVcZrXxQ0Xw94m8Xa7LBqpjh0OxEUdxpd3biSVZb3ajM0P7sMzoodhtJJxnaQNjwN8YNN8RaG91qWja7pmowXMlpdWUel3d4IJUPKGSOHG7GCVIBGcEdyAbf8AZPjz/obdC/8ABBJ/8lVwXwa0fxNP4e1fWdA8V6N9i1vW7/UA76NJIJD5xi3r/pC7VbygwU5IzyTXbar8TtEsNLv7w2mvn7LbvcYl0K+iRlVd2S5hwq8Y3HgYJ6Vy3wd8UaF4a+FXhjT0tdfcpZJLJ5OhX0i75B5rkOIirDc55UkHII4xQAW9h4th+PGmrfeItMuM6FI7+XpTRqYVuot6AecSHbcPnJIGPuHrXdD4f+GB4YsvDw0sf2RZSJLBB50mUZHLqd+7ccMxOCSOa88uPH+kt8dbSVLPXmjh8OTRkDRrvzCXuoiMReX5m35CN23bkgZzxXef8LB0v/oF+Kf/AAnb7/4zQBNN8PvDM2tzas2mlbyeXzpglzKkU0mMbnhDCNz7lTmsPTfhn4AFxqmnWmmSNItmNPuonvLlgtvIwkEalnwBlAfl6Yxxkitb/hYOl/8AQL8U/wDhO33/AMZrltA+IWmDx34rU6b4kOUs3AXQ7tnAKOPmQR7k+6cbgAe2cHAB3E+n6J4bvL7xALS5W6nhit55beKe5do4wdg8tAx4yeQv1NcxpHgj4e+I7vUdb0dftct+8pvJLXVLgBnkUq++NZAFYgkYwCPYitj/AIWDpf8A0C/FP/hO33/xmue1vU/CWs3ZvZdE8V22qINq39loOoQXK+3mJECR/stke1AHSN4K8J6QdK1RNKgtG8PwubWeEurQx+XtbO05k+QY+bd+ZrCuPh/4e8c+I18YX07alpGpaZbLBafvYUdAxlV3wy7wQ4+R1wMc1458dfiZrui+Ehomn6rqU8WqFohd6ho8+n3aRpjeu9lRJM5AJVQQCQeoNavwC+PWlf8ACN6b4Y8TQ3MOo2UUdnZNZ2sk/wBqRQFRQiBm3gADpg4z7UAe4W3h/wAMXF34msI7KKWXUDGdVhfeyyZj2pw3yj5APu46etZV94E8GaPo4iu4L6G0kurZEf8AtK7Z1lL+TCqOJC6DMxXAIX5jnjmsPQPiFpg8d+K1Om+JDlLNwF0O7ZwCjj5kEe5PunG4AHtnBw/4heO9OuNDs449L8TA/wBr6Y5aTQbyNQEvoHPLRjJO3AAySxAAJNAHQTfCvwbNbWts+jkW1vGIVgS6mWN0Dl8SIHAl+ZmPzhskmq+meAPAupas3iHT9LVrxNTkuDMk00ai7hkaJ28vcFyHVgeMNjPPBq9/wsHS/wDoF+Kf/Cdvv/jNcz8PfHenW+h3kcml+Jif7X1Nw0eg3kikPfTuOVjOCN2CDghgQQCKAOluPCXhGDQtP8Hz2CDTpZZJrS1LyllkDGVnWTO5WBckHcDzgeleU/FPSrDxF8EIrrwBr8sPhW7uo1uY54ZLh75nu4YVYyTt5qeW6k/7WMdOa6zxD8RNN/4T3wii6V4lOVvGbOh3SsAI1GQjRhnGSAdoOMjOM18/fDrxnc2/w08F6RPFqs0Ft42t38yGxeSFIF2S+SHVfmlaR2cIuWOD0BUEA9k8U+CfH6+JfB0118TBPdnUJoLWYaBAn2dms53Z9obD5WMpg9N+eoro9f1rxN8P/DVlb6n4hs/Eev6jqBjtpLjTvs+Y/KyY1SJsEgrnczKMMfQAweOPiFpkeseCrgaX4mKxa18ytod1Gx32lzENoeNdxBkBKrlsBiAcYrd1jxT4Y1u2W21nw1ruoW6uJFiu/C15KoYdGAaEjPJ5oA5Xwk/j/wCI3h608U6X45i8O2l9uVdMTRobpYGjYxNiV2DMGaNn56bsc4zWv/whnxN/6Kwv/hNW3/xdbGmeMfD2lWUdnpegeIbKzjyUgt/DF7HGuSWOFWEAZJJ+pNde2pWK7915bLskELZlUbXPRTzwfbrQB85fB7wf41urzx1daP8AEAaZOviO7tLxjosM/wBqljIJmwzfJuLn5BwPWuw+CnhrxdofhrRLu98Zfa9Bs4JQdFi0qPLBd6hVnzvOGww45xisv4GeNLC2s/Gly+n+IJIdR8T317A1vo11OPLfZjJjjYBuDlScirnwC8e2sHwi8OwX1hr01xDHJEXtNFu7iJgsrhcSJGyscAZweuRxjFAHXp4ytfHVh/ZfgfXJdO1a7sI9RhvzZLcLbxedsIdGIXedrrtPI5PauM1vwn8RI/F3hqKb4nxyXEpuRDMdBgTysR5bCbsPkcc4x1p3wkOl+CZPE11caVr4utY1KS5VLXw/qDJDb7mMUQLQA8b3J4xlqd4s+J+jXHxU8E6WNH1wXFrLNf8AmyaROs2xra5i2JEU81gTgkqpX5f9k4AG/EPwl8Q7bwB4mn1D4mre2UWmXLz2v/CP28XnxiJiybw2V3DIyORnNZXwX0n4h+JPhf4f1HT/AIjrpdmYGt4LP+wrefyY4XaFRvJBbiMHJGee/Wuz+JnjnTrv4ceK7aPTvEiPNpN3GrTaDexoCYXALO0QVRzySQB1Nc1+zn4xsNK+DXh6zuLDX5ZYvtGXtdFu7iM5uJTxJHGVPXseDkdRQB0//CGfE3/orC/+E1bf/F1x3wd8K+Pr34ZeHrjSPiQumWElsGhszoME/kruPy72YFvqa9T/AOFg6X/0C/FP/hO33/xmuF+BvjewsfhN4atbjTPEZlhtihaHRLuZGw7cq8cbKwPXIP5HigDY/wCEM+Jv/RWF/wDCatv/AIuj/hDPib/0Vhf/AAmrb/4uui/4WDpf/QL8U/8AhO33/wAZo/4WDpf/AEC/FP8A4Tt9/wDGaAPK5/Cvj/8A4XBaWh+JCnU20GeVb/8AsGD5YhcRAxeXuwcsVbd1G3HevVm0vxsZlK+KdFEXy7lOhvknAzg/aeBnJHBxnHPWuBl8d6a/x3tZxp/iHbF4blRk/sW683L3UZBEXl79vyH59u3OBnPFd5/wsHS/+gX4p/8ACdvv/jNADP7J8ef9DboX/ggk/wDkqsrxbpPj3/hFNbx4q0Nz9hnAUaG8ZJ8tujfaG2n32tj0PStZ/iJpKAb9N8UKD0z4dvh2z/zy9jWb4u+ImiR+EdakNr4hG2xmbD6Dexj/AFbdWaIKv1JAHcgc0AaTaV48LEjxZoIHoNAk4/8AJqpFsPHajH/CQ+Gm920OfJ/K7pf+Fg6J/wA+/iL/AMJ3UP8A4xR/wsHRP+ffxF/4Tuof/GKAD7F47/6D/hj/AMEc/wD8l1zNlaeNk+MMRvdX0GWz/shDL5WmyoSouDuVVM52sQfvlmAwPk6kyf8AC+fhxgH/AISCQgjPGnXR/wDaVY2l/GHwTqnxWtYrLVZXF1YxWUDtZTqsk8k+Fj5QEduSAvI564APaKKKKACvCfG/w98Raz421/VYbe9aN9W0t7CSLUjCFtliVLoqokG3oQeAx7Zr3aigDwaw+HGvM+l6RfWd2PDlv4k1GVoRqJGNOdD5Iysm8qSfu5zycjk1Q8H/AA68XaZpkH2q0u/td14WvdP1AS6iJQ9yWxbpgyEcJgAr8oHBIr6IooA+btN+GPi7RV8J3kV9qCz2Ph++t5pLu6haPSrh7crGIwg3FQ3cb/ujmrH7PFyLzxw7adbTRWFr4dht7x1vRdxS3vnEvJvVmXcw5xnOByB0r6JooAKK5nxt4RHipLNf7f8AEOjNbFiG0e+NsZQ2OH4IbGBjjI59TXLf8Ki/6qF8RP8Awdf/AGFAHK/FCyPib45aT4QcSCyv7XT9RvyDmOW2tJb5mhkXI3B3kiHfBG7BxXVaBHpuhftAeIdL0yxjtn1rQ7fV7loxhXmjuJo2YjOAWEik4HJBJ5JJ8/8Ahv4Lsda+M3jsTeKvFOpJoCWthBcHWJFldZFdpYpJE2sQsqHCggAg5BNa3jXwtpXhf4seDryWXxRNa67FNos11/bl0pt5N6SQDzS+87j5g8svg43AZU7gD0/4sf8AJLPGX/YFvf8A0Q9bXh7S4tD0DTNJtiWgsLWK1jJ6lUQKP0FeQ/HbwRBZ/C3WH0u/8TTXkj21vHE+s3dyJPMuYoyvlPKVfIYjB7msfwR4t+HfjuRNKsPEfjbStZulMcUNxrl6JA5B5RvNaMkdRu69x1FAHe+PPA/ifWvHVjrvhfxXD4fEWmyWEr/YFupDulV8AOduDjrwVKDG7cduRcaX8adAa5k0zxF4b8Vw+UHVNTsjZyhxnKRrDheeOXfGfTknsP8AhX2l/wDQU8U/+FFff/HqP+FfaX/0FPFP/hRX3/x6gDBsvHPjuESTa98LL+3s4oy7vp+r2t5KcDosWVLfQEn0Brj9N+OPh7SfG+uP4k0jxJoUV59mG/UNPKGHEbY8xVLMN2DtwDn8Dj01vh5pTDDal4oIyDz4ivuo6f8ALWuI8L+CNKb4peNrJbzxDGlvbac4ePXLtGbes3DMJAzY28biQM8Ac5AOm0T40/DvWZXjs/FenxsgyTeb7QfgZQoP4Vrn4keBwCT4y8N4HpqcB/8AZqwtb+C3gzXpUk1y21XUpIxhGvNXu5io9i0hxWUn7Ovw1VnJ0SdgzZAN9PhRgDAw/TjPOep7YAAMH49fEvQbvwtDpPhH+xvFGvap5lvAImjuhZx7cySkDO0gYxnA4LHIQg818LfHvwpPh3StP8Z+G9M0bXtN0+AtNqOlo/2kLFvWWOQIWJZArgMASZAF3k5PX69+z94F0yw1fVdMg1Ozlj0u4iSKG+cIrGNsyZOWJKkqVLFCpIKnJqXwd8H/AAf4p+HPg+68QWuoX8h0q2lUTancskZeFCwRfMwgOBwoA4HoKAOQ8SePPFt18Xdcl+EslprmlWFnBe6hBbokyXYUKDGkgBy2GJCoQSQw+YjbXSap8bPB3inw1ZxNetpOppremLNY6ivlPFsvYpHYn7uxVicliRjA3bSwBv8Ag34R+F9L8XeKbbTBq1jaILQJDaapcwD7jEklHBblv4icdsZOaXxS+CfgybSTfm21A6ndahp9o99JqE00wSW6hhY5kZgSEYgZBxx6UAZ4+PWrQ6xrWvP4d+3/AAysr1tNXUrDDXCTKqkSEFwCjEjBIUYkT5iw2t6Z8L9Y06XwNc6ol9bDTm1HVbwXLSBUEJv7hvMJPRdvOT2qlZfBvwnZ6KNJg/tpdN8tomtl1m6WJ1bO4FFkC4bJJGMHJ4ryrTf2dtF1zQ7i88Paxf6DqK6rqdq0q5nQ2q3E1uIdu5TjYgBJY53uG3AjaAdP4R+NHhn4hfEPQLXTUvbCeA3G1b9UTzt8eAEKu2Tx09xjPOOD+A0un614e8G2MlosKnxcbhUjC7S9rpC/OeBy0gVjx1J5zyew8XfAbwjeaz4U0pptZWM20tq05vWkl2RIrJt3hlXB3fKqhfnbAHGPMPD3grStC/afsfBFnPqp0y1kldZvtrxTHzNPEhAaLZtO4EErjIwDkCgD6V+K2rw6SfB3nxu/2zxHZ2ibMfKz78E57cV3VeBfGnwRpemjwILe61xxdeK7C2k8/WLqbCt5mSu+Q7G44dcMOcEV6R/wrTRP+f3xJ/4UF9/8doA3/F2qnQvCmtauqhzp9lPdhSM58uNmxjIz09R9a8ym8G3fiD4qxeN9IvPDt1YW89sPskU7us6+SSLmRlBXzwkyGPgjYVO7kGs/46fD6xtvhpqKaRea0+p3U9raWsVzrN1MkjyXEabfLeQhuCeMHpntWB4U8MaTpnx28ZeFbhtXtNGh0u21C0mj1y5hEMUUUUbBirgsPmwCx+QR4AweADq/2SJGl+D0Ekjl5HvrhnZjkkluST611XwK0lND+FmjadDKZYoWuNjnqVa4kYZ9wCAa8p/Zc8C6Xq3wuW/u7rWY5p72YstpqlxbIMbVHyxOoJwvUgn3wAB1Xwg8C6HdeF7i3m1DWJrvTdUv7C5S21u8ijR0uZMDakigEoUbpzuyeSaAPaa+ZfiF4m06z/bF8HMWlma0tYtMnSNOY5pxMEHzYBGLiJiQTwT1IxXtL/DjQWUgT+IVPqPEF/n9Zq+Qda0a1tPFuveIdUubuaLTvG9vpccst9J5q26NOXBlJ3AhYoQH3ZG00AfYvxY/5JZ4y/7At7/6IeuU/Zc/5IT4Z/7ev/SqWo/iX8PtHsvhz4quobvxA0sGk3cqiXXLyRCVhYgMrSkMOOQQQe9c3+zt4I0vWPg54evru61xJpftGVttYuoIxi4lAwiSBR07Dk5PU0Ae+15P8LNYOg/s26drMcQnbTtGmuxEW2hzGHbbntnbjNdH/wAK00T/AJ/fEn/hQX3/AMdrhPhD8PtI1/4N6K95da3G1/pskEoi1W4EYV1aM7Yi5jHByBtxnt2oA1/hr8XD4pbUm1OxsbezstLi1SW9sLw3MUKuu4wykou2VQDleeh9OdX4PfEaTx9bamt/pR0jULNoZPsxl8wtbzRiSGTOB94Z47Y96zrn4MeHrTSdQgsb3XbS1utLh0+8t7KWIfa0hChXZTGf3rKu0kYyGbgEk1u+Evh74Z0PxCniXwsstmtzYLbGC3cG3mjLB1cggnd0AII44xQBku8Z/aZiQNN5q+EHZlJ+QKb1cED14bPsFr06vBf+EM07/hpD+zvtuveV/wAIp9p83+2bvz9/2vbjzfM37cfw5255xmrsU3hOXxhP4Wtbrxnb69J56W4uNcvVjuJIgxPIn3YO0kFgMjkHmgD22sHx9dpYeBfEd5KheO3025mZR1YLExI/SuE07TPDtrY2Fr4r8T6jpviRrNbi707/AIS673xNs3uFX7QSQMNyMjAJzXA6l4es9a+HniXUNP8AFfxSktYdGuL2BtVvSttfRiJiOq/MrcZU4JU+9AH0vRXlx+D4Oc/EL4i/hrh/+IpP+FPL/wBFD+I3/g9P/wARQB6lXIJKrfFyWLyXDpoaMZSvysGuGG0HuRtJI7bh61zR+DfP/JRviSP+45/9hXNaH8O/sHxxFufGfjO5+xaTa6gGudT3tP8A6TKDDI235ofkHyY53NzQB7zRRRQAUUUUAFFFFABRRRQB5b8cPiz/AMKu/sY/2MupjUBOTuvPs/l+WYxx8jbs+Z7Yx+XG2fxp+IXiW2hi8KfCu8Se7UPa315NIbQrjduLNHGpBUHB3jJIxnofXfHEvgtY7NPHT+HQjFzbLrJhwSAA+zzfYjOPUZpn/Cx/A/8A0OXhv/waQf8AxVAHiPwzl+InhPxV4m3/AA7hvta1KOG+1AR6zbwLukuLx1kH3uDuZNuSR5WScMALPxk8UeNW8P6VrPiL4dHTNP8AD+sWerNOuvQTAskm0IVVN2G8zGR0JB5AIrvdM+IXg0/EvxDcHxXoS250rToVma/iVHdZbxmVWLYYgSJnGcbhmrnjnxp4N1rwV4g0q28ZeHPPvtPuLaPGqW+dzxso6uB1Pcj6igDzv4j+KfHer6z4L0i++HzWF4dXTU7W3j8Q27G9NqjSGMnbhVGVYk8fKB1II3fAnwsSy8Z6z4t/sabQPEDXDSW0LzQ3ViNxdX8oqQ5Vx8xLLGy7wACAQeO+HPxF8OeKfFHw/uNV1O309fCmgyLPd6reJC017KqQMgDsN3yxs+8FshwCFavdP+Fj+B/+hy8N/wDg0g/+KoAwta8aeMrbVGsdI8C22pzIu54/7bS3kUYX59skQDIWJAZGb7vzBD8tQR+MPiU0c7N8LIkaNNyIfEduTIdyjaMJgHBLc4GFPOcA7GreOvBc2n3eo22s6Pq9zpFtNqKwWN7FLPtjjLNsCtnkAg9ueeKt3/jnT7H4bxeM7iG4FhLZQ3qQAAyt5oUpGBnG4l1Xr1NAFTSde8cXOuT2mo+CbOy0+LOL4a2sqy+mxBEG/wC+tvfr0PMeHL/Xk+LHxJkt9Et5blLPTvLhN+FEpEc5T5tnG4kg5HGO4Nd/4F8UWXjLwvZ65pqSxQXG4GKYASRMrFWVgDwQQa888PeNfC1n8XvHk934l0SCGW202OOSW/iRXdBOHUEtglSRkdsjNAHfDUfFH9oWsTeHtP8AsjxFp5xqhJikH8Cr5PzA54bI4ByBwDnR6z47lnulHg7R4oopjHE82vMDMmAQ4C27YBzjBwcg8YwTa/4WP4H/AOhy8N/+DSD/AOKo/wCFj+B/+hy8N/8Ag0g/+KoA5XxhrvjSb4beLZ9U8KWGlLHpl3gjWjLJgRtlwEiAxtyw+YHIAO3OQfDPUfGafDjwoln4b0Oa1XSbQRSSa3JGzp5KYYqLY7SRg4ycep61J8TfH3g68+G3iy1s/Fnh+e5n0m7jiii1GF3kdoXAVQGySSQABR8MvH3g6z+G3hO1vPFnh+C5g0m0jlil1GFHjdYUBVgWyCCCCDQBU8Pat46Pj3xcB4W0XCrZ5D6y6rny25VxbksMYyCi4I/izxJ8Q9T8aHQ7JbnwxoqRHV9M+eLW3fDC9gKAg2y8FgqkjJG7ODjFaGgeNPDA8feK4T4h0lZClo43XaAMPLIO05wcHrjpkZxkZi+JPjfwo+jW1uvifQjcJq2lytENQi3Ki30DsxG7OAoLE9gCelAG5/afjv8A6Fbw/wD+D+X/AORK5v4f6j4zTQboWvhvQ5Y/7W1MlpNbkQhzfTl1wLY8BtwBzyADgZwO0vfGvhWxit5L3xLoltHcKWhaa/iQSgHBKktyARjjvXIfD7x94OtdBuo7rxZ4fhkbVtTkCyajCpKPfzsjYLdCrBge4II60AQa3qPjdvHPhgyeHdBjKx3jIn9sSsJW2oNu/wCzfIQCx+6QcHlSAG8n0mLxBeftc61epoWmS61ZWq3D2zam6wxKbWKLIl8rLZEq8GPqfbNeva78QvBr+NfC7R+K9BeNBdl5Fv4iifu1A3MGwuSeASM84zg1xWl+L/DEX7T+r6s3iXQxpk3hxYVuxfRiIyedF8m8kKXwpOATx75AAJPj5q/imDT/AAZc6to2i2CW3ieynilTVJbhTKokKh1+zqQnUlhkjHCnNdpr/wARNW8O3H2fXrTwXp1wYvOEN14pMcjJkjcFNrkjKkcDkg1xH7SeveG/GXgmw0fRfFuhSzvfNMyxapCAfLtbh1DndgBpFjXLYG5l5HFV/hbpvw5Ggvq/xG1vwfq/jDVpjeahJf6ja3Ajbc2yNBnaoCkZC8Z4yVVQADntS+K+r/Fjx74V8NeGNL09Y9P1OLVnmW9mMVz5C+YELtAjRr95SWjbLbMdOZPizq3iXwZ8TZPEd/pujWcuvaBe6fsk1MzRARRh/kbyoyH3CMBSG3ltoKkgr7npPjP4caPYpZaR4k8I2FnGSUgtb62ijUk5OFVgBkkmvG/2t9d8NeJvh5YPoWv6JqN9ZagkjR22pQvIImR1YhA+W+Yx9ASBk8AE0Aan7NN14ytPhlDDY+HtMubYXDNHNd6s0DurIjAhVhk4ww6sD14FUdA1/wAU+D/DnxIK2ehWeo3eravqMBl1geerrCruYYTCfOCABuduf4lUc12nwl8X+CNA8O3elr4t0KOCzvZLeEzX8cZdI1VAwDNkqdvByQeoJ6187/Ha9Z/G+uy+H/EWj3Gkr5+p281tfxySzG6jt7a4gGwnnC/cIB8sOcmgDtr39qbVo9IszZ6JpEt3CbYXczXUhE+6MtII4iiMhDAgtl1U8DeCGrya+uNVv/ghqGqXqRzxX3iwST3j3B81rj7M7EeVsxg+YSW39eNvesu08KaQIhNdeIbKSNk1X93FPGjobaDdbsdxP+ulIUKBkgHBJPy+r+IdE8IWnwD8P+HLPxdpP9oz3raxfgX0U5iuBp87eXtRiQu9I4hjJywxkkAgHqvx58deJfDXw41JNd8MaWlrq8cmkrJa6y8rRvLDJhypt1yAFJ6jt9a434CeIPFsvwD1i10jSrG7stON5bxT/wBpvaXEeYxKQgWJssGlJDb1OSBxjNZn7UHjrSfE/wAN/CFtpmvWWoXMzreXMNu6OyuIgMyAcxn943ynHfjjib9nfxfoPh74D+LoNU1fTra/NxeTRWct1Gk0w+yxBQiMwLZKkDHU8UAe0+CtS8fr4N0FZ/D2kXUwsLcPPc69KJZW8tcs/wDozfMTyfmbknk9awfglf8Ai+H4UeGU03w/ot1Zi0HlzTazJC7jJ6oLZgD7bj9a6PwT8SvB8vgzQJLzxR4ftLp9Pt2lt5dThDwuY13IwLAgg5ByB0ri5Nfn8FfAv4dx6TfyWE1/BbD7VJHG0Sb4DIVd3G1BuIwdrE4xjnIAPZtBn1a4s3fXdPs7C6EhCx2t41ypTAwxZo48HORjB6DnnAr+H/8AQrq+0huFt28+3H/TCQkgf8BYOoA6KE9a4P4K6xbePNL0nxVqOo28/ieztJ7C8trWVQsatcHa8kY5VmEIIzgYZsDpiT43fEXT/ht/YuqXNpdXd7I0sMcMS7VkiKgsrSEYX5hE3c/L0wSaADxPp+rWHxx0vXNCtrPULq88OXNk1rdXLWqxpDcwuZBIqSbiTOBt2joTntV3QvhJomi+K7PXrS+1VpbS6ubuC2kkjMSvcKyyZ/d72HzHGWJGBz2rN0jx1pWq6j4J8WavdWOiWt9oeonZd3ahUYz2Q2+YwUE/KfQ+3XGz4l+L/gXQdJkv38SaZfhHRPI0+7iuJjuYLkIrZIGdx9gepwCAaumajY+Kr7X9NvPDuqWqWbNaST6jZeVHeIxdCYXzl0wp544dfWvN/iRoWseBfh5q9j4bt9Y8RaNLot3Zyi91WGOPSbdYsBkTYGl+UtwSSAgGea634GfESb4l+EbzWLnT47B4NQltBHHKZAVCo6nJA5CyBT6lSeM7R5h8UfD+qS+N9e8OnWLKLSNVgn1Sxs59ViinuL6W2e3jt1jdwxVpfmHGzjGc5oA9BPjT4mgcfCZT7DxLbf8AxNEfjX4lEfvPhK6n28R2p/oK9NuriGztZrm7mjgt4UMkssrBURQMlmJ4AAGSTWF/wnPhP/oaNC/8GEP/AMVQByX/AAmnxH/6JPL/AOFDaVzeh+IvG1z8a5JbvwBPaedpVnbXaf2vBIttAbmYi4LAYY8yYQfN8h9ePUf+E58J/wDQ0aF/4MIf/iq57R/FXh6f4payYde0mQXOl6bBAUvIz5snn3vyLg/M3zLwOfmHqKAPQ6KKKACiiigAooooAKKKKAMrXfDmh+IPI/t7RtN1PyN3lfbbVJvL3Y3bdwOM4GcdcCsr/hXHgf8A6E3w3/4K4P8A4mjx1onifWfsP/CKeLv+Eb8rf9o/4lsV55+du375G3bhunXd7Vyn/CE/E/8A6K5/5bVr/wDFUASaD4H8Ez+OPFNk3hbw7J9mW0dYTp0JEQeNuQNvGSp+uK6f/hXHgf8A6E3w3/4K4P8A4mvJPD3hPx/L8TPGNtb/ABL8jUIbbT2ubz+wbdvtKss2xdhbCbMNyOu7npXYf8IT8T/+iuf+W1a//FUAdX/wrjwP/wBCb4b/APBXB/8AE0f8K48D/wDQm+G//BXB/wDE1yn/AAhPxP8A+iuf+W1a/wDxVH/CE/E//orn/ltWv/xVAHS6l8O/Db6BrdhomjaRo11qenz2BvLTT40dFlQqfuhSwBwduRnArlF+FGs3vhzRfD2veMftWiaXJbNFFaad9llZIEZUUyCVu+xs46p78Tf8IT8T/wDorn/ltWv/AMVR/wAIT8T/APorn/ltWv8A8VQB0Xw28D/8IKNatrbVJ73Tb68N5BDOmZLdmAEgMm479xAPQY565rktA8GeF774wePYr3w3otzFHb6dKiTWETqryCcuwBXgsQCT3wM1b/4Qn4n/APRXP/Latf8A4quF8JeHvH978VPH1jb/ABH+zahp6adHc3v9hW7/AGtXid0Hlk4TZuYcZ3ZyelAHsv8AwrjwP/0Jvhv/AMFcH/xNH/CuPA//AEJvhv8A8FcH/wATXKf8IT8T/wDorn/ltWv/AMVV628HePUsitx8UbqW83PiRdDtEjCmMhRs2k5D4YndggbcDO6gCt8TfAPg6z+G3iy6s/Cfh+C5g0m7kili06FHjdYXIZSFyCCAQRU/ww8GeF7r4aeGbi68N6LNPe6LZC5kksYmaceVG3zkrlvmVTznlQe1cn8QvCHxFtvAPiWfUPij9usotMuXntf+EftovPjETFk3hsruGRkcjOaPh74Q+Itz4B8NT6f8UfsNlLpls8Fr/wAI/bS+RGYlKpvLZbaMDJ5OM0Ad/wCG9N01PH/jJo7S0E7/AGIy7Y13HETBc/rij4m6ZYPoWmytZWrSQ65pTxOYlJjY38CkqccHazDI7MR3rz3wp4Y8Wv8AF3xXC3xAvENvZ6cb2ePS7USXZaObaBlSsYVgx4UkhsEkjdWz478L+KIPD2lNd/EDU7ojVtLS4B06zRXJvIVDIBFlCrlXGS4+XaQwOaAPV/sNp/z6wf8AfsVzHw6soT4fuvOtoy39sarjfGM4/tC4I/DFR/8ACKeIv+iha7/4BWH/AMj1z/gbw5rtzoly8HjzXYUGqajGVFpZHLLezqW+aAnkgnrjngKMAAG/4j0rT5PHvg+V7G1aWL7ZsYxLlcxAHHFdZ9htP+fWD/v2K8s13w34hHjzwtbjx5rMjtFeS7jY2e+NVWMFhiDbjLqp3A8suMHr0p8J+JvNUj4ia35W05X7BYZJ4wc+R068Y7jkY5AJfGFpbp4h8DBLeJQ2syggIBkf2decGup+w2n/AD6wf9+xXmPirw1rseu+DUl8c61M8urSJG7WlkDC32G7O5cQYJwCuDkYY8ZwR0f/AAiniL/ooWu/+AVh/wDI9AHV/YbT/n1g/wC/Yo+w2n/PrB/37Fcp/wAIp4i/6KFrv/gFYf8AyPR/winiL/ooWu/+AVh/8j0AJ8P9L0+E+JTFY2yGTWrmR9sSjcx25J4611FxpWnXCBLiwtJUDrIFeFWAZWDKeR1DAEHsQDXmPgXwt4jb/hIc+PdXjA1i5A8uys+R8vLboW+b1xtX0UV0/wDwiniL/ooWu/8AgFYf/I9AHTw6Xp8CFILG1jQu0hVIVALMxZm4HUsSSe5JNec/HHQv7T0jSbLS7GCTUbuW+tbdQqoWd9Kvgq7jgDLbepA4HpW//wAIp4i/6KFrv/gFYf8AyPXOeKvDWux674NSXxzrUzy6tIkbtaWQMLfYbs7lxBgnAK4ORhjxnBAB8r+L/E8Hj74c+H7KK3MF74O0hjdybAiTq09rbx7OWLEKVJJ25OSABgV137PE5n+EHxfs5hC8VvpTzxAxruVnt5wx3Y3Efu04zgdsZOeu+K/wisfh58G/Fdzous37xTtbtPBLb22Js3EQALiIOFBwQqsBkdOTn500rTfEGmeDL3xVp109npU9ydCmaKYq1wZImkeMqOqbVXO7jLLjODtAPfPgJ8YdT17xj4U8FPo2jxaOlmLQymJnuG8i0J3b9wX5mjzjbwDjJI3Vo/Bf44XcVp4V0PUtBvW8PhLbQ49WSLCre9FVmyE2hCnGd4Cluc4Hifwl8JeLdftNV1LwA0v9t6bPBGBDJFDIsU0VwrusrspXGAuFOTvz/CCPbNF+GMniD9miBbDVdQeJrF9Sg0sWdrKHulDN8riIS7mIKgh9wVtuSOCAe4/EDxxoXw/sILrU0llu76YQ2tjZRB7m8kJAwiZGcbgSSccgdWUHznxr8RdI8W6DdaDrfwy+IVylymVifRtrK4B2up3kqQQfmAPfgjIrF+Hng/xt8QPEkfjLxlq2u6E2lbrfSbS6toTcRsyjzJSjQJHg7iAfL3HA5HlqT66vhXxCGBPxA1xh6GysP/kegDwDwNrHjjRrTQPC0Pw0S/1LTdHuLiBdQuogwiuLpGhkdSBs2PGAUJDNt3fJtNbXhf4XeJvFnifSpfHXgrwj4W0TS5xdvDpNlbiTUHH3YnIaT92CPmUkAhsYJwU6K/8ADXiuf41XdtpPj28s7tfD0Mj3c+mWs7MhuJgsYUIqgBhuzgk5Iz0x0H/CE/E//orn/ltWv/xVAGp8I9EtvD1x4402xtoLW1j8QySRwwcIiyWttIAB/DgPjA4HQcVgfEHX7HRfjd4QtPEPhnR7zT9WhSCw1WW1SS7gvVm4VXOSqLvjI4HzSZB4IryLxP4p8aeAvF/jjTNR+Ic1rdwQRapBM2hWwXVpWihiCqGPyEYjT5AwxHIxwVOej+JXgz4kL8PofFmreOJNS1HRxa6wumjSIYhBNFklt2QP3YkkJynzBcEcDAB9C+LL2x07wrrN9q9t9r022spprq38tX82JUJdNrcNlQRg8HPNfOK/FL4T3kCDRvhNNfXlwzw2cQ0G0C3EyqD5YZSxz8yZwrEBgcHgG+8XjzxT4/1b4ef8LJj1DTl0k3Go3g0GFVKzBQLfC4zujkVg6uOGODleO/07wH4/0yyis9O+I1haWkI2xwQeF7eNEHoFDgD8KAPLnbxTr8MUvhX9n3wxpyozrMNZsoQznCkbVcQEDk84YHtjaaZ4P+FnifWvita33iG28MeGhpY07WH07SLCMbds0wjiBXoWMUpdvMbrH97aoT13/hEfiV/0VGD/AMJuH/45WN4d8N+OIPinqH23x9FdeTZabPdY0SKP7TB591iAYf5PuyfOMn95/sigD2WiiigAooooAKKKKACiszxPrdp4b8PajrOpFxZ2MDTybBliAM4A9T0H1rnfAfj6HxVqN7ps+l3elala28F35FwyPvhmXcjgqSPYg9DQB0Gu69aaJ5H22HUpfO3bfsWm3F3jGM7vJRtvUY3YzzjODWV/wnmkf8+fiT/wnNR/+MVk/Ff4q6H8Mv7L/t611K4/tHzfK+xRo+3y9m7dudcf6wYxnvXAf8NV+B/+gV4k/wDAeD/49QBueGPGGmRfFnxzdNba6Yp7XTVRV0K9ZwVWfO5BDuQcjBYDPOM4Ndz/AMJ5pH/Pn4k/8JzUf/jFfP8AoH7RfhWx+IPizXLnTNb+xapDZRWyxxRNIPJWTeXBkAXmTjBbgZOOldX/AMNV+B/+gV4k/wDAeD/49QB6r/wnmkf8+fiT/wAJzUf/AIxR/wAJ5pH/AD5+JP8AwnNR/wDjFeVf8NV+B/8AoFeJP/AeD/49R/w1X4H/AOgV4k/8B4P/AI9QB6r/AMJ5pH/Pn4k/8JzUf/jFH/CeaR/z5+JP/Cc1H/4xXlX/AA1X4H/6BXiT/wAB4P8A49R/w1X4H/6BXiT/AMB4P/j1AHqv/CeaR/z5+JP/AAnNR/8AjFeaeBPFunW/xn+KN3Jba2Yrr+y/LWPRbx5F22zA741iLR+28DcORkVV/wCGq/A//QK8Sf8AgPB/8erivCv7QHhXSPiT468Q3NhrbWWu/YfsyRwxGRPIhKPvBkAGSeME8dcUAfRX/CeaR/z5+JP/AAnNR/8AjFH/AAnmkf8APn4k/wDCc1H/AOMV5V/w1X4H/wCgV4k/8B4P/j1H/DVfgf8A6BXiT/wHg/8Aj1AHYfE3xppd18NvFlvFa+IFkl0m7jUy6BfxoCYXA3O0IVR6kkAdSRR8MvGml2vw28J28tr4gaSLSbSNjFoF/IhIhQHa6wlWHoQSD1BNeR/EH9pvRdc8Oa3ouleH9RMOo2E1otxcypGyNJGyZKLuyBnP3ufaqvhD9p6y0Dwnoujt4XuZm06ygtDKLxQHMcapuxs4zjNAHp/hXxnpyfFvx5cyWXiARS22mJHjQ7xnO1JskosRZB82AXC5wcZAzWl4/wDHGkyQ6CPsGvuo1m0Zlk0G9jzh+CN8IDEHDBRljt4BOBXhmg/tG2ml+O/FXiFvD15MmtJZqsDXo/ceQjqcHZ0O7OPXJ78aXiL9qC01Uab5XheeP7JfRXbbrwHcEzlR8nB5oA+i/wDhPNI/58/En/hOaj/8Yrmvh9400u20G6SS18QFjq2pyZj0C/kGGv52HKwkZwRkdQcggEEDzD/hrWw/6FK6/wDA5f8A4isnwx+09Y6Jps1qfDFzMZL68u9wvFXAnuZZguNh6CQDPfFAHrms+MNJm+J/ha6+w+JGS307UR8uh36MrM9rhinlBnXAYHAYAsmcEqa67/hPNI/58/En/hOaj/8AGK+c7v8AaftJvF2l6wvhacR2lldWbRG9GT5zwOGB2dvIxj/a68YPR6X+1joMlww1Tw3qltBtJV7aWOdi2RwVbYAMZ5z+HoAeieLPGmlza94MdLXxAFg1aSRg+gX6kj7Bdr8oMILHLDhcnGTjAJHS/wDCeaR/z5+JP/Cc1H/4xXh3iL9pbwhqGqeGrq20zXwmm6i11MJIYQWQ2txD8uJTlszKcHAwDzW5/wANV+B/+gV4k/8AAeD/AOPUAeq/8J5pH/Pn4k/8JzUf/jFH/CeaR/z5+JP/AAnNR/8AjFeVf8NV+B/+gV4k/wDAeD/49R/w1X4H/wCgV4k/8B4P/j1AHV+AfHumkeIjLp3iOP8A4nNzsxoV7JuX5cH5Im2/7rYYdwK6r/hPNI/58/En/hOaj/8AGK8L8JftMeFtN/tn+0dJ1sfatTnuYPIjif8AdNjbuzIuG4OQMgeprf8A+Gq/A/8A0CvEn/gPB/8AHqAPVf8AhPNI/wCfPxJ/4Tmo/wDxiua8WeNNLm17wY6WviALBq0kjB9Av1JH2C7X5QYQWOWHC5OMnGASOP8A+Gq/A/8A0CvEn/gPB/8AHqw/EH7S3hDUdY8M3MGma+IdNv3u598MIYqbWeEBQJTk7plPJHAPXpQB037R/i3TtT+DHiKztrbW0lk+z7WudFvLeMYuYjzJJEqL07kZOAOSK8m+Dei6J4u+C82ga62txxxeJRqBfT9HurwMqwRqyb4kZVYqXHJJGQdp4ztfGb9oDwr43+G2seHtKsNbhvbzyfLe5hiWMbJkc5KyE9FPY84qH4J/Hfwd4B+HWn6Ff6Tq51CN5ZLqWztoSkrtIxViTIpYhNi5I/hA6AUAehfs/wCvaX4e8KaxbTWOvLNLrd5LIItCvZMHcEAbZG4RgEAKZyCMHmtX4H+MNMsPhN4ZtZ7bXXlitQrNBoV7MhO49HSEqw9wTXnngH9ozwj4f0/VIr3S9fM15qt5qH7qOF1CzTM6jmRSCFIBHPIJzzgN+F/7RXhLwp4A0TQ9Q0/XpbuxtxFI8EEJQnJPBMoOOe4FAHv3/CeaR/z5+JP/AAnNR/8AjFH/AAnmkf8APn4k/wDCc1H/AOMV5V/w1X4H/wCgV4k/8B4P/j1H/DVfgf8A6BXiT/wHg/8Aj1AHTR+NND/4W5cXK2HiATHQ443f+w77eV+0OVHl+VvAB3fNtwc4ySCB1/8Awnmkf8+fiT/wnNR/+MV4Tb/tIeDoviBqGuvo+tNb3Gl21lG/kQ+cjRyzuwx5mNjCVP4uqdOhrof+Gq/A/wD0CvEn/gPB/wDHqANP4k+Hfh98Q9Rs9Q1/TfF631sEjE1toepIZIVLN5TAwFdpLkkgBvRhW78TfGml3fw28WW8Vr4gV5dJu41MugX0aAmFwNzNCFUepJAHciuP/wCGq/A//QK8Sf8AgPB/8erE8b/tK+Dte8F6/pFnpviBLnUNPuLSJpYIQgeSNlBYiUnGSM4BoA7b4T2nhr4d6VPDA3i/U9QuxCLq9uvDuo7nEUYSNFXyPljUZCrkkA4yQBjuv+E80j/nz8Sf+E5qP/xivKv+Gq/A/wD0CvEn/gPB/wDHqP8AhqvwP/0CvEn/AIDwf/HqAPVf+E80j/nz8Sf+E5qP/wAYrn9F8W6dcfFPV/LttbH2nTNNt08zRbxMMJ73l90Q2L84+dsLw3Pytjiv+Gq/A/8A0CvEn/gPB/8AHqoeHP2hvCmofEqea303XyNWtrDTbdfs0bMJUmuCSQJCcH7QmMZJweOmQD6OooooAKKKKACiiigDI8X6DbeKPC+qaHeu6W9/A0DOn3kyOGHuDg/hXNfD7wDN4Y1i/wBW1TWP7W1K5tbexWRbYW6RwwrhRt3Nlj1Jz16AV3lFAHn/AMV/hVofxN/sv+3rrUrf+zvN8r7FIibvM2bt25Gz/qxjGO9cB/wyp4H/AOgr4k/8CIP/AIzXv9FAHyv4a/Z18Jap4x8YaTcajrq22jz20UDJPCHYSW6StvJiIJ3McYA4/Oup/wCGVPA//QV8Sf8AgRB/8Zr1LwpFEfGnje5gjCE3dtbynGC8i2kT5+myWMfgfx62gDwD/hlTwP8A9BXxJ/4EQf8Axmj/AIZU8D/9BXxJ/wCBEH/xmvf6KAPAP+GVPA//AEFfEn/gRB/8Zo/4ZU8D/wDQV8Sf+BEH/wAZr3+igDwD/hlTwP8A9BXxJ/4EQf8AxmuW8Nfs6+EtU8Y+MNJuNR11bbR57aKBknhDsJLdJW3kxEE7mOMAcfnX1RXn3gP/AJKf8Tf+vyx/9IoqAOB/4ZU8D/8AQV8Sf+BEH/xmj/hlTwP/ANBXxJ/4EQf/ABmvf6KAPmXxv+zV4O0HwXr+r2epeIHudP0+4u4llnhKF442YBgIgcZAzgirug/sweC9Q0PTrybU/ESy3FtHM4S4hABZQTjMXTmvcPHtmuoeBvEdlIzIlzptzCzL1AaJhkfnVjwmNvhbRlHQWcI/8cFAHzB4V/Z/8K6v8SfHXh65v9bWy0L7D9meOaISP58Jd95MZBwRxgDjrmtrxT+zV4O0oaSbfVde/wBK1CG0kMs8J+Ryc4xEPm446/Q16L8O/wDku3xc/wC4R/6StWt8YyosPCu8MR/wk2mYwcc+euO1AHn/APwyp4H/AOgr4k/8CIP/AIzWJ4Q/Zq8HazpU91dal4gSSPUL60AjnhA2Q3UsKHmI8lYwT75xjpX01XK/DT/kXLz/ALDWrf8ApxuKAPD7v9mrwdD400rSF1LxAba60+8u3Yzw7w8UlsqgHysYInfPHYdOc7f/AAyp4H/6CviT/wACIP8A4zXqupf8lT8Pf9gXU/8A0fYV1VAHzLr/AOzV4O07VvDVrBqXiBo9S1B7SYvPCSqC1uJsriLg7oVHOeCfYjb/AOGVPA//AEFfEn/gRB/8Zr1Xxl/yMfgT/sNSf+m68rqqAPAP+GVPA/8A0FfEn/gRB/8AGaP+GVPA/wD0FfEn/gRB/wDGa9/ooA+ZvDH7NHhDUxqv2rU9fBtdQmtY/LmhGUXGM5iOTzyeB7Ctr/hlTwP/ANBXxJ/4EQf/ABmvWPAv/Mw/9hi4/wDZa6egDwD/AIZU8D/9BXxJ/wCBEH/xmsTX/wBmrwdp2reGrWDUvEDR6lqD2kxeeElUFrcTZXEXB3QqOc8E+xH01XK+Mv8AkY/An/Yak/8ATdeUAeB/E79nTwl4W8A65rmnajrsl3Y25mjSeeFkJBHDARA4/EVR+DP7P/hXxv8ADbR/EOq3+tw3t553mJbTRLGNkzoMBoyeijuec17t8e/+SOeLf+vFv5isn9lwEfArwzn/AKef/SqWgDznwf8As1+Dta0q4ubnU9fWSLUL60xFcQgbYbqWFCcxHkrGpPuTjA4qj8L/ANnXwl4r8AaJrmo6jrsd3fQebIkE8IQHJHygxE447k19R21tBaxtHawxwxs7yFY1Cgu7FnbA7lmLE9ySe9cL8A43i+DvhVJVZHW0wysMEHc3UUAef/8ADKngf/oK+JP/AAIg/wDjNH/DKngf/oK+JP8AwIg/+M17/RQB8y2n7NXg6bxpqukNqXiAW1rp9ndownh3l5ZLlWBPlYwBAmOO568Y2/8AhlTwP/0FfEn/AIEQf/Ga9V03/kqfiH/sC6Z/6Pv66qgDwD/hlTwP/wBBXxJ/4EQf/GaxPG/7NXg7QfBev6vZ6l4ge50/T7i7iWWeEoXjjZgGAiBxkDOCK+mq5X4sf8ks8Zf9gW9/9EPQB5+37OXhI/8AL9qQ+lvY8/8AktVe5/Zn8H3O3zNR1kY6eWlnH+e23Gele5UUAeJJ+zd4RQYGoar1J5gsT1Oe9tXMeHvgX4Wl+KGv2S3urbdIh0+5jLRWgDSO0rEFfJKlf3MfRVzlwcg8/Slcn4dt4l+IPi+4VAJpEso2b1VY3Kj8CzfnQB1lFFFABRRRQAUUUUAFFFFABRRRQByvg3/kY/Hf/Yaj/wDTdZ11Vcr4N/5GPx3/ANhqP/03WddVQAUUUUAFFFFABXMaBj/hOPFZCqDi0BIUAn923XHU89T2wOgFdPXKeGZ0m8beMgkb5hmtYWk52lvs6vtGR1AcE4J4ZelAHV0UUUAZnin/AJFjV/8Arzm/9ANHhb/kWNI/684f/QBVD4jXbWHw98UXkYy9vpd1Ko91iY+/pWvpFq1lpNlatjdBAkRw27lVA64GenXA+goA81+Hf/Jdvi5/3CP/AElarvxuukt7XwVG4Ytc+LNMiTA4BEpfn2wh/SqXw7/5Lt8XP+4R/wCkrUfH3/mnH/Y56b/7UoA9Vrlfhp/yLl5/2GtW/wDTjcV1Vcp8L0I8G28jtvkubq7unOMfNLcyyMB7Zc0ALqX/ACVPw9/2BdT/APR9hXVVyupf8lT8Pf8AYF1P/wBH2FdVQByvjL/kY/An/Yak/wDTdeV1Vcr4y/5GPwJ/2GpP/TdeV1VABRRRQBx3wzuje2niKcoqf8T2+iChwx/dymPJx0J2ZwfUdeCexrj/AIW20UGg6nJEu17jXdWkkOSdzC+nXPtwqjj0rsKACuW8Roj+NvCO+ONij3UiMyglW8krkHqOGYcetdTXMeIP+R38Kf8Ab3/6KFAGR8e/+SOeLf8Arxb+Yqp+zhZ/Yfgn4WiD790DzZxj/WSu+Pw3Y/Crfx7/AOSOeLf+vFv5ij4Cf8kc8Jf9eK/zNAHfVx/we+0v8MPDM96YzcXNkl0xj+7+9/eDt6MOP59a7CuV+E//ACSzwb/2BbL/ANEJQB1VFFFAHK6b/wAlT8Q/9gXTP/R9/XVVwfhm4ln+MPjmOV9yQWGlRxDAG1T9qbHv8zMefWu8oAK5X4q6tDofw58RahdWSX9vFZyCS1dtqyqw2lScHghq6qvPv2gP+SM+LP8ArzP/AKEtAHoNFFFABXMeH/8Akd/Ff/bp/wCijXT1xHhbUkuPih4509Apa0i093YPk5kjk+UjsQFB/wCBD8QDt6KKKACiiigAooooAKKKKACiiigDmvCdtPBr3jOSeGWOO41aOSFnQgSILC0XcpPUblZcjupHY10tFFABRRRQAUUUUAFc14Ttp4Ne8ZyTwyxx3GrRyQs6ECRBYWi7lJ6jcrLkd1I7GulooAKKKKAOa+JttPefDbxZa2cMs9zPpN3HFFEhZ5HaFwFUDkkkgACuloooA818CabfW3xn+KN9c2dzDZXn9l/ZriSJljn2WzB9jEYbaeDjOD1o+Num32o/8ID/AGfZXN39m8W2FzP5ETP5US+ZukbA+VRkZY8DNelUUAFcx8NFlTwVYJcW9xbSo0ytFcRNE4xK4yVYA4PUHuCD3rp6KAOav7adviToV0sMpto9J1CN5Qp2K7TWRVSegJCOQO+0+hrpaKKAOa8WW08+veDJIIZZI7fVpJJmRCRGhsLtdzEdBuZVye7AdxXS0UUAFFFFAHNfD62ntdBuo7qGWGQ6tqcgWRCpKPfzsjYPYqwYHuCCOtdLRRQAVyPiiO+PjvwVJaQO9os12t1IImYRqbdtuWAwuWCjLYz06muuooA5L4uaXJrPwv8AFNhbx3EtxLp05ijt13SSSKhZUAwc5YAYAyc8c034QaTeaF8MfDWm6nF5N7BZRiWLujEZ2n3GcH3B611V1cwWkJmupooIgQpeRwqgkgAZPqSAPc1W0TV9P1zTor7SLuG7tZVV1kjbPDKHGR1B2spwcHkUAXq5r4ZW09n8NvCdreQywXMGk2kcsUqFXjdYUBVgeQQQQQa6WigAooooA4bwvZXUXxZ8dXctrcR2lxa6YkM7xsqSlFn3BGIw2Ny5x0yM13NFFABXmv7R9rfXvwX8R22kwXNxeSrAqRWyM8jj7RHuAC8kbc59s16VRQAUUUUAFeVfDv8A5Lt8XP8AuEf+krV6rRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQBS1rTLbWdLuNOv1drS4XZKqSMhZc8rlSCAehwehNZ3gfwtY+DfDVpoulNO1rbqADNIXJbADNz0yQWwMDJOAK3qKACiiigAooooAKKKKACiiigAooooAKKKKACiiigD//Z);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    A transeptal catheter is in the left atrium (LA) and the pressure tracing shows large \"v\" waves as a result of mitral regurgitation (MR). The \"v\" wave of 40 mmHg is twice the mean LA pressure which is 20 mm Hg. The asterisk shows where the catheter is pulled back to the right atrium (RA); since the pressure tracing is continuous, it accurately reflects the pressure gradient between the LA and RA. The RA pressure is lower and the a and v waves are diminutive relative to the left side.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Redrawn from Kern MJ (Ed). Cardiac Catheterization Handbook, 2nd Edition. Mosby-Year Book, Inc., St. Louis, 1995.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f36_23_37234=[""].join("\n");
var outline_f36_23_37234=null;
var title_f36_23_37235="Fever in children";
var content_f36_23_37235=[" <h1 id=\"patTopicTitle\">",
"  Patient information: Fever in children (Beyond the Basics)",
" </h1>",
" <div id=\"patTopicContributors\">",
"  <div class=\"rcTop\">",
"   <div>",
"   </div>",
"  </div>",
"  <div class=\"rcContent\">",
"   <table>",
"    <tr>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"mobipreview.htm?36/23/37235/contributors\">",
"       Author",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?36/23/37235/contributors\" id=\"au4844\">",
"       Mark A Ward, MD",
"      </a>",
"     </td>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"mobipreview.htm?36/23/37235/contributors\">",
"       Section Editor",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?36/23/37235/contributors\" id=\"se4583\">",
"       Morven S Edwards, MD",
"      </a>",
"     </td>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"mobipreview.htm?36/23/37235/contributors\">",
"       Deputy Editor",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?36/23/37235/contributors\" id=\"de5754\">",
"       Mary M Torchia, MD",
"      </a>",
"     </td>",
"    </tr>",
"   </table>",
"  </div>",
"  <div class=\"rcBottom\">",
"   <div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"patTopicTool\" id=\"patTopicToolTop\">",
"  <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"   Find",
"  </a>",
"  <a class=\"toolbutton printicon\" href=\"mobipreview.htm?36/23/37235?view=print\" title=\"Print This Topic\">",
"   Print",
"  </a>",
"  <script src=\"file://w.sharethis.com/button/sharethis.js#publisher=357881b8-c7e3-4c31-b7d2-242aeb1528e1&amp;type=website&amp;post_services=care2%2Cfacebook%2Ctwitter%2Cmyspace%2Cdigg%2Cdelicious%2Cfaves%2Creddit%2Cxanga%2Cstumbleupon%2Cblinklist%2Csimpy%2Cyigg%2Ctechnorati%2Cmeneame%2Corkut%2Cmixx%2Cfunp%2Cfresqui%2Cmister_wong%2Cfriendster%2Cfriendfeed%2Clinkedin%2Coknotizie%2Cgoogle_bmarks%2Cyahoo_bmarks%2Cfark%2Cnewsvine%2Clivejournal%2Ctypepad%2Cbus_exchange%2Cpropeller%2Cwordpress%2Cblogger%2Cblogmarks%2Cwindows_live%2Cfurl%2Cybuzz%2Cdiigo\" type=\"text/javascript\">",
"  </script>",
" </div>",
" <div id=\"patTopicMiddle\">",
"  <div id=\"topicContent\">",
"   <div id=\"topicText\">",
"    <p class=\"headingAnchor\" id=\"H1\">",
"     <span class=\"h1\">",
"      FEVER OVERVIEW",
"     </span>",
"    </p>",
"    <p>",
"     Fever is a normal response to a variety of conditions, the most common of which is infection. Fever occurs when the body's temperature is elevated as a result of the body's thermostat being reset to a higher-than-usual temperature.",
"    </p>",
"    <p>",
"     Nearly every child will develop a fever at some point. The challenge for parents is to know when to be concerned. This topic review will discuss the definition of a fever, how to accurately measure a child's temperature, how and when to treat fever, and signs and symptoms that require further evaluation.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H3\">",
"     <span class=\"h1\">",
"      FEVER DEFINITION",
"     </span>",
"    </p>",
"    <p>",
"     Because of the normal variation in body temperature, there is no single value that is defined as fever. However, the following are generally accepted values:",
"    </p>",
"    <p>",
"     <ul class=\"bulletCompact-block\">",
"      <li>",
"       Rectal temperature above 100.4&ordm;F (38&ordm;C)",
"      </li>",
"      <li>",
"       Oral temperature above 100&ordm;F (37.8&ordm;C)",
"      </li>",
"      <li>",
"       Axillary (armpit) temperature above 99&ordm;F (37.2&ordm;C)",
"      </li>",
"      <li>",
"       Ear (tympanic membrane) temperature above 100.4&ordm;F (38&ordm;C) in rectal mode or 99.5&ordm;F (37.5&ordm;C) in oral mode",
"      </li>",
"      <li>",
"       Forehead (temporal artery) temperature above 100.4&ordm;F (38&ordm;C)",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     Axillary, ear, and forehead temperature measurements are easier to obtain than rectal or oral temperatures, but they are less accurate and may need to be confirmed rectally or orally in certain children.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H4\">",
"     <span class=\"h1\">",
"      FEVER CAUSES",
"     </span>",
"    </p>",
"    <p>",
"     Infection is the most common cause of fever in children. Common viral and bacterial illnesses like colds, gastroenteritis, ear infections, croup, bronchiolitis, and urinary tract infections are the most likely illnesses to cause fever. (See",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?39/44/40643?source=see_link\">",
"      \"Patient information: The common cold in children (Beyond the Basics)\"",
"     </a>",
"     and",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?21/54/22371?source=see_link\">",
"      \"Patient information: Nausea and vomiting in infants and children (Beyond the Basics)\"",
"     </a>",
"     and",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?15/16/15619?source=see_link\">",
"      \"Patient information: Ear infections (otitis media) in children (Beyond the Basics)\"",
"     </a>",
"     and",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?2/28/2500?source=see_link\">",
"      \"Patient information: Croup in infants and children (Beyond the Basics)\"",
"     </a>",
"     and",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?27/19/27958?source=see_link\">",
"      \"Patient information: Bronchiolitis (and RSV) in infants and children (Beyond the Basics)\"",
"     </a>",
"     and",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?37/58/38818?source=see_link\">",
"      \"Patient information: Urinary tract infections in children (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p>",
"     There is little or no scientific evidence to support the widespread belief that teething causes fever. Although it is difficult to disprove this notion completely, alternative causes of fever should always be sought and temperatures above 102&deg;F (38.9&deg;C) should never be attributed to teething.",
"    </p>",
"    <p>",
"     Bundling a child who is less than three months old in too many clothes or blankets can increase the child's temperature slightly. However, a rectal temperature of 101&ordm;F (38.5&ordm;C) or greater is not likely to be related to bundling and should be evaluated. (See",
"     <a class=\"local\" href=\"#H12\">",
"      'Evaluation recommended'",
"     </a>",
"     below.)",
"    </p>",
"    <p>",
"     Some childhood immunizations can cause fever. The timing of the fever varies, depending upon which vaccination was given. (See",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?41/36/42566?source=see_link\">",
"      \"Patient information: Vaccines for infants and children age 0 to 6 years (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H5\">",
"     <span class=\"h1\">",
"      HOW DO I MEASURE MY CHILD'S TEMPERATURE?",
"     </span>",
"    </p>",
"    <p>",
"     The best way to measure a child's temperature depends upon several factors. In all children, a rectal temperature is the most accurate. However, it is possible to accurately measure the temperature in the mouth (for children older than four or five years) when the proper technique is used.",
"    </p>",
"    <p>",
"     Temperatures measured in the armpit are less accurate but may be useful as a first test in an infant who is younger than three months or an older child who cannot hold the thermometer under his or her tongue. If the armpit temperature is over 99&ordm;F (37.2&ordm;C), the rectal temperature should be measured. Temperatures measured in the ear or on the forehead also are less accurate than temperatures measured rectally or orally and may need to be confirmed by one of these methods.",
"    </p>",
"    <p>",
"     It is not accurate to measure a child's temperature by feeling the child's skin. This is called a tactile temperature, and it is highly dependent upon the temperature of the person who is feeling the child's skin.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H6\">",
"     <span class=\"h2\">",
"      Glass versus digital thermometers",
"     </span>",
"     &nbsp;&mdash;&nbsp;Digital thermometers are inexpensive, widely available, and the most accurate way to measure temperature. A variety of styles are available.",
"    </p>",
"    <p>",
"     Glass thermometers that contain mercury are not recommended due to the potential risks of exposure to mercury (which is toxic) if the thermometer is broken. If a digital thermometer is not available, be sure to carefully \"shake down\" the glass thermometer before use. Instructions for disposing of thermometers that contain mercury are available online (",
"     <a class=\"external\" href=\"file://www.epa.gov/mercury/spills/index.htm\">",
"      www.epa.gov/mercury/spills/index.htm",
"     </a>",
"     ).",
"    </p>",
"    <p>",
"     Other types of thermometers are available, including plastic strip and pacifier thermometers. However, these are not as accurate as digital thermometers and are not recommended.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H7\">",
"     <span class=\"h2\">",
"      Rectal temperature",
"     </span>",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       The child or infant should lie down on his or her stomach across an adult's lap.",
"      </li>",
"      <li>",
"       Apply a small amount of petroleum jelly (eg, Vaseline) to the end of the thermometer.",
"      </li>",
"      <li>",
"       Gently insert the thermometer into the child's anus until the silver tip of the thermometer is not visible",
"       <span class=\"nowrap\">",
"        (1/4",
"       </span>",
"       to",
"       <span class=\"nowrap\">",
"        1/2",
"       </span>",
"       inch inside the anus) (",
"       <a class=\"graphic graphic_figure graphicRef74460 \" href=\"mobipreview.htm?6/33/6675\">",
"        figure 1",
"       </a>",
"       ).",
"      </li>",
"      <li>",
"       Hold the thermometer in place. A glass thermometer requires two minutes, while most digital thermometers need less than one minute.",
"      </li>",
"     </ul>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H8\">",
"     <span class=\"h2\">",
"      Oral temperature",
"     </span>",
"     &nbsp;&mdash;&nbsp;Do not measure the temperature in a child's mouth if he or she has consumed a hot or cold food or drink in the last 30 minutes.",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       Clean the thermometer with cool water and soap. Rinse with water.",
"      </li>",
"      <li>",
"       Place the tip of the thermometer under the child's tongue toward the back. Ask the child to hold the thermometer with his or her lips.",
"      </li>",
"      <li>",
"       Keep the lips sealed around the thermometer. A glass thermometer requires about three minutes, while most digital thermometers need less than one minute.",
"      </li>",
"     </ul>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H9\">",
"     <span class=\"h2\">",
"      Armpit temperature",
"     </span>",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       Place the tip of the thermometer in the child's dry armpit.",
"      </li>",
"      <li>",
"       Hold the thermometer in place by holding the child's elbow against the chest for four to five minutes.",
"      </li>",
"     </ul>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H10\">",
"     <span class=\"h2\">",
"      Ear temperature",
"     </span>",
"     &nbsp;&mdash;&nbsp;Ear thermometers are not as accurate as rectal or oral thermometers. If the child has been outside on a cold day, wait 15 minutes before measuring the ear temperature. Ear tubes and ear infections do not affect the accuracy of an ear temperature.",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       To measure temperature accurately in the ear, the parent must pull the child's outer ear backward before inserting the thermometer (",
"       <a class=\"graphic graphic_figure graphicRef61085 \" href=\"mobipreview.htm?42/42/43695\">",
"        figure 2",
"       </a>",
"       ).",
"      </li>",
"      <li>",
"       Hold the ear probe in the child's ear for about two seconds.",
"      </li>",
"     </ul>",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H11\">",
"     <span class=\"h1\">",
"      SHOULD I TREAT MY CHILD'S FEVER?",
"     </span>",
"    </p>",
"    <p>",
"     There are pros and cons of treating fever. Fever may play a role in fighting infection, but it can also make a child uncomfortable.",
"    </p>",
"    <p>",
"     The height of a child's fever is not always the best indicator of whether the child needs to be treated",
"     <span class=\"nowrap\">",
"      and/or",
"     </span>",
"     evaluated. Instead, it is important to note how a child behaves and appears. Fever is usually accompanied by other symptoms. Some of these symptoms require evaluation by a healthcare provider, even if there is no fever. The table provides a list of some of these symptoms (",
"     <a class=\"graphic graphic_table graphicRef52493 \" href=\"mobipreview.htm?38/23/39291\">",
"      table 1",
"     </a>",
"     ).",
"    </p>",
"    <p>",
"     In most cases, a child with a fever can be observed",
"     <span class=\"nowrap\">",
"      and/or",
"     </span>",
"     treated at home. However, it is important for parents to know when a child with a fever needs to be evaluated by a healthcare provider, when fever should be treated, and when it is reasonable to observe the child without treating the fever.",
"    </p>",
"    <p>",
"     The guidelines provided below are general guidelines that do not apply to every situation; parents who have questions or are concerned about their child should contact their child's healthcare provider for advice.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H12\">",
"     <span class=\"h2\">",
"      Evaluation recommended",
"     </span>",
"     &nbsp;&mdash;&nbsp;A healthcare provider should be consulted in the following situations:",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       Infants who are less than three months of age who have a rectal temperature of 100.4&ordm;F (38&ordm;C) or greater, regardless of how the infant appears (eg, even well-appearing young infants should be evaluated).",
"      </li>",
"      <li>",
"       Children who are three months to three years who have a rectal temperature of 100.4&ordm;F (38&ordm;C) or greater for more than three days or who appear ill (eg, fussy, clingy, refusing to drink fluids).",
"      </li>",
"      <li>",
"       Children who are 3 to 36 months who have a rectal temperature of 102&ordm;F (38.9&ordm;C) or greater.",
"      </li>",
"      <li>",
"       Children of any age whose oral, rectal, tympanic membrane, or forehead temperature is 104&ordm;F (40&ordm;C) or greater or whose axillary temperature is 103&ordm;F (39.4&ordm;C) or greater.",
"      </li>",
"      <li>",
"       Children of any age who have a febrile seizure. Febrile seizures are convulsions that occur when a child (between six months and six years of age) has a temperature greater than 100.4&ordm; F (38&ordm;C). (See",
"       <a class=\"medical medical_patient\" href=\"mobipreview.htm?38/35/39473?source=see_link\">",
"        \"Patient information: Febrile seizures (Beyond the Basics)\"",
"       </a>",
"       .)",
"      </li>",
"      <li>",
"       Children of any age who have recurrent fevers for more than seven days, even if the fevers last only a few hours.",
"      </li>",
"      <li>",
"       Children of any age who have a fever and have a chronic medical problem such as heart disease, cancer, lupus, or sickle cell anemia.",
"      </li>",
"      <li>",
"       Children who have a fever as well as a new skin rash.",
"      </li>",
"     </ul>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H13\">",
"     <span class=\"h2\">",
"      Treatment recommended",
"     </span>",
"     &nbsp;&mdash;&nbsp;Treatment of fever is recommended if a child has an underlying medical problem, including diseases of the heart, lung, brain, or nervous system. In children who have had febrile seizures in the past, treatment of fever has not been shown to prevent seizures, but is still a reasonable precaution.",
"    </p>",
"    <p>",
"     Treatment of fever may be helpful if the child is uncomfortable, although it is not necessary.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H14\">",
"     <span class=\"h2\">",
"      Treatment not required",
"     </span>",
"     &nbsp;&mdash;&nbsp;In most cases, it is not necessary to treat a child's fever. A child older than three months who has a rectal temperature less than 102&ordm;F (38.9&ordm;C) and who is otherwise healthy and acting normally does not require treatment for fever.",
"    </p>",
"    <p>",
"     Parents who are unsure if their child's fever needs treatment should contact the child's healthcare provider. (See",
"     <a class=\"local\" href=\"#H12\">",
"      'Evaluation recommended'",
"     </a>",
"     above.)",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H15\">",
"     <span class=\"h1\">",
"      FEVER TREATMENT OPTIONS",
"     </span>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H16\">",
"     <span class=\"h2\">",
"      Medications",
"     </span>",
"     &nbsp;&mdash;&nbsp;The most effective way to treat fever is to use a medication such as acetaminophen (sample brand name: Tylenol) or ibuprofen (sample brand names: Advil, Motrin). These treatments can reduce the child's discomfort and lower the child's temperature by 2 to 3&ordm;F (1 to 1.5&ordm;C). Aspirin is not recommended for children under age 18 years due to concerns that it can cause a rare but serious illness known as Reye syndrome.",
"    </p>",
"    <p>",
"     Acetaminophen may be given every four to six hours as needed, but should not be given more than five times in a 24-hour period. Acetaminophen should not be used in children younger than three months of age. The dose of acetaminophen should be calculated based upon the child's weight (not age).",
"    </p>",
"    <p>",
"     Ibuprofen may be given every six hours. Ibuprofen should not be used in children younger than six months of age. The dose of ibuprofen should be calculated based upon the child's weight (not age).",
"    </p>",
"    <p>",
"     Giving combinations of acetaminophen and ibuprofen or alternating acetaminophen and ibuprofen increases the chance of giving the wrong dose of one or the other of the medications.",
"    </p>",
"    <p>",
"     Fever-reducing medications should only be given as needed, and discontinued once bothersome symptoms have resolved.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H6659985\">",
"     <span class=\"h2\">",
"      Increase fluids",
"     </span>",
"     &nbsp;&mdash;&nbsp;Having fever can increase a child's risk of becoming dehydrated. To reduce this risk, parents should encourage their child to drink an adequate amount of fluids. Children with fever may not feel hungry, and it is not necessary to force them to eat. However, fluids such as milk (cow's or breast), formula, and water should be offered frequently. Older children may eat flavored gelatin, soup, or frozen popsicles. If the child is unwilling or unable to drink fluids for more than a few hours, the parent should consult the child's healthcare provider.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H6659992\">",
"     <span class=\"h2\">",
"      Rest",
"     </span>",
"     &nbsp;&mdash;&nbsp;Having a fever causes most children to feel tired and achy. During this time, parents should encourage their child to rest as much as the child wants. It is not necessary to force the child to sleep or rest if he or she begins to feel better. Children may return to school or other activities when the temperature has been normal for 24 hours.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H17\">",
"     <span class=\"h2\">",
"      Sponging and baths",
"     </span>",
"     &nbsp;&mdash;&nbsp;Sponging is not as effective as antifever medications and generally is not recommended. Alcohol should not be used for sponging because of the risk of toxicity if it is absorbed through the skin.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H20\">",
"     <span class=\"h1\">",
"      WHERE TO GET MORE INFORMATION",
"     </span>",
"    </p>",
"    <p>",
"     Your child's healthcare provider is the best source of information for questions and concerns related to your child's medical problem.",
"    </p>",
"    <p>",
"     This article will be updated as needed on our web site (",
"     <a class=\"external\" href=\"file://www.uptodate.com/patients\">",
"      www.uptodate.com/patients",
"     </a>",
"     ). Related topics for patients, as well as selected articles written for healthcare professionals, are also available. Some of the most relevant are listed below.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H2413298919\">",
"     <span class=\"h2\">",
"      Patient level information",
"     </span>",
"     &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H11736269\">",
"     <span class=\"h3\">",
"      The Basics",
"     </span>",
"     &nbsp;&mdash;&nbsp;The Basics patient education pieces answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials.",
"    </p>",
"    <p>",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?39/40/40578?source=see_link\">",
"      Patient information: Fever in children (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?37/53/38738?source=see_link\">",
"      Patient information: Colic (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?11/20/11586?source=see_link\">",
"      Patient information: Febrile seizures (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?35/21/36179?source=see_link\">",
"      Patient information: Giving your child over-the-counter medicines (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?32/50/33569?source=see_link\">",
"      Patient information: Sepsis in adults (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?14/17/14611?source=see_link\">",
"      Patient information: Pneumonia in children (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?22/62/23521?source=see_link\">",
"      Patient information: Sepsis in newborn babies (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?13/7/13426?source=see_link\">",
"      Patient information: Adenovirus infections (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?11/61/12242?source=see_link\">",
"      Patient information: Juvenile rheumatoid arthritis (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?13/44/14019?source=see_link\">",
"      Patient information: Mycoplasma pneumonia in children (The Basics)",
"     </a>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H11736319\">",
"     <span class=\"h3\">",
"      Beyond the Basics",
"     </span>",
"     &nbsp;&mdash;&nbsp;Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are best for patients who want in-depth information and are comfortable with some medical jargon.",
"    </p>",
"    <p>",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?2/28/2500?source=see_link\">",
"      Patient information: Croup in infants and children (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?27/19/27958?source=see_link\">",
"      Patient information: Bronchiolitis (and RSV) in infants and children (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?37/58/38818?source=see_link\">",
"      Patient information: Urinary tract infections in children (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?41/36/42566?source=see_link\">",
"      Patient information: Vaccines for infants and children age 0 to 6 years (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?38/35/39473?source=see_link\">",
"      Patient information: Febrile seizures (Beyond the Basics)",
"     </a>",
"     <br/>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H21\">",
"     <span class=\"h2\">",
"      Professional level information",
"     </span>",
"     &nbsp;&mdash;&nbsp;Professional level articles are designed to keep doctors and other health professionals up-to-date on the latest medical findings. These articles are thorough, long, and complex, and they contain multiple references to the research on which they are based. Professional level articles are best for people who are comfortable with a lot of medical terminology and who want to read the same materials their doctors are reading.",
"    </p>",
"    <p>",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?9/30/9706?source=see_link\">",
"      Approach to the child with fever of unknown origin",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?28/17/28951?source=see_link\">",
"      Definition and etiology of fever in neonates and infants (less than three months of age)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?2/25/2456?source=see_link\">",
"      Drug fever",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?37/63/38905?source=see_link\">",
"      Etiologies of fever of unknown origin in children",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?27/26/28074?source=see_link\">",
"      Evaluation and management of fever in the neonate and young infant (less than three months of age)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?22/14/22762?source=see_link\">",
"      Fever without a source in children 3 to 36 months of age",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?18/8/18570?source=see_link\">",
"      Pathophysiology and management of fever in infants and children",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?39/38/40550?source=see_link\">",
"      Strategies for the evaluation of fever in neonates and infants (less than three months of age)",
"     </a>",
"     <br/>",
"     <br/>",
"     The following organizations also provide reliable health information.",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       National Library of Medicine",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.nlm.nih.gov/medlineplus/healthtopics.html\">",
"      www.nlm.nih.gov/medlineplus/healthtopics.html",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       American Academy of Pediatrics",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.healthychildren.org/english/health-issues/conditions/fever\">",
"      www.healthychildren.org/English/health-issues/conditions/fever",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       The Nemours Foundation",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.kidshealth.org/parent/general/body/fever.html\">",
"      www.kidshealth.org/parent/general/body/fever.html",
"     </a>",
"     , available in Spanish)",
"    </p>",
"    <p>",
"     [",
"     <a class=\"abstract\" href=\"mobipreview.htm?36/23/37235/abstract/1-4\">",
"      1-4",
"     </a>",
"     ]",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Apr 1, 2013.",
"  </div>",
"  <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"   <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"    Find",
"   </a>",
"   <a class=\"toolbutton printicon\" href=\"mobipreview.htm?36/23/37235?view=print\" title=\"Print This Topic\">",
"    Print",
"   </a>",
"  </div>",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <div id=\"patTopicRefHeader\">",
"    <div id=\"patTopicRefHeaderHeader\">",
"     References",
"    </div>",
"    <div id=\"patTopicRefHeaderTop\">",
"     <a href=\"#top\">",
"      <img alt=\"\" src=\"./../images/top_arrow.myextg\">",
"       Top",
"      </img>",
"     </a>",
"    </div>",
"   </div>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/23/37235/abstract/1\">",
"      Baraff LJ. Management of fever without source in infants and children. Ann Emerg Med 2000; 36:602.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/23/37235/abstract/2\">",
"      Mackowiak PA. Fever: blessing or curse? A unifying hypothesis. Ann Intern Med 1994; 120:1037.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/23/37235/abstract/3\">",
"      Meremikwu M, Oyo-Ita A. Paracetamol for treating fever in children. Cochrane Database Syst Rev 2002; :CD003676.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/23/37235/abstract/4\">",
"      Sarrell EM, Wielunsky E, Cohen HA. Antipyretic treatment in young children with fever: acetaminophen, ibuprofen, or both alternating in a randomized, double-blind study. Arch Pediatr Adolesc Med 2006; 160:197.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
" </div>",
" <!-- patTopicMiddle -->",
"</div>"].join("\n");
var script_f36_23_37235=[""].join("\n");
var outline_f36_23_37235=[" <div class=\"patTopicFancyTop\">",
"  <div class=\"rcTop\">",
"   <div>",
"   </div>",
"  </div>",
"  <div class=\"rcContent\">",
"   <p>",
"    Contents of this article",
"   </p>",
"  </div>",
" </div>",
" <div class=\"patTopicFancySpacer\">",
" </div>",
" <div class=\"patTopicOutline\">",
"  <div class=\"rcbBottom\">",
"   <div class=\"rcbLeft\">",
"    <div class=\"rcbRight\">",
"     <div class=\"rcbBottomLeft\">",
"      <div class=\"rcbBottomRight rcbBottomRightBottomOnly\">",
"       <div id=\"outline\">",
"        <ul>",
"         <li class=\"plainItem\">",
"          <a href=\"#H1\">",
"           FEVER OVERVIEW",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H3\">",
"           FEVER DEFINITION",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H4\">",
"           FEVER CAUSES",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H5\">",
"           HOW DO I MEASURE MY CHILD'S TEMPERATURE?",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H11\">",
"           SHOULD I TREAT MY CHILD'S FEVER?",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H15\">",
"           FEVER TREATMENT OPTIONS",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H20\">",
"           WHERE TO GET MORE INFORMATION",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#references\">",
"           REFERENCES",
"          </a>",
"         </li>",
"        </ul>",
"       </div>",
"       <h1>",
"        GRAPHICS",
"       </h1>",
"       <div id=\"relatedGraphics\">",
"        <ul>",
"         <li class=\"plainItem\">",
"          FIGURES",
"         </li>",
"         <li class=\"bulletItem\">",
"          <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?6/33/6675\" title=\"figure 1\">",
"           Rectal temperature PI",
"          </a>",
"         </li>",
"         <li class=\"bulletItem\">",
"          <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?42/42/43695\" title=\"figure 2\">",
"           Ear temperature PI",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          TABLES",
"         </li>",
"         <li class=\"bulletItem\">",
"          <a class=\"graphic graphic_table\" href=\"mobipreview.htm?38/23/39291\" title=\"table 1\">",
"           Pedi needs med attention PI",
"          </a>",
"         </li>",
"        </ul>",
"       </div>",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"  </div>",
" </div>"].join("\n");
var title_f36_23_37236="Normal bone scan";
var content_f36_23_37236=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F62962%7EONC%2F72455&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F62962%7EONC%2F72455&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Hypertrophic pulmonary osteoarthropathy",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 315px; height: 516px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Normal bone scan for comparison.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Hypertrophic pulmonary osteoarthropathy",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 253px; height: 432px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Bone scan showing diffuse uptake by the long bones in a patient with painful arthropathy and lung cancer.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Midthun, DE, Jett, JR. Lung tumors. In: Clinical respiratory medicine, 2nd ed, Albert, RK, Spiro, SG, Jett, JR (Eds), Mosby, Philadelphia 2004. p. 515. Copyright &copy;2004.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f36_23_37236=[""].join("\n");
var outline_f36_23_37236=null;
var title_f36_23_37237="Early liver biopsy Wilson disease";
var content_f36_23_37237=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F64346&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F64346&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 560px\">",
"   <div class=\"ttl\">",
"    Wilson disease",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 540px; height: 175px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Liver biopsy from a 4-year-old girl whose 10-year-old sister presented with liver failure and cirrhosis secondary to previously unrecognized Wilson disease. Liver biopsy was performed because her serum ceruloplasmin was low (4.0 mg/dL) and serum aminotransferases were repeatedly two to three times normal. Left panel: Low power shows portal fibrosis, mild portal inflammation, and fatty infiltration (Masson trichrome). Right panel: High power view shows fatty infiltration of hepatocytes and two glycogen nuclei (Masson trichrome).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Marshall M Kaplan, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f36_23_37237=[""].join("\n");
var outline_f36_23_37237=null;
var title_f36_23_37238="Famciclovir: Drug information";
var content_f36_23_37238=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Famciclovir: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"mobipreview.htm?16/9/16532?source=see_link\">",
"    see \"Famciclovir: Patient drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?4/32/4613?source=see_link\">",
"    see \"Famciclovir: Pediatric drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F169842\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Famvir&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F169843\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Apo-Famciclovir&reg;;",
"     </li>",
"     <li>",
"      Ava-Famciclovir;",
"     </li>",
"     <li>",
"      CO Famciclovir;",
"     </li>",
"     <li>",
"      Famvir&reg;;",
"     </li>",
"     <li>",
"      PMS-Famciclovir;",
"     </li>",
"     <li>",
"      Sandoz-Famciclovir",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F169877\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Antiviral Agent",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F169845\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Immunocompetent patients:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Acute herpes zoster:",
"     </b>",
"     Oral: 500 mg every 8 hours for 7 days (",
"     <b>",
"      Note:",
"     </b>",
"     Initiate therapy as soon as possible after diagnosis and within 72 hours of rash onset)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Genital herpes simplex virus (HSV) infection:",
"     </b>",
"     Oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     <i>",
"      Initial episode:",
"     </i>",
"     250 mg 3 times/day for 7-10 days (CDC, 2010)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     <i>",
"      Recurrence:",
"     </i>",
"     1000 mg twice daily for 1 day (",
"     <b>",
"      Note:",
"     </b>",
"     Initiate therapy as soon as possible and within 6 hours of symptoms/lesions onset)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     Alternatively, the following regimens are also recommended: 125 mg twice daily for 5 days or 500 mg as a single dose, followed by 250 mg twice daily for 2 days (CDC, 2010).",
"     <b>",
"      Note:",
"     </b>",
"     Canadian labeling recommends 125 mg twice daily for 5 days.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     <i>",
"      Suppressive therapy:",
"     </i>",
"     250 mg twice daily for up to 1 year;",
"     <b>",
"      Note:",
"     </b>",
"     Duration not established, but efficacy/safety have been demonstrated for 1 year (CDC, 2010)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">",
"     <b>",
"      Recurrent herpes labialis (cold sores):",
"     </b>",
"     Oral: 1500 mg as a single dose; initiate therapy at first sign or symptom such as tingling, burning, or itching (initiated within 1 hour in clinical studies)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">",
"     <b>",
"      <i>",
"       HIV patients",
"      </i>",
"     </b>",
"     (",
"     <b>",
"      Note:",
"     </b>",
"     Initiate therapy as soon as possible and within 48 hours of symptoms/lesions onset):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">",
"     <b>",
"      Recurrent orolabial/genital (mucocutaneous) HSV infection:",
"     </b>",
"     Oral: 500 mg twice daily for 7 days or 5-10 days (CDC, 2010).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">",
"     <b>",
"      Prevention of HSV reactivation:",
"     </b>",
"     Oral: 500 mg twice daily (CDC, 2010)",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F169846\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F169847\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Dosing adjustment in renal impairment:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Herpes zoster:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &ge;60 mL/minute: No dosage adjustment necessary",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     40-59 mL/minute: Administer 500 mg every 12 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     20-39 mL/minute: Administer 500 mg every 24 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &lt;20 mL/minute: Administer 250 mg every 24 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Hemodialysis: Administer 250 mg after each dialysis session.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Recurrent genital herpes: Treatment:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      U.S. labeling (single-day regimen):",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &ge;60 mL/minute: No dosage adjustment necessary",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     40-59 mL/minute: Administer 500 mg every 12 hours for 1 day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     20-39 mL/minute: Administer 500 mg as a single dose",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &lt;20 mL/minute: Administer 250 mg as a single dose",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Hemodialysis: Administer 250 mg as a single dose after a dialysis session.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Canadian labeling:",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &gt;20 mL/minute/1.73 m",
"     <sup>",
"      2",
"     </sup>",
"     : No dosage adjustment necessary",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &lt;20 mL/minute/1.73 m",
"     <sup>",
"      2",
"     </sup>",
"     : Administer 125 mg every 24 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Hemodialysis: Administer 125 mg after each dialysis session.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Recurrent genital herpes: Suppression:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &ge;40 mL/minute: No dosage adjustment necessary",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     20-39 mL/minute: Administer 125 mg every 12 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &lt;20 mL/minute: Administer 125 mg every 24 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Hemodialysis: Administer 125 mg after each dialysis session.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Recurrent herpes labialis: Treatment (single-dose regimen):",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &ge;60 mL/minute: No dosage adjustment necessary",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     40-59 mL/minute: Administer 750 mg as a single dose",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     20-39 mL/minute: Administer 500 mg as a single dose",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &lt;20 mL/minute: Administer 250 mg as a single dose",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Hemodialysis: Administer 250 mg as a single dose after a dialysis session.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Recurrent orolabial/genital (mucocutaneous) herpes in HIV-infected patients:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &ge;40 mL/minute: No dosage adjustment necessary",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     20-39 mL/minute: Administer 500 mg every 24 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &lt;20 mL/minute: Administer 250 mg every 24 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Hemodialysis: Administer 250 mg after each dialysis session.",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F14274913\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Mild-to-moderate impairment: No dosage adjustment is necessary",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Severe impairment: No dosage adjustment provided in manufacturer&rsquo;s labeling; has not been studied. However, a 44% decrease in the C",
"     <sub>",
"      max",
"     </sub>",
"     of penciclovir (active metabolite) was noted in patients with mild-to-moderate impairment; impaired conversion of famciclovir to penciclovir may affect efficacy.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F169817\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, oral: 125 mg, 250 mg, 500 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Famvir&reg;: 125 mg [contains lactose 26.9 mg/tablet]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Famvir&reg;: 250 mg [contains lactose 53.7 mg/tablet]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Famvir&reg;: 500 mg [contains lactose 107.4 mg/tablet]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F169803\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F9537092\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     May be administered without regard to meals.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F169820\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of acute herpes zoster (shingles) in immunocompetent patients; treatment and suppression of recurrent episodes of genital herpes in immunocompetent patients; treatment of herpes labialis (cold sores) in immunocompetent patients; treatment of recurrent orolabial/genital (mucocutaneous) herpes simplex in HIV-infected patients",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F6743664\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Famvir&reg; may be confused with Femara&reg;",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F169875\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     <b>",
"      Note:",
"     </b>",
"     Frequencies vary with dose and duration.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">",
"     &gt;10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Central nervous system: Headache (9% to 39%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gastrointestinal: Nausea (2% to 13%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     1% to 10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Central nervous system: Fatigue (1% to 5%), migraine (1% to 3%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Dermatologic: Pruritus (&le;4%), rash (&le;3%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Endocrine &amp; metabolic: Dysmenorrhea (&le;8%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gastrointestinal: Diarrhea (2% to 9%), abdominal pain (&le;8%), vomiting (1% to 5%), flatulence (&le;5%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Hematologic: Neutropenia (3%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Hepatic: Transaminases increased (2% to 3%), bilirubin increased (2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Paresthesia (&le;3%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     &lt;1% (Limited to important or life-threatening): Anemia, angioedema (eyelid, face, periorbital, pharyngeal edema), cholestatic jaundice, confusion, delirium, disorientation, dizziness, erythema multiforme, hallucinations, somnolence, Stevens-Johnson syndrome, thrombocytopenia, toxic epidermal necrolysis, urticaria",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F169823\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to famciclovir, penciclovir, or any component of the formulation",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F169807\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Renal impairment: Use with caution in patients with renal impairment; dosage adjustment required. Acute renal failure has been reported with use of inappropriate high doses in patients with underlying renal disease.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Dosage form specific issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Lactose: Tablets contain lactose; do not use with galactose intolerance, severe lactase deficiency, or glucose-galactose malabsorption syndromes.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Appropriate use: Has not been established for use in initial episodes of genital herpes, recurrent episodes of genital herpes in Black and African-American patients, patients with ophthalmic or disseminated zoster, immunocompromised patients (except HIV-infected patients with orolabial or genital herpes).",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13299311\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F6220317\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Zoster Vaccine: Famciclovir may diminish the therapeutic effect of Zoster Vaccine.  Management: When possible, discontinue antiviral agents with anti-zoster activity (i.e., acyclovir, valacyclovir, famciclovir) for at least 24 hours prior to and 14 days after receiving a live attenuated zoster vaccine.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F169839\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Ethanol/Nutrition/Herb Interactions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Food: Rate of absorption and/or conversion to penciclovir and peak concentration are reduced with food, but bioavailability is not affected.",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F169813\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     B (",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F169827\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Teratogenic effects were not observed in animal reproduction studies. Data in pregnant women is limited. A registry has been established for women exposed to famciclovir during pregnancy (888-669-6682).",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F169851\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excretion in breast milk unknown/not recommended",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F169828\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     There is no specific data describing the excretion of famciclovir in breast milk. Breast-feeding is not recommended by the manufacturer unless the potential benefits outweigh any possible risk. If herpes lesions are on breast, breast-feeding should be avoided in order to avoid transmission to infant.",
"    </p>",
"   </div>",
"   <div class=\"block dic drugH1Div\" id=\"F169829\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dietary Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     May be taken without regard to meals.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F169826\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Famciclovir Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     125 mg (30): $174.40",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     250 mg (30): $189.62",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     500 mg (30): $380.80",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Famvir Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     125 mg (30): $257.27",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     250 mg (30): $279.71",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     500 mg (30): $561.73",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F169815\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Periodic CBC during long-term therapy",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F6038615\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Bencavir (LU);",
"     </li>",
"     <li>",
"      Ezovir (AU);",
"     </li>",
"     <li>",
"      Famcir (KP);",
"     </li>",
"     <li>",
"      Famcro (KP);",
"     </li>",
"     <li>",
"      Famicle (KP);",
"     </li>",
"     <li>",
"      Famtrex (IN);",
"     </li>",
"     <li>",
"      Famvir (AT, AU, BB, BE, BF, BG, BJ, BM, BS, BZ, CH, CI, CZ, DE, DK, EE, ES, ET, FI, GB, GH, GM, GN, GR, GY, HK, HN, HR, HU, ID, IE, IL, IT, JM, KE, LR, LU, MA, ML, MR, MT, MU, MW, NE, NG, NL, NO, NZ, PK, PL, PT, RU, SC, SD, SE, SK, SL, SN, SR, TH, TN, TR, TT, TW, TZ, UG, ZA, ZM, ZW);",
"     </li>",
"     <li>",
"      Fanle (CL);",
"     </li>",
"     <li>",
"      Favic (AU);",
"     </li>",
"     <li>",
"      Herfam (KP);",
"     </li>",
"     <li>",
"      Oravir (FR);",
"     </li>",
"     <li>",
"      Pentavir (AR);",
"     </li>",
"     <li>",
"      Vectavir (LU);",
"     </li>",
"     <li>",
"      Zosfam (KP)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F169806\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Famciclovir undergoes rapid biotransformation to the active compound, penciclovir (prodrug), which is phosphorylated by viral thymidine kinase in HSV-1, HSV-2, and VZV-infected cells to a monophosphate form; this is then converted to penciclovir triphosphate and competes with deoxyguanosine triphosphate to inhibit HSV-2 polymerase, therefore, herpes viral DNA synthesis/replication is selectively inhibited.",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F169822\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Absorption: Food decreases maximum peak penciclovir concentration and delays time to penciclovir peak; AUC remains the same",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Distribution: V",
"     <sub>",
"      d",
"     </sub>",
"     : Penciclovir: 0.91-1.25 L/kg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Protein binding: Penciclovir: &lt;20%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: Famciclovir is rapidly deacetylated and oxidized to penciclovir (active prodrug);",
"     <i>",
"      in vitro",
"     </i>",
"     data demonstrate that metabolism does not occur via CYP isoenzymes",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Bioavailability: Penciclovir: 69% to 85%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life elimination: Penciclovir: 2-4 hours; Prolonged in renal impairment: Cl",
"     <sub>",
"      cr",
"     </sub>",
"     20-39 mL/minute: 5-8 hours, Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &lt;20 mL/minute: 3-24 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Time to peak: Penciclovir: ~1 hour",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Excretion: Urine (73% primarily as penciclovir); feces (27%)",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Alrabiah FA and Sacks SL, &ldquo;New Antiherpesvirus Agents. Their Targets and Therapeutic Potential,&rdquo;",
"      <i>",
"       Drugs",
"      </i>",
"      , 1996, 52(1):17-32.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?36/23/37238/abstract-text/8799682/pubmed\" id=\"8799682\" target=\"_blank\">",
"        8799682",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Boike SC, Pue MA, and Freed MI, &ldquo;Pharmacokinetics of Famciclovir in Subjects With Varying Degrees of Renal Impairment,&rdquo;",
"      <i>",
"       Clin Pharmacol Ther",
"      </i>",
"      , 1994, 55(4):418-26.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?36/23/37238/abstract-text/8162668/pubmed\" id=\"8162668\" target=\"_blank\">",
"        8162668",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Boyd MR, Safrin S, and Kern ER, &ldquo;Penciclovir: A Review of Its Spectrum of Activity, Selectivity, and Cross Resistance Pattern,&rdquo;",
"      <i>",
"       Antivir Chem Chemother",
"      </i>",
"      , 1993, 4:3-11.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Centers for Disease Control and Prevention (CDC), \"Sexually Transmitted Diseases Treatment Guidelines, 2010,\"",
"      <i>",
"       MMWR Recomm Rep",
"      </i>",
"      , 2010, 59(RR-12):1-110.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?36/23/37238/abstract-text/21160459/pubmed\" id=\"21160459\" target=\"_blank\">",
"        21160459",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Daniels S and Schentag JJ, &ldquo;Drug Interaction Studies and Safety of Famciclovir in Healthy Volunteers: A Review,&rdquo;",
"      <i>",
"       Antivir Chem Chemother",
"      </i>",
"      , 1993, 4:57-64.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      De Clercq E, &ldquo;Antivirals for the Treatment of Herpesvirus Infections,&rdquo;",
"      <i>",
"       J Antimicrob Chemother",
"      </i>",
"      , 1993, 32(Suppl A):121-32.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?36/23/37238/abstract-text/8407694/pubmed\" id=\"8407694\" target=\"_blank\">",
"        8407694",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Gill KS and Wood MJ, &ldquo;The Clinical Pharmacokinetics of Famciclovir,&rdquo;",
"      <i>",
"       Clin Pharmacokinet",
"      </i>",
"      , 1996, 31(1):1-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?36/23/37238/abstract-text/8827396/pubmed\" id=\"8827396\" target=\"_blank\">",
"        8827396",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Goffin E, Horsmans Y, Pirson Y, et al, &ldquo;Acute Necrotico-Hemorrhagic Pancreatitis After Famciclovir Prescription,&rdquo;",
"      <i>",
"       Transplantation",
"      </i>",
"      , 1995, 59(8):1218-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?36/23/37238/abstract-text/7537399/pubmed\" id=\"7537399\" target=\"_blank\">",
"        7537399",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Hodge RA, &ldquo;Famciclovir and Penciclovir: The Mode of Action of Famciclovir Including Its Conversion to Penciclovir,&rdquo;",
"      <i>",
"       Antivir Chem Chemother",
"      </i>",
"      , 1993, 4:67-84.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Luber AD and Flaherty JF Jr, &ldquo;Famciclovir for Treatment of Herpesvirus Infections,&rdquo;",
"      <i>",
"       Ann Pharmacother",
"      </i>",
"      , 1996, 30(9):978-85.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?36/23/37238/abstract-text/8876860/pubmed\" id=\"8876860\" target=\"_blank\">",
"        8876860",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Pasternak B and Hviid A, \"Use of Acyclovir, Valacyclovir, and Famciclovir in the First Trimester of Pregnancy and the Risk of Birth Defects,\"",
"      <i>",
"       JAMA",
"      </i>",
"      , 2010, 304(8):859-66.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?36/23/37238/abstract-text/20736469/pubmed\" id=\"20736469\" target=\"_blank\">",
"        20736469",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Perry CM and Wagstaff AJ, &ldquo;Famciclovir. A Review of Its Pharmacological Properties and Therapeutic Efficacy in Herpesvirus Infections,&rdquo;",
"      <i>",
"       Drugs",
"      </i>",
"      , 1995, 50(2):396-415.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?36/23/37238/abstract-text/8521764/pubmed\" id=\"8521764\" target=\"_blank\">",
"        8521764",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Pue MA and Benet LZ, &ldquo;Pharmacokinetics of Famciclovir in Man,&rdquo;",
"      <i>",
"       Antivir Chem Chemother",
"      </i>",
"      , 1993, 4(Suppl 1):47-55.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Sacks SL, &ldquo;Genital Herpes Simplex Virus and Its Treatment Focus on Famciclovir,&rdquo;",
"      <i>",
"       Semin Dermatol",
"      </i>",
"      , 1996, 15(2 Suppl 1):32-6.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?36/23/37238/abstract-text/8840414/pubmed\" id=\"8840414\" target=\"_blank\">",
"        8840414",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Spruance SL, Bodsworth N, Resnick H, et al, &ldquo;Single-Dose, Patient-Initiated Famciclovir: A Randomized, Double-Blind, Placebo-Controlled Trial for Episodic Treatment of Herpes Labialis,&rdquo;",
"      <i>",
"       J Am Acad Dermatol",
"      </i>",
"      , 2006, 55(1):47-53.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?36/23/37238/abstract-text/16781291/pubmed\" id=\"16781291\" target=\"_blank\">",
"        16781291",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Tyring SK, Barbarash RA, Nahlik JE, et al, &ldquo;Famciclovir for the Treatment of Acute Herpes Zoster: Effects on Acute Disease and Postherpetic Neuralgia,&rdquo;",
"      <i>",
"       Ann Intern Med",
"      </i>",
"      , 1995, 123(2):89-96.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?36/23/37238/abstract-text/7778840/pubmed\" id=\"7778840\" target=\"_blank\">",
"        7778840",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Tyring SK, &ldquo;Efficacy of Famciclovir in the Treatment of Herpes Zoster,&rdquo;",
"      <i>",
"       Semin Dermatol",
"      </i>",
"      , 1996, 15(2 Suppl 1):27-31.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?36/23/37238/abstract-text/8840413/pubmed\" id=\"8840413\" target=\"_blank\">",
"        8840413",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 8435 Version 40.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-61.55.141.10-629A639819-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f36_23_37238=[""].join("\n");
var outline_f36_23_37238=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F169842\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F169843\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F169877\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F169845\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F169846\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F169847\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14274913\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F169817\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F169803\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9537092\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F169820\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6743664\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F169875\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F169823\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F169807\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13299311\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6220317\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F169839\">",
"      Ethanol/Nutrition/Herb Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F169813\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F169827\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F169851\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F169828\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F169829\">",
"      Dietary Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F169826\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F169815\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6038615\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F169806\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F169822\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/8435\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/8435|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?16/9/16532?source=related_link\">",
"      Famciclovir: Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?4/32/4613?source=related_link\">",
"      Famciclovir: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f36_23_37239="Appendiceal mucocele";
var content_f36_23_37239=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F86274&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=0\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F86274&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=0\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 475px\">",
"   <div class=\"ttl\">",
"    Appendiceal mucocele",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 455px; height: 596px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    (A) Surgically resected specimen showing dilated appendix.",
"    <br/>",
"    (B) Gross pathology of a mucinous cystadenoma.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Richard Devine, MD, Mayo Clinic.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f36_23_37239=[""].join("\n");
var outline_f36_23_37239=null;
var title_f36_23_37240="Thoracic endovascular aneurysm repair";
var content_f36_23_37240=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Thoracic endovascular aneurysm repair",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?36/23/37240/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?36/23/37240/contributors\">",
"     Grace J Wang, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?36/23/37240/contributors\">",
"     Ronald M Fairman, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?36/23/37240/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?36/23/37240/contributors\">",
"     Emile R Mohler III, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?36/23/37240/contributors\">",
"     Gabriel S Aldea, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?36/23/37240/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?36/23/37240/contributors\">",
"     Kathryn A Collins, MD, PhD, FACS",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?36/23/37240/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   May 1, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Thoracic endovascular aneurysm repair (TEVAR) refers to the percutaneous placement of a stent graft in the descending thoracic or thoracoabdominal aorta to improve long-term survival in patients with aortic aneurysms. The complications of elective thoracic aneurysm repair using an open surgical (OS) technique are higher than most elective surgical procedures, given anatomic constraints and operative complexity. TEVAR was initially developed to treat patients who were considered to not be surgical candidates but is now considered a suitable alternative to OS in most cases [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/23/37240/abstract/1,2\">",
"     1,2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Potential benefits of TEVAR relative to OS include avoidance of long incisions in the thorax or abdomen, no cross-clamping of the aorta, less blood loss, lower incidence of visceral, renal, and spinal cord ischemia (SCI), fewer episodes of respiratory dependency, and quicker recovery [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/23/37240/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The pivotal trials of TEVAR for treatment of thoracic aortic aneurysm led to its approval by the United States Food and Drug Administration in 2005 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/23/37240/abstract/1,4-7\">",
"     1,4-7",
"    </a>",
"    ]. TEVAR has been increasingly used for other aortic pathologies such as complicated type B dissection, traumatic aortic transection, and aneurysmal disease extending into the arch. Each will be mentioned in brief, but this topic will principally address the endovascular treatment of thoracic aneurysms.",
"   </p>",
"   <p>",
"    Issues related to etiology, clinical presentation, and diagnosis, as well as the medical and surgical management of thoracic aneurysmal disease, are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?22/11/22712?source=see_link\">",
"     \"Clinical features and diagnosis of thoracic aortic aneurysm\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?10/7/10361?source=see_link\">",
"     \"Management and outcome of thoracic aortic aneurysm\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     INDICATIONS FOR TEVAR",
"    </span>",
"    &nbsp;&mdash;&nbsp;The indications for TEVAR of the descending aorta are similar to those for surgical repair and include width &gt;6 cm, rapidly enlarging diameter (&gt;5 mm of growth over six months), symptoms such as chest pain, and diagnosis of aortic rupture or dissection. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?10/7/10361?source=see_link\">",
"     \"Management and outcome of thoracic aortic aneurysm\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    This issue of whether to choose TEVAR or OS is discussed below. (See",
"    <a class=\"local\" href=\"#H20\">",
"     'TEVAR versus open surgery'",
"    </a>",
"    below and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?10/7/10361?source=see_link\">",
"     \"Management and outcome of thoracic aortic aneurysm\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     PREOPERATIVE PLANNING",
"    </span>",
"    &nbsp;&mdash;&nbsp;Computed tomography angiography (CTA) of the chest, abdomen and pelvis with 3-D reformatting is performed preoperatively. It provides accurate information regarding the external and endoluminal diameter of the aorta to be used for the proximal and distal seal zones, the length of coverage required, the degree of angulation and tortuosity of the aorta, identification of important side branches, as well as characteristics of the lumen and wall of the aorta, including thrombus burden and calcification. From this information, the diameter and length of the graft(s) are chosen.",
"   </p>",
"   <p>",
"    Additionally, the diameter of the external iliacs and the degree of",
"    <span class=\"nowrap\">",
"     calcification/tortuosity",
"    </span>",
"    from the femoral vessels, through the iliacs, to the aortic bifurcation need to be noted, and a decision should be made whether to proceed with transfemoral or alternative access. (See",
"    <a class=\"local\" href=\"#H4\">",
"     'Conduct of the operation'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Magnetic resonance angiography (MRA) can also be used, but the degree of anatomical detailing is no better, and the risk of nephrogenic systemic fibrosis in patients with ESRD or chronic renal insufficiency affords no benefit compared to CTA [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/23/37240/abstract/8\">",
"     8",
"    </a>",
"    ]. MRA also fails to depict vessel wall calcification, which has implications for vascular access.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     CONDUCT OF THE OPERATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The procedure is typically done under general endotracheal anesthesia. A lumbar drain is placed in the L3-L4 disc space for drainage of cerebrospinal fluid (CSF) in cases where extensive coverage of the thoracic aorta is anticipated, where interruption of contributing blood supply to the artery of Adamkiewicz (T8-L1) is high, and in cases where the patient has had prior abdominal aortic aneurysm (AAA) repair. The artery of Adamkiewicz (Arteria Radicularis Magna) is the chief contributor to the anterior spinal artery in the thoracolumbar segment of the spinal cord. Therefore, deployment of a stent graft in this segment of the aorta may exclude blood flow from major contributors of spinal cord perfusion. A prior endograft in the abdominal aorta would cover the orifices of lumbar arteries which likewise contribute to spinal cord perfusion. Lumbar drainage of cerebrospinal fluid to decrease the pressure in the subarachnoid space and increase the spinal cord perfusion pressure (spinal cord perfusion pressure = mean arterial pressure-CSF pressure) is an important adjunct in preventing paraplegia (spinal cord ischemia) following TEVAR [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/23/37240/abstract/9,10\">",
"     9,10",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H12\">",
"     'Spinal cord ischemia'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Performance of the procedure requires the delivery of a large-bore sheath into the aorta as well as angiographic access. This is typically accomplished transfemorally, although patients presenting with disadvantaged femoral access sites may require delivery of the sheath through the common iliac artery, an iliac conduit, or an endovascular stent graft in the external iliac artery.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Anatomic considerations",
"    </span>",
"    &nbsp;&mdash;&nbsp;The thoracic aorta is of larger caliber than that of the infrarenal abdominal aorta, which necessitates the usage of larger diameter stent grafts than those used for AAA repair. Thoracic grafts are housed in large sheaths, which sometimes preclude conventional transfemoral access and require delivery through the distal common iliac artery, creation of an iliac artery conduit, and, at times, direct delivery through the abdominal aorta.",
"   </p>",
"   <p>",
"    In addition, the high force of blood flow in the thoracic aorta requires a longer seal zone (20 mm), defined as to either the proximal or distal ends of the thoracic stent graft where it is opposed to relatively normal aorta, on either end (compared with the abdominal aorta) to prevent displacement. The curve of the thoracic aorta at the arch presents special challenges in attempting to achieve adequate proximal fixation and seal. Radial support, defined as the ability to withstand external compression, must be weighed against the need for enough flexibility and conformability within the device in order to navigate this curve and achieve seal following deployment. The angulation of the aorta often progresses with age, as atherosclerotic changes lead to lengthening and increased tortuosity, adding to the difficulty of accurate device deployment and adequate proximal landing. (See",
"    <a class=\"local\" href=\"#H6\">",
"     'Proximal and distal landing zones'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    When device deployment is performed close to or within the arch, the graft must closely appose the \"inner curve\" of the arch (",
"    <a class=\"graphic graphic_figure graphicRef66551 \" href=\"mobipreview.htm?37/21/38228\">",
"     figure 1",
"    </a>",
"    ). If the proximal end of the graft is oriented towards the apex of such a curve, \"bird-beaking\" where the graft is not apposed to the aortic wall will occur, increasing the risk of graft collapse, migration, and failure of aneurysm exclusion. With adequate preoperative planning, landing more proximally and debranching the arch as needed can usually circumvent these issues.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h3\">",
"     Proximal and distal landing zones",
"    </span>",
"    &nbsp;&mdash;&nbsp;Placement of the proximal or distal end of the device may require covering important side branches. \"Hybrid\" procedures which combine open vascular bypass to important vessels followed by thoracic stent grafting have been developed [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/23/37240/abstract/11\">",
"     11",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The proximal seal zone, also referred to as the landing zone, may abut or involve branch vessels of the arch, namely the brachiocephalic trunk, left common carotid artery, and left subclavian artery. In order to achieve the 20 mm proximal seal required and ensure that the graft will sit in close apposition to the inner curve of the arch, debranching procedures using \"hybrid\" techniques can be performed, which essentially \"move\" the branch vessels to a more proximal location, allowing coverage of the origins of these vessels [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/23/37240/abstract/11\">",
"     11",
"    </a>",
"    ]. When coverage of the left subclavian artery is required, duplex of the vertebral and carotid arteries should be completed to determine whether left common carotid-left subclavian bypass or left subclavian transposition is in order.",
"   </p>",
"   <p>",
"    For more proximal landing zones involving the left common carotid artery or brachiocephalic trunk, antegrade bypass from the ascending",
"    <span class=\"nowrap\">",
"     aorta/transposition",
"    </span>",
"    of the great vessels can be performed or, alternatively, extraanatomic bypass can be performed to avoid sternotomy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/23/37240/abstract/12-15\">",
"     12-15",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The distal seal zone also must be at least 20 mm in length. Typically, the celiac axis is spared. Reports of covering the celiac artery in patients with a documented patent pancreaticoduodenal arcade have been successful in achieving up to an additional 25 mm in seal length with nominal incidence of mesenteric ischemia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/23/37240/abstract/16,17\">",
"     16,17",
"    </a>",
"    ]. Once the device is deployed, the stent graft is typically ballooned at the seal zones and graft junctions.",
"   </p>",
"   <p>",
"    On occasion the distal end of a thoracoabdominal aneurysm may extend below the level of the renal arteries blood flow, and intercostal, visceral and renal arteries may be compromised. Surgical and stenting techniques have been developed to decrease the likelihood of this complication [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/23/37240/abstract/11\">",
"     11",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Endoleak",
"    </span>",
"    &nbsp;&mdash;&nbsp;Repeat angiography is performed at the conclusion of the procedure to ensure effective sac exclusion, preservation of essential vessels, and to detect any evidence of endoleak. An endoleak is the persistent flow in the aneurysm sac following endovascular repair of the aorta. There are five types:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Type I endoleak &ndash; Involves the proximal or distal seal zones. Further ballooning or placement of another graft may be necessary to achieve seal. Vigorous proximal ballooning may be hazardous; retrograde proximal aortic dissection has been reported.",
"     </li>",
"     <li>",
"      Type II endoleak &ndash; Unusual in the thoracic aorta but due to retrograde flow from intercostal arteries into the sac. Typically resolves with observation",
"     </li>",
"     <li>",
"      Type III endoleak &ndash; Occurs with inadequate overlap and seal between modular components. Usually responds with further ballooning or additional graft or stent placement.",
"     </li>",
"     <li>",
"      Type IV endoleak &ndash; Occurs due to porosity of the graft, which is a rare occurrence with current generation devices.",
"     </li>",
"     <li>",
"      Type V endoleak &ndash; Otherwise known as \"endotension,\" occurs in the setting of continued sac expansion despite absence of an identifiable endoleak on subsequent imaging studies.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Once exclusion of the sac has been confirmed, the device sheath is removed, and the arteriotomy is repaired.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Devices",
"    </span>",
"    &nbsp;&mdash;&nbsp;The following devices are currently approved or under investigation for treatment of descending thoracic aneurysms [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/23/37240/abstract/18\">",
"     18",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The Gore-TAG device is made of e-polytetrafluoroethylene and an exoskeleton made of nitinol. The proximal and distal ends of the graft have scalloped flares, which are thought to allow for conformity and better apposition to the tortuous aorta.",
"     </li>",
"     <li>",
"      The Medtronic Talent thoracic stent graft system was studied in the VALOR I trial, which proved its clinical efficacy. It is made of two components, a proximal straight tubular stent graft with a proximal bare stent configuration and a distal tapered tubular stent graft with an open web proximal configuration and closed web distal configuration. It consists of a woven polyester graft with a nitinol endoskeleton.",
"     </li>",
"     <li>",
"      The Medtronic Valiant endograft has a modified proximal bare stent configuration with eight bare peak wires compared with the five bare peak wires found in the Talent stent graft. The long connecting bar of the Talent device was removed in the Valiant device to afford better flexibility of the device.",
"     </li>",
"     <li>",
"      The Cook TX2 stent graft is a two-piece modular endograft system made of proximal and distal tubular endografts. The proximal endograft is covered and has stainless steel barbs, allowing for active fixation to the aortic wall. The distal component has at its distal end a bare metal stent similar to the suprarenal stent in the Zenith device for endovascular repair of AAA. This allows active fixation of the device over the origins of the visceral vessels. The TX2 is made of Dacron fabric covered by stainless steel Z-stents.",
"     </li>",
"     <li>",
"      The Bolton Relay stent graft is an investigational device used for the treatment of thoracic aortic pathologies. It is composed of self-expanding nitinol stents sutured to a polyester fabric graft with a curved longitudinal nitinol wire intended to provide columnar strength. It has a proximal bare stent, which remains constrained until the endograft is fully deployed. The pivotal study is underway.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     OUTCOMES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with thoracic aneurysms have a poor prognosis, particularly if they are large or expanding. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?10/7/10361?source=see_link\">",
"     \"Management and outcome of thoracic aortic aneurysm\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In patients who meet criteria for OS, survival is improved with OS compared to medical therapy. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?10/7/10361?source=see_link&amp;anchor=H14#H14\">",
"     \"Management and outcome of thoracic aortic aneurysm\", section on 'Morbidity and mortality'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?10/7/10361?source=see_link\">",
"     \"Management and outcome of thoracic aortic aneurysm\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    While little comparative data exists between TEVAR and medical management, it is reasonable to assume that outcomes will also be better with TEVAR in those patients with indications for OS, since TEVAR compares favorably with OS.",
"   </p>",
"   <p>",
"    The outcomes presented below suggest that TEVAR is a promising alternative to open surgical (OS) repair [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/23/37240/abstract/1,6,7\">",
"     1,6,7",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Combined perioperative outcomes",
"    </span>",
"    &nbsp;&mdash;&nbsp;In a study where perioperative morbid events including myocardial infarction, respiratory events such as pneumonia or ventilation for more than 24 hours, stroke and paraplegia were combined into a composite score, the percentage of patients who experienced at least one event was significantly lower in the TEVAR group compared to the OS arm (9 percent versus 33 percent) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/23/37240/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     Stroke",
"    </span>",
"    &nbsp;&mdash;&nbsp;Because the proximal seal zone is in proximity to the carotid arteries, embolic strokes can occur following TEVAR. Risk factors for embolic stroke include the need for proximal deployment of the graft, presence of mobile atheromata in the arch, and prior stroke [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/23/37240/abstract/19\">",
"     19",
"    </a>",
"    ]. The vertebral arteries arising from the subclavian may be the source for posterior circulation strokes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/23/37240/abstract/20\">",
"     20",
"    </a>",
"    ]. Perioperative stroke has ranged from 4 percent to 8 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/23/37240/abstract/21-23\">",
"     21-23",
"    </a>",
"    ], comparable to OS [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/23/37240/abstract/24\">",
"     24",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    As described earlier, preoperative planning consists of carotid and vertebral artery duplex, sometimes with a CTA of the head and neck. Planned coverage of the left subclavian in a patient with a dominant left vertebral, hypoplastic right vertebral, or incomplete circle of Willis should be preceded by carotid subclavian bypass, as interruption of blood flow in these circumstances has been associated with an increased incidence of stroke and paraplegia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/23/37240/abstract/20,25,26\">",
"     20,25,26",
"    </a>",
"    ]. Left upper extremity symptoms, while occurring in up to 15.8 percent of patients in one study, only required intervention in a minority of patients (5.3 percent), supporting expectant management in the majority of cases [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/23/37240/abstract/27\">",
"     27",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     Spinal cord ischemia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Extensive coverage of the thoracic aorta as well as prior history of AAA repair places the patient at increased risk for spinal cord ischemia (SCI) with the potential for paraplegia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/23/37240/abstract/28-30\">",
"     28-30",
"    </a>",
"    ]. The risk of spinal cord ischemia has been reported to be between 3 to 11 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/23/37240/abstract/1,3,5,23,31\">",
"     1,3,5,23,31",
"    </a>",
"    ], comparable to the rate of OS [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/23/37240/abstract/24\">",
"     24",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Some studies have demonstrated a lower rate of SCI with TEVAR than with OS. In a well-performed, retrospective review of 724 patients at a single institution who were treated with either TEVAR (n=352) or OS (n=372) for thoracic or thoracoabdominal aneurysms, no statistically significant difference in the rate of SCI was found between the two approaches (4.3 versus 7.5 percent respectively) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/23/37240/abstract/3\">",
"     3",
"    </a>",
"    ]. The extent of aortic disease was the strongest predictor of SCI.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     Visceral ischemia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Visceral ischemia can occur with coverage of the celiac axis. Although, reports have suggested that collateralization through an intact pancreaticoduodenal arcade allows for extension of the distal seal zone to the level of the superior mesenteric artery (SMA) without physiologic consequence [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/23/37240/abstract/16\">",
"     16",
"    </a>",
"    ]. Similarly, stenting to below the SMA or renal artery levels requires revascularization of these vessels, or use of specialized fenestrated grafts [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/23/37240/abstract/32\">",
"     32",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h3\">",
"     Access complications",
"    </span>",
"    &nbsp;&mdash;&nbsp;Because of the obligatory large sheath size for delivery of the device, passage of the sheath through a small diameter, tortuous, or excessively calcified external iliac artery can lead to iliac artery disruption. Intra-aortic balloon control, using a balloon-mounted catheter introduced through the femoral or common iliac artery, helps to stabilize the patient until proximal and distal control of the iliac artery and definitive repair can be conducted. Anticipation of the need for adjunctive access measures is thus important and is required in a significant percentage of patients, ranging from 9.4 percent to 23.8 percent in published reports [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/23/37240/abstract/1,7\">",
"     1,7",
"    </a>",
"    ]. From the percutaneous angiography puncture site, a pseudoaneurysm or hematoma may form. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?37/48/38666?source=see_link&amp;anchor=H23#H23\">",
"     \"Periprocedural complications of percutaneous coronary intervention\", section on 'Vascular complications'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h3\">",
"     Postimplantation syndrome",
"    </span>",
"    &nbsp;&mdash;&nbsp;This syndrome occurs during the early postoperative period and is characterized by leukocytosis, fever, and elevation of inflammatory mediators such as C-reactive protein, IL-6, and TNF-alpha [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/23/37240/abstract/33-35\">",
"     33-35",
"    </a>",
"    ]. It is thought to be due to endothelial activation by the endoprosthesis. For thoracic aortic stent grafts, development of either unilateral or bilateral reactive pleural effusions is not uncommon, with a reported incidence of 37 percent to 73 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/23/37240/abstract/34,36,37\">",
"     34,36,37",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Thirty day mortality",
"    </span>",
"    &nbsp;&mdash;&nbsp;Perioperative mortality with second generation stent grafts is low, ranging from 1.9 percent to 2.1 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/23/37240/abstract/1,2,5\">",
"     1,2,5",
"    </a>",
"    ]. Patients with emergent procedures and aortic dissection have a higher 30-day mortality rate [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/23/37240/abstract/31\">",
"     31",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H21\">",
"     'Emergency stenting'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Short-term",
"    </span>",
"    &nbsp;&mdash;&nbsp;The largest published series, which has reported one year follow up, included 443 patients treated with endovascular stents for a variety of indications, both emergent and elective: thoracic aortic aneurysm (249 patients), thoracic aortic dissection (131 patients), traumatic aortic injury (50 patients) and false anastomotic aneurysm (13 patients) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/23/37240/abstract/31\">",
"     31",
"    </a>",
"    ]. Approximately one-third of the procedures were emergent, and one-half of the patients were deemed high-risk and would not have been considered candidates for surgical repair. The following findings were reported:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Technical success was achieved in 87 percent of patients with aortic aneurysm, and 89 percent of patients with aortic dissection.",
"     </li>",
"     <li>",
"      One year all cause mortality among patients treated for aortic aneurysm and aortic dissection were 20 and 10 percent respectively.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These results should not be compared directly to historical outcomes following surgical repair. Patients included in this series had a greater burden of comorbid disease and many would not have been candidates for surgery. The short duration of follow-up precludes direct comparison with the durable effects of successful surgical repair. (See",
"    <a class=\"local\" href=\"#H20\">",
"     'TEVAR versus open surgery'",
"    </a>",
"    below and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?10/7/10361?source=see_link&amp;anchor=H14#H14\">",
"     \"Management and outcome of thoracic aortic aneurysm\", section on 'Morbidity and mortality'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Medium-term",
"    </span>",
"    &nbsp;&mdash;&nbsp;The largest of the early series, for which there is now medium-term follow up, was a prospective, uncontrolled study of a first-generation, custom-fabricated self-expanding stent graft, including 103 patients with descending thoracic aortic aneurysms, 60 percent of whom were not candidates for conventional surgery [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/23/37240/abstract/23\">",
"     23",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    After a 1.8 year follow up, the following findings were noted:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Late stent graft complications occurred in 38 percent of patients and included stent graft misdeployment or removal, endoleak, aortic dissection, distal embolization, gut ischemia, and infection.",
"     </li>",
"     <li>",
"      Fatal complications occurred in 4 percent, including rupture of the treated aneurysm, stent graft erosion into the esophagus (aortoesophageal fistula), arterial injury, and excessive bleeding",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In a subsequent report at 4.5 years of follow-up, actuarial survival at one, five and eight years was 82, 49, and 27 percent, respectively [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/23/37240/abstract/21\">",
"     21",
"    </a>",
"    ]. Patients who had been identified as suitable surgical candidates at the time of stent graft placement had significantly better survival at one year (93 versus 74 percent) and five years (78 versus 31 percent).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h3\">",
"     Device migration and endoleak",
"    </span>",
"    &nbsp;&mdash;&nbsp;Migration of the graft (&gt;10 mm) caudally can occur, with a published incidence of 1 percent to 2.8 percent over a 6 to 12 month period [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/23/37240/abstract/1,2,5\">",
"     1,2,5",
"    </a>",
"    ]. Factors predisposing to migration include excessive oversizing and tortuous seal zone anatomy.",
"   </p>",
"   <p>",
"    The incidence of endoleak following thoracic aortic stent placement is less common than that for endoscopic repair of the abdominal aorta and is estimated at 3.9 percent to 15.3 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/23/37240/abstract/1,2,5,38\">",
"     1,2,5,38",
"    </a>",
"    ]. The incidence of endoleak at five-year follow-up with the Gore TAG device was 4.3 percent with Type I attachment site leaks being the most common type. Ongoing surveillance for endoleak is necessary and discussed in the next section.",
"   </p>",
"   <p>",
"    The rate of secondary intervention required following stent grafting due to either endoleak or device migration is 3.6 percent to 4.4 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/23/37240/abstract/1,2\">",
"     1,2",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     TEVAR versus open surgery",
"    </span>",
"    &nbsp;&mdash;&nbsp;No randomized trials comparing TEVAR to open surgery (OS) have been published. The strength of the evidence from observational studies comparing TEVAR to OS is limited due to the following concerns [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/23/37240/abstract/24\">",
"     24",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Many studies compare TEVAR with older surgical techniques or operations with greater extents of repair.",
"     </li>",
"     <li>",
"      Many patients enrolled in TEVAR studies were not eligible for OS due to comorbidities.",
"     </li>",
"     <li>",
"      Many patients enrolled in OS studies include patients who would not be eligible for TEVAR because of anatomic constraints.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The best available evidence comes from a 2008 meta-analysis of 17 observational studies (1109 patients) which compared TEVAR to OS [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/23/37240/abstract/39\">",
"     39",
"    </a>",
"    ]. There was a significant reduction in perioperative mortality (OR 0.36; 95% CI 0.23-0.58) and in major neurological injury (OR 0.39; 95% CI 0.25-0.62). There was no difference in major reintervention rates, but a significant reduction in hospital and critical care stay. These benefits were seen predominantly in stable patients.",
"   </p>",
"   <p>",
"    Nonrandomized comparisons published after the meta-analysis have suggested equivalent or better outcomes with the TEVAR:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a single center, retrospective study of over 700 patients who received either TEVAR or OS, mortality was not significantly different at 30 days (5.7 versus 8.3 percent respectively) and 12 months (15.6 versus 15.9 percent respectively) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/23/37240/abstract/3\">",
"       3",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In two smaller studies, each of which included around 230 patients, the perioperative mortality was lowered with TEVAR (2.1 versus 11.7 percent early after surgery, and 1.9 versus 5.7 percent at 30 days) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/23/37240/abstract/1,5\">",
"       1,5",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Patients in the first small study cited above were followed for five years [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/23/37240/abstract/2\">",
"       2",
"      </a>",
"      ]. Aneurysm-related mortality was lower for TEVAR (2.8 versus 11.7 percent) most of which was attributable to fewer perioperative deaths. MACE, defined as prolongation of treatment, new hospitalization, major disability, or death, was also lower (58 versus 79 percent). No significant difference in survival (68 versus 67 percent) or the rate of aneurysm related reintervention (3.6 versus 2.1 percent) was seen.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The evidence cited above argues for the use of TEVAR as opposed to OS in those patients who are candidates for both approaches. Even if patients' important outcomes such as mortality, and the risks of stroke and paraplegia are equivalent, patients undergoing TEVAR have a shorter length of hospital stay, quicker rehabilitation, and a longer average number of months lived (due to a reduction in perioperative mortality).",
"   </p>",
"   <p>",
"    Patients with thoracic aneurysm often have one or more significant comorbidities and both TEVAR and OS are extremely challenging procedures. Patients undergoing either procedure should be referred only to health care teams that are both experienced in the preoperative and intraoperative management of these patients.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h1\">",
"     EMERGENCY STENTING",
"    </span>",
"    &nbsp;&mdash;&nbsp;The efficacy of stenting versus surgery in the emergent setting was specifically addressed in a nonrandomized study of 60 consecutive patients with acute rupture of the thoracic aorta; 28 patients were treated surgically and 32 were treated with an endovascular stent graft [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/23/37240/abstract/40\">",
"     40",
"    </a>",
"    ]. The following findings were reported:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Perioperative mortality was significantly lower in the stented patients (3.1 versus 17.8 percent).",
"     </li>",
"     <li>",
"      At a mean follow-up of 36 months, four additional deaths occurred in stented patients, three of which were attributed to late procedural complications (one aneurysm, one dissection, and one traumatic transection). No additional procedure-related deaths occurred in the surgical patients.",
"     </li>",
"     <li>",
"      Reintervention rates were similar in the two groups. All of the surgical reinterventions were early reexplorations for bleeding. In the patients treated with stents, one required early drainage of an empyema and two required late interventions for endovascular leaks (one repeat stent, complicated by paraplegia; one surgical repair with stent removal).",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h1\">",
"     OTHER POTENTIAL USES OF TEVAR",
"    </span>",
"    &nbsp;&mdash;&nbsp;Because TEVAR is associated with a large reduction in perioperative morbidity and mortality compared to open repair, every effort is made to employ an endovascular strategy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h2\">",
"     Traumatic aortic transection",
"    </span>",
"    &nbsp;&mdash;&nbsp;Traumatic aortic transection typically occurs with high-speed, deceleration-type injuries and at the level of the ligamentum arteriosum. TEVAR has been associated with significantly lower morbidity and mortality compared to open repair in a younger trauma population [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/23/37240/abstract/41\">",
"     41",
"    </a>",
"    ] and in a 2008 meta-analysis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/23/37240/abstract/42\">",
"     42",
"    </a>",
"    ]. No long-term data regarding the longevity of stent repair in this group are available.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h2\">",
"     Type B uncomplicated dissection",
"    </span>",
"    &nbsp;&mdash;&nbsp;The INSTEAD trial (INvestigation of STEnt grafts in patients with type B Aortic Dissection) was a prospective, multicenter randomized trial comparing optimal medical therapy to endovascular stent graft placement for uncomplicated Type B dissection [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/23/37240/abstract/43\">",
"     43",
"    </a>",
"    ]. There was no significant difference in all-cause mortality at one year between groups. The preliminary conclusion of the trial was that careful monitoring and tailored antihypertensive therapy for these patients is justified. The one critique of the INSTEAD trial was that the study was designed to evaluate patients with more chronic dissections (56 days in stent graft group versus 75 days in the medical management group). The ADSORB study, currently underway in Europe, will compare best medical management to stent grafting for patients with uncomplicated type B dissection presenting &lt;14 days after symptom onset.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h2\">",
"     Type B complicated dissection",
"    </span>",
"    &nbsp;&mdash;&nbsp;Treatment of Type B dissection with malperfusion has been successfully treated endovascularly and consists of covering the primary entry tear and re-expanding the true lumen [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/23/37240/abstract/44,45\">",
"     44,45",
"    </a>",
"    ]. Assessment of the restoration of luminal flow to the true lumen can be performed with the use of IVUS (intravascular ultrasound), which offers real-time information regarding the true and false lumina throughout the cardiac cycle. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?25/19/25914?source=see_link\">",
"     \"Clinical manifestations and diagnosis of aortic dissection\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h2\">",
"     Penetrating aortic ulcer/Intramural hematoma",
"    </span>",
"    &nbsp;&mdash;&nbsp;These are lesions lying within the spectrum of aortic dissection pathology; treatment should consist of covering the intimal tear of any coexistent dissection, as well as exclusion of the aortic lesion. Although isolated penetrating ulcers are easy to cover with endovascular devices, it is unclear if extensive intramural hematoma is, in fact, a contraindication to this approach.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h2\">",
"     Thoracoabdominal aneurysms",
"    </span>",
"    &nbsp;&mdash;&nbsp;Endovascular therapy of thoracoabdominal aneurysms is, thus, hindered by the presence of the intervening visceral segment. &nbsp;Hybrid approaches consisting of \"debranching\" procedures have been developed to provide separate blood flow to the visceral arteries and allow coverage of the visceral segment [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/23/37240/abstract/46,47\">",
"     46,47",
"    </a>",
"    ]. While debranching procedures are not without morbidity, they may be a suitable option in patients in whom avoiding a thoracotomy or cardiopulmonary bypass is appropriate [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/23/37240/abstract/11\">",
"     11",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h1\">",
"     LONG-TERM SURVEILLANCE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Computed tomography angiography is usually obtained within a month of the procedure, followed by an imaging study at six months and annually thereafter. Evidence of attachment site endoleak is intervened upon promptly. Type II endoleaks can be observed if the sac does not enlarge. Magnetic resonance angiography can also be used, although it is of limited applicability in patients with ESRD or CRI. Noncontrast computed tomography allows for measurement of the sac diameter and is sufficient in most circumstances to document effective aneurysm exclusion.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topic (see",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?18/48/19202?source=see_link\">",
"       \"Patient information: Endovascular surgery (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;For patients with indications for repair of thoracic aortic aneurysms, we suggest TEVAR instead of OS (",
"    <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"     Grade 2B",
"    </a>",
"    ). This recommendation is based upon the following points:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Patients with thoracic or thoracoabdominal aortic aneurysm have a poor prognosis when they have the following indications for repair: width &gt;6 cm, rapidly enlarging diameter (&gt;5 mm of growth over six months), symptoms such as chest pain, or diagnosis of aortic rupture or dissection. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Indications for TEVAR'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      TEVAR, in patients with or without involvement of the abdominal aorta, has gained acceptance as a reasonable alternative to OS. While no randomized trial data is available to compare the two strategies, observational data suggests equivalent or better patient important outcomes with TEVAR. (See",
"      <a class=\"local\" href=\"#H20\">",
"       'TEVAR versus open surgery'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Despite the significant rate of secondary intervention required following stent grafting (3.6 percent to 4.4 percent), the decreased morbidity of this approach makes it preferable to open repair in the majority of cases. (See",
"      <a class=\"local\" href=\"#H18\">",
"       'Medium-term'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The decision to perform TEVAR requires not only knowledge that the procedure is technically possible but that the patient's general health makes it logical and feasible. (See",
"    <a class=\"local\" href=\"#H4\">",
"     'Conduct of the operation'",
"    </a>",
"    above and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?10/7/10361?source=see_link\">",
"     \"Management and outcome of thoracic aortic aneurysm\"",
"    </a>",
"    .)",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/23/37240/abstract/1\">",
"      Matsumura JS, Cambria RP, Dake MD, et al. International controlled clinical trial of thoracic endovascular aneurysm repair with the Zenith TX2 endovascular graft: 1-year results. J Vasc Surg 2008; 47:247.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/23/37240/abstract/2\">",
"      Makaroun MS, Dillavou ED, Wheatley GH, et al. Five-year results of endovascular treatment with the Gore TAG device compared with open repair of thoracic aortic aneurysms. J Vasc Surg 2008; 47:912.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/23/37240/abstract/3\">",
"      Greenberg RK, Lu Q, Roselli EE, et al. Contemporary analysis of descending thoracic and thoracoabdominal aneurysm repair: a comparison of endovascular and open techniques. Circulation 2008; 118:808.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/23/37240/abstract/4\">",
"      Makaroun MS, Dillavou ED, Kee ST, et al. Endovascular treatment of thoracic aortic aneurysms: results of the phase II multicenter trial of the GORE TAG thoracic endoprosthesis. J Vasc Surg 2005; 41:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/23/37240/abstract/5\">",
"      Bavaria JE, Appoo JJ, Makaroun MS, et al. Endovascular stent grafting versus open surgical repair of descending thoracic aortic aneurysms in low-risk patients: a multicenter comparative trial. J Thorac Cardiovasc Surg 2007; 133:369.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/23/37240/abstract/6\">",
"      Najibi S, Terramani TT, Weiss VJ, et al. Endoluminal versus open treatment of descending thoracic aortic aneurysms. J Vasc Surg 2002; 36:732.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/23/37240/abstract/7\">",
"      Stone DH, Brewster DC, Kwolek CJ, et al. Stent-graft versus open-surgical repair of the thoracic aorta: mid-term results. J Vasc Surg 2006; 44:1188.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/23/37240/abstract/8\">",
"      Grobner T, Prischl FC. Patient characteristics and risk factors for nephrogenic systemic fibrosis following gadolinium exposure. Semin Dial 2008; 21:135.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/23/37240/abstract/9\">",
"      Cheung AT, Weiss SJ, McGarvey ML, et al. Interventions for reversing delayed-onset postoperative paraplegia after thoracic aortic reconstruction. Ann Thorac Surg 2002; 74:413.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/23/37240/abstract/10\">",
"      Khoynezhad A, Donayre CE, Bui H, et al. Risk factors of neurologic deficit after thoracic aortic endografting. Ann Thorac Surg 2007; 83:S882.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/23/37240/abstract/11\">",
"      Greenberg RK, Lytle B. Endovascular repair of thoracoabdominal aneurysms. Circulation 2008; 117:2288.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/23/37240/abstract/12\">",
"      Szeto WY, Bavaria JE, Bowen FW, et al. The hybrid total arch repair: brachiocephalic bypass and concomitant endovascular aortic arch stent graft placement. J Card Surg 2007; 22:97.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/23/37240/abstract/13\">",
"      Zhou W, Reardon M, Peden EK, et al. Hybrid approach to complex thoracic aortic aneurysms in high-risk patients: surgical challenges and clinical outcomes. J Vasc Surg 2006; 44:688.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/23/37240/abstract/14\">",
"      Bergeron P, Mangialardi N, Costa P, et al. Great vessel management for endovascular exclusion of aortic arch aneurysms and dissections. Eur J Vasc Endovasc Surg 2006; 32:38.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/23/37240/abstract/15\">",
"      Chuter TA, Schneider DB, Reilly LM, et al. Modular branched stent graft for endovascular repair of aortic arch aneurysm and dissection. J Vasc Surg 2003; 38:859.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/23/37240/abstract/16\">",
"      Vaddineni SK, Taylor SM, Patterson MA, Jordan WD Jr. Outcome after celiac artery coverage during endovascular thoracic aortic aneurysm repair: preliminary results. J Vasc Surg 2007; 45:467.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/23/37240/abstract/17\">",
"      Jorna FH, Verhoeven EL, Bos WT, et al. Treatment of a ruptured thoracoabdominal aneurysm with a stent-graft covering the celiac axis. J Endovasc Ther 2006; 13:770.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/23/37240/abstract/18\">",
"      Lin PH, El Sayed HF, Kougias P, et al. Endovascular repair of thoracic aortic disease: overview of current devices and clinical results. Vascular 2007; 15:179.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/23/37240/abstract/19\">",
"      Gutsche JT, Cheung AT, McGarvey ML, et al. Risk factors for perioperative stroke after thoracic endovascular aortic repair. Ann Thorac Surg 2007; 84:1195.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/23/37240/abstract/20\">",
"      Feezor RJ, Martin TD, Hess PJ, et al. Risk factors for perioperative stroke during thoracic endovascular aortic repairs (TEVAR). J Endovasc Ther 2007; 14:568.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/23/37240/abstract/21\">",
"      Demers P, Miller DC, Mitchell RS, et al. Midterm results of endovascular repair of descending thoracic aortic aneurysms with first-generation stent grafts. J Thorac Cardiovasc Surg 2004; 127:664.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/23/37240/abstract/22\">",
"      Svensson LG. Device discordancy: lost cords, quick-fix seekers, quality, and ethics. J Thorac Cardiovasc Surg 2006; 131:261.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/23/37240/abstract/23\">",
"      Dake MD, Miller DC, Mitchell RS, et al. The \"first generation\" of endovascular stent-grafts for patients with aneurysms of the descending thoracic aorta. J Thorac Cardiovasc Surg 1998; 116:689.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/23/37240/abstract/24\">",
"      Svensson LG, Kouchoukos NT, Miller DC, et al. Expert consensus document on the treatment of descending thoracic aortic disease using endovascular stent-grafts. Ann Thorac Surg 2008; 85:S1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/23/37240/abstract/25\">",
"      Woo EY, Mcgarvey M, Jackson BM, et al. Spinal cord ischemia may be reduced via a novel technique of intercostal artery revascularization during open thoracoabdominal aneurysm repair. J Vasc Surg 2007; 46:421.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/23/37240/abstract/26\">",
"      Noor N, Sadat U, Hayes PD, et al. Management of the left subclavian artery during endovascular repair of the thoracic aorta. J Endovasc Ther 2008; 15:168.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/23/37240/abstract/27\">",
"      Riesenman PJ, Farber MA, Mendes RR, et al. Coverage of the left subclavian artery during thoracic endovascular aortic repair. J Vasc Surg 2007; 45:90.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/23/37240/abstract/28\">",
"      Amabile P, Grisoli D, Giorgi R, et al. Incidence and determinants of spinal cord ischaemia in stent-graft repair of the thoracic aorta. Eur J Vasc Endovasc Surg 2008; 35:455.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/23/37240/abstract/29\">",
"      Buth J, Harris PL, Hobo R, et al. Neurologic complications associated with endovascular repair of thoracic aortic pathology: Incidence and risk factors. a study from the European Collaborators on Stent/Graft Techniques for Aortic Aneurysm Repair (EUROSTAR) registry. J Vasc Surg 2007; 46:1103.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/23/37240/abstract/30\">",
"      Cheung AT, Pochettino A, McGarvey ML, et al. Strategies to manage paraplegia risk after endovascular stent repair of descending thoracic aortic aneurysms. Ann Thorac Surg 2005; 80:1280.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/23/37240/abstract/31\">",
"      Leurs LJ, Bell R, Degrieck Y, et al. Endovascular treatment of thoracic aortic diseases: combined experience from the EUROSTAR and United Kingdom Thoracic Endograft registries. J Vasc Surg 2004; 40:670.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/23/37240/abstract/32\">",
"      Conrad MF, Cambria RP. Contemporary management of descending thoracic and thoracoabdominal aortic aneurysms: endovascular versus open. Circulation 2008; 117:841.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/23/37240/abstract/33\">",
"      Gabriel EA, Locali RF, Romano CC, et al. Analysis of the inflammatory response in endovascular treatment of aortic aneurysms. Eur J Cardiothorac Surg 2007; 31:406.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/23/37240/abstract/34\">",
"      Ishida M, Kato N, Hirano T, et al. Thoracic CT findings following endovascular stent-graft treatment for thoracic aortic aneurysm. J Endovasc Ther 2007; 14:333.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/23/37240/abstract/35\">",
"      Eggebrecht H, Mehta RH, Metozounve H, et al. Clinical implications of systemic inflammatory response syndrome following thoracic aortic stent-graft placement. J Endovasc Ther 2008; 15:135.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/23/37240/abstract/36\">",
"      Sakai T, Dake MD, Semba CP, et al. Descending thoracic aortic aneurysm: thoracic CT findings after endovascular stent-graft placement. Radiology 1999; 212:169.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/23/37240/abstract/37\">",
"      Schoder M, Cartes-Zumelzu F, Grabenw&ouml;ger M, et al. Elective endovascular stent-graft repair of atherosclerotic thoracic aortic aneurysms: clinical results and midterm follow-up. AJR Am J Roentgenol 2003; 180:709.",
"     </a>",
"    </li>",
"    <li>",
"     Preventza, O, Wheatley, GH III, Ramaiah VG, et al. Management of endoleaks associated with endovascular treatment of descending thoracic aortic diseases. J Vasc Surg 2008.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/23/37240/abstract/39\">",
"      Walsh SR, Tang TY, Sadat U, et al. Endovascular stenting versus open surgery for thoracic aortic disease: systematic review and meta-analysis of perioperative results. J Vasc Surg 2008; 47:1094.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/23/37240/abstract/40\">",
"      Doss M, Wood JP, Balzer J, et al. Emergency endovascular interventions for acute thoracic aortic rupture: four-year follow-up. J Thorac Cardiovasc Surg 2005; 129:645.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/23/37240/abstract/41\">",
"      Demetriades D, Velmahos GC, Scalea TM, et al. Operative repair or endovascular stent graft in blunt traumatic thoracic aortic injuries: results of an American Association for the Surgery of Trauma Multicenter Study. J Trauma 2008; 64:561.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/23/37240/abstract/42\">",
"      Xenos ES, Abedi NN, Davenport DL, et al. Meta-analysis of endovascular vs open repair for traumatic descending thoracic aortic rupture. J Vasc Surg 2008; 48:1343.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/23/37240/abstract/43\">",
"      Nienaber CA, Zannetti S, Barbieri B, et al. INvestigation of STEnt grafts in patients with type B Aortic Dissection: design of the INSTEAD trial--a prospective, multicenter, European randomized trial. Am Heart J 2005; 149:592.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/23/37240/abstract/44\">",
"      Kaya A, Heijmen RH, Overtoom TT, et al. Thoracic stent grafting for acute aortic pathology. Ann Thorac Surg 2006; 82:560.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/23/37240/abstract/45\">",
"      Duebener LF, Lorenzen P, Richardt G, et al. Emergency endovascular stent-grafting for life-threatening acute type B aortic dissections. Ann Thorac Surg 2004; 78:1261.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/23/37240/abstract/46\">",
"      Black SA, Wolfe JH, Clark M, et al. Complex thoracoabdominal aortic aneurysms: endovascular exclusion with visceral revascularization. J Vasc Surg 2006; 43:1081.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/23/37240/abstract/47\">",
"      B&ouml;ckler D, Kotelis D, Geisb&uuml;sch P, et al. Hybrid procedures for thoracoabdominal aortic aneurysms and chronic aortic dissections - a single center experience in 28 patients. J Vasc Surg 2008; 47:724.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 8191 Version 6.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0505-88.81.100.162-2094B74F85-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f36_23_37240=[""].join("\n");
var outline_f36_23_37240=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H29\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      INDICATIONS FOR TEVAR",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      PREOPERATIVE PLANNING",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      CONDUCT OF THE OPERATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Anatomic considerations",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      - Proximal and distal landing zones",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Endoleak",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Devices",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      OUTCOMES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Combined perioperative outcomes",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Stroke",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - Spinal cord ischemia",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - Visceral ischemia",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      - Access complications",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      - Postimplantation syndrome",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Thirty day mortality",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Short-term",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Medium-term",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      - Device migration and endoleak",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      TEVAR versus open surgery",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      EMERGENCY STENTING",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      OTHER POTENTIAL USES OF TEVAR",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      Traumatic aortic transection",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      Type B uncomplicated dissection",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      Type B complicated dissection",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      Penetrating aortic ulcer/Intramural hematoma",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      Thoracoabdominal aneurysms",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      LONG-TERM SURVEILLANCE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"SURG/8191\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"SURG/8191|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?37/21/38228\" title=\"figure 1\">",
"      Endovascular repair of thoracic aortic aneurysm",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?22/11/22712?source=related_link\">",
"      Clinical features and diagnosis of thoracic aortic aneurysm",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?25/19/25914?source=related_link\">",
"      Clinical manifestations and diagnosis of aortic dissection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?10/7/10361?source=related_link\">",
"      Management and outcome of thoracic aortic aneurysm",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?18/48/19202?source=related_link\">",
"      Patient information: Endovascular surgery (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?37/48/38666?source=related_link\">",
"      Periprocedural complications of percutaneous coronary intervention",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f36_23_37241="Classification of and approach to the vasculitides in adults";
var content_f36_23_37241=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Classification of and approach to the vasculitides in adults",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?36/23/37241/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?36/23/37241/contributors\">",
"     Gene G Hunder, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?36/23/37241/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?36/23/37241/contributors\">",
"     John H Stone, MD, MPH",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?36/23/37241/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?36/23/37241/contributors\">",
"     Paul L Romain, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?36/23/37241/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Feb 4, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The vasculitides are defined by the presence of inflammatory leukocytes in vessel walls with reactive damage to mural structures. Loss of vessel integrity may lead to bleeding. Compromise of the lumen leads to downstream tissue ischemia and necrosis. In general, affected vessels vary in size, type, and location in association with the specific vasculitic disorder. Vasculitis may occur as a primary process or may be secondary to another underlying disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/23/37241/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The exact mechanisms underlying these disorders are unclear. Three different pathogenic models of disease have been advanced to help explain why the lesions of a particular vasculitic syndrome are only found in specific vessels [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/23/37241/abstract/2\">",
"     2",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The distribution of the antigen responsible for the vasculitis determines the pattern of vessel involvement.",
"     </li>",
"     <li>",
"      The recruitment and accumulation of the inflammatory infiltrate is determined by the endothelial cell, including the expression of adhesion or other receptor molecules, the secretion of peptides and hormones, and the specific interaction with inflammatory cells. Some endothelial cells are, therefore, able to attract inflammatory cells, while others are not.",
"     </li>",
"     <li>",
"      Non-endothelial structures of the vessel wall are involved in controlling the inflammatory process. In addition to the endothelial cells that provide costimulatory function, other cellular components serve as antigen-presenting cells and contribute proinflammatory mediators.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    It is likely that elements of each model contribute to the pathogenesis of these diseases.",
"   </p>",
"   <p>",
"    The vasculitides are often serious and sometimes fatal diseases that require prompt recognition and therapy. Symptomatic involvement of affected organs may either occur in isolation or in combination with multiple organs. The distribution of affected organs may suggest a particular vasculitic disorder, but significant overlap is observed.",
"   </p>",
"   <p>",
"    Fortunately, available treatments are helpful, particularly in the acute phase. However, during maintenance therapy with glucocorticoids and immunosuppressive agents, the adverse effects of drugs and superimposed infections may assume increasing importance. Mortality data suggest that, while early deaths in vasculitis are due to the active disease, late deaths may be due to the complications of therapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/23/37241/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    This topic will review the classification and diagnostic manifestations of the different vasculitides and will provide an overview of the approach to the patient with suspected vasculitis. An overview of the treatment of these disorders and detailed discussions of the individual disorders are presented separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?28/17/28949?source=see_link\">",
"     \"Overview of the management of the vasculitides in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     CLASSIFICATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Classically, the vasculitic syndromes have been categorized by the predominant sizes of the blood vessels and types of vessels most commonly affected among patients with the disorder (",
"    <a class=\"graphic graphic_table graphicRef63522 \" href=\"mobipreview.htm?3/28/3532\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/23/37241/abstract/4,5\">",
"     4,5",
"    </a>",
"    ]. The presence or absence of antineutrophil cytoplasmic antibodies (ANCA) is a more recent addition to proposed classification criteria [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/23/37241/abstract/6,7\">",
"     6,7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    There has been a trend among experts toward use of names for vasculitic disorders that reflect increased pathophysiologic understanding of these conditions and away from the use of eponyms. Revisions in the commonly used terms for the various vasculitides have been proposed by the 2012 International Chapel Hill Consensus Conference (CHCC) on nomenclature of vasculitides [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/23/37241/abstract/8,9\">",
"     8,9",
"    </a>",
"    ]. Among the notable changes suggested by the 2012 CHCC were use of the term eosinophilic granulomatosis with polyangiitis (Churg-Strauss), abbreviated EGPA, in place of Churg-Strauss syndrome, and formal adoption of the term antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV) for the three disorders microscopic polyangiitis, granulomatosis with polyangiitis (Wegener&rsquo;s), and EGPA.",
"   </p>",
"   <p>",
"    Some of the other changes suggested by the 2012 CHCC included the use of the term immunoglobulin A (IgA) vasculitis (Henoch-Sch&ouml;nlein) in lieu of Henoch-Sch&ouml;nlein purpura, further definition of hypocomplementemic urticarial vasculitis (HUV) as HUV (anti-C1q vasculitis), and use of the term cryoglobulinemic vasculitis in place of essential cryoglobulinemic vasculitis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Large vessel vasculitis",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h3\">",
"     Takayasu arteritis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Takayasu arteritis primarily affects the aorta and its primary branches. The inflammation may be localized to a portion of the thoracic or abdominal aorta and branches or may involve the entire vessel. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?13/19/13624?source=see_link\">",
"     \"Clinical features and diagnosis of Takayasu arteritis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h3\">",
"     Giant cell arteritis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Giant cell or temporal arteritis is a chronic vasculitis of large- and medium-sized vessels. Although it may be generalized, vessel inflammation most prominently involves the cranial branches of the arteries originating from the aortic arch. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?18/33/18969?source=see_link\">",
"     \"Clinical manifestations of giant cell (temporal) arteritis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Medium vessel vasculitis",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     Polyarteritis nodosa",
"    </span>",
"    &nbsp;&mdash;&nbsp;Polyarteritis nodosa is a systemic necrotizing vasculitis that typically affects the medium- and small-sized muscular arteries. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?9/26/9641?source=see_link\">",
"     \"Clinical manifestations and diagnosis of polyarteritis nodosa\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In some cases, however, only the smaller vessels are affected, a condition that has been called microscopic polyarteritis or polyangiitis; this disorder is felt to be more closely associated with granulomatosis with polyangiitis (Wegener&rsquo;s) than classic polyarteritis nodosa. (See",
"    <a class=\"local\" href=\"#H13\">",
"     'Microscopic polyangiitis'",
"    </a>",
"    below and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?16/62/17386?source=see_link\">",
"     \"Clinical manifestations and diagnosis of granulomatosis with polyangiitis (Wegener's) and microscopic polyangiitis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     Kawasaki disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Kawasaki disease is an arteritis of large, medium, and small arteries, particularly the coronary arteries. The disease usually occurs in children and is often associated with a mucocutaneous lymph node syndrome. A small number of cases have also been reported in adults [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/23/37241/abstract/10\">",
"     10",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?11/61/12248?source=see_link\">",
"     \"Kawasaki disease: Clinical features and diagnosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Primary central nervous system vasculitis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Primary or isolated central nervous system vasculitis affects medium and small arteries over a diffuse area of the central nervous system, without symptomatic involvement of extracranial vessels. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?24/50/25386?source=see_link\">",
"     \"Primary angiitis of the central nervous system\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Small vessel vasculitis",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     Eosinophilic granulomatosis with polyangiitis (Churg-Strauss)",
"    </span>",
"    &nbsp;&mdash;&nbsp;Eosinophilic granulomatosis with polyangiitis (Churg-Strauss), abbreviated as EGPA, also called Churg-Strauss syndrome and allergic granulomatosis and angiitis is a vasculitis of the medium- and small-sized muscular arteries and is often found with vascular and extravascular granulomatosis. The vasculitis classically involves the arteries of the lung and skin, but it may be generalized. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?20/56/21383?source=see_link\">",
"     \"Epidemiology, pathogenesis, and pathology of Churg-Strauss syndrome (allergic granulomatosis and angiitis)\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     Granulomatosis with polyangiitis (Wegener&rsquo;s)",
"    </span>",
"    &nbsp;&mdash;&nbsp;Granulomatosis with polyangiitis (Wegener&rsquo;s), abbreviated as GPA, is a systemic vasculitis of the medium and small arteries, as well as the venules and arterioles. It typically produces granulomatous inflammation of the upper and lower respiratory tracts and necrotizing, pauci-immune glomerulonephritis in the kidneys. GPA is usually associated with antineutrophil cytoplasmic antibodies (ANCA). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?16/62/17386?source=see_link\">",
"     \"Clinical manifestations and diagnosis of granulomatosis with polyangiitis (Wegener's) and microscopic polyangiitis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     Microscopic polyangiitis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Microscopic polyangiitis or polyarteritis is a vasculitis that primarily affects capillaries, venules, or arterioles. Involvement of medium- and small- sized arteries may also be present. This disorder is thought by some investigators to represent part of a clinical spectrum that includes GPA, since both are associated with the presence of ANCA and similar histologic changes outside the respiratory tract. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?16/62/17386?source=see_link\">",
"     \"Clinical manifestations and diagnosis of granulomatosis with polyangiitis (Wegener's) and microscopic polyangiitis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h3\">",
"     Henoch-Sch&ouml;nlein purpura (IgA vasculitis)",
"    </span>",
"    &nbsp;&mdash;&nbsp;Henoch-Sch&ouml;nlein purpura (HSP), also termed IgA vasculitis, is a systemic vasculitis that is characterized by the tissue deposition of IgA-containing immune complexes. Biopsy of lesions reveals inflammation of the small blood vessels (most prominent in the postcapillary venules). This disorder is considered a form of hypersensitivity vasculitis but is distinguished from other forms of hypersensitivity by the finding of prominent deposits of IgA. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?39/49/40729?source=see_link\">",
"     \"Clinical manifestations and diagnosis of Henoch-Sch&ouml;nlein purpura (IgA vasculitis)\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h3\">",
"     Cryoglobulinemic vasculitis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cryoglobulinemic vasculitis, previous termed essential cryoglobulinemic vasculitis, is characterized by the presence of cryoglobulins, which are serum proteins that precipitate in the cold and dissolve upon rewarming. Cryoglobulins typically are composed of a mixture of immunoglobulins and complement components. In this disorder, which is most often due to hepatitis C virus infection, immune complexes are deposited in the walls of capillaries, venules, or arterioles, thereby resulting in small vessel inflammation. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?21/63/22522?source=see_link\">",
"     \"Overview of cryoglobulins and cryoglobulinemia\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?33/15/34040?source=see_link\">",
"     \"Clinical manifestations and diagnosis of the mixed cryoglobulinemia syndrome (essential mixed cryoglobulinemia)\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h3\">",
"     Hypersensitivity vasculitis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The term \"hypersensitivity vasculitis\" has been used by some authors to include several forms of vasculitis of small blood vessels. These have included HSP, mixed cryoglobulinemia, allergic vasculitis, and serum sickness. However, the term \"hypersensitivity vasculitis\" is most properly used to refer to vasculitis that occurs as a hypersensitivity reaction to a known or suspected substance such as a vasculitic drug reaction. In hypersensitivity vasculitis, the presence of skin vasculitis with palpable petechiae or purpura is typically a major finding. Biopsy of these lesions reveals inflammation of the small blood vessels, called leukocytoclastic vasculitis, which is most prominent in the postcapillary venules. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?29/57/30614?source=see_link\">",
"     \"Hypersensitivity vasculitis in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h3\">",
"     Vasculitis secondary to connective tissue disorders",
"    </span>",
"    &nbsp;&mdash;&nbsp;A subset of patients with systemic lupus erythematosus, rheumatoid arthritis, relapsing polychondritis, Beh&ccedil;et&rsquo;s disease, and other connective tissue disorders may have or develop a vasculitis associated with the systemic disease. The vasculitic process in this setting most frequently involves the small muscular arteries, arterioles, and venules. A propensity for involvement of particular organs varies with the underlying autoimmune disorder. (See appropriate topic reviews).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h3\">",
"     Vasculitis secondary to viral infection",
"    </span>",
"    &nbsp;&mdash;&nbsp;A number of viral infections may cause a vasculitis of medium",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    small vessels [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/23/37241/abstract/11\">",
"     11",
"    </a>",
"    ]. This association is most commonly observed with hepatitis B and C viruses but may also be seen with HIV, cytomegalovirus, Epstein-Barr virus, and Parvovirus B19. The clinical presentation may be similar to that of polyarteritis nodosa or microscopic polyangiitis. Although the disorder is probably immune complex mediated, it must be distinguished from nonviral associated vasculitides since treatment consists of the administration of antiviral, and not antiinflammatory, regimens.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h1\">",
"     CLINICAL MANIFESTATIONS AND APPROACH TO DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The presence of vasculitis should be considered in patients who present with systemic symptoms in combination with evidence of single",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    multiorgan dysfunction. Although neither sensitive nor specific, common complaints and signs of vasculitis include fatigue, weakness, fever, arthralgias, abdominal pain, hypertension, renal insufficiency (with an active urine sediment containing red and white cell and occasionally red cell casts), and neurologic dysfunction.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Clinical features suggestive of vasculitis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnosis of vasculitis is often delayed because the clinical manifestations can be mimicked by a number of other disorders. However, the presence of certain signs is strongly suggestive. As examples:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Mononeuritis multiplex &mdash; Mononeuritis multiplex (or asymmetric polyneuropathy) is highly suggestive of vasculitis (particularly polyarteritis nodosa), since diabetic neuropathy is the only other common cause of this problem in developed countries. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?21/57/22423?source=see_link\">",
"       \"Clinical manifestations of vasculitic neuropathy\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Palpable purpura &mdash; Patients with palpable purpura alone are likely to have cutaneous leukocytoclastic vasculitis of the hypersensitivity vasculitis type (",
"      <a class=\"graphic graphic_picture graphicRef78697 \" href=\"mobipreview.htm?9/36/9794\">",
"       picture 1",
"      </a>",
"      ); if the purpura is present with systemic organ involvement, such patients are likely to have HSP (IgA vasculitis) or microscopic polyangiitis (polyarteritis). (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?4/15/4345?source=see_link&amp;anchor=H16171977#H16171977\">",
"       \"Evaluation of adults with cutaneous lesions of vasculitis\", section on 'Cutaneous findings'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?38/43/39608?source=see_link&amp;anchor=H933969#H933969\">",
"       \"Approach to the patient with retiform (angulated) purpura\", section on 'Vessel wall pathology'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Pulmonary-renal involvement &mdash; The combination of hemoptysis and renal involvement suggestive of glomerulonephritis suggests the diagnosis of granulomatosis with polyangiitis (Wegener&rsquo;s) or microscopic polyangiitis. However, certain other disorders, particularly anti-glomerular basement membrane (anti-GBM) antibody disease, may cause an identical combination of findings. One report of 97 such patients, for example, found that 48 were ANCA-positive and presumably had granulomatosis with polyangiitis (Wegener&rsquo;s) or microscopic polyangiitis, that 7 had both ANCA and anti-GBM antibodies, and that 6 had anti-GBM antibody disease alone [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/23/37241/abstract/12\">",
"       12",
"      </a>",
"      ]. The remaining patients had a variety of disorders including pulmonary emboli, infection, and lupus. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?26/31/27130?source=see_link&amp;anchor=H14577579#H14577579\">",
"       \"Differential diagnosis and evaluation of glomerular disease\", section on 'Acute glomerulonephritis and pulmonary hemorrhage'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Because of the variability of the manifestations of vasculitic syndromes, it has not been possible to outline a single uniform method of evaluating patients suspected of having one of these conditions. Nevertheless, there are shared elements in the history, physical examination, and laboratory evaluation of the patient suspected of having a vasculitis. In addition, specific procedures are essential in some forms of vasculitis, such as arch angiogram for Takayasu arteritis and temporal artery biopsy for giant cell arteritis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Diagnostic approach",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h3\">",
"     History",
"    </span>",
"    &nbsp;&mdash;&nbsp;A detailed history is important to assess whether the patient has recently been administered drugs (which may produce hypersensitivity vasculitis), has a history of hepatitis (hepatitis C virus is responsible for most cases of mixed cryoglobulinemia and some cases of polyarteritis), or has been diagnosed with any disorder known to be associated with a vasculitis (such as systemic lupus erythematosus).",
"   </p>",
"   <p>",
"    The propensity of certain disorders to occur among certain age groups",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    in women may favor the diagnosis of a specific vasculitic syndrome (",
"    <a class=\"graphic graphic_table graphicRef63522 \" href=\"mobipreview.htm?3/28/3532\">",
"     table 1",
"    </a>",
"    ). In a review of 807 patients from the American College of Rheumatology cohort, the mean age at onset was between 45 and 50 for granulomatosis with polyangiitis (Wegener&rsquo;s) and polyarteritis nodosa compared with 17 and 26 years of age for HSP and Takayasu arteritis and with 69 years for giant cell arteritis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/23/37241/abstract/4\">",
"     4",
"    </a>",
"    ]. The last two disorders occurred primarily in women (86 and 75 percent, respectively).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h3\">",
"     Physical examination",
"    </span>",
"    &nbsp;&mdash;&nbsp;A careful physical examination helps to determine the extent of vascular lesions, the distribution of affected organs, and the presence of additional disease processes. As mentioned above, certain findings, such as mononeuritis multiplex and palpable purpura (",
"    <a class=\"graphic graphic_picture graphicRef78697 \" href=\"mobipreview.htm?9/36/9794\">",
"     picture 1",
"    </a>",
"    ), are highly suggestive of an underlying vasculitic process.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h3\">",
"     Laboratory tests",
"    </span>",
"    &nbsp;&mdash;&nbsp;Laboratory tests help ascertain the type of vasculitis, as well as the degree and types of organs affected. Basic laboratory analysis should include serum creatinine and muscle enzyme concentrations, liver function studies, erythrocyte sedimentation rate, hepatitis serologies, urinalysis, chest x-ray, and electrocardiogram. Other tests that may be warranted include cerebrospinal fluid analysis, central nervous system imaging, pulmonary function testing, and blood and tissue culture. Although many of these tests are nonspecific, they permit the initial assessment of organ involvement, and they may suggest, include, or exclude additional diagnostic possibilities, particularly infection.",
"   </p>",
"   <p>",
"    Additional, more specific laboratory testing may further aid in diagnosis:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      ANA &mdash; A positive antinuclear antibody test suggests the presence of an underlying connective tissue disorder, particularly systemic lupus erythematosus. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?27/54/28520?source=see_link\">",
"       \"Measurement and clinical significance of antinuclear antibodies\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Complement&mdash; Low serum complement levels may be present in mixed cryoglobulinemia and lupus but not in most other vasculitis disorders. Among those with cryoglobulins, infection with hepatitis C virus must be considered. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?10/25/10647?source=see_link\">",
"       \"Overview and clinical assessment of the complement system\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?15/8/15498?source=see_link\">",
"       \"Extrahepatic manifestations of hepatitis C virus infection\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      ANCA &mdash; Although not diagnostic, the presence of ANCA directed against protease 3 strongly suggests a diagnosis of granulomatosis with polyangiitis (Wegener&rsquo;s), while ANCA directed against myeloperoxidase favors a diagnosis of microscopic polyangiitis [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/23/37241/abstract/13,14\">",
"       13,14",
"      </a>",
"      ]. Other ANCA-associated disorders include drug-induced vasculitis and eosinophilic granulomatosis with polyangiitis (Churg-Strauss). (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?9/28/9674?source=see_link\">",
"       \"Clinical spectrum of antineutrophil cytoplasmic antibodies\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h3\">",
"     Electromyography",
"    </span>",
"    &nbsp;&mdash;&nbsp;Electromyography is useful if a systemic vasculitis is suspected and if neuromuscular symptoms are present, such as a mononeuritis multiplex. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?27/13/27863?source=see_link\">",
"     \"Clinical neurophysiology\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h3\">",
"     Tissue biopsy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Biopsy examination of the most clinically involved tissue is",
"    <strong>",
"     essential",
"    </strong>",
"    for diagnosis. The chances of obtaining a diagnostic specimen are greatest when a specimen is taken from an involved portion of an affected organ and when the tissue sample is of adequate size. A \"blind\" biopsy is less likely to be fruitful. Histologic findings evolve as lesions progress and may vary from an acute inflammation to those due to healing and repair. (See",
"    <a class=\"local\" href=\"#H28\">",
"     'Classification criteria'",
"    </a>",
"    below and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?4/15/4345?source=see_link&amp;anchor=H16171991#H16171991\">",
"     \"Evaluation of adults with cutaneous lesions of vasculitis\", section on 'Biopsy'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h3\">",
"     Arteriography",
"    </span>",
"    &nbsp;&mdash;&nbsp;Arteriograms are helpful in identifying and characterizing a vasculitis of large- and medium-sized arteries, such as polyarteritis nodosa, Takayasu arteritis, and giant cell arteritis with an aortic arch syndrome. In these conditions, angiographic abnormalities may not be pathognomonic but usually support a diagnosis when combined with other clinical data. More advanced imaging techniques, including magnetic resonance (MR) imaging, MR angiograms, computerized tomography (CT) angiograms, and ultrasound techniques, have been increasingly used to detect large artery lesions. Thickness of the vessel walls can be demonstrated with these techniques. They are, however, less sensitive than conventional angiograms.",
"   </p>",
"   <p>",
"    Angiograms of mesenteric or renal arteries in polyarteritis nodosa may show aneurysms, occlusions, and vascular wall irregularities (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef65987 \" href=\"mobipreview.htm?35/54/36705\">",
"     image 1",
"    </a>",
"    ). In the patient suspected of having polyarteritis nodosa in whom an obvious area for biopsy is absent, a mesenteric angiogram should be considered, particularly in the presence of abdominal pain. In contrast, angiography is unlikely to be helpful in assessing a small vessel vasculitis, such as microscopic polyangiitis. The affected vessels in this disorder are below the resolution of usual angiograms.",
"   </p>",
"   <p>",
"    The decision to biopsy",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    perform angiography in a patient suspected of a vasculitis is based upon an overall clinical assessment and the relative complications associated with each procedure in a particular clinical setting. As an example, arteriography alone is usually performed to confirm the diagnosis of Takayasu arteritis. The arteriographic changes tend to be most pronounced in the region of the aortic arch and its primary branches, areas relatively inaccessible for biopsy. In contrast, involvement of the skin is characteristic of patients with a leukocytoclastic vasculitis; the skin is easily accessible for biopsy, a procedure not associated with significant morbidity. However, the observed changes are not specific unless there is IgA deposition, establishing the diagnosis of HSP.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h1\">",
"     CLASSIFICATION CRITERIA",
"    </span>",
"    &nbsp;&mdash;&nbsp;Criteria for the classification of most of the major forms of vasculitis have been established by the American College of Rheumatology (ACR) in 1990 and are presented below [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/23/37241/abstract/4\">",
"     4",
"    </a>",
"    ]. These criteria are based upon prospective data from patients with vasculitis; they do not include all characteristics of a particular disorder, only those that help to distinguish the disorder from other vasculitides. As noted above, the diagnosis of a particular form of vasculitis is virtually always confirmed by",
"    <strong>",
"     tissue biopsy",
"    </strong>",
"    .",
"   </p>",
"   <p>",
"    The inappropriate utilization of these classification criteria for the clinical diagnosis of individual patients suspected to have vasculitis is associated with relatively low diagnostic accuracy. As an example, the diagnostic accuracy of these criteria for four forms of vasculitis was directly assessed in a prospective study of 198 patients referred for possible vasculitis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/23/37241/abstract/15\">",
"     15",
"    </a>",
"    ]. The reference diagnosis was the final diagnosis found in an audit of the patient's chart performed two to eight months after presentation. For the diagnosis of granulomatosis with polyangiitis (Wegener&rsquo;s), giant-cell arteritis, polyarteritis nodosa, and hypersensitivity vasculitis, the positive predictive values of the ACR criteria were low: 17 to 29 percent for all patients and only 29 to 75 percent for those with a final diagnosis of vasculitis.",
"   </p>",
"   <p>",
"    This study, therefore, confirms previous views that these classification criteria function poorly when used for clinical diagnosis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/23/37241/abstract/16\">",
"     16",
"    </a>",
"    ]. Separate criteria are, therefore, needed for both classification and diagnosis. However, when used properly, the existence of standardized criteria, which must change over time with the acquisition of new knowledge, permits the comparison of patients from multiple centers, thereby enhancing our understanding of complex diseases [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/23/37241/abstract/16\">",
"     16",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h2\">",
"     Takayasu arteritis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The following classification criteria by the ACR for Takayasu arteritis were primarily designed to distinguish this disorder from other forms of vasculitis (",
"    <a class=\"graphic graphic_table graphicRef62022 \" href=\"mobipreview.htm?37/7/38011\">",
"     table 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/23/37241/abstract/17\">",
"     17",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Age at disease onset &le;40 years",
"     </li>",
"     <li>",
"      Claudication of the extremities",
"     </li>",
"     <li>",
"      Decreased pulsation of one or both brachial arteries",
"     </li>",
"     <li>",
"      Difference of at least 10 mmHg in systolic blood pressure between the arms",
"     </li>",
"     <li>",
"      Bruit over one or both subclavian arteries or the abdominal aorta",
"     </li>",
"     <li>",
"      Arteriographic narrowing or occlusion of the entire aorta, its primary branches, or large arteries in the proximal upper or lower extremities, not due to arteriosclerosis, fibromuscular dysplasia, or other causes",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Patients are said to have Takayasu arteritis if at least three of the six criteria are present; this classification yields a sensitivity and specificity of 90.5 and 97.8 percent, respectively. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?13/19/13624?source=see_link\">",
"     \"Clinical features and diagnosis of Takayasu arteritis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30\">",
"    <span class=\"h2\">",
"     Giant cell arteritis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The ACR criteria for the classification of giant cell arteritis (GCA) were formed by comparing the symptoms and findings of 214 patients with the diagnosis of GCA with the clinical findings of 593 patients with other forms of vasculitis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/23/37241/abstract/18\">",
"     18",
"    </a>",
"    ]. In a patient with vasculitis, the finding of three of the following five criteria was associated with 94 percent sensitivity and 91 percent specificity for the diagnosis of GCA:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Age &ge;50 years at time of disease onset",
"     </li>",
"     <li>",
"      Localized headache of new onset",
"     </li>",
"     <li>",
"      Tenderness or decreased pulse of the temporal artery",
"     </li>",
"     <li>",
"      Erythrocyte sedimentation rate (ESR) greater than 50",
"      <span class=\"nowrap\">",
"       mm/h",
"      </span>",
"      (Westergren)",
"     </li>",
"     <li>",
"      Biopsy that includes an artery and reveals a necrotizing arteritis with a predominance of mononuclear cells or a granulomatous process with multinucleated giant cells (",
"      <a class=\"graphic graphic_picture graphicRef57876 \" href=\"mobipreview.htm?16/56/17289\">",
"       picture 2",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    If an elevated ESR is excluded, but scalp tenderness and claudication of the jaw, tongue, or with deglutition are added as criteria, sensitivity for the diagnosis is now 95 percent with a specificity of 91 percent. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?18/33/18969?source=see_link\">",
"     \"Clinical manifestations of giant cell (temporal) arteritis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H31\">",
"    <span class=\"h2\">",
"     Polyarteritis nodosa",
"    </span>",
"    &nbsp;&mdash;&nbsp;The ACR has established 10 criteria for the classification of polyarteritis nodosa in a patient with a vasculitis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/23/37241/abstract/19\">",
"     19",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Otherwise unexplained weight loss &gt;4 kg",
"     </li>",
"     <li>",
"      Livedo reticularis",
"     </li>",
"     <li>",
"      Testicular pain or tenderness",
"     </li>",
"     <li>",
"      Myalgias (excluding that of the shoulder and hip girdle), weakness, or polyneuropathy",
"     </li>",
"     <li>",
"      Mononeuropathy or polyneuropathy",
"     </li>",
"     <li>",
"      New onset diastolic blood pressure &gt;90 mmHg",
"     </li>",
"     <li>",
"      Elevated levels of serum blood urea nitrogen (&gt;40",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      or 14.3",
"      <span class=\"nowrap\">",
"       mmol/L)",
"      </span>",
"      or creatinine (&gt;1.5",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      or 132",
"      <span class=\"nowrap\">",
"       mcmol/L)",
"      </span>",
"     </li>",
"     <li>",
"      Evidence of hepatitis B virus infection via serum antibody or antigen serology",
"     </li>",
"     <li>",
"      Characteristic arteriographic abnormalities not resulting from noninflammatory disease processes (",
"      <a class=\"graphic graphic_diagnosticimage graphicRef65987 \" href=\"mobipreview.htm?35/54/36705\">",
"       image 1",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      A biopsy of medium- or small-sized artery containing polymorphonuclear cells (",
"      <a class=\"graphic graphic_picture graphicRef74893 \" href=\"mobipreview.htm?8/49/8985\">",
"       picture 3",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A sensitivity and specificity for the diagnosis of polyarteritis of 82 and 87 percent, respectively, have been found in the patient with a documented vasculitis in whom at least three of the criteria are present. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?9/26/9641?source=see_link\">",
"     \"Clinical manifestations and diagnosis of polyarteritis nodosa\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H32\">",
"    <span class=\"h2\">",
"     Kawasaki disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Guidelines for the diagnosis of Kawasaki disease were established by Tomisaku Kawasaki in 1967. Diagnosis requires the presence of fever lasting five days or more without any other explanation, combined with at least four of the five following physical findings [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/23/37241/abstract/20\">",
"     20",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Bilateral conjunctival injection (",
"      <a class=\"graphic graphic_picture graphicRef78898 \" href=\"mobipreview.htm?15/1/15376\">",
"       picture 4",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Oral mucous membrane changes, including injected or fissured lips, injected pharynx, or strawberry tongue",
"     </li>",
"     <li>",
"      Peripheral extremity changes, including erythema of palms or soles or edema of hands or feet (acute phase) (",
"      <a class=\"graphic graphic_picture graphicRef72040 \" href=\"mobipreview.htm?25/12/25793\">",
"       picture 5",
"      </a>",
"      ), as well as periungual desquamation (convalescent phase) (",
"      <a class=\"graphic graphic_picture graphicRef53452 \" href=\"mobipreview.htm?5/29/5587\">",
"       picture 6",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Polymorphous rash",
"     </li>",
"     <li>",
"      Cervical lymphadenopathy (at least one lymph node &gt;1.5 cm in diameter)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    As with all clinical criteria, these are imperfect guidelines with less than 100 percent sensitivity and specificity. Children who do not meet the criteria may have an incomplete or atypical form of Kawasaki disease (see below). In addition, some patients who manifest five or six signs may have other conditions. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?11/61/12248?source=see_link\">",
"     \"Kawasaki disease: Clinical features and diagnosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H33\">",
"    <span class=\"h2\">",
"     Eosinophilic granulomatosis with polyangiitis (Churg-Strauss)",
"    </span>",
"    &nbsp;&mdash;&nbsp;The following six criteria have been formulated by the ACR for the diagnosis of eosinophilic granulomatosis with polyangiitis (Churg-Strauss), abbreviated EGPA, in a patient with documented vasculitis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/23/37241/abstract/21\">",
"     21",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Asthma (a history of wheezing or the finding of diffuse high pitched wheezes on expiration)",
"     </li>",
"     <li>",
"      Eosinophilia of &gt;10 percent on differential white blood cell count",
"     </li>",
"     <li>",
"      Mononeuropathy (including multiplex) or polyneuropathy",
"     </li>",
"     <li>",
"      Migratory or transient pulmonary opacities detected radiographically",
"     </li>",
"     <li>",
"      Paranasal sinus abnormality",
"     </li>",
"     <li>",
"      Biopsy containing a blood vessel showing the accumulation of eosinophils in extravascular areas (",
"      <a class=\"graphic graphic_picture graphicRef57180 graphicRef82366 \" href=\"mobipreview.htm?19/16/19722\">",
"       picture 7A-B",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The presence of four or more of these criteria yields a sensitivity of 85 percent and a specificity of 99.7 percent EGPA. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?26/34/27177?source=see_link&amp;anchor=H25#H25\">",
"     \"Clinical features and diagnosis of eosinophilic granulomatosis with polyangiitis (Churg-Strauss)\", section on 'Diagnostic criteria'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H34\">",
"    <span class=\"h2\">",
"     Primary central nervous system vasculitis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Specific criteria for a diagnosis of primary central nervous system (CNS) vasculitis (PCNSV) have not been formulated. PCNSV is a rare disorder that is most commonly diagnosed in the patient with CNS symptoms and signs in combination with evidence of a cerebral vasculitis by angiography and leptomeningeal biopsy. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?24/50/25386?source=see_link\">",
"     \"Primary angiitis of the central nervous system\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H35\">",
"    <span class=\"h2\">",
"     Granulomatosis with polyangiitis (Wegener&rsquo;s)",
"    </span>",
"    &nbsp;&mdash;&nbsp;The ACR proposed four clinical criteria for the classification of granulomatosis with polyangiitis (Wegener&rsquo;s), abbreviated as GPA, in 1990,",
"    <strong>",
"     before",
"    </strong>",
"    the availability of ANCA testing [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/23/37241/abstract/22\">",
"     22",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Nasal or oral inflammation (painful or painless oral ulcers or purulent or bloody nasal discharge)",
"     </li>",
"     <li>",
"      Abnormal chest radiograph showing nodules, fixed infiltrates, or cavities",
"     </li>",
"     <li>",
"      Abnormal urinary sediment (microscopic hematuria or red cell casts)",
"     </li>",
"     <li>",
"      Granulomatous inflammation on biopsy of an artery or perivascular area",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The presence of two or more of these four criteria yielded a sensitivity of 88 percent and a specificity of 92 percent. As a result, an abnormal chest radiograph or the findings of granulomatous inflammation on biopsy are not absolute requirements to distinguish patients with GPA from those with other forms of vasculitis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H36\">",
"    <span class=\"h3\">",
"     Antineutrophil cytoplasmic antibodies",
"    </span>",
"    &nbsp;&mdash;&nbsp;At present, the diagnosis of GPA is suggested from the clinical and laboratory findings and from the presence of circulating antineutrophil cytoplasmic antibodies (ANCA) that are usually directed against proteinase 3 (C-ANCA) (",
"    <a class=\"graphic graphic_picture graphicRef66748 graphicRef78968 \" href=\"mobipreview.htm?26/1/26640\">",
"     picture 8A-B",
"    </a>",
"    ). Almost all patients with active systemic GPA have a positive ANCA [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/23/37241/abstract/23\">",
"     23",
"    </a>",
"    ]. However, ANCA alone, including the presence of antiproteinase 3 antibodies which are more specific for GPA, does not appear to be sufficiently accurate to preclude the need for tissue biopsy. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?16/62/17386?source=see_link\">",
"     \"Clinical manifestations and diagnosis of granulomatosis with polyangiitis (Wegener's) and microscopic polyangiitis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H37\">",
"    <span class=\"h2\">",
"     Microscopic polyangiitis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Some patients have equivalent vasculitic lesions to those observed in GPA but, at least at presentation, do not have symptomatic or histologic respiratory involvement; such individuals are considered to have microscopic polyangiitis. However, two observations suggest that this disorder is closely related to GPA and should be considered similarly: some patients subsequently develop classic respiratory tract lesions [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/23/37241/abstract/24\">",
"     24",
"    </a>",
"    ], and ANCA are typically present [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/23/37241/abstract/25,26\">",
"     25,26",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?16/62/17386?source=see_link\">",
"     \"Clinical manifestations and diagnosis of granulomatosis with polyangiitis (Wegener's) and microscopic polyangiitis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H38\">",
"    <span class=\"h2\">",
"     Hypersensitivity vasculitis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The ACR proposed the following five criteria for the classification of hypersensitivity vasculitis in a patient with vasculitis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/23/37241/abstract/27\">",
"     27",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Age &gt;16",
"     </li>",
"     <li>",
"      Use of a possible offending drug in temporal relation to the symptoms",
"     </li>",
"     <li>",
"      Palpable purpura (",
"      <a class=\"graphic graphic_picture graphicRef78697 \" href=\"mobipreview.htm?9/36/9794\">",
"       picture 1",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Maculopapular rash",
"     </li>",
"     <li>",
"      Biopsy of a skin lesion showing neutrophils around an arteriole or venule (",
"      <a class=\"graphic graphic_picture graphicRef52548 graphicRef66296 \" href=\"mobipreview.htm?7/58/8106\">",
"       picture 9A-B",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The presence of three or more of these criteria had a sensitivity and specificity of 71 and 84 percent, respectively.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H39\">",
"    <span class=\"h3\">",
"     Henoch-Sch&ouml;nlein purpura (IgA vasculitis)",
"    </span>",
"    &nbsp;&mdash;&nbsp;However, these criteria do not distinguish hypersensitivity vasculitis from Henoch-Sch&ouml;nlein purpura (HSP), also termed IgA vasculitis. As noted above, HSP (IgAV) is characterized by the additional finding of the deposition of IgA on skin or renal biopsy. There are also clinical criteria that can help to distinguish between the two disorders [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/23/37241/abstract/28\">",
"     28",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Palpable purpura",
"     </li>",
"     <li>",
"      Bowel angina",
"     </li>",
"     <li>",
"      Gastrointestinal bleeding",
"     </li>",
"     <li>",
"      Hematuria",
"     </li>",
"     <li>",
"      Age at onset &le;20 years lesion",
"     </li>",
"     <li>",
"      No new medications",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The presence of three or more of the six criteria yielded a correct classification of HSP in 87 percent of cases in which a consensus of experienced clinicians concluded that was the correct diagnosis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/23/37241/abstract/28\">",
"     28",
"    </a>",
"    ]. The presence of two or fewer criteria yielded a correct classification of hypersensitivity vasculitis in 74 percent. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?39/49/40729?source=see_link\">",
"     \"Clinical manifestations and diagnosis of Henoch-Sch&ouml;nlein purpura (IgA vasculitis)\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H40\">",
"    <span class=\"h2\">",
"     Cryoglobulinemic vasculitis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Specific criteria for a diagnosis of cryoglobulinemic vasculitis have not yet been formulated. The diagnosis is typically made from the history, skin purpura, low complement levels, demonstration of circulating cryoglobulins, and histology showing small vessel inflammation with immune deposits found in the vascular walls. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?33/15/34040?source=see_link\">",
"     \"Clinical manifestations and diagnosis of the mixed cryoglobulinemia syndrome (essential mixed cryoglobulinemia)\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H41\">",
"    <span class=\"h2\">",
"     Vasculitis secondary to connective tissue disorders",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnostic criteria for vasculitis",
"    <strong>",
"     secondary",
"    </strong>",
"    to an underlying connective tissue disorder, and not a primary disorder, rest upon histologic evidence of a vasculitis in combination with a firm diagnosis of a connective tissue disorder. Discussions of the criteria for the diagnosis of those connective tissue disorders in which vasculitis may emerge are presented in the appropriate topic reviews.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H42\">",
"    <span class=\"h1\">",
"     DIFFERENTIAL DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with nonvasculitic disease processes may present with symptoms and findings that closely mimic those of the various vasculitides. Perhaps most common are systemic rheumatic diseases, such as systemic lupus erythematosus. Other disorders that should be considered in selected patients include [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/23/37241/abstract/29\">",
"     29",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Fibromuscular dysplasia (which predominantly affects the aorta and its primary branches)",
"     </li>",
"     <li>",
"      Cholesterol emboli",
"     </li>",
"     <li>",
"      Atrial myxoma with emboli",
"     </li>",
"     <li>",
"      Infective endocarditis",
"     </li>",
"     <li>",
"      Malignancies, such as lymphomatoid",
"      <span class=\"nowrap\">",
"       granulomatosis/polymorphic",
"      </span>",
"      reticulosis, angioimmunoblastic T cell lymphoma, and intravascular lymphoma",
"     </li>",
"     <li>",
"      Mycotic aneurysm with embolization (predominantly with arteriole, capillary, and venule involvement)",
"     </li>",
"     <li>",
"      Bacteremia",
"     </li>",
"     <li>",
"      Rickettsial infection",
"     </li>",
"     <li>",
"      Ergotism (which principally affects medium- and small-sized muscular arteries)",
"     </li>",
"     <li>",
"      Thrombocytopenia and other processes associated with purpura",
"     </li>",
"     <li>",
"      Radiation fibrosis (radiation-induced vasculopathy)",
"     </li>",
"     <li>",
"      Neurofibromatosis",
"     </li>",
"     <li>",
"      Congenital coarctation of the aorta",
"     </li>",
"     <li>",
"      Amyloidosis",
"     </li>",
"     <li>",
"      Livedoid vasculopathy (livedo reticularis)",
"     </li>",
"     <li>",
"      Malignant atrophic papulosis (Degos disease or syndrome)",
"     </li>",
"     <li>",
"      Necrotic arachnidism (Loxosceles species spider bites) (see",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?23/43/24248?source=see_link\">",
"       \"Bites of recluse spiders\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Cocaine abuse",
"     </li>",
"     <li>",
"      Hereditary disorders, including Marfan syndrome, Ehlers-Danlos syndrome, Loey-Dietz syndrome, Grange syndrome, and pseudoxanthoma elasticum",
"     </li>",
"     <li>",
"      Segmental arterial mediolysis",
"     </li>",
"     <li>",
"      Atherosclerosis",
"     </li>",
"     <li>",
"      Vasospasm",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Conditions that mimic true CNS vasculitis include vasospastic disorders; hypercoagulable states; infections (syphilis, Lyme disease, Bartonella, tuberculosis, Varicella, hepatitis B and C, human immunodeficiency virus, and fungal disease); other arterial diseases; embolic disease; malignancy; stroke-like syndromes; leukoencephalopathies; and cerebral hemorrhage.",
"   </p>",
"   <p>",
"    Although sometimes difficult, an accurate diagnosis is essential among patients suspected having a vasculitis. As an example, the administration of immunosuppressive therapy to the patient with an undiagnosed infection may result in death.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here is the patient education article that is relevant to this topic. We encourage you to print or e-mail this topic to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?8/59/9138?source=see_link\">",
"       \"Patient information: Polyarteritis nodosa (The Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?11/49/12051?source=see_link\">",
"       \"Patient information: Vasculitis (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?43/22/44389?source=see_link\">",
"       \"Patient information: Vasculitis (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H43128813\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The vasculitides are defined by the presence of inflammatory leukocytes in vessel walls with reactive damage to mural structures. Loss of vessel integrity may lead to bleeding, and compromise of the lumen leads to downstream tissue ischemia and necrosis. In general, affected vessels vary in size, type, and location in association with the specific vasculitic disorder, which may occur as a primary process or may be secondary to another underlying disease. The distribution of affected organs may suggest a particular vasculitic disorder, but significant overlap is observed. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Classically, the vasculitic syndromes have been categorized by the predominant sizes of the blood vessels and types of vessels most commonly affected among patients with the disorder. The presence or absence of antineutrophil cytoplasmic antibodies (ANCA) is included in proposed classification criteria. The vasculitides include (see",
"      <a class=\"local\" href=\"#H2\">",
"       'Classification'",
"      </a>",
"      above):",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Large vessel vasculitis &mdash; Takayasu arteritis and giant cell arteritis (see",
"      <a class=\"local\" href=\"#H3\">",
"       'Large vessel vasculitis'",
"      </a>",
"      above)",
"     </li>",
"     <li>",
"      Medium-sized vessel vasculitis &mdash; Polyarteritis nodosa, Kawasaki disease, primary central nervous system vasculitis (see",
"      <a class=\"local\" href=\"#H6\">",
"       'Medium vessel vasculitis'",
"      </a>",
"      above)",
"     </li>",
"     <li>",
"      Small vessel vasculitis &mdash; Eosinophilic granulomatosis with polyangiitis (Churg-Strauss), granulomatosis with polyangiitis (Wegener&rsquo;s), microscopic polyangiitis, Henoch-Sch&ouml;nlein purpura (IgA vasculitis), cryoglobulinemic vasculitis (formerly essential cryoglobulinemic vasculitis), hypersensitivity vasculitis, vasculitis secondary to connective tissue disease, and vasculitis secondary to viral infection (see",
"      <a class=\"local\" href=\"#H10\">",
"       'Small vessel vasculitis'",
"      </a>",
"      above)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The presence of vasculitis should be considered in patients who present with systemic symptoms in combination with evidence of single",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      multiorgan dysfunction. Although neither sensitive nor specific, common complaints and signs of vasculitis include fatigue, weakness, fever, arthralgias, abdominal pain, hypertension, renal insufficiency (with an active urine sediment containing red and white cell and occasionally red cell casts), and neurologic dysfunction. Certain signs are strongly suggestive of vasculitis, including mononeuritis multiplex, palpable purpura, and combined pulmonary and renal involvement. (See",
"      <a class=\"local\" href=\"#H19\">",
"       'Clinical manifestations and approach to diagnosis'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H20\">",
"       'Clinical features suggestive of vasculitis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The diagnostic evaluation should consider age and gender, which may help direct the evaluation (",
"      <a class=\"graphic graphic_table graphicRef63522 \" href=\"mobipreview.htm?3/28/3532\">",
"       table 1",
"      </a>",
"      ); a detailed history, including drug use, infectious disease exposure, and symptoms of manifestations that may characterize or exclude suspected diagnoses; general laboratory testing to help identify the type of disorder and degree and type of organ involvement; and additional testing, depending on the suspected diagnosis and findings, including tests for antinuclear antibodies, complement levels, and ANCA; electromyography; tissue biopsy; and arteriography. (See",
"      <a class=\"local\" href=\"#H21\">",
"       'Diagnostic approach'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H22\">",
"       'History'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H23\">",
"       'Physical examination'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H24\">",
"       'Laboratory tests'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H25\">",
"       'Electromyography'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H26\">",
"       'Tissue biopsy'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H27\">",
"       'Arteriography'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Criteria for the classification of most of the major forms of vasculitis have been established; they do not include all characteristics of a particular disorder, only those that help to distinguish the disorder from other vasculitides. The classification criteria function poorly when used for clinical diagnosis but are useful in epidemiologic and clinical research. The diagnosis of a particular form of vasculitis is virtually always confirmed by tissue biopsy. (See",
"      <a class=\"local\" href=\"#H28\">",
"       'Classification criteria'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Patients with nonvasculitic disease processes may present with symptoms and findings that closely mimic those of the various vasculitides. Perhaps most common are systemic rheumatic diseases such as systemic lupus erythematosus. Numerous other disorders should be considered in selected patients, depending upon the specific signs and symptoms that are present. (See",
"      <a class=\"local\" href=\"#H42\">",
"       'Differential diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/23/37241/abstract/1\">",
"      Watts RA, Scott DG. Recent developments in the classification and assessment of vasculitis. Best Pract Res Clin Rheumatol 2009; 23:429.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/23/37241/abstract/2\">",
"      Deng J, Ma-Krupa W, Gewirtz AT, et al. Toll-like receptors 4 and 5 induce distinct types of vasculitis. Circ Res 2009; 104:488.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/23/37241/abstract/3\">",
"      Phillip R, Luqmani R. Mortality in systemic vasculitis: a systematic review. Clin Exp Rheumatol 2008; 26:S94.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/23/37241/abstract/4\">",
"      Hunder GG, Arend WP, Bloch DA, et al. The American College of Rheumatology 1990 criteria for the classification of vasculitis. Introduction. Arthritis Rheum 1990; 33:1065.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/23/37241/abstract/5\">",
"      Jennette JC, Falk RJ. Small-vessel vasculitis. N Engl J Med 1997; 337:1512.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/23/37241/abstract/6\">",
"      Watts R, Lane S, Hanslik T, et al. Development and validation of a consensus methodology for the classification of the ANCA-associated vasculitides and polyarteritis nodosa for epidemiological studies. Ann Rheum Dis 2007; 66:222.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/23/37241/abstract/7\">",
"      Liu LJ, Chen M, Yu F, et al. Evaluation of a new algorithm in classification of systemic vasculitis. Rheumatology (Oxford) 2008; 47:708.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/23/37241/abstract/8\">",
"      Jennette JC, Falk RJ, Bacon PA, et al. 2012 revised International Chapel Hill Consensus Conference Nomenclature of Vasculitides. Arthritis Rheum 2013; 65:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/23/37241/abstract/9\">",
"      Jennette JC, Falk RJ, Andrassy K, et al. Nomenclature of systemic vasculitides. Proposal of an international consensus conference. Arthritis Rheum 1994; 37:187.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/23/37241/abstract/10\">",
"      Gomard-Mennesson E, Landron C, Dauphin C, et al. Kawasaki disease in adults: report of 10 cases. Medicine (Baltimore) 2010; 89:149.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/23/37241/abstract/11\">",
"      Hoffman GS. Classification of the systemic vasculitides: antineutrophil cytoplasmic antibodies, consensus and controversy. Clin Exp Rheumatol 1998; 16:111.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/23/37241/abstract/12\">",
"      Niles JL, B&ouml;ttinger EP, Saurina GR, et al. The syndrome of lung hemorrhage and nephritis is usually an ANCA-associated condition. Arch Intern Med 1996; 156:440.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/23/37241/abstract/13\">",
"      Rao JK, Weinberger M, Oddone EZ, et al. The role of antineutrophil cytoplasmic antibody (c-ANCA) testing in the diagnosis of Wegener granulomatosis. A literature review and meta-analysis. Ann Intern Med 1995; 123:925.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/23/37241/abstract/14\">",
"      Lhote F, Guillevin L. Polyarteritis nodosa, microscopic polyangiitis, and Churg-Strauss syndrome. Clinical aspects and treatment. Rheum Dis Clin North Am 1995; 21:911.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/23/37241/abstract/15\">",
"      Rao JK, Allen NB, Pincus T. Limitations of the 1990 American College of Rheumatology classification criteria in the diagnosis of vasculitis. Ann Intern Med 1998; 129:345.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/23/37241/abstract/16\">",
"      Hunder GG. The use and misuse of classification and diagnostic criteria for complex diseases. Ann Intern Med 1998; 129:417.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/23/37241/abstract/17\">",
"      Arend WP, Michel BA, Bloch DA, et al. The American College of Rheumatology 1990 criteria for the classification of Takayasu arteritis. Arthritis Rheum 1990; 33:1129.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/23/37241/abstract/18\">",
"      Hunder GG, Bloch DA, Michel BA, et al. The American College of Rheumatology 1990 criteria for the classification of giant cell arteritis. Arthritis Rheum 1990; 33:1122.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/23/37241/abstract/19\">",
"      Lightfoot RW Jr, Michel BA, Bloch DA, et al. The American College of Rheumatology 1990 criteria for the classification of polyarteritis nodosa. Arthritis Rheum 1990; 33:1088.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/23/37241/abstract/20\">",
"      Centers for Disease Control. Kawasaki disease &mdash; New York. MMWR Morb Mortal Wkly Rep 1980; 29:61.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/23/37241/abstract/21\">",
"      Masi AT, Hunder GG, Lie JT, et al. The American College of Rheumatology 1990 criteria for the classification of Churg-Strauss syndrome (allergic granulomatosis and angiitis). Arthritis Rheum 1990; 33:1094.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/23/37241/abstract/22\">",
"      Leavitt RY, Fauci AS, Bloch DA, et al. The American College of Rheumatology 1990 criteria for the classification of Wegener's granulomatosis. Arthritis Rheum 1990; 33:1101.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/23/37241/abstract/23\">",
"      Savige J, Davies D, Falk RJ, et al. Antineutrophil cytoplasmic antibodies and associated diseases: a review of the clinical and laboratory features. Kidney Int 2000; 57:846.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/23/37241/abstract/24\">",
"      Woodworth TG, Abuelo JG, Austin HA 3rd, Esparza A. Severe glomerulonephritis with late emergence of classic Wegener's granulomatosis. Report of 4 cases and review of the literature. Medicine (Baltimore) 1987; 66:181.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/23/37241/abstract/25\">",
"      Niles JL, Pan GL, Collins AB, et al. Antigen-specific radioimmunoassays for anti-neutrophil cytoplasmic antibodies in the diagnosis of rapidly progressive glomerulonephritis. J Am Soc Nephrol 1991; 2:27.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/23/37241/abstract/26\">",
"      Kallenberg CG, Brouwer E, Weening JJ, Tervaert JW. Anti-neutrophil cytoplasmic antibodies: current diagnostic and pathophysiological potential. Kidney Int 1994; 46:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/23/37241/abstract/27\">",
"      Calabrese LH, Michel BA, Bloch DA, et al. The American College of Rheumatology 1990 criteria for the classification of hypersensitivity vasculitis. Arthritis Rheum 1990; 33:1108.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/23/37241/abstract/28\">",
"      Michel BA, Hunder GG, Bloch DA, Calabrese LH. Hypersensitivity vasculitis and Henoch-Sch&ouml;nlein purpura: a comparison between the 2 disorders. J Rheumatol 1992; 19:721.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/23/37241/abstract/29\">",
"      Bateman H, Rehman A, Valeriano-Marcet J. Vasculitis-like Syndromes. Curr Rheumatol Rep 2009; 11:422.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 8226 Version 14.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-221.10.40.232-7F6A7747C1-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f36_23_37241=[""].join("\n");
var outline_f36_23_37241=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H43128813\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      CLASSIFICATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Large vessel vasculitis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      - Takayasu arteritis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      - Giant cell arteritis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Medium vessel vasculitis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - Polyarteritis nodosa",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - Kawasaki disease",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Primary central nervous system vasculitis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Small vessel vasculitis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Eosinophilic granulomatosis with polyangiitis (Churg-Strauss)",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - Granulomatosis with polyangiitis (Wegener&rsquo;s)",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - Microscopic polyangiitis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      - Henoch-Sch&ouml;nlein purpura (IgA vasculitis)",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      - Cryoglobulinemic vasculitis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      - Hypersensitivity vasculitis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      - Vasculitis secondary to connective tissue disorders",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      - Vasculitis secondary to viral infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      CLINICAL MANIFESTATIONS AND APPROACH TO DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Clinical features suggestive of vasculitis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Diagnostic approach",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      - History",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      - Physical examination",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      - Laboratory tests",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      - Electromyography",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      - Tissue biopsy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      - Arteriography",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      CLASSIFICATION CRITERIA",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      Takayasu arteritis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H30\">",
"      Giant cell arteritis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H31\">",
"      Polyarteritis nodosa",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H32\">",
"      Kawasaki disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H33\">",
"      Eosinophilic granulomatosis with polyangiitis (Churg-Strauss)",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H34\">",
"      Primary central nervous system vasculitis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H35\">",
"      Granulomatosis with polyangiitis (Wegener&rsquo;s)",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H36\">",
"      - Antineutrophil cytoplasmic antibodies",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H37\">",
"      Microscopic polyangiitis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H38\">",
"      Hypersensitivity vasculitis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H39\">",
"      - Henoch-Sch&ouml;nlein purpura (IgA vasculitis)",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H40\">",
"      Cryoglobulinemic vasculitis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H41\">",
"      Vasculitis secondary to connective tissue disorders",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H42\">",
"      DIFFERENTIAL DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H43128813\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"RHEUM/8226\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"RHEUM/8226|DiagnosticImage\">",
"      <a href=\"#\" title=\"DIAGNOSTIC IMAGES\">",
"       DIAGNOSTIC IMAGES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"mobipreview.htm?35/54/36705\" title=\"diagnostic image 1\">",
"      Renal arteriogram in polyarteritis nodosa",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"RHEUM/8226|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?9/36/9794\" title=\"picture 1\">",
"      Leukocytoclastic vasculitis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?16/56/17289\" title=\"picture 2\">",
"      Giant cell arteritis light",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?8/49/8985\" title=\"picture 3\">",
"      Polyarteritis nodosa (light micrograph)",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?15/1/15376\" title=\"picture 4\">",
"      Conjunctivitis in Kawasaki",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?25/12/25793\" title=\"picture 5\">",
"      Edema of hands in Kawasaki disease - acute phase",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?5/29/5587\" title=\"picture 6\">",
"      Periungual desquamation in Kawasaki disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?37/52/38726\" title=\"picture 7A\">",
"      Small vessel vasculitis Churg Strauss",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?39/4/40006\" title=\"picture 7B\">",
"      Lung biopsy Churg Strauss",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?38/51/39742\" title=\"picture 8A\">",
"      C ANCA",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?17/6/17518\" title=\"picture 8B\">",
"      P ANCA",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?42/20/43333\" title=\"picture 9A\">",
"      Leukocytoclastic vasculitis I",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?22/37/23126\" title=\"picture 9B\">",
"      Leukocytoclastic vasculitis II",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"RHEUM/8226|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?3/28/3532\" title=\"table 1\">",
"      Characteristics of vasculitis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?37/7/38011\" title=\"table 2\">",
"      Criteria for Takayasu arteritis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?38/43/39608?source=related_link\">",
"      Approach to the patient with retiform (angulated) purpura",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?23/43/24248?source=related_link\">",
"      Bites of recluse spiders",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?13/19/13624?source=related_link\">",
"      Clinical features and diagnosis of Takayasu arteritis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?26/34/27177?source=related_link\">",
"      Clinical features and diagnosis of eosinophilic granulomatosis with polyangiitis (Churg-Strauss)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?39/49/40729?source=related_link\">",
"      Clinical manifestations and diagnosis of Henoch-Sch&ouml;nlein purpura (IgA vasculitis)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?16/62/17386?source=related_link\">",
"      Clinical manifestations and diagnosis of granulomatosis with polyangiitis (Wegener's) and microscopic polyangiitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?9/26/9641?source=related_link\">",
"      Clinical manifestations and diagnosis of polyarteritis nodosa",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?33/15/34040?source=related_link\">",
"      Clinical manifestations and diagnosis of the mixed cryoglobulinemia syndrome (essential mixed cryoglobulinemia)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?18/33/18969?source=related_link\">",
"      Clinical manifestations of giant cell (temporal) arteritis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?21/57/22423?source=related_link\">",
"      Clinical manifestations of vasculitic neuropathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?27/13/27863?source=related_link\">",
"      Clinical neurophysiology",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?9/28/9674?source=related_link\">",
"      Clinical spectrum of antineutrophil cytoplasmic antibodies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?26/31/27130?source=related_link\">",
"      Differential diagnosis and evaluation of glomerular disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?20/56/21383?source=related_link\">",
"      Epidemiology, pathogenesis, and pathology of Churg-Strauss syndrome (allergic granulomatosis and angiitis)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?4/15/4345?source=related_link\">",
"      Evaluation of adults with cutaneous lesions of vasculitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?15/8/15498?source=related_link\">",
"      Extrahepatic manifestations of hepatitis C virus infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?29/57/30614?source=related_link\">",
"      Hypersensitivity vasculitis in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?11/61/12248?source=related_link\">",
"      Kawasaki disease: Clinical features and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?27/54/28520?source=related_link\">",
"      Measurement and clinical significance of antinuclear antibodies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?10/25/10647?source=related_link\">",
"      Overview and clinical assessment of the complement system",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?21/63/22522?source=related_link\">",
"      Overview of cryoglobulins and cryoglobulinemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?28/17/28949?source=related_link\">",
"      Overview of the management of the vasculitides in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?8/59/9138?source=related_link\">",
"      Patient information: Polyarteritis nodosa (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?43/22/44389?source=related_link\">",
"      Patient information: Vasculitis (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?11/49/12051?source=related_link\">",
"      Patient information: Vasculitis (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?24/50/25386?source=related_link\">",
"      Primary angiitis of the central nervous system",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f36_23_37242="Neurologic complications of platinum-based chemotherapy";
var content_f36_23_37242=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"6\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Neurologic complications of platinum-based chemotherapy",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?36/23/37242/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?36/23/37242/contributors\">",
"     Eudocia Quant Lee, MD, MPH",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?36/23/37242/contributors\">",
"     Patrick Y Wen, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?36/23/37242/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?36/23/37242/contributors\">",
"     Jerome B Posner, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?36/23/37242/contributors\">",
"     Reed E Drews, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?36/23/37242/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?36/23/37242/contributors\">",
"     Diane MF Savarese, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?36/23/37242/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Dec 21, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Neurologic complications of anticancer therapy may result from direct toxic effects on the nervous system or indirectly from drug-induced metabolic derangements or cerebrovascular disorders. A wide range of neurologic complications are associated with antineoplastic drug treatment (",
"    <a class=\"graphic graphic_table graphicRef55758 \" href=\"mobipreview.htm?35/9/35998\">",
"     table 1",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/23/37242/abstract/1-4\">",
"     1-4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Their recognition is important because of potential confusion with metastatic disease, paraneoplastic syndromes or comorbid neurologic disorders that do not require dose reduction or discontinuation. If the neurologic disorder is caused by the chemotherapy, discontinuation of the offending agent may prevent irreversible injury.",
"   </p>",
"   <p>",
"    Among the widely used anticancer drugs, the platinum compounds",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?20/51/21305?source=see_link\">",
"     cisplatin",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/11/2233?source=see_link\">",
"     oxaliplatin",
"    </a>",
"    are most commonly associated with various forms of neurotoxicity. The neurotoxicity of cisplatin, oxaliplatin, and the less neurotoxic analog",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/61/38873?source=see_link\">",
"     carboplatin",
"    </a>",
"    will be reviewed here. The neurologic complications of other chemotherapy agents and biologic therapies are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?42/32/43530?source=see_link\">",
"     \"Neurologic complications of non-platinum cancer chemotherapy\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?42/3/43064?source=see_link\">",
"     \"Neurologic complications of cancer treatment with biologic agents\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     CISPLATIN",
"    </span>",
"    &nbsp;&mdash;&nbsp;The range of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?20/51/21305?source=see_link\">",
"     cisplatin",
"    </a>",
"    -induced neurotoxicity includes peripheral neuropathy, ototoxicity (hearing impairment and tinnitus), Raynaud&rsquo;s phenomenon, myelotoxicity, and encephalopathy; the most common are a peripheral neuropathy and ototoxicity.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Peripheral neuropathy",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?20/51/21305?source=see_link\">",
"     Cisplatin",
"    </a>",
"    causes an axonal neuropathy that predominantly affects large myelinated sensory fibers (",
"    <a class=\"graphic graphic_table graphicRef67516 \" href=\"mobipreview.htm?34/34/35373\">",
"     table 2",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/23/37242/abstract/5-8\">",
"     5-8",
"    </a>",
"    ]. The primary site of damage is the dorsal root ganglion [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/23/37242/abstract/9\">",
"     9",
"    </a>",
"    ], although the peripheral nerve may also be affected.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h3\">",
"     Clinical manifestations",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is a subacute development of numbness, paresthesias, and occasionally pain, which usually begins in the toes and fingers, spreading proximally to affect the legs and arms. The symptoms of peripheral neuropathy may sometimes be confused with those of hand-foot syndrome (acral erythema), which can occasionally be seen with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?20/51/21305?source=see_link\">",
"     cisplatin",
"    </a>",
"    . (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?36/7/36986?source=see_link&amp;anchor=H23#H23\">",
"     \"Cutaneous complications of conventional chemotherapy agents\", section on 'Acral erythema (hand-foot skin reaction)'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Proprioception is impaired and reflexes are lost, but pinprick, temperature sensation, and motor strength are almost always spared. Nerve conduction studies show decreased amplitude of sensory action potentials and prolonged sensory latencies, compatible with a sensory axonopathy. On sural nerve biopsy, both demyelination and axonal loss are evident. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?27/13/27863?source=see_link\">",
"     \"Clinical neurophysiology\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The neuropathy caused by intravenous",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?20/51/21305?source=see_link\">",
"     cisplatin",
"    </a>",
"    is usually generalized, but arterial infusion into an extremity or the neck (eg, for treatment of sarcomas, brain tumors, head and neck cancer) may cause focal neuropathies. Autonomic neuropathies are rare [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/23/37242/abstract/10\">",
"     10",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Neuropathy usually develops only after a cumulative dose beyond 300",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"     ;",
"    </span>",
"    however, there is marked interindividual variation in susceptibility [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/23/37242/abstract/5,11,12\">",
"     5,11,12",
"    </a>",
"    ]. Higher",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?20/51/21305?source=see_link\">",
"     cisplatin",
"    </a>",
"    dose intensity (ie, higher doses per unit time) does not appear to enhance the severity of the neuropathy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/23/37242/abstract/13\">",
"     13",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The differential diagnosis includes paraneoplastic neuropathies and those associated with autoimmune disorders. Paraneoplastic neuropathies usually involve all sensory fibers, and there may be an antineuronal antibody (anti-Hu) in the serum. Patients with autoimmune neuropathies often have clinical features of an underlying connective tissue disease, and autoantibodies are usually present in the serum. Tetany in the hands and feet resulting from",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?20/51/21305?source=see_link\">",
"     cisplatin",
"    </a>",
"    -related electrolyte imbalance (ie, hypomagnesemia, hypocalcemia) may also be confused with peripheral neuropathy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/23/37242/abstract/14\">",
"     14",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?8/32/8712?source=see_link\">",
"     \"Differential diagnosis of peripheral nerve and muscle disease\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?36/27/37304?source=see_link&amp;anchor=H3#H3\">",
"     \"Paraneoplastic syndromes affecting peripheral nerve and muscle\", section on 'Subacute sensory neuronopathy'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?11/1/11287?source=see_link\">",
"     \"Clinical manifestations of Sj&ouml;gren's syndrome: Exocrine gland disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Once established, there is no effective treatment. Patients with mild neuropathy can continue to receive full",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?20/51/21305?source=see_link\">",
"     cisplatin",
"    </a>",
"    doses; however, if the neuropathy interferes with function, the risk of potentially disabling neurotoxicity must be weighed against the benefit of continued treatment. Alternative strategies include dose reduction or replacement of cisplatin with a less neurotoxic agent such as",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/61/38873?source=see_link\">",
"     carboplatin",
"    </a>",
"    .",
"   </p>",
"   <p>",
"    Even if",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?20/51/21305?source=see_link\">",
"     cisplatin",
"    </a>",
"    is discontinued, the neuropathy continues to worsen for several months in 30 percent of patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/23/37242/abstract/6,7\">",
"     6,7",
"    </a>",
"    ]. Neuropathy may even begin after therapy is discontinued. It eventually improves in most patients, although recovery is often incomplete. Higher levels of residual serum platinum, which can persist for years after treatment, appear to correlate with the severity of long-term peripheral neuropathy in cisplatin-treated survivors of testicular cancer [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/23/37242/abstract/15\">",
"     15",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H109349878\">",
"    <span class=\"h3\">",
"     Mechanism",
"    </span>",
"    &nbsp;&mdash;&nbsp;The major site of pathology is the dorsal root ganglion. Both",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?20/51/21305?source=see_link\">",
"     cisplatin",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/11/2233?source=see_link\">",
"     oxaliplatin",
"    </a>",
"    (see below) enter into the dorsal root ganglion and bind to nuclear and mitochondrial DNA, causing apoptosis. Peripheral nerves are then secondarily damaged. Oxaliplatin forms fewer platinum-DNA adducts then does cisplatin and thus is slightly less neurotoxic [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/23/37242/abstract/16\">",
"     16",
"    </a>",
"    ]. Genetic polymorphisms in some enzymes responsible for cisplatin metabolism (eg, glutathione S transferase) may contribute to the observed interindividual differences in the severity of neuropathy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/23/37242/abstract/17\">",
"     17",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h3\">",
"     Preventive strategies",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several prophylactic pharmacologic strategies have been studied to delay or prevent the development of neuropathy in patients receiving",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?20/51/21305?source=see_link\">",
"     cisplatin",
"    </a>",
"    , including vitamin E [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/23/37242/abstract/18-20\">",
"     18-20",
"    </a>",
"    ],",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?0/42/678?source=see_link\">",
"     amifostine",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/23/37242/abstract/21-28\">",
"     21-28",
"    </a>",
"    ], acetyl-L-carnitine [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/23/37242/abstract/29,30\">",
"     29,30",
"    </a>",
"    ], glutathione [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/23/37242/abstract/31,32\">",
"     31,32",
"    </a>",
"    ], the ACTH analog Org 2766 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/23/37242/abstract/33\">",
"     33",
"    </a>",
"    ] and diethyldithiocarbamate [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/23/37242/abstract/34\">",
"     34",
"    </a>",
"    ]. An updated Cochrane Database review of interventions for preventing cisplatin neuropathy concluded that the data were insufficient to conclude that any of the purported chemoprotective agents \"prevent or limited neurotoxicity of platinum drugs among human patients\" [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/23/37242/abstract/35\">",
"     35",
"    </a>",
"    ]. The review did not include the use of intravenous calcium and magnesium for oxaliplatin-induced sensory neuropathy (see",
"    <a class=\"local\" href=\"#H15\">",
"     'Oxaliplatin'",
"    </a>",
"    below).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H93783170\">",
"    <span class=\"h4\">",
"     Vitamin E",
"    </span>",
"    &nbsp;&mdash;&nbsp;A protective effect of vitamin E intake during and after",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?20/51/21305?source=see_link\">",
"     cisplatin",
"    </a>",
"    -containing chemotherapy has been suggested in three very small placebo-controlled randomized trials [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/23/37242/abstract/18-20\">",
"     18-20",
"    </a>",
"    ]. The largest of these trials randomly assigned 108 patients receiving cisplatin (dose not stated) for a variety of cancers to vitamin E (400 international units daily during and for three months following the discontinuation of cisplatin) or placebo [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/23/37242/abstract/20\">",
"     20",
"    </a>",
"    ]. Neurotoxicity was prospectively assessed prior to, during, and one month following the completion of therapy by a neurologist who was blinded as to the randomization, and by electrophysiologic testing prior to, and following treatment. A cumulative neurotoxicity score was assigned to each patient based upon neuropathic signs and symptoms and electrophysiologic changes.",
"   </p>",
"   <p>",
"    The analysis was limited to the 41 patients (17 vitamin E and 24 placebo) who received at least 300",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?20/51/21305?source=see_link\">",
"     cisplatin",
"    </a>",
"    . Patients who received vitamin E had significantly lower total neuropathy scores (1.4 versus 4.1), and a significantly lower incidence of grade 3 neurotoxicity (6 versus 42 percent).",
"   </p>",
"   <p>",
"    Despite the small size of this and the other two trials, given the consistency of the results, the safety of treatment, the lack of evidence that vitamin E interferes with antitumor efficacy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/23/37242/abstract/36,37\">",
"     36,37",
"    </a>",
"    ], the sometimes incomplete reversibility of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?20/51/21305?source=see_link\">",
"     cisplatin",
"    </a>",
"    -induced neurotoxicity, and the absence of other effective neuroprotective agents, it would seem reasonable to utilize this strategy in patients who are expected to receive more than 300",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    of cisplatin for treatment of their cancer.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H93783185\">",
"    <span class=\"h4\">",
"     Amifostine",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?0/42/678?source=see_link\">",
"     Amifostine",
"    </a>",
"    is the best studied neuroprotective agent. Amifostine is an organic thiophosphate that diminishes",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?20/51/21305?source=see_link\">",
"     cisplatin",
"    </a>",
"    -induced toxicity by donating a protective thiol group, an effect that is highly selective for normal but not malignant tissue [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/23/37242/abstract/38\">",
"     38",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Multiple randomized trials have addressed the benefit of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?0/42/678?source=see_link\">",
"     amifostine",
"    </a>",
"    in preventing platinum-induced (both",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?20/51/21305?source=see_link\">",
"     cisplatin",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/61/38873?source=see_link\">",
"     carboplatin",
"    </a>",
"    ) neurotoxicity, with mixed results [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/23/37242/abstract/21-28\">",
"     21-28",
"    </a>",
"    ]. A meta-analysis of five trials and a 2008 review by the American Society of Clinical Oncology (ASCO) concluded that the data were insufficient to ascertain if amifostine prevented or limited platinum-associated neurotoxicity, in large part because of the lack of quantitative sensory testing as an objective endpoint in most trials [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/23/37242/abstract/39,40\">",
"     39,40",
"    </a>",
"    ]",
"   </p>",
"   <p>",
"    The meta-analysis also concluded that the disparate measures of neuropathy used in the randomized trials of Org 2766 (four trials), diethyldithiocarbamate (one trial), and glutathione (five trials) also precluded any determination of benefit [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/23/37242/abstract/39\">",
"     39",
"    </a>",
"    ]. The benefit of acetyl-L-carnitine was not addressed.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12919875\">",
"    <span class=\"h4\">",
"     Future strategies",
"    </span>",
"    &nbsp;&mdash;&nbsp;In laboratory studies, nerve growth factor [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/23/37242/abstract/41,42\">",
"     41,42",
"    </a>",
"    ], neurotrophin-3 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/23/37242/abstract/43,44\">",
"     43,44",
"    </a>",
"    ], and glial growth factor 2 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/23/37242/abstract/45\">",
"     45",
"    </a>",
"    ] have been useful for preventing or reversing",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?20/51/21305?source=see_link\">",
"     cisplatin",
"    </a>",
"    -induced neuropathy. Clinical trials of some of these agents are ongoing.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H109349925\">",
"    <span class=\"h3\">",
"     Symptomatic treatment of neuropathic pain",
"    </span>",
"    &nbsp;&mdash;&nbsp;In some patients with platinum-induced neuropathy, pain is a prominent symptom. Amelioration of pain from the chronic neuropathy and of the symptoms of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/11/2233?source=see_link\">",
"     oxaliplatin",
"    </a>",
"    -induced hyperexcitability may be achieved through use of antiepileptic drugs such as",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?19/19/19768?source=see_link\">",
"     gabapentin",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?16/31/16887?source=see_link\">",
"     pregabalin",
"    </a>",
"    , antidepressants such as",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?36/62/37864?source=see_link\">",
"     duloxetine",
"    </a>",
"    , physical modalities such as cutaneous electrical stimulation, and interventional procedures. Symptomatic treatment for chemotherapy-induced neuropathy is discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?38/9/39066?source=see_link&amp;anchor=H18#H18\">",
"     \"Cancer pain management: Adjuvant analgesics (coanalgesics)\", section on 'Drugs used for neuropathic pain'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?31/26/32170?source=see_link&amp;anchor=H44713474#H44713474\">",
"     \"Psychological, rehabilitative, and integrative therapies for cancer pain\", section on 'Physical modalities'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?20/38/21098?source=see_link\">",
"     \"Cancer pain management: Interventional therapies\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h3\">",
"     Summary",
"    </span>",
"    &nbsp;&mdash;&nbsp;Symmetrical, predominantly sensory peripheral neuropathy is a common complication of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?20/51/21305?source=see_link\">",
"     cisplatin",
"    </a>",
"    therapy that develops in most patients, only after a cumulative dose of 300",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    is reached. Once established, there is no effective therapy. Most patients improve over time, although recovery is often incomplete.",
"   </p>",
"   <p>",
"    At least three small randomized trials suggest neuroprotective benefit of prophylactic vitamin E during",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?20/51/21305?source=see_link\">",
"     cisplatin",
"    </a>",
"    therapy. Despite their small size, given the consistency of the results, the safety of treatment, the lack of evidence that vitamin E interferes with antitumor efficacy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/23/37242/abstract/36,37\">",
"     36,37",
"    </a>",
"    ], the sometimes incomplete reversibility of cisplatin-induced neurotoxicity, and the absence of other effective neuroprotective agents, it would seem reasonable to utilize this strategy in patients who are expected to receive more than 300",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    of cisplatin for treatment of their cancer.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Ototoxicity",
"    </span>",
"    &nbsp;&mdash;&nbsp;Ototoxicity is the second most common",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?20/51/21305?source=see_link\">",
"     cisplatin",
"    </a>",
"    -related neurotoxic effect; it is characterized by a dose-dependent high-frequency sensorineural hearing loss with tinnitus [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/23/37242/abstract/46\">",
"     46",
"    </a>",
"    ]. Although ototoxicity is typically reported after intravenous cisplatin administration, it has also been seen after intraperitoneal use [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/23/37242/abstract/47\">",
"     47",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?0/33/537?source=see_link&amp;anchor=H13#H13\">",
"     \"Intraperitoneal chemotherapy for treatment of ovarian cancer\", section on 'Complications'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The variable reported incidence is related to the specific diagnostic criteria used to define hearing loss, the total dose of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?20/51/21305?source=see_link\">",
"     cisplatin",
"    </a>",
"    , the use of concomitant ototoxic treatments, and the population under study [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/23/37242/abstract/48\">",
"     48",
"    </a>",
"    ], and possibly to inherited polymorphisms in drug metabolism genes:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Although symptomatic hearing loss affects only 15 to 20 percent of patients receiving",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?20/51/21305?source=see_link\">",
"       cisplatin",
"      </a>",
"      , audiometric evidence of impaired hearing can be documented in more than three-fourths of patients.",
"     </li>",
"     <li>",
"      Ototoxicity has a general dose dependence, but with considerable interindividual variability. Genetic polymorphisms in enzymes responsible for",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?20/51/21305?source=see_link\">",
"       cisplatin",
"      </a>",
"      metabolism (eg, glutathione S-transferase, thiopurine methyltransferase, catechol O-methyltransferase) may contribute to the observed interindividual differences in the severity of hearing loss [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/23/37242/abstract/49-51\">",
"       49-51",
"      </a>",
"      ]. In addition, higher levels of residual serum platinum, which can persist for years following treatment, may also contribute to the severity of ototoxicity [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/23/37242/abstract/15\">",
"       15",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Radiotherapy (RT) to the normal cochlea or cranial nerve VIII can also cause sensorineural hearing loss. Concurrent administration of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?20/51/21305?source=see_link\">",
"       cisplatin",
"      </a>",
"      and RT results in synergistic ototoxicity, especially in the high-frequency speech range [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/23/37242/abstract/52\">",
"       52",
"      </a>",
"      ]. The ototoxicity of combined modality therapy with cisplatin and RT is discussed in more detail elsewhere. Care should be taken to distinguish sensorineural hearing loss versus conductive hearing loss due to serious otitis, an early complication of radiation. Conductive hearing loss can be treated. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?36/22/37226?source=see_link&amp;anchor=H36#H36\">",
"       \"Complications of cranial irradiation\", section on 'Ototoxicity'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Ototoxicity can be particularly severe in children [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/23/37242/abstract/48,53-56\">",
"       48,53-56",
"      </a>",
"      ]. Cofactors contributing to neurotoxicity include young age, the use of cranial irradiation, high cumulative doses of platinum compounds, and the use of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?37/61/38873?source=see_link\">",
"       carboplatin",
"      </a>",
"      in addition to",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?20/51/21305?source=see_link\">",
"       cisplatin",
"      </a>",
"      as part of the treatment regimen. Although children may have a slightly greater capacity for improvement once treatment is discontinued, profound hearing impairment is not infrequent and can interfere with subsequent speech and language development [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/23/37242/abstract/48\">",
"       48",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Early detection of ototoxicity in children may minimize the risk of severe impairment in the frequencies required for speech recognition. In children being treated with either",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?20/51/21305?source=see_link\">",
"     cisplatin",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/61/38873?source=see_link\">",
"     carboplatin",
"    </a>",
"    , extended high frequency audiometry (ie, at frequencies above 8 kHz) is more sensitive to early hearing loss than conventional audiometry [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/23/37242/abstract/57\">",
"     57",
"    </a>",
"    ]. This procedure is readily carried out in children more than five years old. For children less than five years of age, distortion product otoacoustic emissions (DPOAEs) are also more sensitive than conventional audiometry.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     Mechanism",
"    </span>",
"    &nbsp;&mdash;&nbsp;The main targets of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?20/51/21305?source=see_link\">",
"     cisplatin",
"    </a>",
"    -related ototoxicity are the outer hair cells in the organ of Corti and the vascularized epithelium in the lateral wall of the cochlea [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/23/37242/abstract/51,58\">",
"     51,58",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The related drug",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/11/2233?source=see_link\">",
"     oxaliplatin",
"    </a>",
"    is neurotoxic but ototoxicity is rarely observed. This difference is attributed to lower cochlear uptake of oxaliplatin as compared to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?20/51/21305?source=see_link\">",
"     cisplatin",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/23/37242/abstract/59\">",
"     59",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H15\">",
"     'Oxaliplatin'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Prevention",
"    </span>",
"    &nbsp;&mdash;&nbsp;Various strategies have been considered to minimize",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?20/51/21305?source=see_link\">",
"     cisplatin",
"    </a>",
"    ototoxicity.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?17/18/17700?source=see_link\">",
"       Sodium thiosulfate",
"      </a>",
"      &ndash; Protection against platinum-induced hearing loss has been achieved in animal models and in patients using sodium thiosulfate (STS) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/23/37242/abstract/60,61\">",
"       60,61",
"      </a>",
"      ]. Two phase III randomized trials are ongoing testing STS for the prevention of hearing loss in children with a variety of malignancies [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/23/37242/abstract/62,63\">",
"       62,63",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?0/42/678?source=see_link\">",
"       Amifostine",
"      </a>",
"      &ndash; Whether amifostine offers protection in children receiving",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?20/51/21305?source=see_link\">",
"       cisplatin",
"      </a>",
"      is unclear. Benefit has been suggested in some [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/23/37242/abstract/64\">",
"       64",
"      </a>",
"      ] but not all uncontrolled trials [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/23/37242/abstract/65\">",
"       65",
"      </a>",
"      ], while two small randomized trials (one in patients with osteosarcoma, the other in hepatoblastoma) failed to show benefit for prophylactic amifostine [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/23/37242/abstract/66,67\">",
"       66,67",
"      </a>",
"      ]. A year 2012 Cochrane review concluded that the data were insufficient to make any definite conclusions as to amifostine efficacy or lack thereof [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/23/37242/abstract/68\">",
"       68",
"      </a>",
"      ]. Year 2008 guidelines from ASCO concluded that the data were insufficient to support the routine use of amifostine to prevent cisplatin ototoxicity [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/23/37242/abstract/40\">",
"       40",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A major challenge to the development of otoprotective agents is the lack of consensus on the best ototoxicity assessment criteria [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/23/37242/abstract/51,69\">",
"     51,69",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Myelotoxicity (Lhermitte's sign)",
"    </span>",
"    &nbsp;&mdash;&nbsp;Lhermitte's sign is a shock-like sensation of paresthesias radiating from the back to the feet during neck flexion. This symptom develops in 20 to 40 percent of patients receiving",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?20/51/21305?source=see_link\">",
"     cisplatin",
"    </a>",
"    , typically after weeks or months of treatment. It has also been reported in patients receiving high cumulative doses of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/11/2233?source=see_link\">",
"     oxaliplatin",
"    </a>",
"    . (See",
"    <a class=\"local\" href=\"#H14\">",
"     'Carboplatin'",
"    </a>",
"    below and",
"    <a class=\"local\" href=\"#H15\">",
"     'Oxaliplatin'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    The neurologic examination is normal and symptoms resolve spontaneously several months after",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?20/51/21305?source=see_link\">",
"     cisplatin",
"    </a>",
"    is discontinued. Lhermitte's sign is believed to result from transient demyelination of the posterior columns. A true myelopathy is rare [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/23/37242/abstract/10,70\">",
"     10,70",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Encephalopathy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Encephalopathy is rare and more common after intraarterial administration [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/23/37242/abstract/71\">",
"     71",
"    </a>",
"    ]. Symptoms include seizures and focal neurologic symptoms, including cortical blindness [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/23/37242/abstract/72,73\">",
"     72,73",
"    </a>",
"    ]. The encephalopathy is associated with reversible abnormalities in the white matter of the occipital, parietal, and frontal lobes (reversible posterior leucoencephalopathy). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?42/16/43273?source=see_link\">",
"     \"Reversible posterior leukoencephalopathy syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?20/51/21305?source=see_link\">",
"     Cisplatin",
"    </a>",
"    -induced encephalopathy must be distinguished from metabolic causes, including water intoxication caused by prehydration, treatment-induced renal impairment, hypomagnesemia, hypocalcemia, and the syndrome of inappropriate secretion of antidiuretic hormone (SIADH). Paraneoplastic SIADH may accompany some malignancies for which cisplatin is commonly used, particularly small cell lung cancer. Rare cases of cisplatin-induced SIADH are reported [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/23/37242/abstract/74,75\">",
"     74,75",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?7/46/7913?source=see_link\">",
"     \"Pathophysiology and etiology of the syndrome of inappropriate antidiuretic hormone secretion (SIADH)\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?29/8/29833?source=see_link\">",
"     \"Cisplatin nephrotoxicity\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?15/57/16282?source=see_link\">",
"     \"Overview of the risk factors, pathology, and clinical manifestations of lung cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Vascular toxicity",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?20/51/21305?source=see_link\">",
"     Cisplatin",
"    </a>",
"    can cause arterial ischemia or thrombosis in major cerebral vessels, resulting in a stroke [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/23/37242/abstract/76-79\">",
"     76-79",
"    </a>",
"    ]. In addition, cisplatin-based chemotherapy for urothelial transitional cell carcinoma has been associated with a 13 percent risk of vascular events, primarily venous thromboembolism, most of which occurred during the first two cycles of chemotherapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/23/37242/abstract/80\">",
"     80",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?6/36/6730?source=see_link\">",
"     \"Drug-induced thrombosis and vascular disease in patients with malignancy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Other complications",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?20/51/21305?source=see_link\">",
"     Cisplatin",
"    </a>",
"    has been associated with a number of other complications, including:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A vestibulopathy, resulting in ataxia and vertigo, dysgeusia, and a myasthenic syndrome [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/23/37242/abstract/10\">",
"       10",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The development of hiccups in patients receiving",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?20/51/21305?source=see_link\">",
"       cisplatin",
"      </a>",
"      -based regimens. Although cisplatin may contribute to this toxicity,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?33/4/33856?source=see_link\">",
"       dexamethasone",
"      </a>",
"      also appears to play a causative role [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/23/37242/abstract/81\">",
"       81",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Intracarotid",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?20/51/21305?source=see_link\">",
"       cisplatin",
"      </a>",
"      infusion may be associated with optic neuritis and retinopathy [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/23/37242/abstract/10,82\">",
"       10,82",
"      </a>",
"      ]. In contrast, cisplatin does not appear to interfere with olfactory function [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/23/37242/abstract/83\">",
"       83",
"      </a>",
"      ]. Focal lumbosacral plexopathy or mononeuropathy has been reported following infusion of the internal or external iliac arteries [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/23/37242/abstract/84\">",
"       84",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Muscle cramps unrelated to electrolyte abnormalities are relatively common and resolve spontaneously [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/23/37242/abstract/85\">",
"       85",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h1\">",
"     CARBOPLATIN",
"    </span>",
"    &nbsp;&mdash;&nbsp;Peripheral neuropathy and central nervous system (CNS) toxicity are uncommon when",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/61/38873?source=see_link\">",
"     carboplatin",
"    </a>",
"    is given at conventional doses (",
"    <a class=\"graphic graphic_table graphicRef67516 \" href=\"mobipreview.htm?34/34/35373\">",
"     table 2",
"    </a>",
"    ). However, a severe neuropathy can develop after higher than standard dose carboplatin, as used in the setting of high dose therapy with hematopoietic cell transplantation (",
"    <a class=\"graphic graphic_table graphicRef55758 \" href=\"mobipreview.htm?35/9/35998\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/23/37242/abstract/86\">",
"     86",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?24/34/25130?source=see_link\">",
"     \"Preparative regimens for hematopoietic cell transplantation\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The administration of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/61/38873?source=see_link\">",
"     carboplatin",
"    </a>",
"    to young children treated for retinoblastoma usually does not lead to acute or subacute hearing loss [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/23/37242/abstract/87-89\">",
"     87-89",
"    </a>",
"    ]. In one of these studies, hearing loss affected only 5 percent of patients at a median of 3.7 years after treatment [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/23/37242/abstract/89\">",
"     89",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    However, much higher rates of ototoxicity were reported in another study of 60 children receiving",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/61/38873?source=see_link\">",
"     carboplatin",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?29/57/30617?source=see_link\">",
"     etoposide",
"    </a>",
"    for retinoblastoma [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/23/37242/abstract/90\">",
"     90",
"    </a>",
"    ]. Twelve (20 percent) developed ototoxicity at a median of 8 months after the start of therapy, and nine required hearing aids. The only factor that predicted sustained hearing loss was younger age at start of treatment (median age of the patients who developed hearing loss versus those who did not was 2.2 versus 8.6 years).",
"   </p>",
"   <p>",
"    One of the reasons hypothesized to account for these findings was the dosing of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/61/38873?source=see_link\">",
"     carboplatin",
"    </a>",
"    based upon body surface area (BSA) rather than body weight alone. Particularly in small children weighing &lt;10 kg, this could result in exposure to potentially toxic serum levels of drugs [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/23/37242/abstract/91\">",
"     91",
"    </a>",
"    ]. The common practice of normalizing chemotherapy doses to weight rather than BSA in infants weighing &lt;10 kg (which was done in the other three studies [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/23/37242/abstract/87-89\">",
"     87-89",
"    </a>",
"    ]) results in lower doses that offset differences in drug disposition and end organ sensitivity.",
"   </p>",
"   <p>",
"    Long-term audiometric follow-up is advisable for all children who receive",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/61/38873?source=see_link\">",
"     carboplatin",
"    </a>",
"    for treatment of retinoblastoma. Testing for early evidence of ototoxicity in children is discussed above. (See",
"    <a class=\"local\" href=\"#H7\">",
"     'Ototoxicity'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Other manifestations of neurotoxicity from",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/61/38873?source=see_link\">",
"     carboplatin",
"    </a>",
"    include a microangiopathic hemolytic anemia resulting in progressive neurologic impairment and death [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/23/37242/abstract/92\">",
"     92",
"    </a>",
"    ], reversible posterior leukoencephalopathy syndrome [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/23/37242/abstract/93\">",
"     93",
"    </a>",
"    ], and retinal toxicity following intraarterial administration for brain tumors [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/23/37242/abstract/94\">",
"     94",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    As with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?20/51/21305?source=see_link\">",
"     cisplatin",
"    </a>",
"    , the available data from randomized trials are insufficient to conclude if prophylactic use of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?0/42/678?source=see_link\">",
"     amifostine",
"    </a>",
"    , vitamin E, glutathione, Org 2766 or diethyldithiocarbamate can prevent or limit",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/61/38873?source=see_link\">",
"     carboplatin",
"    </a>",
"    -associated neurotoxicity [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/23/37242/abstract/39\">",
"     39",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h1\">",
"     OXALIPLATIN",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/11/2233?source=see_link\">",
"     Oxaliplatin",
"    </a>",
"    is a third-generation platinum compound used in the treatment of metastatic colorectal cancer. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?43/32/44554?source=see_link&amp;anchor=H27#H27\">",
"     \"Systemic chemotherapy for metastatic colorectal cancer: Completed clinical trials\", section on 'Oxaliplatin'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Two distinct syndromes have been reported: an acute neurosensory complex, which can appear during or shortly after the first few infusions, and a cumulative sensory neuropathy, with distal loss of sensation and dysesthesias (",
"    <a class=\"graphic graphic_table graphicRef67516 \" href=\"mobipreview.htm?34/34/35373\">",
"     table 2",
"    </a>",
"    ). Neuromotor toxicity is much less common. Ototoxicity is rare with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/11/2233?source=see_link\">",
"     oxaliplatin",
"    </a>",
"    , unlike",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?20/51/21305?source=see_link\">",
"     cisplatin",
"    </a>",
"    .",
"   </p>",
"   <p>",
"    Other rare manifestations of neurotoxicity include urinary retention and Lhermitte's sign, which have been reported in patients receiving high cumulative",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/11/2233?source=see_link\">",
"     oxaliplatin",
"    </a>",
"    doses [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/23/37242/abstract/95,96\">",
"     95,96",
"    </a>",
"    ]. Reversible posterior leukoencephalopathy is also reported [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/23/37242/abstract/97-99\">",
"     97-99",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Acute neurotoxicity",
"    </span>",
"    &nbsp;&mdash;&nbsp;The majority of patients treated with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/11/2233?source=see_link\">",
"     oxaliplatin",
"    </a>",
"    (&gt;85 percent in one report [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/23/37242/abstract/100\">",
"     100",
"    </a>",
"    ]) experience symptoms of acute neurotoxicity [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/23/37242/abstract/100\">",
"     100",
"    </a>",
"    ]. Typical symptoms include striking paresthesias and dysesthesias of the hands, feet, and perioral region. Symptoms are often induced or aggravated by exposure to cold.",
"    <br/>",
"   </p>",
"   <p>",
"    In addition to sensory symptoms, motor symptoms may also develop, including cramps, jaw tightness, voice changes, ptosis, visual field abnormalities, and rarely priapism [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/23/37242/abstract/101\">",
"     101",
"    </a>",
"    ]. One case report suggests that motor symptoms may be particularly responsive to treatment with oral",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?16/31/16887?source=see_link\">",
"     pregabalin",
"    </a>",
"    (Lyrica) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/23/37242/abstract/102\">",
"     102",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The range and frequency of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/11/2233?source=see_link\">",
"     oxaliplatin",
"    </a>",
"    -induced acute neurotoxicity from a series of 170 patients treated with an oxaliplatin-based regimen for metastatic colorectal cancer, 146 of whom (86 percent) manifested any degree of acute neuropathy, was as follows [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/23/37242/abstract/100\">",
"     100",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Cold-induced perioral paresthesias &ndash; 95 percent",
"     </li>",
"     <li>",
"      Cold-induced pharyngolaryngeal dysesthesia &ndash; 92 percent",
"     </li>",
"     <li>",
"      Dyspnea &ndash; 40 percent",
"     </li>",
"     <li>",
"      Muscle cramps &ndash; 34 percent",
"     </li>",
"     <li>",
"      Jaw stiffness &ndash; 34 percent",
"     </li>",
"     <li>",
"      Dysphagia &ndash; 30 percent",
"     </li>",
"     <li>",
"      Visible fasciculations &ndash; 30 percent",
"     </li>",
"     <li>",
"      Voice changes &ndash; 6 percent",
"     </li>",
"     <li>",
"      Ocular changes &ndash; 0.7 percent &nbsp;",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Acute symptoms are observed more frequently at doses &ge;130",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    than at &le;85",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    and are infusion-rate dependent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/23/37242/abstract/103\">",
"     103",
"    </a>",
"    ]. Increasing the duration of infusion from two to six hours during subsequent treatments can prevent recurrence, particularly of the pseudolaryngospasm.",
"   </p>",
"   <p>",
"    Acute neurotoxicity caused by",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/11/2233?source=see_link\">",
"     oxaliplatin",
"    </a>",
"    is thought to result from chelation of calcium by oxalate (a metabolite of oxaliplatin) with transient activation of disinhibited peripheral nerve voltage-gated calcium-dependent sodium channels causing hyperexcitability of peripheral nerves [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/23/37242/abstract/104,105\">",
"     104,105",
"    </a>",
"    ]. This has been attributed to disruption in cell membrane ion channels [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/23/37242/abstract/106-111\">",
"     106-111",
"    </a>",
"    ]. Acute changes in axonal excitability seem to become less pronounced in later treatment cycles, possibly because chronic nerve dysfunction and sensory loss mask the acute effects at higher cumulative doses [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/23/37242/abstract/109\">",
"     109",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Cumulative sensory neuropathy",
"    </span>",
"    &nbsp;&mdash;&nbsp;The dose-limiting, late-onset neuropathy seen with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/11/2233?source=see_link\">",
"     oxaliplatin",
"    </a>",
"    is comparable to that observed with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?20/51/21305?source=see_link\">",
"     cisplatin",
"    </a>",
"    . Characteristically, this is a cumulative, sensory, symmetric distal axonal neuropathy without motor involvement. The relationship between cumulative dose and neuropathy is addressed below.",
"   </p>",
"   <p>",
"    The mechanism of neuropathy appears similar to that discussed for",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?20/51/21305?source=see_link\">",
"     cisplatin",
"    </a>",
"    , although",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/11/2233?source=see_link\">",
"     oxaliplatin",
"    </a>",
"    forms fewer platinum-DNA adducts then does cisplatin and thus is slightly less neurotoxic [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/23/37242/abstract/16\">",
"     16",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H109349878\">",
"     'Mechanism'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    In many cases (often in the face of responding disease), neuropathy forces at least a temporary discontinuation of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/11/2233?source=see_link\">",
"     oxaliplatin",
"    </a>",
"    . In about three-fourths of patients, the neuropathy is reversible with a median time to recovery of 13 weeks after treatment discontinuation. Recommended management of oxaliplatin dose and schedule based upon neurotoxicity is presented in the table (",
"    <a class=\"graphic graphic_table graphicRef57185 \" href=\"mobipreview.htm?16/3/16444\">",
"     table 3",
"    </a>",
"    ). Possible approaches to prevention are discussed below. (See",
"    <a class=\"local\" href=\"#H20\">",
"     'Prevention'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h3\">",
"     Incidence, characteristics, severity, and reversibility",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H93783210\">",
"    <span class=\"h4\">",
"     Data from clinical trials",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      NSABP C-07 &mdash;",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?2/11/2233?source=see_link\">",
"       Oxaliplatin",
"      </a>",
"      neurotoxicity was studied in detail in the phase III NSABP C-07 trial involving 2492 patients receiving adjuvant chemotherapy after surgery for colon cancer, including 400 who participated in a patient-reported substudy [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/23/37242/abstract/112\">",
"       112",
"      </a>",
"      ]. Patients were randomly assigned to bolus",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?32/32/33280?source=see_link\">",
"       fluorouracil",
"      </a>",
"      plus",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?23/54/24423?source=see_link\">",
"       leucovorin",
"      </a>",
"      with or without oxaliplatin (85",
"      <span class=\"nowrap\">",
"       mg/m",
"       <sup>",
"        2",
"       </sup>",
"      </span>",
"      on weeks 1, 3, and 5 of each of three eight week cycles). (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?33/44/34506?source=see_link&amp;anchor=H16#H16\">",
"       \"Adjuvant therapy for resected stage III (node-positive) colon cancer\", section on 'NSABP C-07 trial'",
"      </a>",
"      .)",
"      <br/>",
"      <br/>",
"      The following findings were noted with respect to neurotoxicity:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Patient-reported neurotoxicity was significantly more common with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?2/11/2233?source=see_link\">",
"       oxaliplatin",
"      </a>",
"      , including sensory symptoms (hand-foot pain, 26 versus 3 percent with",
"      <span class=\"nowrap\">",
"       FU/LV)",
"      </span>",
"      and moderate motor weakness (27 versus 16 percent). Although hand symptoms generally resolved by 18 months, foot numbness and tingling persisted (22 versus 5 percent).",
"     </li>",
"     <li>",
"      In contrast, observer-reported toxicity primarily consisted of low-grade neurosensory changes. This was more common in patients receiving FLOX (68 versus 8 percent with",
"      <span class=\"nowrap\">",
"       FU/LV),",
"      </span>",
"      and the time to resolution was significantly longer (9.0 versus 4.8 months).",
"     </li>",
"     <li>",
"      In a later analysis of 353 of these patients who had longitudinal data on neurotoxicity and were reassessed at a median of six years after random assessment, the group receiving",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?2/11/2233?source=see_link\">",
"       oxaliplatin",
"      </a>",
"      had a statistically significant but not clinically significant increase in total neurotoxicity scores compared to those not receiving oxaliplatin (a difference of 1.8 points on a point scale ranging from 0 to 48) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/23/37242/abstract/113\">",
"       113",
"      </a>",
"      ]. These authors had previously proposed that a difference of four on this patient-reported scale should be considered a minimal clinically significant difference [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/23/37242/abstract/112\">",
"       112",
"      </a>",
"      ], although this has not been validated by others. When separate categories of neurotoxicity were assessed, the odds of numbness and tingling in the hands or feet 2 to 2.78-fold higher in those who did versus did not receive oxaliplatin.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      MOSAIC trial &mdash; Information on the reversibility of neurotoxicity is available from the MOSAIC trial, a randomized comparison of short-term infusional",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?23/54/24423?source=see_link\">",
"       leucovorin",
"      </a>",
"      -modulated 5-FU with and without",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?2/11/2233?source=see_link\">",
"       oxaliplatin",
"      </a>",
"      (85",
"      <span class=\"nowrap\">",
"       mg/m",
"       <sup>",
"        2",
"       </sup>",
"      </span>",
"      every other week for 24 weeks), as adjuvant chemotherapy after colon cancer resection [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/23/37242/abstract/114\">",
"       114",
"      </a>",
"      ]. Although some form of peripheral neuropathy developed in 92 percent of patients receiving oxaliplatin, it was severe (grade 3) in only 13 percent and generally reversible. By 48 months, grade 1, 2, or 3 neuropathy was observed in 12, 3, and 0.7 percent of patients, respectively. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?33/44/34506?source=see_link&amp;anchor=H15#H15\">",
"       \"Adjuvant therapy for resected stage III (node-positive) colon cancer\", section on 'MOSAIC trial'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H93783218\">",
"    <span class=\"h4\">",
"     Impact of dose intensity and length of treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;Early reports suggested that higher dose intensity therapy (ie, doses above 85",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    every two weeks) was not associated with a greater incidence or severity of neurotoxicity [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/23/37242/abstract/115\">",
"     115",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In the setting of metastatic disease, patients are often treated for longer than six months. The relationship between cumulative dose and neuropathy has been addressed in two reports:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a literature review, severe neuropathy was observed in 10 to 15 percent of patients after a cumulative dose of 780 to 850",
"      <span class=\"nowrap\">",
"       mg/m",
"       <sup>",
"        2",
"       </sup>",
"      </span>",
"      [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/23/37242/abstract/116\">",
"       116",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A preliminary report of a large intergroup trial found that the incidence of grade 2 or 3 neurotoxicity rapidly increased after a cumulative",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?2/11/2233?source=see_link\">",
"       oxaliplatin",
"      </a>",
"      -dose of 680",
"      <span class=\"nowrap\">",
"       mg/m",
"       <sup>",
"        2",
"       </sup>",
"      </span>",
"      (incidence 33 and 63 percent at 800 and 1020",
"      <span class=\"nowrap\">",
"       mg/m",
"       <sup>",
"        2",
"       </sup>",
"       ,",
"      </span>",
"      respectively, versus 22 to 25 percent at doses &le;680",
"      <span class=\"nowrap\">",
"       mg/m",
"       <sup>",
"        2",
"       </sup>",
"       )",
"      </span>",
"      [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/23/37242/abstract/117\">",
"       117",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These findings have important implications for clinical care. Clinicians should be particularly vigilant about assessing sensory neuropathy after four months of therapy with an",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/11/2233?source=see_link\">",
"     oxaliplatin",
"    </a>",
"    -based regimen containing 85",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    oxaliplatin every two weeks. The use of oxaliplatin-free intervals in patients treated for metastatic colorectal cancer as a means of delaying or preventing neuropathy is discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?21/20/21833?source=see_link&amp;anchor=H183911634#H183911634\">",
"     \"Systemic chemotherapy for metastatic colorectal cancer: General principles\", section on 'Oxaliplatin'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Whether other clinical factors are useful in predicting higher rates or greater severity of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/11/2233?source=see_link\">",
"     oxaliplatin",
"    </a>",
"    -related peripheral neuropathy is unclear [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/23/37242/abstract/118\">",
"     118",
"    </a>",
"    ]. At least some data suggest that patients who have a more complex combination of acute neuropathy phenomenon are those who eventually develop more severe chronic cumulative neuropathy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/23/37242/abstract/100\">",
"     100",
"    </a>",
"    ]. Others suggest that patients with diabetes do not necessarily have a greater severity of peripheral neuropathy, but that they develop it at a lower cumulative dose of oxaliplatin [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/23/37242/abstract/119\">",
"     119",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H16\">",
"     'Acute neurotoxicity'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h3\">",
"     Molecular predictors of neurotoxicity",
"    </span>",
"    &nbsp;&mdash;&nbsp;Inheritance of certain polymorphisms may influence the risk of neurotoxicity [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/23/37242/abstract/120,121\">",
"     120,121",
"    </a>",
"    ]. As an example, in a study of 166 patients receiving",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/11/2233?source=see_link\">",
"     oxaliplatin",
"    </a>",
"    -based therapy for advanced colorectal cancer, grade 3 (",
"    <a class=\"graphic graphic_table graphicRef78736 \" href=\"mobipreview.htm?11/35/11836\">",
"     table 4",
"    </a>",
"    ) neuropathy was significantly more common among those who inherited a specific polymorphism (the",
"    <span class=\"nowrap\">",
"     G/G",
"    </span>",
"    genotype) in the drug metabolizing enzyme glutathione-S transferase (GSTP1-105) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/23/37242/abstract/120\">",
"     120",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    While pharmacogenetic profiling may hold some promise for identifying patients at a greater risk for severe neurotoxicity, the data are insufficient to justify routine genetic testing for GSTP1-105 genotype prior to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/11/2233?source=see_link\">",
"     oxaliplatin",
"    </a>",
"    -based chemotherapy. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?43/32/44554?source=see_link\">",
"     \"Systemic chemotherapy for metastatic colorectal cancer: Completed clinical trials\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Prevention",
"    </span>",
"    &nbsp;&mdash;&nbsp;Multiple approaches have been used to prevent or minimize the cumulative neurotoxicity associated with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/11/2233?source=see_link\">",
"     oxaliplatin",
"    </a>",
"    therapy. These include interrupting and reintroducing oxaliplatin therapy, lengthening the duration of infusion, and various pharmacologic agents.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h3\">",
"     Stopping and reintroducing oxaliplatin",
"    </span>",
"    &nbsp;&mdash;&nbsp;As the clinical situation permits, if significant neuropathy develops during treatment, it is reasonable to discontinue the",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/11/2233?source=see_link\">",
"     oxaliplatin",
"    </a>",
"    and switch to a non-oxaliplatin-containing chemotherapy regimen to permit as much recovery as possible before reintroducing oxaliplatin.",
"   </p>",
"   <p>",
"    Others suggest that interspersing a non-",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/11/2233?source=see_link\">",
"     oxaliplatin",
"    </a>",
"    -containing \"maintenance\" chemotherapy regimen is a reasonable maneuver to prevent or delay the development of neuropathy in responding patients who have received three or four months of therapy with oxaliplatin but have no clinically significant neuropathy. Data from the OPTIMOX-1 and CONcePT trials in patients undergoing palliative chemotherapy for metastatic colorectal cancer suggest that this strategy decreases the risk of severe neuropathy without compromising antitumor efficacy. However, continued treatment with oxaliplatin is also an option in this setting, particularly in a responding patient who is tolerating chemotherapy well and has aggressive",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    bulky disease. Totally chemotherapy-free intervals have the potential to worsen outcomes in this setting and are not recommended.",
"   </p>",
"   <p>",
"    The use of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/11/2233?source=see_link\">",
"     oxaliplatin",
"    </a>",
"    in the management of metastatic colorectal cancer and the role of interrupted treatment schedules are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?21/20/21833?source=see_link&amp;anchor=H183911634#H183911634\">",
"     \"Systemic chemotherapy for metastatic colorectal cancer: General principles\", section on 'Oxaliplatin'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h3\">",
"     Lengthened infusion duration",
"    </span>",
"    &nbsp;&mdash;&nbsp;Benefits from prolonging the duration of the infusion appear to be limited to preventing the acute neuropathy. The dose-limiting, cumulative neurotoxicity is not influenced by the duration of infusion or fractionation and is only dependent on the cumulative dose administered.",
"   </p>",
"   <p>",
"    Lengthening the duration of the",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/11/2233?source=see_link\">",
"     oxaliplatin",
"    </a>",
"    infusion from two to six hours was evaluated in a randomized trial, in which 64 patients receiving adjuvant chemotherapy for colorectal or gastric carcinoma were randomly assigned to six- or two-hour infusions of oxaliplatin [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/23/37242/abstract/122\">",
"     122",
"    </a>",
"    ]. The overall percentage of patients with sensory neurotoxicity was not significantly decreased with the six-hour infusion (84 versus 93 percent with the two-hour infusion), although there was a significant decrease in the number of treatment cycles with grade 2 or greater neurotoxicity (6 versus 19 percent).",
"   </p>",
"   <p>",
"    The utility of this approach is limited by the logistical issues associated with a prolonged infusion, combined with the lack of effect on cumulative neurotoxicity.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h3\">",
"     Pharmacologic approaches",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several pharmacologic agents have shown promise in uncontrolled studies and small randomized trials to diminish the incidence and severity of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/11/2233?source=see_link\">",
"     oxaliplatin",
"    </a>",
"    -induced neurotoxicity. These include concomitant calcium and magnesium infusions [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/23/37242/abstract/123-125\">",
"     123-125",
"    </a>",
"    ], glutathione [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/23/37242/abstract/31\">",
"     31",
"    </a>",
"    ], oxcarbazepine [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/23/37242/abstract/126\">",
"     126",
"    </a>",
"    ], glutamine [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/23/37242/abstract/127\">",
"     127",
"    </a>",
"    ], neurotropin [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/23/37242/abstract/128\">",
"     128",
"    </a>",
"    ], and the Japanese traditional herbal formula Goshajinkigan (Gosha-Jinki-Gan) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/23/37242/abstract/129\">",
"     129",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Although initial results have been promising for these agents, appropriately powered randomized trials are required to confirm the neuroprotective effect of an intervention and to rule out any interference with antitumor activity before these pharmacologic approaches can be widely adopted.",
"   </p>",
"   <p>",
"    The potential pitfalls of relying upon phase II studies to guide practice can be illustrated by the experience with xaliproden, a nonpeptide neurotrophic agent that showed promise in small phase II studies. A phase III trial was conducted in which 649 patients were randomly assigned to xaliproden or placebo in conjunction with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/11/2233?source=see_link\">",
"     oxaliplatin",
"    </a>",
"    -based chemotherapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/23/37242/abstract/130\">",
"     130",
"    </a>",
"    ]. In a preliminary report presented in 2006, there was a lower incidence of grade 3 sensory neuropathy with xaliproden (17 versus 11 percent with placebo). However, the overall incidence of neurotoxicity was the same (73 percent on both arms), there was no increase in the total cumulative dose of oxaliplatin, or in the time patients could remain on treatment, or the percentage of patients with complete recovery after finishing treatment with oxaliplatin (49 versus 47 percent). Thus, there appeared to be no clinically meaningful benefit from the use of xaliproden.",
"   </p>",
"   <p>",
"    A Cochrane Database review of interventions for preventing",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?20/51/21305?source=see_link\">",
"     cisplatin",
"    </a>",
"    neuropathy concluded that the data were insufficient to conclude that any of the purported chemoprotective agents \"prevent or limited neurotoxicity of platinum drugs among human patients\" [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/23/37242/abstract/35\">",
"     35",
"    </a>",
"    ]. The review did not include",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?21/45/22233?source=see_link\">",
"     venlafaxine",
"    </a>",
"    or intravenous calcium and magnesium for",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/11/2233?source=see_link\">",
"     oxaliplatin",
"    </a>",
"    -induced sensory neuropathy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19082722\">",
"    <span class=\"h4\">",
"     Venlafaxine",
"    </span>",
"    &nbsp;&mdash;&nbsp;Potential benefit from",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?21/45/22233?source=see_link\">",
"     venlafaxine",
"    </a>",
"    was suggested in a small placebo-controlled randomized trial conducted in 48 patients who developed distressing",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/11/2233?source=see_link\">",
"     oxaliplatin",
"    </a>",
"    -induced acute neurotoxicity [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/23/37242/abstract/131\">",
"     131",
"    </a>",
"    ]. Patients were randomly assigned to venlafaxine 50 mg one hour prior to the oxaliplatin infusion followed by 37.5 mg twice daily from days 2 to 11 or placebo. The proportion of patients experiencing full relief of acute neurotoxicity during subsequent cycles of therapy was significantly higher in the venlafaxine group (31 versus 5 percent). Furthermore, at three months posttreatment, at a time when no patient remained on oxaliplatin therapy, a significantly higher number of patients in the venlafaxine arm had no neurotoxicity (39 versus 6 percent), and significantly fewer had grade 3 neurotoxicity (0 versus 33 percent).",
"   </p>",
"   <p>",
"    While these data seem promising, confirmation in larger trials is needed. &nbsp; &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H93783276\">",
"    <span class=\"h4\">",
"     Calcium and magnesium infusions",
"    </span>",
"    &nbsp;&mdash;&nbsp;Based upon an early report suggesting benefit for intravenous calcium and magnesium (IV",
"    <span class=\"nowrap\">",
"     Ca/Mg)",
"    </span>",
"    prior to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/11/2233?source=see_link\">",
"     oxaliplatin",
"    </a>",
"    infusion in patients with advanced disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/23/37242/abstract/123\">",
"     123",
"    </a>",
"    ], placebo-controlled phase III trials were initiated in patients receiving oxaliplatin for metastatic colorectal cancer (the CONcePT trial [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/23/37242/abstract/132\">",
"     132",
"    </a>",
"    ]) and in the adjuvant setting (the N04C7 trial [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/23/37242/abstract/133\">",
"     133",
"    </a>",
"    ]). However, a planned interim analysis of the first 180 patients enrolled in the CONcePT trial found that there was a significantly lower response rate in patients treated with IV",
"    <span class=\"nowrap\">",
"     Ca/Mg",
"    </span>",
"    compared to the control group [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/23/37242/abstract/125\">",
"     125",
"    </a>",
"    ], and the trial was closed by an independent data monitoring committee; enrollment in the N04C7 trial was also suspended. The lower response rate in patients with metastatic CRC who were receiving IV",
"    <span class=\"nowrap\">",
"     Ca/Mg",
"    </span>",
"    in conjunction with oxaliplatin was not confirmed in subsequent preliminary reports detailing independent blinded central review of the response data from the CONcePT trial, or in a preliminary report of patients with metastatic disease who were enrolled on the randomized French NEUROXO study [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/23/37242/abstract/132,134\">",
"     132,134",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Data on the neuroprotective benefit of IV",
"    <span class=\"nowrap\">",
"     Ca/Mg",
"    </span>",
"    have been reported from the N04C7 trial, and a preliminary report is also available from the CONcePT trial [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/23/37242/abstract/132,133\">",
"     132,133",
"    </a>",
"    ]; additional information is also available from the phase III CAIRO2 trial [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/23/37242/abstract/135\">",
"     135",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The double-blind, placebo-controlled N04C7 trial reported a significantly lower severity (grade 2 or worse in 22 versus 41 percent when assessed by NCI-CTC criteria; 28 versus 51 percent using an",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?2/11/2233?source=see_link\">",
"       oxaliplatin",
"      </a>",
"      -specific scale) and significantly longer time to develop grade 2 or worse sensory neurotoxicity in patients who received IV",
"      <span class=\"nowrap\">",
"       Ca/Mg",
"      </span>",
"      (1 gram",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?26/25/27031?source=see_link\">",
"       magnesium sulfate",
"      </a>",
"      and 1 gram",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?18/11/18616?source=see_link\">",
"       calcium gluconate",
"      </a>",
"      pre- and post-oxaliplatin) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/23/37242/abstract/133\">",
"       133",
"      </a>",
"      ]. Acute muscle spasms associated with oxaliplatin were significantly reduced, but there was no reduction in cold sensitivity in patients treated with IV",
"      <span class=\"nowrap\">",
"       Ca/Mg.",
"       <br/>",
"       <br/>",
"       The",
"      </span>",
"      authors did not report on whether this benefit translated into more patients being able to complete the entire course of oxaliplatin or fewer with long-term chronic sensory neuropathy. Because study accrual was terminated prematurely due to concerns as to response rates, which were not substantiated, there were only 102 patients available for analysis (one-third of the planned enrollment), and the impact of IV",
"      <span class=\"nowrap\">",
"       Ca/Mg",
"      </span>",
"      on oncologic outcomes could not be assessed.",
"     </li>",
"     <li>",
"      In the CONcePT trial, there was also a suggestion of a beneficial impact of IV",
"      <span class=\"nowrap\">",
"       Ca/Mg",
"      </span>",
"      supplementation on patient-related neurotoxicity outcomes (sense of touch in",
"      <span class=\"nowrap\">",
"       hands/fingers",
"      </span>",
"      or",
"      <span class=\"nowrap\">",
"       feet/toes,",
"      </span>",
"      or mouth area) although there was no evidence of benefit in clinician-assessed neurotoxicity outcomes [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/23/37242/abstract/132\">",
"       132",
"      </a>",
"      ]. Interpretation of these data is limited by the small sample size (139 patients), early discontinuation of the trial, and the fact that one-half of the patients on the trial received intermittent rather than continuous",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?2/11/2233?source=see_link\">",
"       oxaliplatin",
"      </a>",
"      , a maneuver that also contributes to less neurotoxicity.",
"     </li>",
"     <li>",
"      The CAIRO2 trial was a randomized comparison of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?40/0/40967?source=see_link\">",
"       capecitabine",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?2/11/2233?source=see_link\">",
"       oxaliplatin",
"      </a>",
"      , and",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?2/20/2377?source=see_link\">",
"       bevacizumab",
"      </a>",
"      with or without",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?9/58/10151?source=see_link\">",
"       cetuximab",
"      </a>",
"      in 755 previously untreated patients with metastatic colorectal cancer [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/23/37242/abstract/135\">",
"       135",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?43/32/44554?source=see_link&amp;anchor=H64#H64\">",
"       \"Systemic chemotherapy for metastatic colorectal cancer: Completed clinical trials\", section on 'Dual antibody therapy'",
"      </a>",
"      .) The prophylactic use of",
"      <span class=\"nowrap\">",
"       Ca/Mg",
"      </span>",
"      was left to the discretion of the treating physician; 551 patients received prophylactic",
"      <span class=\"nowrap\">",
"       Ca/Mg",
"      </span>",
"      before and after the oxaliplatin infusion at least during the first treatment cycle (with 369 [67 percent] receiving prophylaxis for all six oxaliplatin infusions), while 181 did not receive",
"      <span class=\"nowrap\">",
"       Ca/Mg",
"      </span>",
"      during the first cycle (133 of whom [73 percent] did not receive",
"      <span class=\"nowrap\">",
"       Ca/Mg",
"      </span>",
"      during subsequent treatment courses).",
"      <br/>",
"      <br/>",
"      There was a trend toward a lower incidence of all-grade late neurotoxicity with",
"      <span class=\"nowrap\">",
"       Ca/Mg",
"      </span>",
"      (30 versus 39 percent, p=0.07), but the incidence of &ge;grade 2 late neurotoxicity was comparable. While there was significantly less all-grade acute neurotoxicity with",
"      <span class=\"nowrap\">",
"       Ca/Mg",
"      </span>",
"      (81 versus 91 percent), the difference in the rates of &ge;grade 2 acute neurotoxicity was not statistically significant (27 versus 34 percent, p=0.06). The use of",
"      <span class=\"nowrap\">",
"       Ca/Mg",
"      </span>",
"      was not associated with a greater number of delivered treatment cycles or with higher relative dose intensity (96 percent in both groups).",
"      <br/>",
"      <br/>",
"      Although this was not a randomized trial of chemotherapy with and without",
"      <span class=\"nowrap\">",
"       Ca/Mg,",
"      </span>",
"      there was no suggestion that use of",
"      <span class=\"nowrap\">",
"       Ca/Mg",
"      </span>",
"      interfered with efficacy; the median progression-free survival was similar with and without",
"      <span class=\"nowrap\">",
"       Ca/Mg",
"      </span>",
"      (10.1 versus 10.7 months) as was overall best response rate.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h3\">",
"     Summary",
"    </span>",
"    &nbsp;&mdash;&nbsp;Taken together, these data suggest that supplemental calcium and magnesium infusions (IV",
"    <span class=\"nowrap\">",
"     Ca/Mg)",
"    </span>",
"    may reduce some forms of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/11/2233?source=see_link\">",
"     oxaliplatin",
"    </a>",
"    neurotoxicity. However, there is still no strong data from an adequately powered prospective randomized study in advanced disease on which to base an assessment of the real value of the",
"    <span class=\"nowrap\">",
"     Ca/Mg",
"    </span>",
"    infusions and their relationship to progression-free or overall survival.",
"   </p>",
"   <p>",
"    Given the lack of confirmatory evidence that IV",
"    <span class=\"nowrap\">",
"     Ca/Mg",
"    </span>",
"    interferes with antitumor efficacy, and the absence of other effective neuroprotective agents, it is reasonable to consider this, at least in patients being treated for metastatic disease. Until further information is available, we would not pursue this approach in the adjuvant setting. Accrual to a confirmatory randomized, placebo-controlled trial in patients receiving adjuvant therapy for colon cancer has been completed by the North Central Cancer Treatment Group (NCCTC, NCT00316914), which should settle the question of whether this therapy is worthwhile and safe in the adjuvant setting.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12919949\">",
"    <span class=\"h3\">",
"     Symptomatic treatment of neuropathic pain",
"    </span>",
"    &nbsp;&mdash;&nbsp;In some patients with platinum-induced neuropathy, pain is a prominent symptom. Amelioration of pain from the chronic neuropathy and of the symptoms of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/11/2233?source=see_link\">",
"     oxaliplatin",
"    </a>",
"    -induced hyperexcitability may be achieved through use of antiepileptic drugs such as",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?19/19/19768?source=see_link\">",
"     gabapentin",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?16/31/16887?source=see_link\">",
"     pregabalin",
"    </a>",
"    , antidepressants such as",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?36/62/37864?source=see_link\">",
"     duloxetine",
"    </a>",
"    , physical modalities such as cutaneous electrical stimulation, and interventional procedures. Symptomatic treatment for chemotherapy-induced neuropathy is discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?38/9/39066?source=see_link&amp;anchor=H18#H18\">",
"     \"Cancer pain management: Adjuvant analgesics (coanalgesics)\", section on 'Drugs used for neuropathic pain'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?31/26/32170?source=see_link&amp;anchor=H44713474#H44713474\">",
"     \"Psychological, rehabilitative, and integrative therapies for cancer pain\", section on 'Physical modalities'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?20/38/21098?source=see_link\">",
"     \"Cancer pain management: Interventional therapies\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H645668\">",
"    <span class=\"h2\">",
"     Reversible posterior leukoencephalopathy syndrome",
"    </span>",
"    &nbsp;&mdash;&nbsp;Reversible posterior leukoencephalopathy syndrome (RPLS) has been observed rarely in clinical trials (&lt;0.1 percent) and in postmarketing experience. Signs and symptoms include headache, altered mental function, seizures, and visual changes, with or without hypertension. The diagnosis is confirmed by brain imaging. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?42/16/43273?source=see_link\">",
"     \"Reversible posterior leukoencephalopathy syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28589094\">",
"    <span class=\"h1\">",
"     TREATMENT OF NEUROPATHIC PAIN",
"    </span>",
"    &nbsp;&mdash;&nbsp;In some patients with platinum-induced neuropathy, pain is a prominent symptom. Individual case reports describe amelioration of pain from the chronic neuropathy and of the symptoms of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/11/2233?source=see_link\">",
"     oxaliplatin",
"    </a>",
"    -induced hyperexcitability with antiepileptic drugs including",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?25/10/25770?source=see_link\">",
"     carbamazepine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?19/19/19768?source=see_link\">",
"     gabapentin",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?16/31/16887?source=see_link\">",
"     pregabalin",
"    </a>",
"    . However, a phase III randomized double-blind placebo-controlled crossover trial of gabapentin for symptomatic chemotherapy-induced peripheral neuropathy failed to show efficacy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/23/37242/abstract/136\">",
"     136",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?38/9/39066?source=see_link&amp;anchor=H20#H20\">",
"     \"Cancer pain management: Adjuvant analgesics (coanalgesics)\", section on 'Anticonvulsant analgesics'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Among the widely used anticancer drugs, the platinum compounds",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?20/51/21305?source=see_link\">",
"     cisplatin",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/11/2233?source=see_link\">",
"     oxaliplatin",
"    </a>",
"    are most commonly associated with neurotoxicity. (See",
"    <a class=\"local\" href=\"#H2\">",
"     'Cisplatin'",
"    </a>",
"    above and",
"    <a class=\"local\" href=\"#H15\">",
"     'Oxaliplatin'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    In contrast, neurotoxicity is uncommon with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/61/38873?source=see_link\">",
"     carboplatin",
"    </a>",
"    when the drug is given at conventional doses, although a severe neuropathy can develop after higher than standard dose carboplatin, as used in the setting of high dose therapy with hematopoietic cell transplantation. (See",
"    <a class=\"local\" href=\"#H14\">",
"     'Carboplatin'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h2\">",
"     Cisplatin",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?20/51/21305?source=see_link\">",
"     Cisplatin",
"    </a>",
"    causes an axonal neuropathy, which usually begins in the toes and fingers, and spreads proximally to affect the legs and arms. There is no effective therapy once peripheral neuropathy is established, although gradual improvement occurs in most patients after discontinuation of therapy.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Given the safety of treatment, the lack of evidence that vitamin E interferes with antitumor efficacy, the sometimes incomplete reversibility of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?20/51/21305?source=see_link\">",
"       cisplatin",
"      </a>",
"      -induced neurotoxicity, and the absence of other effective neuroprotective agents, we suggest administration of vitamin E (400 international units daily) during cisplatin-containing chemotherapy, and for at least three months following treatment discontinuation to reduce the incidence and severity of cisplatin-induced neuropathy (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Preventive strategies'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      There is insufficient evidence to support benefit from prophylactic treatment with the organic thiophosphate",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?0/42/678?source=see_link\">",
"       amifostine",
"      </a>",
"      , and we recommend against its use as a neuroprotectant (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Preventive strategies'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Pain associated with neuropathy may respond to antiepileptic drugs such as",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?19/19/19768?source=see_link\">",
"       gabapentin",
"      </a>",
"      or",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?16/31/16887?source=see_link\">",
"       pregabalin",
"      </a>",
"      , or antidepressants such as",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?36/62/37864?source=see_link\">",
"       duloxetine",
"      </a>",
"      . (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?38/9/39066?source=see_link&amp;anchor=H18#H18\">",
"       \"Cancer pain management: Adjuvant analgesics (coanalgesics)\", section on 'Drugs used for neuropathic pain'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Ototoxicity is the second most common",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?20/51/21305?source=see_link\">",
"     cisplatin",
"    </a>",
"    -related neurotoxic effect; it is characterized by a dose-dependent high-frequency sensorineural hearing loss with tinnitus.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      There are insufficient data to support the routine use of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?0/42/678?source=see_link\">",
"       amifostine",
"      </a>",
"      to prevent",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?20/51/21305?source=see_link\">",
"       cisplatin",
"      </a>",
"      ototoxicity, and we recommend against its use (",
"      <a class=\"grade\" href=\"._grade_1?title=Grade 1A\">",
"       Grade 1A",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Ototoxicity'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h2\">",
"     Oxaliplatin",
"    </span>",
"    &nbsp;&mdash;&nbsp;Two distinct neurologic syndromes are reported in patients receiving",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/11/2233?source=see_link\">",
"     oxaliplatin",
"    </a>",
"    &nbsp;(see",
"    <a class=\"local\" href=\"#H15\">",
"     'Oxaliplatin'",
"    </a>",
"    above).",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      An acute neurosensory complex consists of striking paresthesias and dysesthesias of the hands, feet, and perioral region and unusual cold-induced pharyngolaryngeal dysesthesias.",
"     </li>",
"     <li>",
"      A cumulative, dose-limiting, late-onset sensory, symmetric distal axonal neuropathy without motor involvement is comparable to that observed with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?20/51/21305?source=see_link\">",
"       cisplatin",
"      </a>",
"      . However, in contrast to cisplatin neuropathy, it is generally reversible.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Some maneuvers may help to prevent or delay",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/11/2233?source=see_link\">",
"     oxaliplatin",
"    </a>",
"    related neurotoxicity:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      When appropriate in the clinical setting, we suggest interspersing a non-",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?2/11/2233?source=see_link\">",
"       oxaliplatin",
"      </a>",
"      -containing \"maintenance\" chemotherapy regimen with the oxaliplatin regimen in patients undergoing palliative chemotherapy for metastatic colorectal cancer (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H21\">",
"       'Stopping and reintroducing oxaliplatin'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Infusions of calcium and magnesium (IV",
"      <span class=\"nowrap\">",
"       Ca/Mg)",
"      </span>",
"      prior to and following each dose of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?2/11/2233?source=see_link\">",
"       oxaliplatin",
"      </a>",
"      may provide some protection against some forms of oxaliplatin neurotoxicity. However, only one of the three randomized trials exploring this strategy has been published as a final manuscript, the benefits remain unclear, and concerns remain as to the impact of this strategy on antitumor efficacy, particularly in the setting of adjuvant therapy.",
"      <br/>",
"      <br/>",
"      Until further information becomes available, we suggest not pursuing this strategy in patients who are receiving oxaliplatin in a potentially curative (ie, adjuvant) situation (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). Given the preliminary reports suggesting that antitumor efficacy is not adversely affected by the use of IV",
"      <span class=\"nowrap\">",
"       Ca/Mg",
"      </span>",
"      in patients with metastatic colorectal cancer, and the absence of other effective neuroprotectants, it is reasonable to consider this on a case by case basis in patients being treated in a palliative setting. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Prevention'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      There are insufficient data to support the routine use of xaliproden to prevent",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?2/11/2233?source=see_link\">",
"       oxaliplatin",
"      </a>",
"      neurotoxicity, and we recommend against its use (",
"      <a class=\"grade\" href=\"._grade_1?title=Grade 1A\">",
"       Grade 1A",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Ototoxicity'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      There are insufficient data to support a benefit from lengthening the duration of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?2/11/2233?source=see_link\">",
"       oxaliplatin",
"      </a>",
"      infusion, and we suggest against its use (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      )&nbsp;(see",
"      <a class=\"local\" href=\"#H22\">",
"       'Lengthened infusion duration'",
"      </a>",
"      above).",
"     </li>",
"     <li>",
"      Pain associated with neuropathy may respond to antiepileptic drugs such as",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?19/19/19768?source=see_link\">",
"       gabapentin",
"      </a>",
"      or",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?16/31/16887?source=see_link\">",
"       pregabalin",
"      </a>",
"      , or antidepressants such as",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?36/62/37864?source=see_link\">",
"       duloxetine",
"      </a>",
"      . (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?38/9/39066?source=see_link&amp;anchor=H18#H18\">",
"       \"Cancer pain management: Adjuvant analgesics (coanalgesics)\", section on 'Drugs used for neuropathic pain'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H127138957\">",
"    <span class=\"h1\">",
"     ACKNOWLEDGMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The authors and editors would like to recognize Dr. Scott Plotkin, who contributed to previous versions of this topic review.",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     Dietrich J, Wen PY. Neurologic complications of chemotherapy. In: Cancer Neurology in Clinical Practice, 2nd, Schiff D, Kesari S, Wen PY (Eds), Humana Press, Totowa, New Jersey 2008. p.287.",
"    </li>",
"    <li>",
"     DeAngelis LM, Posner JB. Side Effects of Chemotherapy. In: Neurologic Complications of Cancer, 2nd, Oxford University Press, New York 2009. p.447.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/23/37242/abstract/3\">",
"      Schiff D, Wen PY, van den Bent MJ. Neurological adverse effects caused by cytotoxic and targeted therapies. Nat Rev Clin Oncol 2009; 6:596.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/23/37242/abstract/4\">",
"      Sioka C, Kyritsis AP. Central and peripheral nervous system toxicity of common chemotherapeutic agents. Cancer Chemother Pharmacol 2009; 63:761.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/23/37242/abstract/5\">",
"      van der Hoop RG, Vecht CJ, van der Burg ME, et al. Prevention of cisplatin neurotoxicity with an ACTH(4-9) analogue in patients with ovarian cancer. N Engl J Med 1990; 322:89.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/23/37242/abstract/6\">",
"      Siegal T, Haim N. Cisplatin-induced peripheral neuropathy. Frequent off-therapy deterioration, demyelinating syndromes, and muscle cramps. Cancer 1990; 66:1117.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/23/37242/abstract/7\">",
"      von Schlippe M, Fowler CJ, Harland SJ. Cisplatin neurotoxicity in the treatment of metastatic germ cell tumour: time course and prognosis. Br J Cancer 2001; 85:823.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/23/37242/abstract/8\">",
"      Mollman JE, Glover DJ, Hogan WM, Furman RE. Cisplatin neuropathy. Risk factors, prognosis, and protection by WR-2721. Cancer 1988; 61:2192.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/23/37242/abstract/9\">",
"      Krarup-Hansen A, Helweg-Larsen S, Schmalbruch H, et al. Neuronal involvement in cisplatin neuropathy: prospective clinical and neurophysiological studies. Brain 2007; 130:1076.",
"     </a>",
"    </li>",
"    <li>",
"     Posner JB. Side effects of chemotherapy. In: Neurologic complications of cancer, Davis FA (Ed), Philadelphia 1995. p.282.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/23/37242/abstract/11\">",
"      Roelofs RI, Hrushesky W, Rogin J, Rosenberg L. Peripheral sensory neuropathy and cisplatin chemotherapy. Neurology 1984; 34:934.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/23/37242/abstract/12\">",
"      van der Hoop RG, van der Burg ME, ten Bokkel Huinink WW, et al. Incidence of neuropathy in 395 patients with ovarian cancer treated with or without cisplatin. Cancer 1990; 66:1697.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/23/37242/abstract/13\">",
"      Hilkens PH, van der Burg ME, Moll JW, et al. Neurotoxicity is not enhanced by increased dose intensities of cisplatin administration. Eur J Cancer 1995; 31A:678.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/23/37242/abstract/14\">",
"      Stuart-Harris R, Ponder BA, Wrigley PF. Tetany associated with cis-platin. Lancet 1980; 2:1303.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/23/37242/abstract/15\">",
"      Sprauten M, Darrah TH, Peterson DR, et al. Impact of long-term serum platinum concentrations on neuro- and ototoxicity in Cisplatin-treated survivors of testicular cancer. J Clin Oncol 2012; 30:300.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/23/37242/abstract/16\">",
"      Ta LE, Espeset L, Podratz J, Windebank AJ. Neurotoxicity of oxaliplatin and cisplatin for dorsal root ganglion neurons correlates with platinum-DNA binding. Neurotoxicology 2006; 27:992.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/23/37242/abstract/17\">",
"      Khrunin AV, Moisseev A, Gorbunova V, Limborska S. Genetic polymorphisms and the efficacy and toxicity of cisplatin-based chemotherapy in ovarian cancer patients. Pharmacogenomics J 2010; 10:54.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/23/37242/abstract/18\">",
"      Pace A, Savarese A, Picardo M, et al. Neuroprotective effect of vitamin E supplementation in patients treated with cisplatin chemotherapy. J Clin Oncol 2003; 21:927.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/23/37242/abstract/19\">",
"      Argyriou AA, Chroni E, Koutras A, et al. Vitamin E for prophylaxis against chemotherapy-induced neuropathy: a randomized controlled trial. Neurology 2005; 64:26.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/23/37242/abstract/20\">",
"      Pace A, Giannarelli D, Gali&egrave; E, et al. Vitamin E neuroprotection for cisplatin neuropathy: a randomized, placebo-controlled trial. Neurology 2010; 74:762.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/23/37242/abstract/21\">",
"      Kemp G, Rose P, Lurain J, et al. Amifostine pretreatment for protection against cyclophosphamide-induced and cisplatin-induced toxicities: results of a randomized control trial in patients with advanced ovarian cancer. J Clin Oncol 1996; 14:2101.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/23/37242/abstract/22\">",
"      Planting AS, Catimel G, de Mulder PH, et al. Randomized study of a short course of weekly cisplatin with or without amifostine in advanced head and neck cancer. EORTC Head and Neck Cooperative Group. Ann Oncol 1999; 10:693.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/23/37242/abstract/23\">",
"      Glover D, Ibrahim J, Kirkwood J, et al. Phase II randomized trial of cisplatin and WR-2721 versus cisplatin alone for metastatic melanoma: an Eastern Cooperative Oncology Group Study (E1686). Melanoma Res 2003; 13:619.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/23/37242/abstract/24\">",
"      Leong SS, Tan EH, Fong KW, et al. Randomized double-blind trial of combined modality treatment with or without amifostine in unresectable stage III non-small-cell lung cancer. J Clin Oncol 2003; 21:1767.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/23/37242/abstract/25\">",
"      De Vos FY, Bos AM, Schaapveld M, et al. A randomized phase II study of paclitaxel with carboplatin +/- amifostine as first line treatment in advanced ovarian carcinoma. Gynecol Oncol 2005; 97:60.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/23/37242/abstract/26\">",
"      Kanat O, Evrensel T, Baran I, et al. Protective effect of amifostine against toxicity of paclitaxel and carboplatin in non-small cell lung cancer: a single center randomized study. Med Oncol 2003; 20:237.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/23/37242/abstract/27\">",
"      Hilpert F, St&auml;hle A, Tom&eacute; O, et al. Neuroprotection with amifostine in the first-line treatment of advanced ovarian cancer with carboplatin/paclitaxel-based chemotherapy--a double-blind, placebo-controlled, randomized phase II study from the Arbeitsgemeinschaft Gyn&auml;kologische Onkologoie (AGO) Ovarian Cancer Study Group. Support Care Cancer 2005; 13:797.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/23/37242/abstract/28\">",
"      Moore DH, Donnelly J, McGuire WP, et al. Limited access trial using amifostine for protection against cisplatin- and three-hour paclitaxel-induced neurotoxicity: a phase II study of the Gynecologic Oncology Group. J Clin Oncol 2003; 21:4207.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/23/37242/abstract/29\">",
"      Pisano C, Pratesi G, Laccabue D, et al. Paclitaxel and Cisplatin-induced neurotoxicity: a protective role of acetyl-L-carnitine. Clin Cancer Res 2003; 9:5756.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/23/37242/abstract/30\">",
"      Bianchi G, Vitali G, Caraceni A, et al. Symptomatic and neurophysiological responses of paclitaxel- or cisplatin-induced neuropathy to oral acetyl-L-carnitine. Eur J Cancer 2005; 41:1746.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/23/37242/abstract/31\">",
"      Cascinu S, Catalano V, Cordella L, et al. Neuroprotective effect of reduced glutathione on oxaliplatin-based chemotherapy in advanced colorectal cancer: a randomized, double-blind, placebo-controlled trial. J Clin Oncol 2002; 20:3478.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/23/37242/abstract/32\">",
"      Smyth JF, Bowman A, Perren T, et al. Glutathione reduces the toxicity and improves quality of life of women diagnosed with ovarian cancer treated with cisplatin: results of a double-blind, randomised trial. Ann Oncol 1997; 8:569.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/23/37242/abstract/33\">",
"      Roberts JA, Jenison EL, Kim K, et al. A randomized, multicenter, double-blind, placebo-controlled, dose-finding study of ORG 2766 in the prevention or delay of cisplatin-induced neuropathies in women with ovarian cancer. Gynecol Oncol 1997; 67:172.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/23/37242/abstract/34\">",
"      Gandara DR, Nahhas WA, Adelson MD, et al. Randomized placebo-controlled multicenter evaluation of diethyldithiocarbamate for chemoprotection against cisplatin-induced toxicities. J Clin Oncol 1995; 13:490.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/23/37242/abstract/35\">",
"      Albers JW, Chaudhry V, Cavaletti G, Donehower RC. Interventions for preventing neuropathy caused by cisplatin and related compounds. Cochrane Database Syst Rev 2011; :CD005228.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/23/37242/abstract/36\">",
"      Block KI, Koch AC, Mead MN, et al. Impact of antioxidant supplementation on chemotherapeutic toxicity: a systematic review of the evidence from randomized controlled trials. Int J Cancer 2008; 123:1227.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/23/37242/abstract/37\">",
"      Block KI, Koch AC, Mead MN, et al. Impact of antioxidant supplementation on chemotherapeutic efficacy: a systematic review of the evidence from randomized controlled trials. Cancer Treat Rev 2007; 33:407.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/23/37242/abstract/38\">",
"      Castiglione F, Dalla Mola A, Porcile G. Protection of normal tissues from radiation and cytotoxic therapy: the development of amifostine. Tumori 1999; 85:85.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/23/37242/abstract/39\">",
"      Albers J, Chaudhry V, Cavaletti G, Donehower R. Interventions for preventing neuropathy caused by cisplatin and related compounds. Cochrane Database Syst Rev 2007; :CD005228.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/23/37242/abstract/40\">",
"      Hensley ML, Hagerty KL, Kewalramani T, et al. American Society of Clinical Oncology 2008 clinical practice guideline update: use of chemotherapy and radiation therapy protectants. J Clin Oncol 2009; 27:127.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/23/37242/abstract/41\">",
"      Apfel SC, Arezzo JC, Lipson L, Kessler JA. Nerve growth factor prevents experimental cisplatin neuropathy. Ann Neurol 1992; 31:76.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/23/37242/abstract/42\">",
"      Fischer SJ, Podratz JL, Windebank AJ. Nerve growth factor rescue of cisplatin neurotoxicity is mediated through the high affinity receptor: studies in PC12 cells and p75 null mouse dorsal root ganglia. Neurosci Lett 2001; 308:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/23/37242/abstract/43\">",
"      Gao WQ, Dybdal N, Shinsky N, et al. Neurotrophin-3 reverses experimental cisplatin-induced peripheral sensory neuropathy. Ann Neurol 1995; 38:30.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/23/37242/abstract/44\">",
"      Pradat PF, Finiels F, Kennel P, et al. Partial prevention of cisplatin-induced neuropathy by electroporation-mediated nonviral gene transfer. Hum Gene Ther 2001; 12:367.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/23/37242/abstract/45\">",
"      ter Laak MP, Hamers FP, Kirk CJ, Gispen WH. rhGGF2 protects against cisplatin-induced neuropathy in the rat. J Neurosci Res 2000; 60:237.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/23/37242/abstract/46\">",
"      Rademaker-Lakhai JM, Crul M, Zuur L, et al. Relationship between cisplatin administration and the development of ototoxicity. J Clin Oncol 2006; 24:918.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/23/37242/abstract/47\">",
"      Nieves L, Currie J, Hoffman J, Sorosky JI. Ototoxicity after intraperitoneal chemotherapy: a case report. Int J Gynecol Cancer 2007; 17:1133.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/23/37242/abstract/48\">",
"      Knight KR, Kraemer DF, Neuwelt EA. Ototoxicity in children receiving platinum chemotherapy: underestimating a commonly occurring toxicity that may influence academic and social development. J Clin Oncol 2005; 23:8588.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/23/37242/abstract/49\">",
"      Oldenburg J, Kraggerud SM, Cvancarova M, et al. Cisplatin-induced long-term hearing impairment is associated with specific glutathione s-transferase genotypes in testicular cancer survivors. J Clin Oncol 2007; 25:708.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/23/37242/abstract/50\">",
"      Ross CJ, Katzov-Eckert H, Dub&eacute; MP, et al. Genetic variants in TPMT and COMT are associated with hearing loss in children receiving cisplatin chemotherapy. Nat Genet 2009; 41:1345.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/23/37242/abstract/51\">",
"      Brock PR, Knight KR, Freyer DR, et al. Platinum-induced ototoxicity in children: a consensus review on mechanisms, predisposition, and protection, including a new International Society of Pediatric Oncology Boston ototoxicity scale. J Clin Oncol 2012; 30:2408.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/23/37242/abstract/52\">",
"      Low WK, Toh ST, Wee J, et al. Sensorineural hearing loss after radiotherapy and chemoradiotherapy: a single, blinded, randomized study. J Clin Oncol 2006; 24:1904.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/23/37242/abstract/53\">",
"      Kolinsky DC, Hayashi SS, Karzon R, et al. Late onset hearing loss: a significant complication of cancer survivors treated with Cisplatin containing chemotherapy regimens. J Pediatr Hematol Oncol 2010; 32:119.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/23/37242/abstract/54\">",
"      Li Y, Womer RB, Silber JH. Predicting cisplatin ototoxicity in children: the influence of age and the cumulative dose. Eur J Cancer 2004; 40:2445.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/23/37242/abstract/55\">",
"      St&ouml;hr W, Langer T, Kremers A, et al. Cisplatin-induced ototoxicity in osteosarcoma patients: a report from the late effects surveillance system. Cancer Invest 2005; 23:201.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/23/37242/abstract/56\">",
"      Kushner BH, Budnick A, Kramer K, et al. Ototoxicity from high-dose use of platinum compounds in patients with neuroblastoma. Cancer 2006; 107:417.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/23/37242/abstract/57\">",
"      Knight KR, Kraemer DF, Winter C, Neuwelt EA. Early changes in auditory function as a result of platinum chemotherapy: use of extended high-frequency audiometry and evoked distortion product otoacoustic emissions. J Clin Oncol 2007; 25:1190.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/23/37242/abstract/58\">",
"      Rybak LP, Whitworth CA, Mukherjea D, Ramkumar V. Mechanisms of cisplatin-induced ototoxicity and prevention. Hear Res 2007; 226:157.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/23/37242/abstract/59\">",
"      Hellberg V, Wallin I, Eriksson S, et al. Cisplatin and oxaliplatin toxicity: importance of cochlear kinetics as a determinant for ototoxicity. J Natl Cancer Inst 2009; 101:37.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/23/37242/abstract/60\">",
"      Dickey DT, Wu YJ, Muldoon LL, Neuwelt EA. Protection against cisplatin-induced toxicities by N-acetylcysteine and sodium thiosulfate as assessed at the molecular, cellular, and in vivo levels. J Pharmacol Exp Ther 2005; 314:1052.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/23/37242/abstract/61\">",
"      Doolittle ND, Muldoon LL, Brummett RE, et al. Delayed sodium thiosulfate as an otoprotectant against carboplatin-induced hearing loss in patients with malignant brain tumors. Clin Cancer Res 2001; 7:493.",
"     </a>",
"    </li>",
"    <li>",
"     Information on Children's Oncology Group study protocol # ACCL0431 available online at www.cancer.gov/clinicaltrials/COG-ACCL05C1 (Accessed on May 03, 2011).",
"    </li>",
"    <li>",
"     Information on International tumor Strategy Study Group protocol SIOPEL (study CCLG-LT-2007-03) available online at file://clinicaltrials.gov/ct2/show/NCT00652132 (Accessed on May 03, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/23/37242/abstract/64\">",
"      Fouladi M, Chintagumpala M, Ashley D, et al. Amifostine protects against cisplatin-induced ototoxicity in children with average-risk medulloblastoma. J Clin Oncol 2008; 26:3749.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/23/37242/abstract/65\">",
"      Marina N, Chang KW, Malogolowkin M, et al. Amifostine does not protect against the ototoxicity of high-dose cisplatin combined with etoposide and bleomycin in pediatric germ-cell tumors: a Children's Oncology Group study. Cancer 2005; 104:841.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/23/37242/abstract/66\">",
"      Katzenstein HM, Chang KW, Krailo M, et al. Amifostine does not prevent platinum-induced hearing loss associated with the treatment of children with hepatoblastoma: a report of the Intergroup Hepatoblastoma Study P9645 as a part of the Children's Oncology Group. Cancer 2009; 115:5828.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/23/37242/abstract/67\">",
"      Gallegos-Castorena S, Mart&iacute;nez-Avalos A, Mohar-Betancourt A, et al. Toxicity prevention with amifostine in pediatric osteosarcoma patients treated with cisplatin and doxorubicin. Pediatr Hematol Oncol 2007; 24:403.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/23/37242/abstract/68\">",
"      van As JW, van den Berg H, van Dalen EC. Medical interventions for the prevention of platinum-induced hearing loss in children with cancer. Cochrane Database Syst Rev 2012; 5:CD009219.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/23/37242/abstract/69\">",
"      Chang KW, Chinosornvatana N. Practical grading system for evaluating cisplatin ototoxicity in children. J Clin Oncol 2010; 28:1788.",
"     </a>",
"    </li>",
"    <li>",
"     Forsyth PA, Cascino TL. Neurologic complications of chemotherapy. In: Neurologic complications of cancer, Wiley RG (Ed), Marcel Dekker, New York 1995. p.241.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/23/37242/abstract/71\">",
"      Newton HB, Page MA, Junck L, Greenberg HS. Intra-arterial cisplatin for the treatment of malignant gliomas. J Neurooncol 1989; 7:39.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/23/37242/abstract/72\">",
"      Ito Y, Arahata Y, Goto Y, et al. Cisplatin neurotoxicity presenting as reversible posterior leukoencephalopathy syndrome. AJNR Am J Neuroradiol 1998; 19:415.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/23/37242/abstract/73\">",
"      Lyass O, Lossos A, Hubert A, et al. Cisplatin-induced non-convulsive encephalopathy. Anticancer Drugs 1998; 9:100.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/23/37242/abstract/74\">",
"      Otsuka F, Hayashi Y, Ogura T, et al. Syndrome of inappropriate secretion of antidiuretic hormone following intra-thoracic cisplatin. Intern Med 1996; 35:290.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/23/37242/abstract/75\">",
"      Sthoeger ZM, Breisilovsky S, Sthoeger D, et al. Syndrome of inappropriate antidiuretic hormone secretion following cis-dichlorodiammineplatinum II in a patient with laryngeal carcinoma. Eur J Med 1993; 2:175.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/23/37242/abstract/76\">",
"      Doll DC, List AF, Greco FA, et al. Acute vascular ischemic events after cisplatin-based combination chemotherapy for germ-cell tumors of the testis. Ann Intern Med 1986; 105:48.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/23/37242/abstract/77\">",
"      Gerl A, Clemm C, Wilmanns W. Acute cerebrovascular event after cisplatin-based chemotherapy for testicular cancer. Lancet 1991; 338:385.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/23/37242/abstract/78\">",
"      El Amrani M, Heinzlef O, Debroucker T, et al. Brain infarction following 5-fluorouracil and cisplatin therapy. Neurology 1998; 51:899.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/23/37242/abstract/79\">",
"      Dietrich J, Marienhagen J, Schalke B, et al. Vascular neurotoxicity following chemotherapy with cisplatin, ifosfamide, and etoposide. Ann Pharmacother 2004; 38:242.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/23/37242/abstract/80\">",
"      Czaykowski PM, Moore MJ, Tannock IF. High risk of vascular events in patients with urothelial transitional cell carcinoma treated with cisplatin based chemotherapy. J Urol 1998; 160:2021.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/23/37242/abstract/81\">",
"      Liaw CC, Wang CH, Chang HK, et al. Cisplatin-related hiccups: male predominance, induction by dexamethasone, and protection against nausea and vomiting. J Pain Symptom Manage 2005; 30:359.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/23/37242/abstract/82\">",
"      Dropcho EJ, Rosenfeld SS, Vitek J, et al. Phase II study of intracarotid or selective intracerebral infusion of cisplatin for treatment of recurrent anaplastic gliomas. J Neurooncol 1998; 36:191.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/23/37242/abstract/83\">",
"      Yakirevitch A, Talmi YP, Baram Y, et al. Effects of cisplatin on olfactory function in cancer patients. Br J Cancer 2005; 92:1611.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/23/37242/abstract/84\">",
"      Castellanos AM, Glass JP, Yung WK. Regional nerve injury after intra-arterial chemotherapy. Neurology 1987; 37:834.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/23/37242/abstract/85\">",
"      Steiner I, Siegal T. Muscle cramps in cancer patients. Cancer 1989; 63:574.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/23/37242/abstract/86\">",
"      Heinzlef O, Lotz JP, Roullet E. Severe neuropathy after high dose carboplatin in three patients receiving multidrug chemotherapy. J Neurol Neurosurg Psychiatry 1998; 64:667.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/23/37242/abstract/87\">",
"      Lambert MP, Shields C, Meadows AT. A retrospective review of hearing in children with retinoblastoma treated with carboplatin-based chemotherapy. Pediatr Blood Cancer 2008; 50:223.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/23/37242/abstract/88\">",
"      Smits C, Swen SJ, Theo Goverts S, et al. Assessment of hearing in very young children receiving carboplatin for retinoblastoma. Eur J Cancer 2006; 42:492.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/23/37242/abstract/89\">",
"      Jehanne M, Lumbroso-Le Rouic L, Savignoni A, et al. Analysis of ototoxicity in young children receiving carboplatin in the context of conservative management of unilateral or bilateral retinoblastoma. Pediatr Blood Cancer 2009; 52:637.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/23/37242/abstract/90\">",
"      Qaddoumi I, Bass JK, Wu J, et al. Carboplatin-associated ototoxicity in children with retinoblastoma. J Clin Oncol 2012; 30:1034.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/23/37242/abstract/91\">",
"      Kearns GL, Abdel-Rahman SM, Alander SW, et al. Developmental pharmacology--drug disposition, action, and therapy in infants and children. N Engl J Med 2003; 349:1157.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/23/37242/abstract/92\">",
"      Walker RW, Rosenblum MK, Kempin SJ, Christian MC. Carboplatin-associated thrombotic microangiopathic hemolytic anemia. Cancer 1989; 64:1017.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/23/37242/abstract/93\">",
"      Vieillot S, Pouessel D, de Champfleur NM, et al. Reversible posterior leukoencephalopathy syndrome after carboplatin therapy. Ann Oncol 2007; 18:608.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/23/37242/abstract/94\">",
"      Stewart DJ, Belanger JM, Grahovac Z, et al. Phase I study of intracarotid administration of carboplatin. Neurosurgery 1992; 30:512.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/23/37242/abstract/95\">",
"      Taieb S, Trillet-Lenoir V, Rambaud L, et al. Lhermitte sign and urinary retention: atypical presentation of oxaliplatin neurotoxicity in four patients. Cancer 2002; 94:2434.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/23/37242/abstract/96\">",
"      Park SB, Lin CS, Krishnan AV, et al. Oxaliplatin-induced lhermitte's phenomenon as a manifestation of severe generalized neurotoxicity. Oncology 2009; 77:342.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/23/37242/abstract/97\">",
"      Pinedo DM, Shah-Khan F, Shah PC. Reversible posterior leukoencephalopathy syndrome associated with oxaliplatin. J Clin Oncol 2007; 25:5320.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/23/37242/abstract/98\">",
"      Mor&iacute;s G, Ribacoba R, Gonz&aacute;lez C. Delayed posterior encephalopathy syndrome following chemotherapy with oxaliplatin and gemcitabine. J Neurol 2007; 254:534.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/23/37242/abstract/99\">",
"      Skelton MR, Goldberg RM, O'Neil BH. A case of oxaliplatin-related posterior reversible encephalopathy syndrome. Clin Colorectal Cancer 2007; 6:386.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/23/37242/abstract/100\">",
"      Argyriou AA, Cavaletti G, Briani C, et al. Clinical pattern and associations of oxaliplatin acute neurotoxicity: a prospective study in 170 patients with colorectal cancer. Cancer 2013; 119:438.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/23/37242/abstract/101\">",
"      Adenis A, Mailliez A, Rigot JM, et al. Recurrent priapism related to oxaliplatin infusion. J Clin Oncol 2008; 26:1016.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/23/37242/abstract/102\">",
"      Saif MW, Hashmi S. Successful amelioration of oxaliplatin-induced hyperexcitability syndrome with the antiepileptic pregabalin in a patient with pancreatic cancer. Cancer Chemother Pharmacol 2008; 61:349.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/23/37242/abstract/103\">",
"      Gamelin E, Gamelin L, Bossi L, Quasthoff S. Clinical aspects and molecular basis of oxaliplatin neurotoxicity: current management and development of preventive measures. Semin Oncol 2002; 29:21.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/23/37242/abstract/104\">",
"      Park SB, Lin CS, Krishnan AV, et al. Oxaliplatin-induced neurotoxicity: changes in axonal excitability precede development of neuropathy. Brain 2009; 132:2712.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/23/37242/abstract/105\">",
"      Grolleau F, Gamelin L, Boisdron-Celle M, et al. A possible explanation for a neurotoxic effect of the anticancer agent oxaliplatin on neuronal voltage-gated sodium channels. J Neurophysiol 2001; 85:2293.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/23/37242/abstract/106\">",
"      Wilson RH, Lehky T, Thomas RR, et al. Acute oxaliplatin-induced peripheral nerve hyperexcitability. J Clin Oncol 2002; 20:1767.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/23/37242/abstract/107\">",
"      Lehky TJ, Leonard GD, Wilson RH, et al. Oxaliplatin-induced neurotoxicity: acute hyperexcitability and chronic neuropathy. Muscle Nerve 2004; 29:387.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/23/37242/abstract/108\">",
"      Gamelin L, Capitain O, Morel A, et al. Predictive factors of oxaliplatin neurotoxicity: the involvement of the oxalate outcome pathway. Clin Cancer Res 2007; 13:6359.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/23/37242/abstract/109\">",
"      Park SB, Goldstein D, Lin CS, et al. Acute abnormalities of sensory nerve function associated with oxaliplatin-induced neurotoxicity. J Clin Oncol 2009; 27:1243.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/23/37242/abstract/110\">",
"      Park SB, Lin CS, Krishnan AV, et al. Dose effects of oxaliplatin on persistent and transient Na+ conductances and the development of neurotoxicity. PLoS One 2011; 6:e18469.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/23/37242/abstract/111\">",
"      Webster RG, Brain KL, Wilson RH, et al. Oxaliplatin induces hyperexcitability at motor and autonomic neuromuscular junctions through effects on voltage-gated sodium channels. Br J Pharmacol 2005; 146:1027.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/23/37242/abstract/112\">",
"      Land SR, Kopec JA, Cecchini RS, et al. Neurotoxicity from oxaliplatin combined with weekly bolus fluorouracil and leucovorin as surgical adjuvant chemotherapy for stage II and III colon cancer: NSABP C-07. J Clin Oncol 2007; 25:2205.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/23/37242/abstract/113\">",
"      Kidwell KM, Yothers G, Ganz PA, et al. Long-term neurotoxicity effects of oxaliplatin added to fluorouracil and leucovorin as adjuvant therapy for colon cancer: results from National Surgical Adjuvant Breast and Bowel Project trials C-07 and LTS-01. Cancer 2012; 118:5614.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/23/37242/abstract/114\">",
"      Andr&eacute; T, Boni C, Navarro M, et al. Improved overall survival with oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment in stage II or III colon cancer in the MOSAIC trial. J Clin Oncol 2009; 27:3109.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/23/37242/abstract/115\">",
"      Maindrault-Goebel F, de Gramont A, Louvet C, et al. Evaluation of oxaliplatin dose intensity in bimonthly leucovorin and 48-hour 5-fluorouracil continuous infusion regimens (FOLFOX) in pretreated metastatic colorectal cancer. Oncology Multidisciplinary Research Group (GERCOR). Ann Oncol 2000; 11:1477.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/23/37242/abstract/116\">",
"      Cassidy J, Misset JL. Oxaliplatin-related side effects: characteristics and management. Semin Oncol 2002; 29:11.",
"     </a>",
"    </li>",
"    <li>",
"     Green E, Sargent DJ, Goldberg RM, Grothey A. Detailed analysis of oxaliplatin-associated neurotoxicity in Intergroup trial N9741 (abstract). Data presented at the 2005 ASCO Gastrointestinal Cancers Symposium, Hollywood, Florida, January 28, 2005.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/23/37242/abstract/118\">",
"      Alejandro LM, Behrendt CE, Chen K, et al. Predicting Acute and Persistent Neuropathy Associated With Oxaliplatin. Am J Clin Oncol 2012.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/23/37242/abstract/119\">",
"      Uwah AN, Ackler J, Leighton JC Jr, et al. The effect of diabetes on oxaliplatin-induced peripheral neuropathy. Clin Colorectal Cancer 2012; 11:275.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/23/37242/abstract/120\">",
"      Ruzzo A, Graziano F, Loupakis F, et al. Pharmacogenetic profiling in patients with advanced colorectal cancer treated with first-line FOLFOX-4 chemotherapy. J Clin Oncol 2007; 25:1247.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/23/37242/abstract/121\">",
"      Won HH, Lee J, Park JO, et al. Polymorphic markers associated with severe oxaliplatin-induced, chronic peripheral neuropathy in colon cancer patients. Cancer 2012; 118:2828.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/23/37242/abstract/122\">",
"      Petrioli R, Pascucci A, Francini E, et al. Neurotoxicity of FOLFOX-4 as adjuvant treatment for patients with colon and gastric cancer: a randomized study of two different schedules of oxaliplatin. Cancer Chemother Pharmacol 2008; 61:105.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/23/37242/abstract/123\">",
"      Gamelin L, Boisdron-Celle M, Delva R, et al. Prevention of oxaliplatin-related neurotoxicity by calcium and magnesium infusions: a retrospective study of 161 patients receiving oxaliplatin combined with 5-Fluorouracil and leucovorin for advanced colorectal cancer. Clin Cancer Res 2004; 10:4055.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/23/37242/abstract/124\">",
"      Hochster HS, Grothey A, Childs BH. Use of calcium and magnesium salts to reduce oxaliplatin-related neurotoxicity. J Clin Oncol 2007; 25:4028.",
"     </a>",
"    </li>",
"    <li>",
"     Hochster HS, Grothey A, Shpilsky A, Childs BH. Effect of intravenous (IV) calcium and magnesium vs placebo on response to FOLFOX + bevacizumab in the CONcePT trial. Presented at the 2008 Gastrointestinal Cancers Symposium, Orlando, FL, January 20, 2008.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/23/37242/abstract/126\">",
"      Argyriou AA, Chroni E, Polychronopoulos P, et al. Efficacy of oxcarbazepine for prophylaxis against cumulative oxaliplatin-induced neuropathy. Neurology 2006; 67:2253.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/23/37242/abstract/127\">",
"      Wang WS, Lin JK, Lin TC, et al. Oral glutamine is effective for preventing oxaliplatin-induced neuropathy in colorectal cancer patients. Oncologist 2007; 12:312.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/23/37242/abstract/128\">",
"      Zhang RX, Lu ZH, Wan DS, et al. Neuroprotective effect of neurotropin on chronic oxaliplatin-induced neurotoxicity in stage II and stage III colorectal cancer patients: results from a prospective, randomised, single-centre, pilot clinical trial. Int J Colorectal Dis 2012; 27:1645.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/23/37242/abstract/129\">",
"      Nishioka M, Shimada M, Kurita N, et al. The Kampo medicine, Goshajinkigan, prevents neuropathy in patients treated by FOLFOX regimen. Int J Clin Oncol 2011; 16:322.",
"     </a>",
"    </li>",
"    <li>",
"     Cassidy J, Bjarnason GA, Hickish T, et al. Randomized double blind placebo controlled phase III study assessing the efficacy of xaliproden in reduicng the cumulative peripheral sensory neuropathy induced by the oxaliplatin and 5-FU/LV combination (FOLFOX4) in first-line treatment of patients with metastatic colorectal cancer (abstract). J Clin Oncol 2006; 24:147s.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/23/37242/abstract/131\">",
"      Durand JP, Deplanque G, Montheil V, et al. Efficacy of venlafaxine for the prevention and relief of oxaliplatin-induced acute neurotoxicity: results of EFFOX, a randomized, double-blind, placebo-controlled phase III trial. Ann Oncol 2012; 23:200.",
"     </a>",
"    </li>",
"    <li>",
"     Grothey A, Hart LL, Rowland KM, et al. Intermittent oxaliplatin administration and time to treatment failure in metastatic colorectal cancer: Final results of the phase III CONcePT trial (abstract). J Clin Oncol 2008; 26s:abstr 4010. file://www.asco.org/ASCOv2/Meetings/Abstracts?&amp;vmview=abst_detail_view&amp;confID=55&amp;abstractID=34113 (Accessed on July 26, 2012).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/23/37242/abstract/133\">",
"      Grothey A, Nikcevich DA, Sloan JA, et al. Intravenous calcium and magnesium for oxaliplatin-induced sensory neurotoxicity in adjuvant colon cancer: NCCTG N04C7. J Clin Oncol 2011; 29:421.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/23/37242/abstract/134\">",
"      Gamelin L, Boisdron-Celle M, Morel A, et al. Oxaliplatin-related neurotoxicity: interest of calcium-magnesium infusion and no impact on its efficacy. J Clin Oncol 2008; 26:1188.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/23/37242/abstract/135\">",
"      Knijn N, Tol J, Koopman M, et al. The effect of prophylactic calcium and magnesium infusions on the incidence of neurotoxicity and clinical outcome of oxaliplatin-based systemic treatment in advanced colorectal cancer patients. Eur J Cancer 2011; 47:369.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/23/37242/abstract/136\">",
"      Rao RD, Michalak JC, Sloan JA, et al. Efficacy of gabapentin in the management of chemotherapy-induced peripheral neuropathy: a phase 3 randomized, double-blind, placebo-controlled, crossover trial (N00C3). Cancer 2007; 110:2110.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 2826 Version 27.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1005-197.136.42.3-858ECED34C-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f36_23_37242=[""].join("\n");
var outline_f36_23_37242=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H25\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      CISPLATIN",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Peripheral neuropathy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      - Clinical manifestations",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H109349878\">",
"      - Mechanism",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      - Preventive strategies",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H93783170\">",
"      Vitamin E",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H93783185\">",
"      Amifostine",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H12919875\">",
"      Future strategies",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H109349925\">",
"      - Symptomatic treatment of neuropathic pain",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      - Summary",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Ototoxicity",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - Mechanism",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Prevention",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Myelotoxicity (Lhermitte's sign)",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Encephalopathy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Vascular toxicity",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Other complications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      CARBOPLATIN",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      OXALIPLATIN",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Acute neurotoxicity",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Cumulative sensory neuropathy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      - Incidence, characteristics, severity, and reversibility",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H93783210\">",
"      Data from clinical trials",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H93783218\">",
"      Impact of dose intensity and length of treatment",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      - Molecular predictors of neurotoxicity",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Prevention",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      - Stopping and reintroducing oxaliplatin",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      - Lengthened infusion duration",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      - Pharmacologic approaches",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H19082722\">",
"      Venlafaxine",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H93783276\">",
"      Calcium and magnesium infusions",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      - Summary",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12919949\">",
"      - Symptomatic treatment of neuropathic pain",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H645668\">",
"      Reversible posterior leukoencephalopathy syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H28589094\">",
"      TREATMENT OF NEUROPATHIC PAIN",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      Cisplatin",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      Oxaliplatin",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H127138957\">",
"      ACKNOWLEDGMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ONC/2826\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ONC/2826|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?35/9/35998\" title=\"table 1\">",
"      Neurologic complications CA Rx",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?34/34/35373\" title=\"table 2\">",
"      Neurotox cytotoxic agents",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?16/3/16444\" title=\"table 3\">",
"      Dose modif neurotox oxaliplatin",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?11/35/11836\" title=\"table 4\">",
"      NCI CTCAE grading of neurotoxicity",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?33/44/34506?source=related_link\">",
"      Adjuvant therapy for resected stage III (node-positive) colon cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?38/9/39066?source=related_link\">",
"      Cancer pain management: Adjuvant analgesics (coanalgesics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?20/38/21098?source=related_link\">",
"      Cancer pain management: Interventional therapies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?29/8/29833?source=related_link\">",
"      Cisplatin nephrotoxicity",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?11/1/11287?source=related_link\">",
"      Clinical manifestations of Sj&ouml;gren's syndrome: Exocrine gland disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?27/13/27863?source=related_link\">",
"      Clinical neurophysiology",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?36/22/37226?source=related_link\">",
"      Complications of cranial irradiation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?36/7/36986?source=related_link\">",
"      Cutaneous complications of conventional chemotherapy agents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?8/32/8712?source=related_link\">",
"      Differential diagnosis of peripheral nerve and muscle disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?6/36/6730?source=related_link\">",
"      Drug-induced thrombosis and vascular disease in patients with malignancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?0/33/537?source=related_link\">",
"      Intraperitoneal chemotherapy for treatment of ovarian cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?42/3/43064?source=related_link\">",
"      Neurologic complications of cancer treatment with biologic agents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?42/32/43530?source=related_link\">",
"      Neurologic complications of non-platinum cancer chemotherapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?15/57/16282?source=related_link\">",
"      Overview of the risk factors, pathology, and clinical manifestations of lung cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?36/27/37304?source=related_link\">",
"      Paraneoplastic syndromes affecting peripheral nerve and muscle",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?7/46/7913?source=related_link\">",
"      Pathophysiology and etiology of the syndrome of inappropriate antidiuretic hormone secretion (SIADH)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?24/34/25130?source=related_link\">",
"      Preparative regimens for hematopoietic cell transplantation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?31/26/32170?source=related_link\">",
"      Psychological, rehabilitative, and integrative therapies for cancer pain",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?42/16/43273?source=related_link\">",
"      Reversible posterior leukoencephalopathy syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?43/32/44554?source=related_link\">",
"      Systemic chemotherapy for metastatic colorectal cancer: Completed clinical trials",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?21/20/21833?source=related_link\">",
"      Systemic chemotherapy for metastatic colorectal cancer: General principles",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f36_23_37243="Follic lymphoma int prog index";
var content_f36_23_37243=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=HEME%2F55987&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=HEME%2F55987&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Follicular lymphoma international prognostic index (FLIPI)",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td colspan=\"4\" rowspan=\"1\">",
"        &bull; Age &gt;60",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"4\" rowspan=\"1\">",
"        &bull; Serum lactate dehydrogenase concentration above normal",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"4\" rowspan=\"1\">",
"        &bull; Hemoglobin level &lt;12.0 g/dL",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"4\" rowspan=\"1\">",
"        &bull; Ann Arbor stage III or IV",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"4\" rowspan=\"1\">",
"        &bull; Number of involved nodal areas &gt;4",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"4\" rowspan=\"1\">",
"        One point is given for each of the",
"above characteristics present in the patient with follicular lymphoma",
"(FL), for a total score ranging from zero to five. When applied to an",
"international study of long-term survival in 4, 167 patients with FL",
"diagnosed between 1985 and 1992, the following three risk groups and",
"their corresponding 5- and 10-year overall survivals (OS) were, as",
"follows:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2\">",
"        Score",
"       </td>",
"       <td class=\"subtitle2\">",
"        Risk Group",
"       </td>",
"       <td class=\"subtitle2\">",
"        5-yr OS, percent",
"       </td>",
"       <td class=\"subtitle2\">",
"        &nbsp;10-yr OS, percent",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        0 to 1",
"       </td>",
"       <td>",
"        Low risk",
"       </td>",
"       <td>",
"        91",
"       </td>",
"       <td>",
"        71",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        2",
"       </td>",
"       <td>",
"        Intermediate risk",
"       </td>",
"       <td>",
"        78",
"       </td>",
"       <td>",
"        51",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        3 or more",
"       </td>",
"       <td>",
"        High risk",
"       </td>",
"       <td>",
"        52",
"       </td>",
"       <td>",
"        36",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Adapted from Solal-Celigny, P, Roy, P, Colombat, P, et al. Follicular lymphoma international prognostic index. Blood 2004; 104:1258.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f36_23_37243=[""].join("\n");
var outline_f36_23_37243=null;
var title_f36_23_37244="Classification of opioid agents";
var content_f36_23_37244=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F66571&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=6\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F66571&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=6\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Classification of opioid agents",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Origin",
"       </td>",
"       <td class=\"subtitle1\">",
"        Agent (Brand Name)",
"       </td>",
"       <td class=\"subtitle1\">",
"        Comments",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"1\" rowspan=\"3\">",
"        Natural",
"       </td>",
"       <td>",
"        Codeine",
"       </td>",
"       <td>",
"        AT",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Morphine",
"       </td>",
"       <td>",
"        -",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Paregoric",
"       </td>",
"       <td>",
"        -",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"1\" rowspan=\"7\">",
"        Synthetic",
"       </td>",
"       <td>",
"        Diphenoxylate (Lomotil)",
"       </td>",
"       <td>",
"        AD",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Fentanyl (Sublimaze)",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Loperamide (Imodium)",
"       </td>",
"       <td>",
"        AD",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Meperidine (Demerol)",
"       </td>",
"       <td>",
"        S,1",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Methadone (Dolophine)",
"       </td>",
"       <td>",
"        Long-acting",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Propoxyphene (Darvon)",
"       </td>",
"       <td>",
"        S",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Tramadol (Ultram)",
"       </td>",
"       <td>",
"        S",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"1\" rowspan=\"14\">",
"        Semisynthetic",
"       </td>",
"       <td>",
"        Heroin&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;",
"       </td>",
"       <td>",
"        -",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Hydrocodone (Lortab)",
"       </td>",
"       <td>",
"        -",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Hydromorphone (Dilaudid)",
"       </td>",
"       <td>",
"        -",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Levorphanol (Levodromoran)",
"       </td>",
"       <td>",
"        Long-acting",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Oxycodone (Percocet)",
"       </td>",
"       <td>",
"        -",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Oxymorphone (Numorphan)",
"       </td>",
"       <td>",
"        -",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Buprenorphine (Buprenex)",
"       </td>",
"       <td>",
"        S",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Butorphanol (Stadol)",
"       </td>",
"       <td>",
"        2,3",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Nalburphine (Nubain)",
"       </td>",
"       <td>",
"        2,3",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Pentazocine (Talwin)",
"       </td>",
"       <td>",
"        2,3",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Nalmefene (Revex)",
"       </td>",
"       <td>",
"        -",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Naloxone (Narcane)",
"       </td>",
"       <td>",
"        -",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Naltrexone (Re Via)",
"       </td>",
"       <td>",
"        -",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Dextromethorphan",
"       </td>",
"       <td>",
"        AT",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     AD: antidiarrheal; AT: antitussive; S: seizures; 1: use cautiously with renal compromise; 2: may cause withdrawal symptoms in opioid-dependent patients; 3: has ceiling for analgesia and respiratory depression.",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f36_23_37244=[""].join("\n");
var outline_f36_23_37244=null;
var title_f36_23_37245="Vaccine administration guidelines for adults";
var content_f36_23_37245=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F81508&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F81508&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Administering vaccines to adults: Dose, route, site, needle size, and preparation",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Vaccine",
"       </td>",
"       <td class=\"subtitle1\">",
"        Dose",
"       </td>",
"       <td class=\"subtitle1\">",
"        Route",
"       </td>",
"       <td class=\"subtitle1\">",
"        Site",
"       </td>",
"       <td class=\"subtitle1\">",
"        Needle size",
"       </td>",
"       <td class=\"subtitle1\">",
"        Vaccine preparation",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Tetanus, Diphtheria (Td) with Pertussis (Tdap)",
"       </td>",
"       <td>",
"        0.5 mL",
"       </td>",
"       <td>",
"        IM",
"       </td>",
"       <td>",
"        Deltoid muscle",
"       </td>",
"       <td>",
"        22-25 g, 1-1&frac12;\"*",
"       </td>",
"       <td rowspan=\"9\">",
"        Shake vial vigorously to obtain a uniform suspension prior to withdrawing each dose. Whenever solution and container permit, inspect vaccine visually for particulate matter and/or discoloration prior to administration. If problems are noted (eg, vaccine cannot be resuspended), the vaccine should not be administered.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Hepatitis A (HepA)",
"       </td>",
"       <td>",
"        &le;18 yrs.:0.5 mL",
"        <br/>",
"        &le;19 yrs.:1.0 mL",
"       </td>",
"       <td>",
"        IM",
"       </td>",
"       <td>",
"        Deltoid muscle",
"       </td>",
"       <td>",
"        22-25 g, 1-1&frac12;\"*",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Hepatitis B (HepB)",
"       </td>",
"       <td>",
"        &le;19 yrs.:0.5 mL",
"        <br/>",
"        &ge;20 yrs.:1.0 mL",
"       </td>",
"       <td>",
"        IM",
"       </td>",
"       <td>",
"        Deltoid muscle",
"       </td>",
"       <td>",
"        22-25 g, 1-1&frac12;\"*",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        HepA+HepB (Twinrix)",
"       </td>",
"       <td>",
"        &ge;18 yrs.:1.0 mL",
"       </td>",
"       <td>",
"        IM",
"       </td>",
"       <td>",
"        Deltoid muscle",
"       </td>",
"       <td>",
"        22-25 g, 1-1&frac12;\"*",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Human papillomavirus (HPV)",
"       </td>",
"       <td>",
"        0.5 mL",
"       </td>",
"       <td>",
"        IM",
"       </td>",
"       <td>",
"        Deltoid muscle",
"       </td>",
"       <td>",
"        22-25 g, 1-1&frac12;\"*",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Influenza, trivalent inactivated (TIV)",
"       </td>",
"       <td>",
"        0.5 mL",
"       </td>",
"       <td>",
"        IM",
"       </td>",
"       <td>",
"        Deltoid muscle",
"       </td>",
"       <td>",
"        22-25 g, 1-1&frac12;\"*",
"       </td>",
"      </tr>",
"      <tr>",
"       <td rowspan=\"2\">",
"        Pneumococcal polysaccharide (PPSV)",
"       </td>",
"       <td rowspan=\"2\">",
"        0.5 mL",
"       </td>",
"       <td>",
"        IM",
"       </td>",
"       <td>",
"        Deltoid muscle",
"       </td>",
"       <td>",
"        22-25 g, 1-1&frac12;\"*",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        SC",
"       </td>",
"       <td>",
"        Fatty tissue over triceps",
"       </td>",
"       <td>",
"        23-25 g, \"",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Meningococcal, conjugated (MCV)",
"       </td>",
"       <td>",
"        0.5 mL",
"       </td>",
"       <td>",
"        IM",
"       </td>",
"       <td>",
"        Deltoid muscle",
"       </td>",
"       <td>",
"        22-25 g, 1-1&frac12;\"*",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        Meningococcal, polysaccharide (MPSV)",
"       </td>",
"       <td>",
"        0.5 mL",
"       </td>",
"       <td>",
"        SC",
"       </td>",
"       <td>",
"        Fatty tissue over triceps",
"       </td>",
"       <td>",
"        23-25 g, \"",
"       </td>",
"       <td rowspan=\"4\">",
"        <p>",
"         Reconstitute just before using. Use only the diluent supplied with the vaccine. Inject the volume of the diluent shown on the diluent label into the vial of lyophilized vaccine and gently agitate to mix thoroughly. Withdraw the entire contents and administer immediately after reconstitution.",
"        </p>",
"        <p>",
"         Discard single dose MPSV, varicella, and zoster vaccines if not used within 30 minutes after reconstitution.",
"        </p>",
"        <p>",
"         <strong>",
"          Note:",
"         </strong>",
"         Unused reconstituted MMR vaccine and multidose MPSV vaccine may be stored at 35&deg;46&deg;F (2&deg;8&deg;C) for a limited time. The reconstituted MPSV vaccine must be used within 35 days; the reconstituted MMR vaccine must be used within 8 hours. Do not freeze either reconstituted vaccine.",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Measles, mumps, rubella (MMR)",
"       </td>",
"       <td>",
"        0.5 mL",
"       </td>",
"       <td>",
"        SC",
"       </td>",
"       <td>",
"        Fatty tissue over triceps",
"       </td>",
"       <td>",
"        23-25 g, \"",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Zoster (Zos)",
"       </td>",
"       <td>",
"        0.65 mL",
"       </td>",
"       <td>",
"        SC",
"       </td>",
"       <td>",
"        Fatty tissue over triceps",
"       </td>",
"       <td>",
"        23-25 g, \"",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Varicella (Var)",
"       </td>",
"       <td>",
"        0.5 mL",
"       </td>",
"       <td>",
"        SC",
"       </td>",
"       <td>",
"        Fatty tissue over triceps",
"       </td>",
"       <td>",
"        23-25 g, \"",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        Influenza, live, attenuated (LAIV)",
"       </td>",
"       <td>",
"        0.2 mL (0.1 mL into each nostril)",
"       </td>",
"       <td>",
"        Intranasal spray",
"       </td>",
"       <td>",
"        Intranasal",
"       </td>",
"       <td>",
"        NA",
"       </td>",
"       <td>",
"        Consult package insert",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <strong>",
"     Please note:",
"    </strong>",
"    Always refer to the package insert included with each biologic for complete vaccine administration information. CDC's Advisory Committee on Immunization Practices (ACIP) recommendations for the particular vaccine should be reviewed as well. Access the ACIP recommendations at",
"    <a href=\"file://www.immunize.org/acip\" target=\"_blank\">",
"     www.immunize.org/acip",
"    </a>",
"    .",
"    <div class=\"footnotes\">",
"     * When giving intramuscular injections, a \" needle is sufficient in adults weighing &lt;130 lbs (&lt;60 kg); a 1\" needle is sufficient in adults weighing 130 to 152 lbs (60 to 70 kg); a 1 to 1&frac12;\" needle is recommended in women weighing 152 to 200 lbs (70 to 90 kg) and men weighing 152 to 260 lbs (70 to 118 kg); a 1&frac12;\" needle is recommended in women weighing &gt;200 lbs (&gt;90 kg) or men weighing &gt;260 lbs (&gt;118 kg). A \" (16 mm) needle may be used only if the skin is stretched tight, the subcutaneous tissue is not bunched, and injection is made at a 90-degree angle.",
"    </div>",
"    <div class=\"reference\">",
"     Acquired from:",
"     <a href=\"file://www.immunize.org/catg.d/p3084.pdf\" target=\"_blank\">",
"      file://www.immunize.org/catg.d/p3084.pdf",
"     </a>",
"     on January 12, 2012. We thank the Immunization Action Coalition.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f36_23_37245=[""].join("\n");
var outline_f36_23_37245=null;
var title_f36_23_37246="Lateral view of comminuted midshaft femur fracture";
var content_f36_23_37246=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F68722&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F68722&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Lateral view of comminuted midshaft femur fracture",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 289px; height: 355px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    This lateral plain radiograph shows a comminuted midshaft femur fracture prior to operative repair.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Thomas J Mezzanotte, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f36_23_37246=[""].join("\n");
var outline_f36_23_37246=null;
var title_f36_23_37247="SCFE Blanch sign of Steel";
var content_f36_23_37247=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F58172&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F58172&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 484px\">",
"   <div class=\"ttl\">",
"    Blanch sign of Steel",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 464px; height: 221px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    With posterior slippage of the femoral epiphysis, the portion that is located behind the metaphysis may be projected as a semicircular area of increased density on the neck of the femur. This radiographic sign is known as the \"Blanch sign of Steel.\"",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Steel, HH. J Bone Joint Surg 1986; 68A:920. Copyright &copy; 1986 The Journal of Bone and Joint Surgery, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f36_23_37247=[""].join("\n");
var outline_f36_23_37247=null;
